

=> d his

(FILE 'HOME' ENTERED AT 13:48:12 ON 16 SEP 2010)

FILE 'REGISTRY' ENTERED AT 13:51:19 ON 16 SEP 2010

L1 STRUCTURE UPLOADED
 L2 50 S L1
 L3 3126 S L1 SSS FUL
 L4 STRUCTURE UPLOADED
 L5 1192 S L4 SUB=L3 FUL
 L6 1934 S L3 NOT L5
 L7 3421 S 2436.13/RID
 L8 1182 S L5 AND L7
 L9 1811 S L6 AND CAPLUS/LC
 L10 123 S L6 NOT L9
 L11 1159 S L8 AND CAPLUS/LC
 L12 23 S L8 NOT L11

FILE 'CAPLUS' ENTERED AT 13:57:38 ON 16 SEP 2010

L13 440 S L6
 L14 26 S L8
 L15 ANALYZE L13 1- RN HIT : 1811 TERMS

FILE 'REGISTRY' ENTERED AT 13:58:27 ON 16 SEP 2010

L16 1 S 237430-03-4/RN
 L17 100 S 1422737/RN
 L18 1 S 210101-16-9/RN
 L19 1 S 168626-94-6/RN
 L20 7 S L17 AND L6

FILE 'CAPLUS' ENTERED AT 14:02:15 ON 16 SEP 2010

FILE 'REGISTRY' ENTERED AT 14:05:15 ON 16 SEP 2010

L21 492 S 5300.5/RID
 L22 11 S 4469.23/RID
 L23 1495 S L6 NOT (L21 OR L22)

FILE 'CAPLUS' ENTERED AT 14:08:27 ON 16 SEP 2010

L24 247 S L23
 L25 ANALYZE L24 1- RN HIT : 1412 TERMS

FILE 'REGISTRY' ENTERED AT 14:09:41 ON 16 SEP 2010

L26 1493 S L23 NOT (L18 OR L19)


FILE 'CAPLUS' ENTERED AT 14:09:48 ON 16 SEP 2010

L27 120 S L26
 L28 96 S L27 NOT (2010/SO OR 2009/SO OR 2008/SO OR 2007/SO OR 2006/SO

=> d l1

L1 HAS NO ANSWERS
 L1 STR

10/565,702



G1 O,S,N


G2 C,N

Structure attributes must be viewed using STN Express query preparation.

=> d 14

L4 HAS NO ANSWERS

L4 STR



G1 O,S,N



Structure attributes must be viewed using STN Express query preparation.

=> d ibib abs hitstr total

L28 ANSWER 1 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2010:563318 CAPLUS
 DOCUMENT NUMBER: 152:548103
 TITLE: Preparation of dihydrochromenopyrazolecarboxamide derivatives and analogs for use as glutamate receptor modulators
 INVENTOR(S): Bertinato, Peter; Fichman, Merav; Ghosh, Shomir; Lin, Jian; Segal, Dalia; Zhang, Zhaoda
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 132pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010049366	A1	20100506	WO 2009-EP64015	20091023
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2008-108666P P 20081027
 OTHER SOURCE(S): MARPAT 152:548103
 GI



AB Title compds. I [A = O, CONH, NHCO, etc.; ring B = aryl, heteroaryl, or heterocyclyl; T = CO or CR7R8, wherein at least one is CR7R8; each V independently = N or CR2; X = NR4 or CR7R8; Y and Z independently = N or NR11; R2 = alkoxy, alkyl, aryl, etc.; R3 = cycloalkyl, CN, halo, heteroaryl, etc.; R4 = alkyl, alkylsulfonyl, alkanoyl, H, etc.; R7 and R8 independently = alkoxy, alkyl, halo, H, OH, or haloalkyl; or taken together are oxo, carbocycle, or heterocycle; R11 = alkyl, cycloalkyl, or haloalkyl; m = 1 to 3; n = 0 to 2], and their pharmaceutically acceptable salts, are prepared and disclosed as glutamate receptor modulators. Thus, e.g., II was prepared by coupling of 6-fluorochroman-4-one with di-Et oxalate followed by cyclization with methylhydrazine, hydrolysis, and amidation with 3-chloroaniline. Select I were evaluated in mGluR5 antagonist activity assays, e.g., II demonstrated an IC50 value of <1 μ M.


IT 1225376-75-9P 1225376-77-1P 1225376-80-6P
1225377-18-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of dihydrochromenopyrazolecarboxamide derivs. and analogs for use as glutamate receptor modulators)

RN 1225376-75-9 CAPLUS


CN Pyrazolo[3,4-d]pyrido[3,2-b]azepine-3-carboxamide,
1,4,5,6-tetrahydro-1,6-dimethyl-N-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 1225376-77-1 CAPLUS
 CN Pyrazolo[4,3-d][1]benzazepine-3-carboxamide,
 1,4,5,6-tetrahydro-1-methyl-N-(6-methyl-2-pyridinyl)-5-oxo- (CA INDEX
 NAME)



RN 1225376-80-6 CAPLUS
 CN Pyrazolo[4,3-d][1]benzazepine-3-carboxamide,
 1,4,5,6-tetrahydro-1,6-dimethyl-N-(6-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 1225377-18-3 CAPLUS
 CN Pyrazolo[4,3-d][1]benzazepine-3-carboxamide,
 9-fluoro-1,4,5,6-tetrahydro-1-methyl-N-(6-methyl-2-pyridinyl)-5-oxo- (CA
 INDEX NAME)



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 2 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2010:529065 CAPLUS

DOCUMENT NUMBER: 152:493519

TITLE: Methods and motor neuron survival-promoting compounds for treatment of neurodegenerative disorders

INVENTOR(S): Rubin, Lee; Sinor, Amy; Makhortova, Nina Ruslanovna; Yang, Yin Miranda; Bennett, Monica Hayhurst

PATENT ASSIGNEE(S): President and Fellows of Harvard College, USA

SOURCE: PCT Int. Appl., 236pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010048273	A2	20100429	WO 2009-US61468	20091021
WO 2010048273	A3	20100819		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, QA				
PRIORITY APPLN. INFO.:			US 2008-107280P	P 20081021
			US 2009-223366P	P 20090706
AB	Methods, compds. and compns. for promoting motor neuron survival and the treatment of a neurodegenerative disorders such as Spinal Muscular Atrophy (SMA) are described herein. In one aspect, the invention provides for a method of promoting motor neuron survival, the method comprising: contacting a motor neuron with a compound that modulates a biol. pathway or a target described herein. The compds. that modulate the biol. pathway or target described herein can be a small mols., peptides, antibodies, antibody fragments, peptidomimetics (e.g., peptoids), amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorg. compds. etc.			
IT	676596-65-9 RL: PAC (Pharmacological activity); PRPH (Prophetic); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (methods and motor neuron survival-promoting compds. for treatment of neurodegenerative disorders)			
RN	676596-65-9 CAPLUS			
CN	Pyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one, 9-bromo-7,12-dihydro- (CA INDEX NAME)			

10/565,702



L28 ANSWER 3 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2010:507048 CAPLUS
 DOCUMENT NUMBER: 152:496169
 TITLE: Methods and compositions for stem cell self-renewal,
 particularly hematopoietic stem cell (HSC), by
 modulating Wnt pathway
 INVENTOR(S): Perry, John M.; Li, Linheng; Grindley, Justin C.
 PATENT ASSIGNEE(S): Stowers Institute for Medical Research, USA
 SOURCE: U.S. Pat. Appl. Publ., 85pp., Cont.-in-part of Appl.
 No. PCT/US2008/005230.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20100099186	A1	20100422	US 2009-589551	20091023
WO 2008133904	A1	20081106	WO 2008-US5230	20080423
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRIORITY APPLN. INFO.:			US 2007-926065P	P 20070423
			US 2008-66693P	P 20080222
			WO 2008-US5230	A2 20080423

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


- AB The present invention relates to methods and kits for expanding a stem cell population using a modulator of the Wnt pathway. More particularly, the invention relates, inter alia, to methods, kits, and compns. for expanding a stem cell population, particularly a hematopoietic stem cell population, in a population of mononuclear cells. The kit comprises a GSK-3 β (glycogen synthase kinase 3 β) inhibitor, and instructions for the use of the inhibitor. It was demonstrated, that loss of PTEN with constitutively active β -catenin leads to HSC expansion with loss of early hematopoietic progenitors. It was also demonstrated, that ex vivo pharmacol. manipulation of the PTEN/Akt and Wnt/ β -catenin signaling pathways cooperatively drive functional HSC expansion. Bone marrow cells harvested from C57BI/6 (CD45.2) mice were cultured in a HSC expansion media that included CHIR99021, a reversible small mol. inhibitor of GSK-3 β . After 14 days, cultured cells were transplanted into lethally irradiated mice. Ex vivo expansion in the presence of CHIR99021 substantially increased the level of longterm, multilineage engraftment and the longterm survival of the recipients.
- IT 676596-65-9, 1-Azakenpaulone
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (as reversible GSK-3 β inhibitor; methods and compns. for stem cell

10/565,702

self-renewal, particularly hematopoietic stem cells (HSCs), by
modulating Wnt pathway with GSK-3 β inhibitors)

RN 676596-65-9 CAPLUS

CN Pyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one, 9-bromo-7,12-dihydro- (CA
INDEX NAME)




L28 ANSWER 4 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:1165454 CAPLUS
 DOCUMENT NUMBER: 151:396147
 TITLE: Benzazepine compound conivaptan derivatives,
 compositions, and therapeutic use
 INVENTOR(S): Liu, Julie F.; Persichetti, Rose A.
 PATENT ASSIGNEE(S): Concert Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009117144	A1	20090924	WO 2009-US1767	20090320
WO 2009117144	A9	20091230		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2008-70075P P 20080320
 OTHER SOURCE(S): MARPAT 151:396147
 GI



I

AB The invention discloses compds. that are benzazepines derivs. and pharmaceutically acceptable salts thereof. More specifically, the invention discloses benzazepines derivs. that are derivs. of conivaptan. Compds. of the invention include I (Z1a, Z1b, Z2a, Z2b = H, D; R1 = CD3, CH2D, CD3, provided that when R1 is CH3 at least one Z is D). The invention also provides compns. comprising one or more compds. of the invention and a carrier, as well as the use of the compds. and compns. in methods for treating diseases and conditions that are beneficially treated by administering a dual antagonist of arginine vasopressin (AVP) V1A and V2 receptors, e.g. conivaptan.

IT 1129433-64-2 1129433-66-4 1187823-44-4
 1187823-45-5 1187823-46-6 1187823-47-7
 1187823-48-8 1187823-49-9 1187823-50-2
 1187823-51-3 1187823-52-4 1187823-53-5
 1187823-54-6


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(Benzazepine compound conivaptan derivs., compns., and therapeutic use)

RN 1129433-64-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(methyl-d3)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1129433-66-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-4,5-d2-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl-4,5-d2]carbonyl]phenyl]- (CA INDEX NAME)



RN 1187823-44-4 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-4,5-d2-2-(methyl-d3)imidazo[4,5-d][1]benzazepin-6(1H)-yl-4,5-d2]carbonyl]phenyl]- (CA INDEX NAME)



RN 1187823-45-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-4-d-2-(methyl-d3)imidazo[4,5-d][1]benzazepin-6(1H)-yl-4-d]carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1187823-46-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-5-d-2-(methyl-d₃)imidazo[4,5-d][1]benzazepin-6(1H)-yl-5-d]carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1187823-47-7 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-4-d-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl-4-d)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1187823-48-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-5-d-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl-5-d)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1187823-49-9 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-([4-([4,5-dihydro-4-d-2-(methyl-
 d)imidazo[4,5-d][1]benzazepin-6(1H)-yl-4-d]carbonyl)phenyl]- (CA INDEX
 NAME)

PAGE 1-A




PAGE 2-A



RN 1187823-50-2 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-([4-([4,5-dihydro-5-d-2-(methyl-d)imidazo[4,5-d][1]benzazepin-6(1H)-yl-5-d]carbonyl)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1187823-51-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(methyl-d)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1187823-52-4 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-([4-[[4,5-dihydro-4,5-d2-2-(methyl-
 d2)imidazo[4,5-d][1]benzazepin-6(1H)-yl-4,5-d2]carbonyl]phenyl]- (CA
 INDEX NAME)



RN 1187823-53-5 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-4-d-2-(methyl-
 d2)imidazo[4,5-d][1]benzazepin-6(1H)-yl-4-d]carbonyl]phenyl]- (CA INDEX
 NAME)

PAGE 1-A




PAGE 2-A



RN 1187823-54-6 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-5-d-2-(methyl-
 d2)imidazo[4,5-d][1]benzazepin-6(1H)-yl-5-d]carbonyl]phenyl]- (CA INDEX
 NAME)

PAGE 1-A




PAGE 2-A




L28 ANSWER 5 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:1050008 CAPLUS
 DOCUMENT NUMBER: 151:236777
 TITLE: FXR agonists for treating vitamin D associated diseases
 INVENTOR(S): Harnish, Douglas
 PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
 SOURCE: U.S. Pat. Appl. Publ., 53pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090215748	A1	20090827	US 2008-318039	20081219
PRIORITY APPLN. INFO.:			US 2007-8307P	P 20071220
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
AB	Provided are certain methods of treating at least one condition that can be treated by elevating the vitamin D receptor (VDR) activity level in a patient with at least one farnesoid X receptor (FXR) agonist. Also provided are certain methods of modulating levels of Cytochrome P 450, family 27, subfamily B, polypeptide 1 (CYP27B1) and 1 α ,25-dihydroxyvitamin D3 in cells, certain methods of modulating VDR activity levels, certain methods of modulating levels of an extracellular matrix protein, renin angiotensin system (RAS) pathway, parathyroid hormone, serum creatinine, serum albumin, proteinuria, lipid metabolism, renal lipid deposition, mesangial expansion, glomerulosclerosis, kidney inflammation, blood pressure, bone resorption, and bone formation, certain methods of identifying FXR modulators, certain methods of diagnosing the risk that a patient will develop at least one condition that can be treated by elevating the VDR activity level, and certain methods of characterizing the levels of FXR activity in mammals.			
IT	629664-83-1	837429-85-3	837429-86-4	
	837429-88-6	837429-90-0,		
	6-(3,4-Difluoro-benzoyl)-4,4-dimethyl-5,6-dihydro-4H-thieno[2,3-d]azepine-8-carboxylic acid ethyl ester	837429-91-1		
	837429-92-2	837429-93-3	847865-38-7	
	847865-39-8	847865-40-1	1088713-88-5	
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (FXR agonists for treating vitamin D associated diseases)			
RN	629664-83-1	CAPLUS		
CN	Spiro[azepino[4,5-b]indole-1(2H),1'-cyclopentane]-5-carboxylic acid, 3-(3,4-difluorobenzoyl)-3,6-dihydro-, ethyl ester (CA INDEX NAME)			




RN 837429-85-3 CAPLUS
 CN Imidazo[4,5-d]azepine-4-carboxylic acid,
 6-(4-fluorobenzoyl)-3,6,7,8-tetrahydro-, ethyl ester (CA INDEX NAME)




RN 837429-86-4 CAPLUS
 CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid,
 6-(3,4-difluorobenzoyl)-5,6-dihydro-, ethyl ester (CA INDEX NAME)




RN 837429-88-6 CAPLUS
 CN Azepino[4,5-b]indole-5-carboxylic acid,
 3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-, ethyl ester (CA INDEX
 NAME)




RN 837429-90-0 CAPLUS
 CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid,
 6-(3,4-difluorobenzoyl)-5,6-dihydro-4,4-dimethyl-, ethyl ester (CA INDEX
 NAME)



RN 837429-91-1 CAPLUS
 CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-diethyl
 ester (CA INDEX NAME)




RN 837429-92-2 CAPLUS
 CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2-ethyl
 8-(1-methylethyl) ester (CA INDEX NAME)




RN 837429-93-3 CAPLUS

CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-1,4,4-trimethyl-, 2-ethyl
8-(1-methylethyl) ester (CA INDEX NAME)




RN 847865-38-7 CAPLUS

CN Spiro[azepino[4,5-b]indole-1(2H),1'-cyclobutane]-5-carboxylic acid,
3-(3,4-difluorobenzoyl)-3,6-dihydro-, ethyl ester (CA INDEX NAME)




RN 847865-39-8 CAPLUS

CN Spiro[azepino[4,5-b]indole-1(2H),1'-cyclopropane]-5-carboxylic acid,
3-(3,4-difluorobenzoyl)-3,6-dihydro-, ethyl ester (CA INDEX NAME)




RN 847865-40-1 CAPLUS

CN Spiro[azepino[4,5-b]indole-1(2H),1'-cyclopropane]-5-carboxylic acid,
3-(3,4-difluorobenzoyl)-3,6-dihydro-, 1-methylethyl ester (CA INDEX NAME)



RN 1088713-88-5 CAPLUS

CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-dimethyl
ester (CA INDEX NAME)




OS.CITING REF COUNT: 1

THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)


L28 ANSWER 6 OF 96 CAPLUS COPYRIGHT 2010 ACS ON STN
 ACCESSION NUMBER: 2009:769550 CAPLUS
 DOCUMENT NUMBER: 151:94051
 TITLE: Farnesoid X receptor (FXR) agonists for the treatment of nonalcoholic fatty liver and cholesterol gallstone diseases
 INVENTOR(S): Zhang, Songwen; Harnish, Douglas; Evans, Mark J.; Wang, Juan
 PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
 SOURCE: U.S. Pat. Appl. Publ., 61pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090163474	A1	20090625	US 2008-253010	20081016
PRIORITY APPLN. INFO.:			US 2007-960925P	P 20071019
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
AB The invention provides methods for treating nonalcoholic fatty liver disease with farnesoid X receptor (FXR) agonists. The invention also provides methods for modulating levels of keratinocyte-derived chemokine (KC), alanine aminotransferase (ALT), aspartate aminotransferase (AST), cytokeratin 18 (CK-18), matrix metalloproteinase-9 (MMP-9), matrix metalloproteinase-14 (MMP-14), tissue inhibitor of metalloproteinase 1 (TIMP-1), and Cytochrome P 450 2E1 (CYP2E1); methods for identifying FXR modulators; and methods for treating patients with existing cholesterol gallstone disease.				
IT 629664-83-1	837429-85-3	837429-86-4		
837429-89-7	837429-90-0	837429-91-1		
837429-92-2	837429-93-3	847865-38-7		
847865-39-8	847865-40-1	1088713-88-5		
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (FXR agonist for treatment of nonalcoholic fatty liver and cholesterol gallstone disease)				
RN 629664-83-1	CAPLUS			
CN Spiro[azepino[4,5-b]indole-1(2H),1'-cyclopentane]-5-carboxylic acid, 3-(3,4-difluorobenzoyl)-3,6-dihydro-, ethyl ester (CA INDEX NAME)				




RN 837429-85-3 CAPLUS
 CN Imidazo[4,5-d]azepine-4-carboxylic acid,


6-(4-fluorobenzoyl)-3,6,7,8-tetrahydro-, ethyl ester (CA INDEX NAME)



RN 837429-86-4 CAPLUS


CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid,
6-(3,4-difluorobenzoyl)-5,6-dihydro-, ethyl ester (CA INDEX NAME)

RN 837429-89-7 CAPLUS

CN Azepino[4,5-b]indole-5-carboxylic acid,
3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-1,1-dimethyl-, ethyl ester
(CA INDEX NAME)


RN 837429-90-0 CAPLUS

CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid,
6-(3,4-difluorobenzoyl)-5,6-dihydro-4,4-dimethyl-, ethyl ester (CA INDEX
NAME)




RN 837429-91-1 CAPLUS

CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-diethyl
ester (CA INDEX NAME)




RN 837429-92-2 CAPLUS

CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2-ethyl
8-(1-methylethyl) ester (CA INDEX NAME)




RN 837429-93-3 CAPLUS

CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-1,4,4-trimethyl-, 2-ethyl
8-(1-methylethyl) ester (CA INDEX NAME)



RN 1088713-88-5 CAPLUS

CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-dimethyl
ester (CA INDEX NAME)




OS.CITING REF COUNT: 1

THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L28 ANSWER 7 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:647976 CAPLUS
 DOCUMENT NUMBER: 151:1373
 TITLE: 1,4,5,6-Tetrahydropyrrolo[2,3-d]azepines AND
 -imidazo[4,5-d]azepines as modulators of nuclear
 receptor activity
 INVENTOR(S): Mehlmann, John Francis; Lundquist, Joseph Theodore,
 IV; Mahaney, Paige Erin; Crawley, Matthew Lantz; Kim,
 Callain Younghee
 PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
 SOURCE: U.S. Pat. Appl. Publ., 26pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090137554	A1	20090528	US 2008-255216	20081021
PRIORITY APPLN. INFO.:			US 2007-999990P	P 20071022
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):		MARPAT 151:1373		

GI



AB Disclosed are chemical entities including compds. of Formula (I and pharmaceutically acceptable salts thereof, wherein X is chosen from CN, CF3, CF2H, S(O)nR8, and S(O)2N(R9)R10; n is 1, 2 or 3; Y is chosen from CR11 and N; Z is chosen from O and NH; R1 is chosen from optionally substituted alkyl, cycloalkyl, etc.; R2 is H or optionally substituted alkyl; R3 is chosen from -C(O)R12 and -C(O)N(R9)R10; R4, R5, R6 and R7 are independently chosen from H and optionally substituted alkyl; R8 is chosen from optionally substituted alkyl or cycloalkyl; R9 and R10 is chosen from H or optionally substituted aryl or heteroaryl, etc.; R11 is H or lower alkyl; R12 is H, optionally substituted aryl or heteroaryl, etc.); compns. comprising one or more such chemical entities; and methods of using one or more such chemical entities for modulating the activity of certain nuclear receptors (e.g., farnesoid X) or for the treatment or prevention of one or more symptoms of disease or disorder related to the activity of those receptors.

IT	1158716-04-1P	1158716-05-2P	1158716-06-3P
	1158716-07-4P	1158716-08-5P	1158716-09-6P

1158716-10-9P 1158716-11-0P 1158716-12-1P


1158716-13-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(tetrahydropyrroloazepines and -imidazoazepines as modulators of farnesoid X receptors for disease treatment)


RN 1158716-04-1 CAPLUS

CN Pyrrolo[2,3-d]azepine-8-carboxylic acid,
2-cyano-6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-,
1-methylethyl ester (CA INDEX NAME)




RN 1158716-05-2 CAPLUS

CN Pyrrolo[2,3-d]azepine-8-carboxylic acid,
2-cyano-6-(cyclohexylcarbonyl)-1,4,5,6-tetrahydro-4,4-dimethyl-,
1-methylethyl ester (CA INDEX NAME)




RN 1158716-06-3 CAPLUS

CN Pyrrolo[2,3-d]azepine-8-carboxylic acid,
2-cyano-6-(3-fluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-,
1-methylethyl ester (CA INDEX NAME)




RN 1158716-07-4 CAPLUS

CN Pyrrolo[2,3-d]azepine-8-carboxylic acid,
2-cyano-6-(4-fluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-
1-methylethyl ester (CA INDEX NAME)




RN 1158716-08-5 CAPLUS

CN Pyrrolo[2,3-d]azepine-8-carboxylic acid,
2-cyano-6-(4-cyanobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl- 1-methylethyl
ester (CA INDEX NAME)




RN 1158716-09-6 CAPLUS

CN Pyrrolo[2,3-d]azepine-8-carboxylic acid,
6-(3-chlorobenzoyl)-2-cyano-1,4,5,6-tetrahydro-4,4-dimethyl-
1-methylethyl ester (CA INDEX NAME)




RN 1158716-10-9 CAPLUS

CN Pyrrolo[2,3-d]azepine-8-carboxylic acid,
2-cyano-1,4,5,6-tetrahydro-4,4-dimethyl-6-(2-thienylcarbonyl)-,
1-methylethyl ester (CA INDEX NAME)




RN 1158716-11-0 CAPLUS

CN Pyrrolo[2,3-d]azepine-8-carboxylic acid,
2-cyano-1,4,5,6-tetrahydro-4,4-dimethyl-6-[3-(trifluoromethyl)benzoyl]-,
1-methylethyl ester (CA INDEX NAME)




RN 1158716-12-1 CAPLUS

CN Pyrrolo[2,3-d]azepine-8-carboxylic acid,
2-cyano-1,4,5,6-tetrahydro-4,4-dimethyl-6-[(tetrahydro-2H-pyran-4-yl)carbonyl]-, 1-methylethyl ester (CA INDEX NAME)



RN 1158716-13-2 CAPLUS

CN Spiro[4H-pyran-4,4'(1'H)-pyrrolo[2,3-d]azepine]-8'-carboxylic acid,
2'-cyano-6'-(3,4-difluorobenzoyl)-2,3,5',6,6'-hexahydro-, 1-methylethyl
ester (CA INDEX NAME)




IT 1155659-03-2P 1158716-22-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(tetrahydropyrroloazepines and -imidazoazepines as modulators of
farnesoid X receptors for disease treatment)

RN 1155659-03-2 CAPLUS

CN Pyrrolo[2,3-d]azepine-8-carboxylic acid,
2-cyano-1,4,5,6-tetrahydro-4,4-dimethyl-, 1-methylethyl ester (CA INDEX
NAME)




RN 1158716-22-3 CAPLUS

CN Spiro[4H-pyran-4,4'(1'H)-pyrrolo[2,3-d]azepine]-8'-carboxylic acid,

10/565,702

2'-cyano-2,3,5,5',6,6'-hexahydro-, 1-methylethyl ester (CA INDEX NAME)




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L28 ANSWER 8 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:615712 CAPLUS
 DOCUMENT NUMBER: 150:555909
 TITLE: 1,4,5,6,7,8-Hexahydro-pyrrolo[2,3-d]azepines and
 -imidazo[4,5-d]azepines as modulators of nuclear
 receptor activity
 INVENTOR(S): Mehlmann, John Francis; Lundquist, Joseph Theodore,
 IV; Mahaney, Paige Erin; Crawley, Matthew Lantz; Kim,
 Callain Younghee
 PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
 SOURCE: U.S. Pat. Appl. Publ., 25pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090131409	A1	20090521	US 2008-255232	20081021
PRIORITY APPLN. INFO.:			US 2007-11P	P 20071022
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):		MARPAT 150:555909		

GI



AB Disclosed are chemical entities including compds. of Formula (I and pharmaceutically acceptable salts thereof, wherein X is chosen from CN, CF₃, CF₂H, S(O)nR₈, and S(O)2N(R₉)R₁₀; n is 1, 2 or 3; Y is chosen from CR₁₁ and N; Z is chosen from O and NH; R₁ is chosen from optionally substituted alkyl, cycloalkyl, etc.; R₂ is H or optionally substituted alkyl; R₃ is chosen from -C(O)R₁₂ and -C(O)N(R₉)R₁₀; R₄, R₅, R₆ and R₇ are independently chosen from H and optionally substituted alkyl; R₈ is chosen from optionally substituted alkyl or cycloalkyl; R₉ and R₁₀ is chosen from H or optionally substituted aryl or heteroaryl, etc.; R₁₁ is H or lower alkyl; R₁₂ is H, optionally substituted aryl or heteroaryl, etc.); compns. comprising one or more such chemical entities; and methods of using one or more such chemical entities for modulating the activity of certain nuclear receptors (e.g., farnesoid X) or for the treatment or prevention of one or more symptoms of disease or disorder related to the activity of those receptors.


IT 1155659-03-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(hexahydro-pyrroloazepines and -imidazoazepines as modulators of
farnesoid X receptor activity for treatment of disease)

RN 1155659-03-2 CAPLUS

CN Pyrrolo[2,3-d]azepine-8-carboxylic acid,
2-cyano-1,4,5,6-tetrahydro-4,4-dimethyl-, 1-methylethyl ester (CA INDEX
NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L28 ANSWER 9 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:292039 CAPLUS
 DOCUMENT NUMBER: 150:298942
 TITLE: Deuterium-enriched conivaptan
 INVENTOR(S): Czarnik, Anthony W.
 PATENT ASSIGNEE(S): Protia, LLC, USA
 SOURCE: U.S. Pat. Appl. Publ., 11pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090069295	A1	20090312	US 2008-196330	20080822
PRIORITY APPLN. INFO.:			US 2007-970983P	P 20070909

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 150:298942

AB The present application describes deuterium-enriched conivaptan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.

IT 1129433-59-5 1129433-60-8 1129433-61-9
 1129433-62-0 1129433-63-1 1129433-64-2
 1129433-65-3 1129433-66-4


RL: PRPH (Prophetic); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(deuterium-enriched conivaptan for treatment of hyponatremia)


RN 1129433-59-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1129433-60-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A



RN 1129433-61-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A



RN 1129433-62-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A



RN 1129433-63-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A



RN 1129433-64-2 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(methyl-d3)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1129433-65-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A



PAGE 2-A




RN 1129433-66-4 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-4,5-d2-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl-4,5-d2)carbonyl]phenyl]- (CA INDEX NAME)




L28 ANSWER 10 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2008:1457368 CAPLUS
 DOCUMENT NUMBER: 150:16134
 TITLE: Farnesoid X receptor (FXR) agonists for reducing
 lectin-like oxidized low-density lipoprotein receptor
 1 (LOX-1) expression, and therapeutic use
 INVENTOR(S): Harnish, Douglas; Zhang, Songwen
 PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
 SOURCE: U.S. Pat. Appl. Publ., 26pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080300235	A1	20081204	US 2008-130322	20080530
PRIORITY APPLN. INFO.:			US 2007-924822P	P 20070601
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
AB	The invention provides methods for treating at least one disease state characterized by elevated expression of the lectin-like oxidized low-d. lipoprotein receptor 1 (LOX-1) in a patient with farnesoid X receptor (FXR) agonists. Also provided are methods for reducing expression of LOX-1 in a cell with FXR agonists.			
IT	629664-83-1	837429-85-3,		
	6-(4-Fluorobenzoyl)-3,6,7,8-tetrahydroimidazo(4,5-d)azepine-4-carboxylic acid ethyl ester 837429-86-4,			
	6-(3,4-Difluorobenzoyl)-5,6-dihydro-4H-thieno(2,3-d)azepine-8-carboxylic acid ethyl ester 837429-88-6,			
	3-(4-Fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydroazepino[4,5-b]indole-5-carboxylic acid ethyl ester 837429-89-7,			
	3-(4-Fluorobenzoyl)-1,1-dimethyl-1,2,3,6,7,8,9,10-octahydroazepino[4,5-b]indole-5-carboxylic acid ethyl ester 837429-90-0			
	837429-91-1, 6-(3,4-Difluorobenzoyl)-4,4-dimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid diethyl ester 837429-92-2			
	837429-93-3 847865-38-7			
	847865-39-8 847865-40-1 1088713-88-5			
RL:	PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
	(FXR agonists for reducing LOX-1 expression, and therapeutic use)			
RN	629664-83-1 CAPLUS			
CN	Spiro[azepino[4,5-b]indole-1(2H),1'-cyclopentane]-5-carboxylic acid, 3-(3,4-difluorobenzoyl)-3,6-dihydro-, ethyl ester (CA INDEX NAME)			




RN 837429-85-3 CAPLUS

CN Imidazo[4,5-d]azepine-4-carboxylic acid,
6-(4-fluorobenzoyl)-3,6,7,8-tetrahydro-, ethyl ester (CA INDEX NAME)




RN 837429-86-4 CAPLUS

CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid,
6-(3,4-difluorobenzoyl)-5,6-dihydro-, ethyl ester (CA INDEX NAME)




RN 837429-88-6 CAPLUS

CN Azepino[4,5-b]indole-5-carboxylic acid,
3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-, ethyl ester (CA INDEX NAME)




RN 837429-89-7 CAPLUS


CN Azepino[4,5-b]indole-5-carboxylic acid,
3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-1,1-dimethyl-, ethyl ester
(CA INDEX NAME)




RN 837429-90-0 CAPLUS
 CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid,
 6-(3,4-difluorobenzoyl)-5,6-dihydro-4,4-dimethyl-, ethyl ester (CA INDEX
 NAME)



RN 837429-91-1 CAPLUS
 CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-diethyl
 ester (CA INDEX NAME)




RN 837429-92-2 CAPLUS
 CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2-ethyl
 8-(1-methylethyl) ester (CA INDEX NAME)




RN 837429-93-3 CAPLUS

CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-1,4,4-trimethyl-, 2-ethyl
8-(1-methylethyl) ester (CA INDEX NAME)




RN 847865-38-7 CAPLUS

CN Spiro[azepino[4,5-b]indole-1(2H),1'-cyclobutane]-5-carboxylic acid,
3-(3,4-difluorobenzoyl)-3,6-dihydro-, ethyl ester (CA INDEX NAME)




RN 847865-39-8 CAPLUS

CN Spiro[azepino[4,5-b]indole-1(2H),1'-cyclopropane]-5-carboxylic acid,
3-(3,4-difluorobenzoyl)-3,6-dihydro-, ethyl ester (CA INDEX NAME)




RN 847865-40-1 CAPLUS

CN Spiro[azepino[4,5-b]indole-1(2H),1'-cyclopropane]-5-carboxylic acid,
3-(3,4-difluorobenzoyl)-3,6-dihydro-, 1-methylethyl ester (CA INDEX NAME)



RN 1088713-88-5 CAPLUS

CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-dimethyl
ester (CA INDEX NAME)



OS.CITING REF COUNT: 1

THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L28 ANSWER 11 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2008:1455334 CAPLUS
 DOCUMENT NUMBER: 150:16058
 TITLE: FXR agonists for the treatment of malignancies
 INVENTOR(S): Hartman, Helen B.; Evans, Mark J.
 PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
 SOURCE: U.S. Pat. Appl. Publ., 25pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080299118	A1	20081204	US 2008-130221	20080530
PRIORITY APPLN. INFO.:			US 2007-924823P	P 20070601

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


AB Provided are certain methods of treating malignancies with farnesoid X receptor agonists. Also provided are certain methods of inducing RECK gene expression with farnesoid X receptor agonists and methods of reducing at least one feature of a cell with farnesoid X receptor agonists.

IT 629664-83-1 837429-85-3,
 6-(4-Fluorobenzoyl)-3,6,7,8-tetrahydroimidazo[4,5-D]azepine-4-carboxylic acid ethyl ester 837429-86-4,
 6-(3,4-Difluorobenzoyl)-5,6-dihydro-4H-thieno[2,3-D]azepine-8-carboxylic acid ethyl ester 837429-88-6,
 3-(4-Fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydroazepino[4,5-b]indole-5-carboxylic acid ethyl ester 837429-89-7,
 3-(4-Fluorobenzoyl)-1,1-dimethyl-1,2,3,6,7,8,9,10-octahydroazepino[4,5-b]indole-5-carboxylic acid ethyl ester 837429-90-0,
 6-(3,4-Difluorobenzoyl)-4,4-dimethyl-5,6-dihydro-4H-thieno[2,3-d]azepine-8-carboxylic acid ethyl ester 837429-91-1,
 6-(3,4-Difluorobenzoyl)-4,4-dimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid diethyl ester 837429-92-2
 837429-93-3 847865-38-7 847865-39-8
 847865-40-1 1088713-88-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (farnesoid X receptor agonists for treatment of malignancies by inducing RECK gene expression)


RN 629664-83-1 CAPLUS

CN Spiro[azepino[4,5-b]indole-1(2H),1'-cyclopentane]-5-carboxylic acid, 3-(3,4-difluorobenzoyl)-3,6-dihydro-, ethyl ester (CA INDEX NAME)




RN 837429-85-3 CAPLUS

CN Imidazo[4,5-d]azepine-4-carboxylic acid,
6-(4-fluorobenzoyl)-3,6,7,8-tetrahydro-, ethyl ester (CA INDEX NAME)




RN 837429-86-4 CAPLUS

CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid,
6-(3,4-difluorobenzoyl)-5,6-dihydro-, ethyl ester (CA INDEX NAME)




RN 837429-88-6 CAPLUS

CN Azepino[4,5-b]indole-5-carboxylic acid,
3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-, ethyl ester (CA INDEX NAME)




RN 837429-89-7 CAPLUS


CN Azepino[4,5-b]indole-5-carboxylic acid,
3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-1,1-dimethyl-, ethyl ester
(CA INDEX NAME)




RN 837429-90-0 CAPLUS
 CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid,
 6-(3,4-difluorobenzoyl)-5,6-dihydro-4,4-dimethyl-, ethyl ester (CA INDEX
 NAME)



RN 837429-91-1 CAPLUS
 CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-diethyl
 ester (CA INDEX NAME)




RN 837429-92-2 CAPLUS
 CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2-ethyl
 8-(1-methylethyl) ester (CA INDEX NAME)




RN 837429-93-3 CAPLUS

CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-1,4,4-trimethyl-, 2-ethyl
8-(1-methylethyl) ester (CA INDEX NAME)




RN 847865-38-7 CAPLUS

CN Spiro[azepino[4,5-b]indole-1(2H),1'-cyclobutane]-5-carboxylic acid,
3-(3,4-difluorobenzoyl)-3,6-dihydro-, ethyl ester (CA INDEX NAME)




RN 847865-39-8 CAPLUS

CN Spiro[azepino[4,5-b]indole-1(2H),1'-cyclopropane]-5-carboxylic acid,
3-(3,4-difluorobenzoyl)-3,6-dihydro-, ethyl ester (CA INDEX NAME)




RN 847865-40-1 CAPLUS

CN Spiro[azepino[4,5-b]indole-1(2H),1'-cyclopropane]-5-carboxylic acid,
3-(3,4-difluorobenzoyl)-3,6-dihydro-, 1-methylethyl ester (CA INDEX NAME)



RN 1088713-88-5 CAPLUS

CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-dimethyl
ester (CA INDEX NAME)



OS.CITING REF COUNT: 1

THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L28 ANSWER 12 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:1339565 CAPLUS

DOCUMENT NUMBER: 149:509677

TITLE: Methods and compositions for stem cell self-renewal, particularly hematopoietic stem cell (HSC), by modulating PTEN and Wnt pathways

INVENTOR(S): Perry, John M.; Li, Linheng; Grindley, Justin C.

PATENT ASSIGNEE(S): Stowers Institute for Medical Research, USA

SOURCE: PCT Int. Appl., 110pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008133904	A1	20081106	WO 2008-US5230	20080423
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 2148569	A1	20100203	EP 2008-743210	20080423
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS			
JP 2010524499	T	20100722	JP 2010-506243	20080423
US 20100099186	A1	20100422	US 2009-589551	20091023
US 20100196337	A1	20100805	US 2010-451038	20100405
PRIORITY APPLN. INFO.:			US 2007-926065P	P 20070423
			US 2008-66693P	P 20080222
			WO 2008-US5230	W 20080423

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention relates to methods for expanding a stem cell population without significant stem cell differentiation by modulating a PTEN phosphatase pathway and a Wnt pathway. More particularly, the invention relates, to methods and compns. for expanding a stem cell population, particularly a hematopoietic stem cell (HSC) population obtained from peripheral blood, cord blood, or bone marrow. The expanded HSC population comprises cells with a phenotype consisting of CD34-, CD34+/CD38-Thy1+/CD90+/Kit-/Lin-/CD133+/VEGFR2+, CD150+/CD48-/CD244-, CD150-/CD48-/CD244+, CD150-/CD48+/CD244+, and combinations thereof. In one embodiment the invention provides a kit for expanding HSC population for subsequent transplantation into a patient in need thereof. The kit comprises a PTEN inhibitor, a GSK-3 β (glycogen synthase kinase 3 β) inhibitor, and instructions for the use of the inhibitors. It was demonstrated, that loss of PTEN with constitutively active β -catenin leads to HSC expansion with loss of early hematopoietic progenitors. It was also demonstrated, that ex vivo pharmacol.

manipulation of the PTEN/Akt and Wnt/ β -catenin signaling pathways cooperatively drive functional HSC expansion.


IT 676596-65-9, 1-Azakenpauellone

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(reversible GSK-3 β inhibitor; methods and compns. for stem cell self-renewal, particularly hematopoietic stem cell (HSC), by modulating PTEN and Wnt pathways)

RN 676596-65-9 CAPLUS

CN Pyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one, 9-bromo-7,12-dihydro- (CA INDEX NAME)



REFERENCE COUNT:


7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 13 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2008:1218777 CAPLUS
 DOCUMENT NUMBER: 149:458368
 TITLE: Photosensitive material composition for lithographic
 printing plate precursors and method for image
 formation on the same
 INVENTOR(S): Ishiji, Yohei; Matsushita, Tetsunori
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 37pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2008242241	A	20081009	JP 2007-85012	20070328
PRIORITY APPLN. INFO.:			JP 2007-85012	20070328
OTHER SOURCE(S):		MARPAT 149:458368		


GI




I

AB The title composition contains hexaarylbiimidazole, a chemical sensitizer dye
 of 350-850 nm maximum absorption, and ethylenic unsatd. polymerizable compds.,
 wherein the hexaarylbiimidazole has general structure I (R1-3,5-7 =
 mono-valent non-metallic group; R4,8 = di-valent non-metallic group; l,m,n
 = integer 0-5). The composition shows good storageability and provides
 printing plate precursor showing high sensitivity short-wavelength
 semiconductor laser beams.
 IT 1068163-76-7 1068163-78-9
 RL: TEM (Technical or engineered material use); USES (Uses)
 (hexaarylbiimidazole in photosensitive material composition for lithog.
 printing plate precursors)
 RN 1068163-76-7 CAPLUS
 CN 1 (8H), 2'-Bidibenz[b,f]imidazo[4,5-d]azepine,
 2,2'-bis(2-chlorophenyl)-2',8'-dihydro-8,8'-dimethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1068163-78-9 CAPLUS
 CN 1(8H),2'-Bidibenz[b,f]imidazo[4,5-d]azepine,
 2,2'-bis(2-chloro-4-methoxyphenyl)-2',8'-dihydro-8,8'-dimethyl- (CA INDEX
 NAME)

PAGE 1-A



PAGE 2-A



L28 ANSWER 14 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:977734 CAPLUS

DOCUMENT NUMBER: 149:285597

TITLE: Inducing the differentiation of stem cells into cardiovascular progenitor cells by modulation of the Wnt signaling pathway

INVENTOR(S): Chien, Kenneth R.; Qyang, Yibing; Martin-Puig, Silvia

PATENT ASSIGNEE(S): The General Hospital Corporation, USA

SOURCE: PCT Int. Appl., 139pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008098184	A2	20080814	WO 2008-US53449	20080208
WO 2008098184	A3	20081120		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW,			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
JP 2010517578	T	20100527	JP 2009-549261	20080208
EP 2222837	A2	20100901	EP 2008-729415	20080208
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR			

PRIORITY APPLN. INFO.:

US 2007-900496P P 20070209

WO 2008-US53449 W 20080208

AB Methods of inducing stem cells to differentiate and enter the Islet 1+ (Isl1+) lineage that leads to the development of cardiovascular tissue is described. These cells that have entered the Isl1+ lineage can then be induced to enter endothelial, smooth muscle, or cardiac lineages. The differentiation can be brought about by either activating or inhibiting Wnt-dependent signal transduction pathways. Cells are induced to enter the pathway by inhibiting Wnt-dependent signaling, and cells that have entered the pathway can be induced to expand by activating Wnt signaling. Another aspect of the present invention relates to use of cells of the Isl1+ lineage in subjects for therapeutic and preventative treatment of cardiovascular diseases.

IT 676596-65-9D, 1-Azakenpallone, analogs

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)


(for regulation of cell differentiation; inducing differentiation of stem cells into cardiovascular progenitor cells by modulation of Wnt signaling pathway)

RN 676596-65-9 CAPLUS

CN Pyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one, 9-bromo-7,12-dihydro- (CA

10/565,702


INDEX NAME)



L28 ANSWER 15 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2008:946469 CAPLUS
 DOCUMENT NUMBER: 149:215928
 TITLE: Drosophila models for diseases affecting learning and memory
 INVENTOR(S): McBride, Sean M.J.; Jongens, Thomas A.; Choi, Catherine H.
 PATENT ASSIGNEE(S): Yeshiva University, USA
 SOURCE: U.S. Pat. Appl. Publ., 65 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080187492	A1	20080807	US 2007-578077	20071001
WO 2005104836	A3	20060526	WO 2005-US12543	20050414
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2004-562922P	P 20040416
			WO 2005-US12543	W 20050414
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
AB	Methods of evaluating a compound for the ability to reduce a mental defect in a metazoan are provided, where the mental defect is caused by Fragile X syndrome, a tauopathy, Huntington's disease, neurofibromatosis 1, or Parkinson's disease. The methods comprise determining whether the compound reduces a mental effect of the analogous disease in a Drosophila melanogaster. Also provided are methods of evaluating a compound for the ability to improve learning or memory in a mammal. The methods comprise determining whether the compound improves learning or memory in a Drosophila melanogaster that is deficient in a dFRM1. Addnl., methods of treatment of a mammal deficient in expression of an FMR1 gene are provided. The methods comprise treating the mammal with a compound in a pharmaceutically acceptable excipient, where the compound inhibits expression or activity of a group II or group I metabotropic glutamate receptor (mGluR), an inositol trisphosphate receptor (InsP3R), a glycogen synthase kinase-3 β (GSK-3 β), or a phosphodiesterase-4 (PDE-4) in the mammal.			
IT	676596-65-9, 1-Azakenpauillone RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Drosophila models for screening drugs for diseases affecting learning and memory)			
RN	676596-65-9 CAPLUS			
CN	Pyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one, 9-bromo-7,12-dihydro- (CA INDEX NAME)			

10/565,702



OS.CITING REF COUNT:

1

THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L28 ANSWER 16 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2008:946238 CAPLUS
 DOCUMENT NUMBER: 149:231486
 TITLE: Modulation of neurogenesis with biguanides and GSK3- β agents
 INVENTOR(S): Barlow, Carrolee; Carter, Todd; Morse, Andrew; Treuner, Kai; Lorrain, Kym I.
 PATENT ASSIGNEE(S): Braincells, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 43pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080188457	A1	20080807	US 2008-24923	20080201
WO 2008097861	A2	20080814	WO 2008-US52839	20080201
WO 2008097861	A3	20090827		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRIORITY APPLN. INFO.: US 2007-888030P P 20070202

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compns. and methods based on use of one or more biguanides in combination with one or more GSK3- β agents, to stimulate or activate the formation of new nerve cells.

IT 676596-65-9, 1-Azakenpaullone
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (modulation of neurogenesis with biguanides and GSK3- β agents)

RN 676596-65-9 CAPLUS

CN Pyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one, 9-bromo-7,12-dihydro- (CA INDEX NAME)

10/565,702




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L28 ANSWER 17 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2008:825260 CAPLUS
 DOCUMENT NUMBER: 149:112667
 TITLE: Aminoalkyl methacrylate copolymer E for maintaining
 solubility of poorly water-soluble drug
 INVENTOR(S): Yoshida, Takatsune; Yoshihara, Keiichi; Umejima,
 Hiroyuki; Kurimoto, Ippei
 PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan
 SOURCE: PCT Int. Appl., 40pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008081829	A1	20080710	WO 2007-JP74998	20071226
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
CA 2673959	A1	20080710	CA 2007-2673959	20071226
US 20080221047	A1	20080911	US 2007-3473	20071226
EP 2127677	A1	20091202	EP 2007-860227	20071226
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR			
PRIORITY APPLN. INFO.:			US 2006-877165P	P 20061227
			WO 2007-JP74998	W 20071226
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
AB	Disclosed is a pharmaceutical composition containing an aminoalkyl methacrylate copolymer E uniformly blended with an acidic substance and a poorly water-soluble drug. This pharmaceutical composition enables to maintain solubility of the poorly water-soluble drug for at least 30 min. For example, Eudragit E, diluted HCl, Tween 80, and distilled water were blended and spray-dried. The above product, tacrolimus, and sucrose were ball milled to obtain a solid dispersion.			
IT	1034748-23-6D, derivs. RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (aminoalkyl methacrylate copolymer for maintaining solubility of poorly water-soluble drug)			
RN	1034748-23-6 CAPLUS			
CN	Imidazo[4,5-d][1]benzazepine, 1,4,5,6-tetrahydro- (CA INDEX NAME)			

10/565,702



REFERENCE COUNT:

17

THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 18 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2008:493006 CAPLUS
 DOCUMENT NUMBER: 148:472014
 TITLE: Thienodibenzoazulene compounds as tumor necrosis factor inhibitors and their preparation, pharmaceutical compositions and use in the treatment of inflammation
 INVENTOR(S): Mercep, Mladen; Mesic, Milan; Pesic, Dijana; Zupanovic, Zeljko; Hrvacic, Boska
 PATENT ASSIGNEE(S): Pliva Farmaceutska Industrija, Dionicko Društvo, Croatia
 SOURCE: U.S. Pat. Appl. Publ., 23pp., Cont.-in-part of Appl. No. PCT/HR2001/00027.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030153750	A1	20030814	US 2002-298217	20021118
US 6897211	B2	20050524		
HR 2000000310	A2	20020228	HR 2000-310	20000517
WO 2001087890	A1	20011122	WO 2001-HR27	20010516
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20050171091	A1	20050804	US 2005-90743	20050325
PRIORITY APPLN. INFO.:			HR 2000-310	A 20000517
			WO 2001-HR27	A2 20010516
			US 2002-298217	A1 20021118

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 148:472014; MARPAT 148:472014


GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The invention relates to the dibenzoazulene compds. of formula I as well as to their pharmaceutical preps. for the inhibition of tumor necrosis factor alpha (TNF- α) and interleukine 1 (IL-1) in mammal at all diseases and conditions where these mediators are excessively secreted. The compds. of the invention also demonstrate an analgetic action and can be used to relieve pain. Compds. of formula I wherein X is CH₂, O, SO₂-2 and NH and derivs.; R₁-R₉ are independently H, halo, C₁-7 alkyl, alkenyl, (hetero)aryl, OH, C₁-7 alkoxy, etc.; R₁₀ is C₂-15 alkyl, C₂-15 alkenyl, C₂-15 alkynyl, (hetero)aryl, C₁-15 haloalkyl, etc.; and their pharmaceutically acceptable salts and solvates thereof, are claimed.

Example compound II•HCl was prepared by O-alkylation of 3-(8-oxa-1-thiadibenzo[e,h]azulene)methanol with 3-dimethylaminopropyl chloride. All the invention compds. were evaluated for their TNF- α inhibitory activity (some data given).


IT 1019856-26-8P 1019856-27-9P 1019856-28-0P
 1019856-29-1P 1019856-40-6P 1019856-41-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (drug candidate; preparation of thienodibenzoazulene compds. as TNF
 inhibitors useful in the treatment of inflammation)
 RN 1019856-26-8 CAPLUS
 CN Methanone, [2-[[3-(dimethylamino)propoxy]methyl]-8H-dibenzo[b,f]thieno[3,2-
 d]azepin-8-yl]phenyl- (CA INDEX NAME)



RN 1019856-27-9 CAPLUS
 CN Methanone, [2-[[2-(dimethylamino)ethoxy]methyl]-8H-dibenzo[b,f]thieno[2,3-
 d]azepin-8-yl]phenyl- (CA INDEX NAME)




RN 1019856-28-0 CAPLUS
 CN 1-Propanamine, 3-(8H-dibenzo[b,f]thieno[2,3-d]azepin-2-ylmethoxy)-N,N-
 dimethyl- (CA INDEX NAME)




RN 1019856-29-1 CAPLUS

CN Ethanamine, 2-(8H-dibenzo[b,f]thieno[2,3-d]azepin-2-ylmethoxy)-N,N-dimethyl- (CA INDEX NAME)




RN 1019856-40-6 CAPLUS

CN 1-Propanamine, N,N-dimethyl-3-[[8-(phenylmethyl)-8H-dibenzo[b,f]thieno[2,3-d]azepin-2-yl]methoxy]- (CA INDEX NAME)




RN 1019856-41-7 CAPLUS


CN Ethanamine, N,N-dimethyl-2-[[8-(phenylmethyl)-8H-dibenzo[b,f]thieno[3,2-d]azepin-2-yl]methoxy]- (CA INDEX NAME)



IT 1019856-55-3P 1019856-61-1P 1019856-62-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of thienodibenzoazulene compds. as TNF inhibitors
 useful in the treatment of inflammation)
 RN 1019856-55-3 CAPLUS
 CN 8H-Dibenzo[b,f]thieno[3,2-d]azepine-2-methanol, 8-(phenylmethyl)- (CA
 INDEX NAME)




RN 1019856-61-1 CAPLUS
 CN Methanone, [2-(hydroxymethyl)-8H-dibenzo[b,f]thieno[2,3-d]azepin-8-
 yl]phenyl- (CA INDEX NAME)



10/565,702

RN 1019856-62-2 CAPLUS

CN 8H-Dibenzo[b,f]thieno[3,2-d]azepine-2-methanol (CA INDEX NAME)




IT 1019856-84-8 1019856-89-3 1019856-90-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of thienodibenzoazulene compds. as TNF inhibitors useful in the treatment of inflammation)

RN 1019856-84-8 CAPLUS


CN 8H-Dibenzo[b,f]thieno[3,2-d]azepine-2-carboxylic acid, 8-(phenylmethyl)-, ethyl ester (CA INDEX NAME)



RN 1019856-89-3 CAPLUS


CN 8H-Dibenzo[b,f]thieno[2,3-d]azepine-2-carboxylic acid, 8-benzoyl-, ethyl ester (CA INDEX NAME)

10/565,702



RN 1019856-90-6 CAPLUS

CN 8H-Dibenzo[b,f]thieno[2,3-d]azepine-2-carboxylic acid, ethyl ester (CA
INDEX NAME)



L28 ANSWER 19 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2008:381058 CAPLUS
 DOCUMENT NUMBER: 148:394352
 TITLE: HMG CoA reductase inhibitor combination for modulation of neurogenesis
 INVENTOR(S): Barlow, Carrolee; Carter, Todd A.; Morse, Andrew; Treuner, Kai; Lorrain, Kym I.; Redwine, Jeff; Hoffmaster, Christine
 PATENT ASSIGNEE(S): Braincells, Inc., USA
 SOURCE: PCT Int. Appl., 141pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008036846	A2	20080327	WO 2007-US79079	20070920
WO 2008036846	A3	20081113		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA AU 2007299726 A1 20080327 AU 2007-299726 20070920 CA 2664421 A1 20080327 CA 2007-2664421 20070920 US 20080103105 A1 20080501 US 2007-858790 20070920 EP 2076288 A2 20090708 EP 2007-842912 20070920 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
PRIORITY APPLN. INFO.:			US 2006-826710P	P 20060922
			WO 2007-US79079	W 20070920

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


AB The instant disclosure describes methods of treating diseases and conditions of the central and peripheral nervous system including by stimulating or increasing neurogenesis, neuroproliferation, and/or neurodifferentiation. The disclosure includes compns. and methods based on use of an HMGR modulating agent, optionally in combination with one or more other neurogenic agents, to stimulate or increase a neurogenic response and/or to treat disease. Atorvastatin combined with folic acid synergistically enhanced differentiation of human neural stem cells in vitro.

IT 676596-65-9, 1-Azakenpaulone 1015242-98-4
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (HMG-CoA reductase inhibitor combination for modulation of neurogenesis)

RN 676596-65-9 CAPLUS

10/565,702

CN Pyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one, 9-bromo-7,12-dihydro- (CA INDEX NAME)




RN 1015242-98-4 CAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (BR,8R)-, mixt. with 9-bromo-7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one (CA INDEX NAME)

CM 1

CRN 676596-65-9

CMF C15 H10 Br N3 O




CM 2

CRN 134523-00-5

CMF C33 H35 F N2 O5

Absolute stereochemistry.



10/565,702

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

L28 ANSWER 20 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2008:285086 CAPLUS
 DOCUMENT NUMBER: 148:347284
 TITLE: Prediction of an agent's or agents' activity across
 different cells and tissue types
 INVENTOR(S): Theodorescu, Dan; Lee, Jae Kyun
 PATENT ASSIGNEE(S): USA
 SOURCE: PCT Int. Appl., 124pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008027912	A2	20080306	WO 2007-US77022	20070828
WO 2008027912	A3	20081009		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
US 20080118576	A1	20080522	US 2007-846340	20070828
EP 2062181	A2	20090527	EP 2007-841494	20070828
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
PRIORITY APPLN. INFO.:			US 2006-840644P	P 20060828
			US 2006-840834P	P 20061122
			WO 2007-US77022	W 20070828

AB The present invention relates to a novel algorithm that uses mol. profile signatures to extrapolate the physiol. processes of one type of cell set (e.g., cell line, tissue, normal or diseased) to predict the activity of an agent or agents against another type of cell set that has never been exposed to the agent in question (drug efficacy prediction). The novel algorithm also allows one to predict the therapeutic response of a patient to a therapeutic regimen even though the patient (or patients) may have never been exposed to that agent before, thereby allowing for selecting a therapeutic agent or combination of agents that would best suit the patient (i.e., personalized medicine). The present invention also relates to methods of using the agents identified by the novel algorithm to treat a variety of diseases, including cancer.

IT 153079-85-7, NSC 672230
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (prediction of an agent's or agents' activity across different cells and tissue types for treatment of diseases such as cancer)

RN 153079-85-7 CAPLUS
 CN Indolo[3,2-d][1,2,4]triazolo[4,3-a][1]benzazepine, 9,14-dihydro-6-methyl-

(CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L28 ANSWER 21 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2007:1177815 CAPLUS
 DOCUMENT NUMBER: 147:464593
 TITLE: Culture of non-embryonic multipotent progenitor cells
 at high cell density in the presence of a GSK-3
 inhibitor
 INVENTOR(S): Mays, Robert W.
 PATENT ASSIGNEE(S): Athersys, Inc., USA
 SOURCE: PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007117262	A2	20071018	WO 2006-US29547	20060731
WO 2007117262	A3	20080110		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA US 20080194024 A1 20080814 US 2008-996882 20080125 PRIORITY APPLN. INFO.: US 2005-703823P P 20050729 WO 2006-US29547 W 20060731				

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 147:464593


AB The present invention is directed to the culture of mammalian non-embryonic stem cells (i.e., multipotent adult progenitor cells), that can differentiate into cell types of more than one embryonic lineage, at high densities in culture under conditions that maintain differentiation capacity during expansion; more particularly, culturing non-embryonic stem cells at high densities in the presence of a glycogen synthase kinase 3 inhibitor, such as 6-bromoindirubin-3'-oxime (BIO).

IT 676596-65-9, 1-Azakenpaullone
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (glycogen synthase kinase 3 inhibitor; culture of non-embryonic multipotent progenitor cells at high cell d. in presence of glycogen synthase kinase 3 inhibitor)

RN 676596-65-9 CAPLUS

CN Pyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one, 9-bromo-7,12-dihydro- (CA INDEX NAME)

10/565,702




L28 ANSWER 22 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2007:383636 CAPLUS
 DOCUMENT NUMBER: 146:401967
 TITLE: Preparation of tetracyclic inhibitors of Janus kinases
 INVENTOR(S): Arvanitis, Argyrios G.; Rodgers, James D.; Combs,
 Andrew P.; Sparks, Richard B.; Robinson, Darius J.;
 Fridman, Jordan S.; Vaddi, Krishna
 PATENT ASSIGNEE(S): Incyte Corporation, USA
 SOURCE: PCT Int. Appl., 148pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007038215	A1	20070405	WO 2006-US36872	20060921
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2621261	A1	20070405	CA 2006-2621261	20060921
US 20070149506	A1	20070628	US 2006-524641	20060921
EP 1926735	A1	20080604	EP 2006-825052	20060921
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009508968	T	20090305	JP 2008-532395	20060921
AR 58067	A1	20080123	AR 2006-104186	20060925
US 20090197869	A1	20090806	US 2009-418132	20090403
PRIORITY APPLN. INFO.:			US 2005-719462P	P 20050922
			US 2006-810490P	P 20060602
			US 2006-524641	B1 20060921
			WO 2006-US36872	W 20060921


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 146:401967; MARPAT 146:401967


GI




I



II



III



IV

AB The invention is related to tetracyclic compds. I, II, and III [D1-D7 = independently CR1, N; E = O, S, SO, SO2, NH and derivs.; G = N, CH and derivs.; Q1, Q2 = independently H, NH and derivs.; W = -W1-W2-W3-W4; W1 = absent, O, S, NH and derivs., SO2, NHCONH and derivs., alkyl, etc.; W2 = absent, (un)substituted alk(en/yn)yl, (hetero)aryl, etc.; W3 = absent, :N, :NO, alkoxy, CONH and derivs., SONH and derivs., (un)substituted alk(en/yn)yl, etc.; W4 = H, CN, NH2 and derivs., (un)substituted cyclo/alkyl, heterocycloalkyl, etc.; provided that when D7 = N, E = O, S; and G = N, then W is other than H] and their pharmaceutically acceptable salts or prodrugs, that modulate, especially inhibit, the activity of Janus kinases. Thus, IV was prepared by a general procedure. Selected tetracyclic compds. I-III showed an IC50 of 10 μ M or less for the inhibition of JAK1 and/or JAK2, and/or JAK3 in an in vitro assay. Thus, I-III are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.


IT 933762-71-1P 933765-14-1P 933766-77-9P
933767-61-4P 933767-64-7P 933767-67-0P
933768-22-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of tetracyclic inhibitors of Janus kinases)


RN 933762-71-1 CAPLUS

CN Cyclohexanecarbonitrile, 4-(3,8-dihydro-3-hydroxyimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)



RN 933765-14-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[3-(difluoromethyl)-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl]-1,8-dihydro- (CA INDEX NAME)




RN 933766-77-9 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-(ethylthio)phenyl]-1,8-dihydro-, 2,2,2-trifluoroacetate
(1:2) (CA INDEX NAME)

CM 1

CRN 933766-76-8

CMF C21 H15 C12 N5 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933767-61-4 CAPLUS

CN Phenol, 3,5-dichloro-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)



RN 933767-64-7 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine, 2-(2,6-dichloro-4-methoxyphenyl)-1,8-dihydro-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

10/565,702

CM 1

CRN 933767-63-6

CMF C20 H13 Cl2 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 933767-67-0 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-(1-methylethoxy)phenyl]-1,8-dihydro-,
2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933767-66-9

CMF C22 H17 Cl2 N5 O

10/565,702



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 933768-22-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3,5-dichloro-4-pyridinyl)-1,8-dihydro-, 2,2,2-trifluoroacetate (1:2)
(CA INDEX NAME)

CM 1

CRN 933762-77-7

CMF C18 H10 Cl2 N6



CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT	933762-31-3P	933762-32-4P	933762-33-5P
	933762-34-6P	933762-35-7P	933762-36-8P
	933762-37-9P	933762-38-0P	933762-39-1P
	933762-41-5P	933762-42-6P	933762-43-7P
	933762-44-8P	933762-45-9P	933762-46-0P
	933762-47-1P	933762-48-2P	933762-49-3P
	933762-50-6P	933762-51-7P	933762-52-8P
	933762-53-9P	933762-54-0P	933762-55-1P
	933762-56-2P	933762-57-3P	933762-58-4P
	933762-59-5P	933762-60-8P	933762-61-9P
	933762-62-0P	933762-63-1P	933762-64-2P
	933762-65-3P	933762-66-4P	933762-67-5P
	933762-68-6P	933762-69-7P	933762-70-0P
	933762-72-2P	933762-73-3P	933762-74-4P
	933762-75-5P	933762-76-6P	933762-77-7P
	933762-78-8P	933762-79-9P	933762-80-2P
	933762-81-3P	933762-82-4P	933762-83-5P
	933762-84-6P	933762-85-7P	933762-86-8P
	933762-87-9P	933762-88-0P	933762-89-1P
	933762-90-4P	933762-91-5P	933762-92-6P
	933762-93-7P	933762-94-8P	933762-95-9P
	933762-96-0P	933762-97-1P	933762-98-2P
	933762-99-3P	933763-00-9P	933763-01-0P
	933763-02-1P	933763-03-2P	933763-04-3P
	933763-05-4P	933763-06-5P	933763-07-6P
	933763-08-7P	933763-09-8P	933763-10-1P
	933763-11-2P	933763-12-3P	933763-13-4P
	933763-14-5P	933763-15-6P	933763-16-7P
	933763-17-8P	933763-18-9P	933763-19-0P
	933763-20-3P	933763-21-4P	933763-22-5P
	933763-23-6P	933763-24-7P	933763-25-8P
	933763-26-9P	933763-27-0P	933763-29-2P
	933763-30-5P	933763-32-7P	933763-33-8P
	933763-35-0P	933763-36-1P	933763-38-3P
	933763-39-4P	933763-41-8P	933763-42-9P
	933763-44-1P	933763-45-2P	933763-47-4P
	933763-48-5P	933763-50-9P	933763-51-0P
	933763-53-2P	933763-54-3P	933763-56-5P
	933763-57-6P	933763-58-7P	933763-59-8P
	933763-60-1P	933763-61-2P	933763-62-3P
	933763-63-4P	933763-64-5P	933763-65-6P
	933763-66-7P	933763-67-8P	933763-68-9P
	933763-69-0P	933763-70-3P	933763-71-4P
	933763-72-5P	933763-73-6P	933763-74-7P


933763-75-8P	933763-76-9P	933763-77-0P
933763-78-1P	933763-79-2P	933763-80-5P
933763-81-6P	933763-82-7P	933763-83-8P
933763-84-9P	933763-85-0P	933763-86-1P
933763-87-2P	933763-88-3P	933763-89-4P
933763-90-7P	933763-91-8P	933763-92-9P
933763-93-0P	933763-94-1P	933763-95-2P
933763-96-3P	933763-97-4P	933763-98-5P
933763-99-6P	933764-00-2P	933764-01-3P
933764-02-4P	933764-03-5P	933764-04-6P
933764-05-7P	933764-06-8P	933764-07-9P
933764-09-1P	933764-10-4P	933764-11-5P
933764-12-6P	933764-13-7P	933764-14-8P
933764-15-9P	933764-16-0P	933764-17-1P
933764-18-2P	933764-19-3P	933764-20-6P
933764-21-7P	933764-22-8P	933764-23-9P
933764-24-0P	933764-25-1P	933764-26-2P
933764-27-3P	933764-28-4P	933764-29-5P
933764-30-8P	933764-31-9P	933764-32-0P
933764-33-1P	933764-34-2P	933764-35-3P
933764-36-4P	933764-37-5P	933764-38-6P
933764-39-7P	933764-40-0P	933764-41-1P
933764-42-2P	933764-43-3P	933764-44-4P
933764-46-6P	933764-47-7P	933764-48-8P
933764-49-9P	933764-50-2P	933764-51-3P
933764-52-4P	933764-53-5P	933764-54-6P
933764-55-7P	933764-56-8P	933764-57-9P
933764-58-0P	933764-59-1P	933764-60-4P
933764-61-5P	933764-62-6P	933764-63-7P
933764-64-8P	933764-65-9P	933764-66-0P
933764-67-1P	933764-68-2P	933764-69-3P
933764-70-6P	933764-71-7P	933764-72-8P
933764-73-9P	933764-74-0P	933764-75-1P
933764-76-2P	933764-77-3P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of tetracyclic inhibitors of Janus kinases)

RN 933762-31-3 CAPLUS


CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
2-(1,1-dimethylethyl)-10-fluoro-3,8-dihydro- (CA INDEX NAME)



RN 933762-32-4 CAPLUS


CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,

2-cyclopropyl-10-fluoro-3,8-dihydro- (CA INDEX NAME)




RN 933762-33-5 CAPLUS

CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
2-cyclohexyl-10-fluoro-3,8-dihydro- (CA INDEX NAME)




RN 933762-34-6 CAPLUS

CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
10-fluoro-3,8-dihydro-2-(2-methylpropyl)- (CA INDEX NAME)




RN 933762-35-7 CAPLUS


CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
2-cyclopentyl-10-fluoro-3,8-dihydro- (CA INDEX NAME)



RN 933762-36-8 CAPLUS
 CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
 10-fluoro-3,8-dihydro-2-(tetrahydro-3-furanyl)- (CA INDEX NAME)




RN 933762-37-9 CAPLUS
 CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
 2-(3-cyclohexen-1-yl)-10-fluoro-3,8-dihydro- (CA INDEX NAME)




RN 933762-38-0 CAPLUS
 CN Cyclopropanecarboxylic acid, 2-(10-fluoro-3,8-dihydroimidazo[4,5-
 d]pyrido[2,3-b][1]benzazepin-2-yl)-, ethyl ester (CA INDEX NAME)

10/565,702



RN 933762-39-1 CAPLUS

CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
2-bicyclo[2.2.1]hept-5-en-2-yl-10-fluoro-3,8-dihydro- (CA INDEX NAME)




RN 933762-41-5 CAPLUS

CN Cyclopropanemethanol, 2-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][1]benzazepin-2-yl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 933762-40-4

CMF C18 H15 F N4 O




CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 933762-42-6 CAPLUS


CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
2-(1-ethylpentyl)-10-fluoro-3,8-dihydro- (CA INDEX NAME)

RN 933762-43-7 CAPLUS

CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine-2-butanenitrile,
γ,γ-diethyl-10-fluoro-3,8-dihydro- (CA INDEX NAME)


RN 933762-44-8 CAPLUS

CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
2-cyclopentyl-10,11-difluoro-3,8-dihydro- (CA INDEX NAME)




RN 933762-45-9 CAPLUS

CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
2-(1-ethylpentyl)-10,11-difluoro-3,8-dihydro- (CA INDEX NAME)




RN 933762-46-0 CAPLUS

CN Cyclohexanepropanenitrile, 1-(10-fluoro-3,8-dihydroimidazo[4,5-
d]pyrido[2,3-b][1]benzazepin-2-yl)- (CA INDEX NAME)




RN 933762-47-1 CAPLUS

CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine-2-butanenitrile,
10-fluoro-3,8-dihydro-γ,γ-dimethyl- (CA INDEX NAME)




RN 933762-48-2 CAPLUS

CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
2-(1-ethylpropyl)-10-fluoro-3,8-dihydro- (CA INDEX NAME)




RN 933762-49-3 CAPLUS

CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
10-fluoro-3,8-dihydro-2-[2-(methylthio)ethyl]- (CA INDEX NAME)




RN 933762-50-6 CAPLUS

CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
10-fluoro-3,8-dihydro-2-[2-(methylsulfinyl)ethyl]- (CA INDEX NAME)



RN 933762-51-7 CAPLUS


CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
10-fluoro-3,8-dihydro-2-[(phenylmethoxy)methyl]- (CA INDEX NAME)



RN 933762-52-8 CAPLUS

CN Cyclohexanemethanol, 4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][1]benzazepin-2-yl)-, cis- (CA INDEX NAME)

Relative stereochemistry.




RN 933762-53-9 CAPLUS

CN Cyclohexanemethanol, 4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][1]benzazepin-2-yl)-, trans- (CA INDEX NAME)

10/565,702


Relative stereochemistry.



RN 933762-54-0 CAPLUS

CN Cyclohexanol, 4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][1]benzazepin-2-yl)-, cis- (CA INDEX NAME)

Relative stereochemistry.




RN 933762-55-1 CAPLUS

CN Cyclohexanol, 4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][1]benzazepin-2-yl)-, trans- (CA INDEX NAME)

Relative stereochemistry.


10/565,702



RN 933762-56-2 CAPLUS


CN Cyclohexanecarbonitrile, 4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][1]benzazepin-2-yl)-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 933762-57-3 CAPLUS


CN Cyclohexanecetamide, 4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][1]benzazepin-2-yl)- (CA INDEX NAME)



RN 933762-58-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][1]benzazepin-2-yl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 933762-59-5 CAPLUS
 CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine, 10-fluoro-3,8-dihydro-2-(4-piperidinyl)- (CA INDEX NAME)




RN 933762-60-8 CAPLUS

CN 1-Piperidinepropanenitrile, 4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][1]benzazepin-2-yl)- β -oxo- (CA INDEX NAME)




RN 933762-61-9 CAPLUS

CN Ethanone, 1-[4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][1]benzazepin-2-yl)-1-piperidinyl]- (CA INDEX NAME)




RN 933762-62-0 CAPLUS

CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
10-fluoro-3,8-dihydro-2-[1-(methylsulfonyl)-4-piperidinyl]- (CA INDEX
NAME)




RN 933762-63-1 CAPLUS

CN 1-Piperidineacetonitrile, 4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-
b][1]benzazepin-2-yl)- (CA INDEX NAME)




RN 933762-64-2 CAPLUS

CN 1-Piperidineacetic acid, 4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][1]benzazepin-2-yl)-, ethyl ester (CA INDEX NAME)




RN 933762-65-3 CAPLUS

CN 1-Piperidineethanol, 4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][1]benzazepin-2-yl)- (CA INDEX NAME)




RN 933762-66-4 CAPLUS

CN 1-Piperidinepropanol, 4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][1]benzazepin-2-yl)- (CA INDEX NAME)




RN 933762-67-5 CAPLUS

CN 1-Piperidinebutanenitrile, 4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][1]benzazepin-2-yl)- (CA INDEX NAME)




RN 933762-68-6 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine-2-butanenitrile,
γ,γ-diethyl-1,8-dihydro- (CA INDEX NAME)




RN 933762-69-7 CAPLUS

CN Cyclohexanemethanol, 4-(3,8-dihydro-3-hydroxyimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)




RN 933762-70-0 CAPLUS

CN Cyclohexanemethanol, 4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)




RN 933762-72-2 CAPLUS

CN Cyclohexanecetonitrile, 4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)




RN 933762-73-3 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine-2-propanenitrile, 1,8-dihydro- β,β -dimethyl- (CA INDEX NAME)




RN 933762-74-4 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine-2-propanenitrile,
β,β-diethyl-1,8-dihydro- (CA INDEX NAME)




RN 933762-75-5 CAPLUS

CN Cyclopentaneacetonitrile, 3-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-
f]azepin-2-yl)- (CA INDEX NAME)




RN 933762-76-6 CAPLUS

CN Cyclopentanecarbonitrile, 3-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-
f]azepin-2-yl)- (CA INDEX NAME)



RN 933762-77-7 CAPLUS
 CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
 2-(3,5-dichloro-4-pyridinyl)-1,8-dihydro- (CA INDEX NAME)




RN 933762-78-8 CAPLUS
 CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
 2-(3,5-dichloro-4-pyridinyl)-1,8-dihydro-, 2,2,2-trifluoroacetate (1:3)
 (CA INDEX NAME)

CM 1

CRN 933762-77-7
 CMF C18 H10 C12 N6

10/565,702



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933762-79-9 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,6-dichlorophenyl)-1,8-dihydro-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 933762-80-2 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,6-dimethylphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933762-81-3 CAPLUS
 CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
 2-(2,6-dimethylphenyl)-1,8-dihydro-, 2,2,2-trifluoroacetate (1:2) (CA
 INDEX NAME)

CM 1

CRN 933762-80-2

CMF C21 H17 N5




CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 933762-82-4 CAPLUS
 CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
 2-(2-fluoro-6-methoxyphenyl)-1,8-dihydro- (CA INDEX NAME)



RN 933762-83-5 CAPLUS
 CN Imidazo[4,5-d]dipyrido[2,3-b:4',2'-f]azepine,
 2-(2-fluoro-6-methoxyphenyl)-1,8-dihydro-, 2,2,2-trifluoroacetate (1:2)
 (CA INDEX NAME)

CM 1

CRN 933762-82-4
 CMF C20 H14 F N5 O




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 933762-84-6 CAPLUS
 CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
 2-(6-chloro-2-fluoro-3-methylphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933762-85-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2-fluoro-6-(trifluoromethyl)phenyl]-1,8-dihydro- (CA INDEX NAME)




RN 933762-86-8 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2-chloro-6-fluoro-3-methylphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933762-87-9 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[3-chloro-2-fluoro-6-(trifluoromethyl)phenyl]-1,8-dihydro- (CA INDEX
NAME)



RN 933762-88-0 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2-chloro-6-fluorophenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933762-89-1 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2-chloro-5-(trifluoromethyl)phenyl]-1,8-dihydro- (CA INDEX NAME)




RN 933762-90-4 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,6-difluorophenyl)-1,8-dihydro- (CA INDEX NAME)



RN 933762-91-5 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,5-dichlorophenyl)-1,8-dihydro- (CA INDEX NAME)



RN 933762-92-6 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,

2-(3,5-dibromo-4-pyridinyl)-1,8-dihydro- (CA INDEX NAME)




RN 933762-93-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2-bromophenyl)-1,8-dihydro- (CA INDEX NAME)



RN 933762-94-8 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(2-methylphenyl)- (CA INDEX NAME)



RN 933762-95-9 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,

2-(2-chlorophenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933762-96-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2-ethylphenyl)-1,8-dihydro- (CA INDEX NAME)



RN 933762-97-1 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,5-dimethylphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933762-98-2 CAPLUS

10/565,702


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2-chloro-3-(trifluoromethyl)phenyl]-1,8-dihydro- (CA INDEX NAME)



RN 933762-99-3 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,5-bis(trifluoromethyl)phenyl]-1,8-dihydro- (CA INDEX NAME)




RN 933763-00-9 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3-chloro-2,6-difluorophenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933763-01-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(2-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 933763-02-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,3-dichlorophenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933763-03-2 CAPLUS

CN Propanenitrile, 3-[[4-(1,8-dihydroimidazo[4,5-d]dipyrido[3,4-b:3',2'-




RN 933763-06-5 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(5-bromo-2,3-dimethoxyphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933763-07-6 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-1,8-dihydro- (CA INDEX NAME)




RN 933763-08-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3-chloro-4-pyridinyl)-1,8-dihydro- (CA INDEX NAME)




RN 933763-09-8 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,3-dimethylphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933763-10-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2-fluoro-3-(trifluoromethyl)phenyl]-1,8-dihydro- (CA INDEX NAME)




RN 933763-11-2 CAPLUS

CN Imidazo[4,5-d]dipyrido[3,4-b:4',3'-f]azepine,
2-(3-fluoro-2-methylphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933763-12-3 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2-fluorophenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933763-13-4 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(5-bromo-2-methoxyphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933763-14-5 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2-fluoro-5-(trifluoromethyl)phenyl]-1,8-dihydro- (CA INDEX NAME)



RN 933763-15-6 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2-fluoro-3-methoxyphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933763-16-7 CAPLUS

10/565,702


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2-fluoro-5-methoxyphenyl)-1,8-dihydro- (CA INDEX NAME)



RN 933763-17-8 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,3-difluorophenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933763-18-9 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(4-quinoliny)- (CA INDEX NAME)




RN 933763-19-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(5-fluoro-2-methoxyphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933763-20-3 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(5-bromo-2-fluorophenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933763-21-4 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,5-dimethoxyphenyl)-1,8-dihydro- (CA INDEX NAME)



RN 933763-22-5 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,5-difluorophenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933763-23-6 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3,5-dimethyl-1H-pyrrol-2-yl)-1,8-dihydro- (CA INDEX NAME)




RN 933763-24-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,6-dimethoxyphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933763-25-8 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(4-methyl-1H-imidazol-5-yl)- (CA INDEX NAME)




RN 933763-26-9 CAPLUS

CN Phenol, 4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-
3,5-dimethoxy- (CA INDEX NAME)




RN 933763-27-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(1,1,2,2-pentafluoroethyl)- (CA INDEX NAME)



RN 933763-29-2 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(5-bromo-1,3-benzodioxol-4-yl)-1,8-dihydro- (CA INDEX NAME)



RN 933763-30-5 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(5-bromo-1,3-benzodioxol-4-yl)-1,8-dihydro-, 2,2,2-trifluoroacetate


10/565,702

(1:2) (CA INDEX NAME)

CM 1

CRN 933763-29-2

CMF C20 H12 Br N5 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933763-32-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine-2-butanenitrile,
1,8-dihydro-γ-methyl-γ-phenyl- (CA INDEX NAME)



RN 933763-33-8 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine-2-butanenitrile,

1,8-dihydro- γ -methyl- γ -phenyl-, 2,2,2-trifluoroacetate (1:2)
(CA INDEX NAME)

CM 1

CRN 933763-32-7

CMF C24 H20 N6



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933763-35-0 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2-fluoro-4-(trifluoromethyl)phenyl]-1,8-dihydro- (CA INDEX NAME)



RN 933763-36-1 CAPLUS
 CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
 2-[2-fluoro-4-(trifluoromethyl)phenyl]-1,8-dihydro-,
 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933763-35-0
 CMF C20 H11 F4 N5




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 933763-38-3 CAPLUS
 CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
 2-(cyclohexylmethyl)-1,8-dihydro- (CA INDEX NAME)




RN 933763-39-4 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(cyclohexylmethyl)-1,8-dihydro-, 2,2,2-trifluoroacetate (1:2) (CA INDEX
NAME)

CM 1

CRN 933763-38-3

CMF C20 H21 N5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933763-41-8 CAPLUS

CN Phenol, 3-bromo-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-6-methoxy- (CA INDEX NAME)




RN 933763-42-9 CAPLUS

CN Phenol, 3-bromo-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-6-methoxy-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933763-41-8

CMF C20 H14 Br N5 O2




CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 933763-44-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3-fluoro-4-pyridinyl)-1,8-dihydro- (CA INDEX NAME)


RN 933763-45-2 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3-fluoro-4-pyridinyl)-1,8-dihydro-, 2,2,2-trifluoroacetate (1:3) (CA
INDEX NAME)

CM 1

CRN 933763-44-1

CMF C18 H11 F N6



CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/565,702



RN 933763-47-4 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[1,1'-biphenyl]-2-yl-1,8-dihydro- (CA INDEX NAME)




RN 933763-48-5 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[1,1'-biphenyl]-2-yl-1,8-dihydro-, 2,2,2-trifluoroacetate (1:2) (CA
INDEX NAME)

CM 1

CRN 933763-47-4

CMF C25 H17 N5



CM 2

CRN 76-05-1


10/565,702

CMF C2 H F3 O2



RN 933763-50-9 CAPLUS

CN Benzoic acid, 4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-, methyl ester (CA INDEX NAME)




RN 933763-51-0 CAPLUS

CN Benzoic acid, 4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-, methyl ester 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933763-50-9

CMF C21 H15 N5 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933763-53-2 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2-(ethylthio)phenyl]-1,8-dihydro- (CA INDEX NAME)



RN 933763-54-3 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2-(ethylthio)phenyl]-1,8-dihydro-, 2,2,2-trifluoroacetate (1:2) (CA
INDEX NAME)

10/565,702

CM 1

CRN 933763-53-2

CMF C21 H17 N5 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933763-56-5 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(1H-pyrrol-2-yl)- (CA INDEX NAME)



RN 933763-57-6 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(1H-pyrrol-2-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX
NAME)

10/565,702

CM 1

CRN 933763-56-5

CMF C17 H12 N6



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933763-58-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[4-[(trifluoromethyl)thio]phenyl]- (CA INDEX NAME)




RN 933763-59-8 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[4-(trifluoromethyl)thiophenyl]-, 2,2,2-trifluoroacetate
(1:2) (CA INDEX NAME)

CM 1

CRN 933763-58-7

CMF C20 H12 F3 N5 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933763-60-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(2-naphthalenyl)- (CA INDEX NAME)



10/565,702


RN 933763-61-2 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(2-naphthalenyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX
NAME)

CM 1

CRN 933763-60-1

CMF C23 H15 N5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933763-62-3 CAPLUS

CN Carbamic acid, N-[1-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-
f]azepin-2-yl)-2-phenylethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 933763-63-4 CAPLUS
 CN Carbamic acid, N-[1-(1,8-dihydroimidazo[4,5-d]dipyrdo[2,3-b:4',3'-f]azepin-2-yl)-2-phenylethyl]-, 1,1-dimethylethyl ester
 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933763-62-3

CMF C26 H26 N6 O2




CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 933763-64-5 CAPLUS
 CN Imidazo[4,5-d]dipyrdo[2,3-b:4',3'-f]azepine,
 1,8-dihydro-2-(2-pyrrolidinyl)- (CA INDEX NAME)




RN 933763-65-6 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(2-pyrrolidinyl)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX
NAME)

CM 1

CRN 933763-64-5

CMF C17 H16 N6



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933763-66-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2-chloro-6-methoxy-3-quinolinyl)-1,8-dihydro- (CA INDEX NAME)




RN 933763-67-8 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2-chloro-6-methoxy-3-quinolinyl)-1,8-dihydro-, 2,2,2-trifluoroacetate
(1:3) (CA INDEX NAME)

CM 1

CRN 933763-66-7

CMF C23 H15 Cl N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 933763-68-9 CAPLUS

CN Ethanone, 1-[(2S)-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-
f]azepin-2-yl)-1-pyrrolidinyl]- (CA INDEX NAME)

10/565,702

Absolute stereochemistry.



RN 933763-69-0 CAPLUS


CN Ethanone, 1-[(2S)-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933763-68-9

CMF C19 H18 N6 O

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 933763-70-3 CAPLUS

10/565,702

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine, 1,8-dihydro-2-(2-thiazolyl)-
(CA INDEX NAME)




RN 933763-71-4 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(2-thiazolyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX
NAME)

CM 1

CRN 933763-70-3

CMF C16 H10 N6 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



10/565,702

RN 933763-72-5 CAPLUS

CN Ethanone, 1-[2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-4-hydroxy-1-pyrrolidinyl]- (CA INDEX NAME)




RN 933763-73-6 CAPLUS

CN Ethanone, 1-[2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-4-hydroxy-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933763-72-5

CMF C19 H18 N6 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/565,702



RN 933763-74-7 CAPLUS

CN Acetamide, N-[1-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)ethyl]- (CA INDEX NAME)




RN 933763-75-8 CAPLUS

CN Acetamide, N-[1-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933763-74-7

CMF C17 H16 N6 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/565,702



RN 933763-76-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-4-hydroxy-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 933763-77-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-4-hydroxy-, 1,1-dimethylethyl ester 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933763-76-9

CMF C22 H24 N6 O3




CM 2

10/565,702

CRN 76-05-1
CMF C2 H F3 O2




RN 933763-78-1 CAPLUS
CN Acetamide, N-[4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)phenyl]- (CA INDEX NAME)



RN 933763-79-2 CAPLUS
CN Acetamide, N-[4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)phenyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933763-78-1
CMF C21 H16 N6 O




CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 933763-80-5 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[4-(difluoromethoxy)phenyl]-1,8-dihydro- (CA INDEX NAME)

RN 933763-81-6 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[4-(difluoromethoxy)phenyl]-1,8-dihydro-, 2,2,2-trifluoroacetate (1:2)
(CA INDEX NAME)

10/565,702

CM 1

CRN 933763-80-5

CMF C20 H13 F2 N5 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933763-82-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(6-chloro-3-pyridinyl)-1,8-dihydro- (CA INDEX NAME)




10/565,702

RN 933763-83-8 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(6-chloro-3-pyridinyl)-1,8-dihydro-, 2,2,2-trifluoroacetate (1:2) (CA
INDEX NAME)

CM 1

CRN 933763-82-7
CMF C18 H11 Cl N6




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 933763-84-9 CAPLUS
CN 3-Pyridinecarbonitrile, 6-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-
f]azepin-2-yl)-2-(methylthio)- (CA INDEX NAME)

10/565,702




RN 933763-85-0 CAPLUS

CN 3-Pyridinecarbonitrile, 6-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-2-(methylthio)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933763-84-9

CMF C20 H13 N7 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



10/565,702

RN 933763-86-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(6-methoxy-3-pyridinyl)- (CA INDEX NAME)




RN 933763-87-2 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(6-methoxy-3-pyridinyl)-, 2,2,2-trifluoroacetate (1:3) (CA
INDEX NAME)

CM 1

CRN 933763-86-1

CMF C19 H14 N6 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/565,702



RN 933763-88-3 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(6-bromo-3-pyridinyl)-1,8-dihydro- (CA INDEX NAME)




RN 933763-89-4 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(6-bromo-3-pyridinyl)-1,8-dihydro-, 2,2,2-trifluoroacetate (1:3) (CA
INDEX NAME)

CM 1

CRN 933763-88-3

CMF C18 H11 Br N6



10/565,702

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933763-90-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(6-bromo-2-pyridinyl)-1,8-dihydro- (CA INDEX NAME)



RN 933763-91-8 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(6-bromo-2-pyridinyl)-1,8-dihydro-, 2,2,2-trifluoroacetate (1:3) (CA
INDEX NAME)

CM 1

CRN 933763-90-7

CMF C18 H11 Br N6

10/565,702



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933763-92-9 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(1H-imidazol-5-yl)- (CA INDEX NAME)



RN 933763-93-0 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(1H-imidazol-5-yl)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 933763-92-9

10/565,702

CMF C16 H11 N7



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933763-94-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(3-methoxyphenyl)- (CA INDEX NAME)




RN 933763-95-2 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(3-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

10/565,702

CRN 933763-94-1
CMF C20 H15 N5 O




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 933763-96-3 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 933763-97-4 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,

1,8-dihydro-2-(4-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933763-96-3

CMF C20 H15 N5 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933763-98-5 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[2-(methylthio)ethyl]- (CA INDEX NAME)



RN 933763-99-6 CAPLUS


10/565,702

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[2-(methylthio)ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA
INDEX NAME)

CM 1

CRN 933763-98-5

CMF C16 H15 N5 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933764-00-2 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(4-piperidinyl)- (CA INDEX NAME)




RN 933764-01-3 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(4-piperidinyl)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX
NAME)

CM 1

CRN 933764-00-2

CMF C18 H18 N6



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933764-02-4 CAPLUS

CN 1-Piperidinepropanenitrile, 4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- β -oxo- (CA INDEX NAME)




RN 933764-03-5 CAPLUS
 CN 1-Piperidinepropanenitrile, 4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-β-oxo-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933764-02-4

CMF C21 H19 N7 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/565,702



RN 933764-04-6 CAPLUS

CN 1-Piperidinepropanenitrile, 3-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-β-oxo- (CA INDEX NAME)




RN 933764-05-7 CAPLUS

CN 1-Piperidinepropanenitrile, 3-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-β-oxo-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933764-04-6

CMF C21 H19 N7 O



10/565,702

CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 933764-06-8 CAPLUS

CN 1-Piperidinepropanenitrile, 4-[(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)methyl]-β-oxo- (CA INDEX NAME)



RN 933764-07-9 CAPLUS


CN 1-Piperidinepropanenitrile, 3-[(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)methyl]-β-oxo- (CA INDEX NAME)



RN 933764-09-1 CAPLUS
 CN Ethanone, 1-[4-((1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-1-piperidinyl)-2,2,2-trifluoro-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933764-08-0
 CMF C20 H17 F3 N6 O



CM 2


CRN 76-05-1
 CMF C2 H F3 O2

10/565,702



RN 933764-10-4 CAPLUS

CN Ethanone, 1-[3-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-1-piperidiny1]-2,2,2-trifluoro- (CA INDEX NAME)




RN 933764-11-5 CAPLUS

CN Ethanone, 1-[3-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-1-piperidiny1]-2,2,2-trifluoro-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933764-10-4

CMF C20 H17 F3 N6 O



10/565,702

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933764-12-6 CAPLUS

CN Ethanone, 1-[4-[(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)methyl]-1-piperidiny]-2,2,2-trifluoro- (CA INDEX NAME)



RN 933764-13-7 CAPLUS


CN Ethanone, 1-[4-[(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)methyl]-1-piperidiny]-2,2,2-trifluoro-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933764-12-6

CMF C21 H19 F3 N6 O

10/565,702



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 933764-14-8 CAPLUS

CN Ethanone, 1-[3-[(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)methyl]-1-piperidiny]-2,2,2-trifluoro- (CA INDEX NAME)


10/565,702



RN 933764-15-9 CAPLUS
CN Ethanone, 1-[3-[(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)methyl]-1-piperidiny]-2,2,2-trifluoro-, 2,2,2-trifluoroacetate (1:2)
(CA INDEX NAME)

CM 1

CRN 933764-14-8
CMF C21 H19 F3 N6 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2

10/565,702



RN 933764-16-0 CAPLUS

CN Ethanone, 1-[4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-1-piperidinyl]- (CA INDEX NAME)




RN 933764-17-1 CAPLUS

CN Ethanone, 1-[4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-1-piperidinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933764-16-0

CMF C20 H20 N6 O



10/565,702

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933764-18-2 CAPLUS

CN 1-Piperidinecarboxaldehyde, 3-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)




RN 933764-19-3 CAPLUS

CN 1-Piperidinecarboxaldehyde, 3-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933764-18-2

CMF C19 H18 N6 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 933764-20-6 CAPLUS

CN Ethanone, 1-[4-[(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 933764-21-7 CAPLUS

CN Ethanone, 1-[3-[(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 933764-22-8 CAPLUS
 CN Ethanone, 1-[3-[(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)methyl]-1-piperidiny]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)
 CM 1
 CRN 933764-21-7
 CMF C21 H22 N6 O




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2

10/565,702



RN 933764-23-9 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(1-methyl-3-piperidinyl)- (CA INDEX NAME)




RN 933764-24-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(1-methyl-3-piperidinyl)-, 2,2,2-trifluoroacetate (1:3) (CA
INDEX NAME)

CM 1

CRN 933764-23-9

CMF C19 H20 N6




CM 2

10/565,702


CRN 76-05-1
CMF C2 H F3 O2




RN 933764-25-1 CAPLUS
CN Benzonitrile, 4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)



RN 933764-26-2 CAPLUS
CN Benzonitrile, 4-(3,8-dihydro-3-hydroxyimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)




RN 933764-27-3 CAPLUS
CN Benzonitrile, 3-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)



RN 933764-28-4 CAPLUS
 CN Benzonitrile, 3-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933764-27-3
 CMF C20 H12 N6




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 933764-29-5 CAPLUS
 CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine, 1,8-dihydro-2-(3-pyridinyl)-


(CA INDEX NAME)



RN 933764-30-8 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
3,8-dihydro-3-hydroxy-2-(3-pyridinyl)- (CA INDEX NAME)


RN 933764-31-9 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
3,8-dihydro-3-hydroxy-2-(2-pyridinyl)- (CA INDEX NAME)

RN 933764-32-0 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine, 1,8-dihydro-2-(4-pyridinyl)-

(CA INDEX NAME)




RN 933764-33-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
3,8-dihydro-3-hydroxy-2-(4-pyridinyl)- (CA INDEX NAME)



RN 933764-34-2 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(3-piperidinyl)- (CA INDEX NAME)



RN 933764-35-3 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,

1,8-dihydro-2-(3-piperidinyl)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 933764-34-2

CMF C18 H18 N6



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933764-36-4 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 933764-37-5 CAPLUS
 CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
 1,8-dihydro-2-[4-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:2)
 (CA INDEX NAME)

CM 1

CRN 933764-36-4
 CMF C20 H12 F3 N5




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 933764-38-6 CAPLUS
 CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
 1,8-dihydro-2-[6-(trifluoromethyl)-3-pyridinyl]- (CA INDEX NAME)




RN 933764-39-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[6-(trifluoromethyl)-3-pyridinyl]-, 2,2,2-trifluoroacetate
(1:3) (CA INDEX NAME)

CM 1

CRN 933764-38-6

CMF C19 H11 F3 N6




CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 933764-40-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)


RN 933764-41-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[3-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:2)
(CA INDEX NAME)

CM 1

CRN 933764-40-0

CMF C20 H12 F3 N5




CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 933764-42-2 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3,5-dimethyl-4-isoxazolyl)-3,8-dihydro-3-hydroxy- (CA INDEX NAME)

RN 933764-43-3 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[4-(methylthio)phenyl]- (CA INDEX NAME)


RN 933764-44-4 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[4-(methylthio)phenyl]-, 2,2,2-trifluoroacetate (1:2) (CA
INDEX NAME)

CM 1

10/565,702

CRN 933764-43-3
CMF C20 H15 N5 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 933764-46-6 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
3,8-dihydro-3-hydroxy-2-[4-(methylthio)phenyl]-, 2,2,2-trifluoroacetate
(1:2) (CA INDEX NAME)

CM 1

CRN 933764-45-5
CMF C20 H15 N5 O S




CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 933764-47-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)

RN 933764-48-8 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[4-(methylsulfonyl)phenyl]-, 2,2,2-trifluoroacetate (1:2)


10/565,702

(CA INDEX NAME)

CM 1

CRN 933764-47-7

CMF C20 H15 N5 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933764-49-9 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(1H-imidazol-2-yl)- (CA INDEX NAME)




RN 933764-50-2 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(1H-imidazol-2-yl)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX
NAME)

CM 1

CRN 933764-49-9

CMF C16 H11 N7



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933764-51-3 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(1-methyl-1H-imidazol-2-yl)- (CA INDEX NAME)




RN 933764-52-4 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(1-methyl-1H-imidazol-2-yl)-, 2,2,2-trifluoroacetate (1:3)
(CA INDEX NAME)

CM 1

CRN 933764-51-3

CMF C17 H13 N7



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 933764-53-5 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine, 1,8-dihydro-2-phenyl- (CA

INDEX NAME)




RN 933764-54-6 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine, 1,8-dihydro-2-phenyl-,
2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933764-53-5

CMF C19 H13 N5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933764-55-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
3,8-dihydro-3-hydroxy-2-phenyl- (CA INDEX NAME)




RN 933764-56-8 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
3,8-dihydro-3-hydroxy-2-phenyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX
NAME)

CM 1

CRN 933764-55-7

CMF C19 H13 N5 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933764-57-9 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(phenylmethyl)- (CA INDEX NAME)




RN 933764-58-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(phenylmethyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX
NAME)

CM 1

CRN 933764-57-9

CMF C20 H15 N5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933764-59-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
3,8-dihydro-3-hydroxy-2-(phenylmethyl)- (CA INDEX NAME)




RN 933764-60-4 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
3,8-dihydro-3-hydroxy-2-(phenylmethyl)-, 2,2,2-trifluoroacetate (1:2) (CA
INDEX NAME)

CM 1

CRN 933764-59-1

CMF C20 H15 N5 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933764-61-5 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(2-phenylethyl)- (CA INDEX NAME)




RN 933764-62-6 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(2-phenylethyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX
NAME)

CM 1

CRN 933764-61-5

CMF C21 H17 N5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933764-63-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
3,8-dihydro-3-hydroxy-2-(2-phenylethyl)- (CA INDEX NAME)




RN 933764-64-8 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
3,8-dihydro-3-hydroxy-2-(2-phenylethyl)-, 2,2,2-trifluoroacetate (1:2)
(CA INDEX NAME)

CM 1

CRN 933764-63-7

CMF C21 H17 N5 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 933764-65-9 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
3,8-dihydro-3-hydroxy-2-(4-piperidinyl)- (CA INDEX NAME)

10/565,702




RN 933764-66-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
3,8-dihydro-3-hydroxy-2-(4-piperidinyl)-, 2,2,2-trifluoroacetate (1:3)
(CA INDEX NAME)

CM 1

CRN 933764-65-9

CMF C18 H18 N6 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 933764-67-1 CAPLUS

10/565,702


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(4-piperidinylmethyl)- (CA INDEX NAME)



RN 933764-68-2 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(4-piperidinylmethyl)-, 2,2,2-trifluoroacetate (1:3) (CA
INDEX NAME)

CM 1

CRN 933764-67-1
CMF C19 H20 N6



CM 2


CRN 76-05-1
CMF C2 H F3 O2

10/565,702



RN 933764-69-3 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
3,8-dihydro-3-hydroxy-2-(4-piperidinylmethyl)- (CA INDEX NAME)




RN 933764-70-6 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
3,8-dihydro-3-hydroxy-2-(4-piperidinylmethyl)-, 2,2,2-trifluoroacetate
(1:3) (CA INDEX NAME)

CM 1

CRN 933764-69-3

CMF C19 H20 N6 O




CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 933764-71-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(3-piperidinylmethyl)- (CA INDEX NAME)

RN 933764-72-8 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(3-piperidinylmethyl)-, 2,2,2-trifluoroacetate (1:3) (CA
INDEX NAME)

CM 1

CRN 933764-71-7

CMF C19 H20 N6

10/565,702



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933764-73-9 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[(tetrahydro-2H-pyran-4-yl)methyl]- (CA INDEX NAME)




RN 933764-74-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[(tetrahydro-2H-pyran-4-yl)methyl]-, 2,2,2-trifluoroacetate
(1:2) (CA INDEX NAME)

10/565,702

CM 1

CRN 933764-73-9
CMF C19 H19 N5 O




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 933764-75-1 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
3,8-dihydro-3-hydroxy-2-[(tetrahydro-2H-pyran-4-yl)methyl]- (CA INDEX
NAME)




RN 933764-76-2 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
3,8-dihydro-3-hydroxy-2-[(tetrahydro-2H-pyran-4-yl)methyl]-,
2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933764-75-1

CMF C19 H19 N5 O2




CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 933764-77-3 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine,
2-(3,5-dichloro-4-pyridinyl)-1,8-dihydro- (CA INDEX NAME)

IT	933764-78-4P	933764-79-5P	933764-80-8P
	933764-81-9P	933764-82-0P	933764-83-1P
	933764-84-2P	933764-85-3P	933764-86-4P
	933764-87-5P	933764-88-6P	933764-89-7P
	933764-90-0P	933764-91-1P	933764-92-2P
	933764-93-3P	933764-94-4P	933764-95-5P
	933764-96-6P	933764-97-7P	933764-99-9P
	933765-00-5P	933765-01-6P	933765-02-7P
	933765-03-8P	933765-04-9P	933765-05-0P
	933765-06-1P	933765-07-2P	933765-08-3P
	933765-09-4P	933765-10-7P	933765-11-8P
	933765-12-9P	933765-13-0P	933765-15-2P
	933765-17-4P	933765-18-5P	933765-19-6P
	933765-20-9P	933765-21-0P	933765-22-1P
	933765-23-2P	933765-24-3P	933765-25-4P
	933765-26-5P	933765-27-6P	933765-28-7P
	933765-29-8P	933765-30-1P	933765-31-2P
	933765-32-3P	933765-33-4P	933765-34-5P
	933765-35-6P	933765-36-7P	933765-37-8P
	933765-38-9P	933765-39-0P	933765-40-3P
	933765-41-4P	933765-42-5P	933765-43-6P
	933765-44-7P	933765-45-8P	933765-46-9P
	933765-47-0P	933765-48-1P	933765-49-2P
	933765-50-5P	933765-51-6P	933765-52-7P
	933765-53-8P	933765-54-9P	933765-55-0P
	933765-56-1P	933765-57-2P	933765-58-3P
	933765-59-4P	933765-60-7P	933765-61-8P
	933765-62-9P	933765-63-0P	933765-64-1P
	933765-65-2P	933765-66-3P	933765-67-4P
	933765-68-5P	933765-69-6P	933765-70-9P


933765-71-0P	933765-72-1P	933765-73-2P
933765-74-3P	933765-75-4P	933765-76-5P
933765-77-6P	933765-78-7P	933765-79-8P
933765-80-1P	933765-81-2P	933765-82-3P
933765-83-4P	933765-84-5P	933765-85-6P
933765-86-7P	933765-87-8P	933765-88-9P
933765-89-0P	933765-90-3P	933765-91-4P
933765-92-5P	933765-93-6P	933765-94-7P
933765-95-8P	933765-96-9P	933765-97-0P
933765-98-1P	933765-99-2P	933766-00-8P
933766-01-9P	933766-02-0P	933766-03-1P
933766-04-2P	933766-05-3P	933766-06-4P
933766-07-5P	933766-08-6P	933766-09-7P
933766-10-0P	933766-11-1P	933766-12-2P
933766-13-3P	933766-14-4P	933766-15-5P
933766-16-6P	933766-17-7P	933766-18-8P
933766-19-9P	933766-20-2P	933766-21-3P
933766-22-4P	933766-23-5P	933766-24-6P
933766-25-7P	933766-26-8P	933766-27-9P
933766-28-0P	933766-29-1P	933766-30-4P
933766-31-5P	933766-32-6P	933766-33-7P
933766-34-8P	933766-35-9P	933766-36-0P
933766-37-1P	933766-38-2P	933766-39-3P
933766-40-6P	933766-41-7P	933766-42-8P
933766-43-9P	933766-44-0P	933766-45-1P
933766-46-2P	933766-47-3P	933766-48-4P
933766-49-5P	933766-50-8P	933766-51-9P
933766-52-0P	933766-53-1P	933766-54-2P
933766-55-3P	933766-56-4P	933766-57-5P
933766-58-6P	933766-59-7P	933766-60-0P
933766-61-1P	933766-62-2P	933766-63-3P
933766-64-4P	933766-65-5P	933766-66-6P
933766-67-7P	933766-68-8P	933766-69-9P
933766-70-2P	933766-71-3P	933766-72-4P
933766-73-5P	933766-74-6P	933766-75-7P
933766-76-8P	933766-78-0P	933766-79-1P
933766-80-4P	933766-81-5P	933766-82-6P
933766-83-7P	933766-84-8P	933766-85-9P
933766-86-0P	933766-87-1P	933766-88-2P
933766-89-3P	933766-90-6P	933766-91-7P
933766-93-9P	933766-94-0P	933766-95-1P
933766-96-2P	933766-97-3P	933766-98-4P
933766-99-5P	933767-00-1P	933767-01-2P
933767-02-3P	933767-03-4P	933767-04-5P
933767-05-6P	933767-06-7P	933767-08-9P
933767-09-0P	933767-10-3P	933767-11-4P
933767-12-5P	933767-13-6P	933767-14-7P
933767-15-8P	933767-16-9P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)


(drug candidate; preparation of tetracyclic inhibitors of Janus kinases)

RN 933764-78-4 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine,
2-(2,6-dichlorophenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933764-79-5 CAPLUS
 CN Imidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine,
 2-(2,6-difluorophenyl)-1,8-dihydro- (CA INDEX NAME)



RN 933764-80-8 CAPLUS
 CN Imidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine,
 2-(2,6-difluorophenyl)-1,8-dihydro-, 2,2,2-trifluoroacetate (1:2) (CA
 INDEX NAME)

CM 1

CRN 933764-79-5
 CMF C19 H11 F2 N5



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 933764-81-9 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine,
2-(2-chloro-6-fluorophenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933764-82-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine,
2-(2,6-dimethylphenyl)-1,8-dihydro- (CA INDEX NAME)



RN 933764-83-1 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine-2-butanenitrile,
γ,γ-diethyl-1,8-dihydro- (CA INDEX NAME)



RN 933764-84-2 CAPLUS
 CN Imidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine-2-butanenitrile,
 γ,γ-diethyl-1,8-dihydro-, 2,2,2-trifluoroacetate (1:2) (CA
 INDEX NAME)

CM 1

CRN 933764-83-1
 CMF C21 H22 N6




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 933764-85-3 CAPLUS
 CN Imidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine,
 3,8-dihydro-3-hydroxy-2-[1-[(4-methoxyphenyl)methyl]-5-methyl-3-

(trifluoromethyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)



RN 933764-86-4 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine,
1,8-dihydro-2-[1-[(4-methoxyphenyl)methyl]-5-methyl-3-(trifluoromethyl)-1H-
pyrazol-4-yl]- (CA INDEX NAME)




RN 933764-87-5 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine,
1,8-dihydro-2-[1-[4-methoxyphenyl)methyl]-5-methyl-3-(trifluoromethyl)-1H-
pyrazol-4-yl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933764-86-4

CMF C26 H20 F3 N7 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 933764-88-6 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine,
3,8-dihydro-3-hydroxy-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-
(CA INDEX NAME)



RN 933764-89-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine,
1,8-dihydro-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]- (CA INDEX
NAME)



RN 933764-90-0 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine,
1,8-dihydro-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-,
2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933764-89-7

CMF C18 H12 F3 N7

10/565,702



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933764-91-1 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine,
2-(2,3-dimethylphenyl)-3,8-dihydro-3-hydroxy- (CA INDEX NAME)



RN 933764-92-2 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine,
2-(2,3-dimethylphenyl)-1,8-dihydro- (CA INDEX NAME)


10/565,702



RN 933764-93-3 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine,
2-(2,3-dimethylphenyl)-1,8-dihydro-, 2,2,2-trifluoroacetate (1:2) (CA
INDEX NAME)

CM 1

CRN 933764-92-2
CMF C21 H17 N5




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 933764-94-4 CAPLUS

CN 2-Pyridinamine, 3-(3,8-dihydro-3-hydroxyimidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepin-2-yl)-N,N-dimethyl- (CA INDEX NAME)



RN 933764-95-5 CAPLUS

CN 2-Pyridinamine, 3-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepin-2-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 933764-96-6 CAPLUS

CN 2-Pyridinamine, 3-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepin-2-yl)-N,N-dimethyl-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 933764-95-5

CMF C20 H17 N7



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 933764-97-7 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepin-2-yl)-3-fluoro- (CA INDEX NAME)



RN 933764-99-9 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine, 1,8-dihydro-2-[(tetrahydro-2H-thiopyran-4-yl)methyl]- (CA INDEX NAME)




RN 933765-00-5 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[(tetrahydro-2H-thiopyran-4-yl)methyl]-,
2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933764-99-9

CMF C19 H19 N5 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933765-01-6 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
3,8-dihydro-3-hydroxy-2-[(tetrahydro-2H-thiopyran-4-yl)methyl]- (CA INDEX
NAME)




RN 933765-02-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
3,8-dihydro-3-hydroxy-2-[(tetrahydro-2H-thiopyran-4-yl)methyl]-,
2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933765-01-6

CMF C19 H19 N5 O S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933765-03-8 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[3-methyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]- (CA INDEX
NAME)



RN 933765-04-9 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[3-methyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]-,
2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

10/565,702

CM 1

CRN 933765-03-8

CMF C18 H12 F3 N7



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 933765-05-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[5-(difluoromethyl)-3-methyl-1H-pyrazol-4-yl]-1,8-dihydro- (CA INDEX
NAME)




RN 933765-06-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[1-(4-methoxyphenyl)methyl]-5-methyl-3-(trifluoromethyl)-1H-
pyrazol-4-yl]- (CA INDEX NAME)




RN 933765-07-2 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[1,5-dimethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-1,8-dihydro- (CA
INDEX NAME)




RN 933765-08-3 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[1-ethyl-5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-1,8-dihydro- (CA
INDEX NAME)




RN 933765-09-4 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[1-(cyclopropylmethyl)-5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-1,8-
dihydro- (CA INDEX NAME)




RN 933765-10-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[3-methyl-5-(1,1,2,2,2-pentafluoroethyl)-1H-pyrazol-4-yl]-,
hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 933765-11-8 CAPLUS
CN 1H-Pyrazole-1-sulfonamide, 4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-N,N,5-trimethyl-3-(trifluoromethyl)- (CA INDEX NAME)



RN 933765-12-9 CAPLUS
CN 1H-Pyrazole-1-sulfonamide, 4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-N,N,5-trimethyl-3-(trifluoroacetyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933765-11-8
CMF C20 H17 F3 N8 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 933765-13-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[3-(chlorodifluoromethyl)-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-
pyrazol-4-yl]-1,8-dihydro- (CA INDEX NAME)



RN 933765-15-2 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3,5-dimethyl-1H-pyrazol-4-yl)-1,8-dihydro- (CA INDEX NAME)


RN 933765-17-4 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[5-methyl-3-(2-methylpropyl)-1H-pyrazol-4-yl]-,
2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933765-16-3

CMF C21 H21 N7



CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/565,702



RN 933765-18-5 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3-ethyl-5-methyl-1H-pyrazol-4-yl)-1,8-dihydro- (CA INDEX NAME)




RN 933765-19-6 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3-ethyl-5-methyl-1H-pyrazol-4-yl)-1,8-dihydro-, 2,2,2-trifluoroacetate
(1:2) (CA INDEX NAME)

CM 1

CRN 933765-18-5

CMF C19 H17 N7




CM 2

10/565,702

CRN 76-05-1
CMF C2 H F3 O2




RN 933765-20-9 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3-butyl-5-methyl-1H-pyrazol-4-yl)-1,8-dihydro- (CA INDEX NAME)



RN 933765-21-0 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3-butyl-5-methyl-1H-pyrazol-4-yl)-1,8-dihydro-, 2,2,2-trifluoroacetate
(1:2) (CA INDEX NAME)

CM 1

CRN 933765-20-9
CMF C21 H21 N7



10/565,702

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933765-22-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3,5-diethyl-1H-pyrazol-4-yl)-1,8-dihydro- (CA INDEX NAME)



RN 933765-23-2 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3,5-diethyl-1H-pyrazol-4-yl)-1,8-dihydro-, 2,2,2-trifluoroacetate (1:2)
(CA INDEX NAME)

CM 1

CRN 933765-22-1

CMF C20 H19 N7

10/565,702



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933765-24-3 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3-cyclopropyl-5-methyl-1H-pyrazol-4-yl)-1,8-dihydro- (CA INDEX NAME)




RN 933765-25-4 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3-cyclopropyl-5-methyl-1H-pyrazol-4-yl)-1,8-dihydro-,
2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

10/565,702


CRN 933765-24-3
CMF C20 H17 N7



CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 933765-26-5 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2-chloro-6-methylphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933765-27-6 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2-chloro-6-methylphenyl)-1,8-dihydro-, 2,2,2-trifluoroacetate (1:2)
(CA INDEX NAME)

10/565,702

CM 1

CRN 933765-26-5

CMF C20 H14 Cl N5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933765-28-7 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3-methyl- (CA INDEX NAME)



RN 933765-29-8 CAPLUS


CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

10/565,702

CM 1

CRN 933765-28-7

CMF C21 H14 N6



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933765-30-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,4-dimethyl-3-thienyl)-1,8-dihydro- (CA INDEX NAME)



RN 933765-31-2 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,4-dimethyl-3-thienyl)-1,8-dihydro-, 2,2,2-trifluoroacetate (1:2) (CA
INDEX NAME)

10/565,702

CM 1

CRN 933765-30-1

CMF C19 H15 N5 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933765-32-3 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[4-(methylsulfinyl)phenyl]- (CA INDEX NAME)



RN 933765-33-4 CAPLUS
 CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
 1,8-dihydro-2-[4-(methylsulfinyl)phenyl]-, 2,2,2-trifluoroacetate (1:2)
 (CA INDEX NAME)

CM 1

CRN 933765-32-3
 CMF C20 H15 N5 O S




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 933765-34-5 CAPLUS
 CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
 2-[4-(ethylthio)phenyl]-1,8-dihydro- (CA INDEX NAME)




RN 933765-35-6 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[2-(5-methyl-2-furanyl)propyl]- (CA INDEX NAME)




RN 933765-36-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-benzo[b]thien-5-yl-1,8-dihydro- (CA INDEX NAME)




RN 933765-37-8 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,4-dimethyl-5-thiazolyl)-1,8-dihydro- (CA INDEX NAME)




RN 933765-38-9 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(5-methyl-3-phenyl-4-isoxazolyl)- (CA INDEX NAME)




RN 933765-39-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(4-chloro-1-methyl-1H-pyrazol-3-yl)-1,8-dihydro- (CA INDEX NAME)




RN 933765-40-3 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(1,3,5-trimethyl-1H-pyrazol-4-yl)- (CA INDEX NAME)




RN 933765-41-4 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)-1,8-dihydro- (CA INDEX NAME)




RN 933765-42-5 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3,5-dimethyl-4-isoxazolyl)-1,8-dihydro- (CA INDEX NAME)




RN 933765-43-6 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[1-(2-methoxyethyl)-2,5-dimethyl-1H-pyrrol-3-yl]- (CA INDEX NAME)



RN 933765-44-7 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(1-cyclopropyl-2,5-dimethyl-1H-pyrrol-3-yl)-1,8-dihydro- (CA INDEX NAME)

RN 933765-45-8 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,5-dimethoxy-4-(methylthio)phenyl]-1,8-dihydro- (CA INDEX NAME)


RN 933765-46-9 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(trifluoromethyl)- (CA INDEX NAME)




RN 933765-47-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,4-dimethoxy-3-methylphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933765-48-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[2-(methylthio)phenyl]- (CA INDEX NAME)




RN 933765-49-2 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2-ethoxyphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933765-50-5 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,4-dimethoxyphenyl)-1,8-dihydro- (CA INDEX NAME)



RN 933765-51-6 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(2,3,4,5,6-pentamethylphenyl)- (CA INDEX NAME)



10/565,702


RN 933765-52-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2-chloro-4-methoxyphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933765-53-8 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(4-methoxy-2-methylphenyl)- (CA INDEX NAME)




RN 933765-54-9 CAPLUS

CN Phenol, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-
(CA INDEX NAME)




RN 933765-55-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(4-methoxy-2,5-dimethylphenyl)- (CA INDEX NAME)




RN 933765-56-1 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2-chloro-3,4-dimethoxyphenyl)-1,8-dihydro- (CA INDEX NAME)



RN 933765-57-2 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(4-methoxy-2,3-dimethylphenyl)- (CA INDEX NAME)

RN 933765-58-3 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,6-dichloro-3,4-dimethoxyphenyl)-1,8-dihydro- (CA INDEX NAME)


RN 933765-59-4 CAPLUS

CN Phenol, 2,4-dichloro-3-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-6-methoxy- (CA INDEX NAME)




RN 933765-60-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(2,4,5-trimethylphenyl)- (CA INDEX NAME)




RN 933765-61-8 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,4-dichlorophenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933765-62-9 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2-chloro-4-fluorophenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933765-63-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,4-dimethylphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933765-64-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 933765-65-2 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2-(difluoromethoxy)phenyl]-1,8-dihydro- (CA INDEX NAME)



RN 933765-66-3 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,

1,8-dihydro-2-(2-methoxy-3-pyridinyl)- (CA INDEX NAME)




RN 933765-67-4 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[4-fluoro-2-(trifluoromethyl)phenyl]-1,8-dihydro- (CA INDEX NAME)



RN 933765-68-5 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(2-methoxyphenyl)- (CA INDEX NAME)



10/565,702


RN 933765-69-6 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 933765-70-9 CAPLUS

CN Phenol, 2-chloro-3-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-
2-yl)-6-methoxy- (CA INDEX NAME)




RN 933765-71-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(3-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 933765-72-1 CAPLUS

CN Benzenamine, 4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3-ethoxy-N,N-diethyl- (CA INDEX NAME)



RN 933765-73-2 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine, 2-(4-bromo-2,5-dimethoxyphenyl)-1,8-dihydro- (CA INDEX NAME)



10/565,702


RN 933765-74-3 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[2-(2-methylpropoxy)phenyl]- (CA INDEX NAME)




RN 933765-75-4 CAPLUS

CN 2-Pyridinamine, 3-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)



RN 933765-76-5 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(1H-indol-4-yl)- (CA INDEX NAME)



10/565,702


RN 933765-77-6 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[2-(trifluoromethyl)thio]phenyl]- (CA INDEX NAME)




RN 933765-78-7 CAPLUS

CN Phenol, 4-bromo-3-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)




RN 933765-79-8 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2-chloro-4-(methylsulfonyl)phenyl]-1,8-dihydro- (CA INDEX NAME)




RN 933765-80-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2-chloro-4-methylsulfonylphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933765-81-2 CAPLUS

CN Phenol, 4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-
3,5-dimethyl- (CA INDEX NAME)




RN 933765-82-3 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2-chloro-4,6-dimethoxyphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933765-83-4 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3-chlorophenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933765-84-5 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[3-fluoro-5-(trifluoromethyl)phenyl]-1,8-dihydro- (CA INDEX NAME)




RN 933765-85-6 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3,5-dichlorophenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933765-86-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3-chloro-4-methoxyphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933765-87-8 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(4-chloro-1,3-benzodioxol-5-yl)-1,8-dihydro- (CA INDEX NAME)




RN 933765-88-9 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(4-chloro-2,6-difluorophenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933765-89-0 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(6-chloro-2,3-difluorophenyl)-1,8-dihydro- (CA INDEX NAME)



RN 933765-90-3 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,6-dichloro-3-fluorophenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933765-91-4 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2-chloro-6-fluoro-3-methoxyphenyl)-1,8-dihydro- (CA INDEX NAME)



RN 933765-92-5 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(2,4,6-trifluorophenyl)- (CA INDEX NAME)




RN 933765-93-6 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(2,4,6-trifluorophenyl)-, 2,2,2-trifluoroacetate (1:2) (CA
INDEX NAME)

CM 1

CRN 933765-92-5

CMF C19 H10 F3 N5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933765-94-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[2-methoxy-4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 933765-95-8 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[2-methoxy-4-(trifluoromethoxy)phenyl]-,
2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

10/565,702

CM 1

CRN 933765-94-7

CMF C21 H14 F3 N5 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933765-96-9 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3-chloro-4-fluorophenyl)-1,8-dihydro- (CA INDEX NAME)



10/565,702


RN 933765-97-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3-chloro-4-fluorophenyl)-1,8-dihydro-, 2,2,2-trifluoroacetate (1:2)
(CA INDEX NAME)

CM 1

CRN 933765-96-9

CMF C19 H11 Cl F N5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933765-98-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(4-fluoro-2-methylphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933765-99-2 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(4-fluoro-2-methylphenyl)-1,8-dihydro-, 2,2,2-trifluoroacetate (1:2)
(CA INDEX NAME)

CM 1

CRN 933765-98-1

CMF C20 H14 F N5




CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 933766-00-8 CAPLUS
 CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
 2-(2,4-dichloro-6-methoxyphenyl)-1,8-dihydro- (CA INDEX NAME)



RN 933766-01-9 CAPLUS
 CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
 2-(2,4-dichloro-6-methoxyphenyl)-1,8-dihydro-, 2,2,2-trifluoroacetate
 (1:2) (CA INDEX NAME)

CM 1

CRN 933766-00-8
 CMF C20 H13 Cl2 N5 O



CM 2


CRN 76-05-1
 CMF C2 H F3 O2

10/565,702



RN 933766-02-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,6-dichloro-3-methoxyphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933766-03-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,6-dichloro-3-methoxyphenyl)-1,8-dihydro-, 2,2,2-trifluoroacetate
(1:2) (CA INDEX NAME)

CM 1

CRN 933766-02-0

CMF C20 H13 Cl2 N5 O




CM 2

10/565,702

CRN 76-05-1
CMF C2 H F3 O2




RN 933766-04-2 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-(methylthio)phenyl]-1,8-dihydro- (CA INDEX NAME)



RN 933766-05-3 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-(methylthio)phenyl]-1,8-dihydro-, 2,2,2-trifluoroacetate
(1:2) (CA INDEX NAME)

CM 1

CRN 933766-04-2
CMF C20 H13 Cl2 N5 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933766-06-4 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-(methylsulfinyl)phenyl]-1,8-dihydro- (CA INDEX NAME)



RN 933766-07-5 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-(methylsulfonyl)phenyl]-1,8-dihydro-


10/565,702

2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-06-4

CMF C20 H13 Cl2 N5 O S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933766-08-6 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-(methylsulfonyl)phenyl]-1,8-dihydro- (CA INDEX NAME)




RN 933766-09-7 CAPLUS
 CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
 2-[2,6-dichloro-4-(methylsulfonyl)phenyl]-1,8-dihydro-,
 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-08-6

CMF C20 H13 Cl2 N5 O2 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/565,702



RN 933766-10-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(6-chloro-2-fluoro-3-methoxyphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933766-11-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(6-chloro-2-fluoro-3-methoxyphenyl)-1,8-dihydro-, 2,2,2-trifluoroacetate
(1:2) (CA INDEX NAME)

CM 1

CRN 933766-10-0

CMF C20 H13 Cl F N5 O




CM 2

10/565,702

CRN 76-05-1
CMF C2 H F3 O2




RN 933766-12-2 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2-chloro-6-fluoro-4-methoxyphenyl)-1,8-dihydro- (CA INDEX NAME)



RN 933766-13-3 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2-chloro-6-fluoro-4-methoxyphenyl)-1,8-dihydro-, 2,2,2-trifluoroacetate
(1:2) (CA INDEX NAME)

CM 1

CRN 933766-12-2
CMF C20 H13 Cl F N5 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 933766-14-4 CAPLUS

CN Benzenemethanol, 3,5-dichloro-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)




RN 933766-15-5 CAPLUS

CN Benzenemethanol, 4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3,5-difluoro- (CA INDEX NAME)




RN 933766-16-6 CAPLUS

CN Phenol, 3,5-dichloro-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)



RN 933766-17-7 CAPLUS

CN 3-Pyridinecarbonitrile, 5-chloro-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)




RN 933766-18-8 CAPLUS

CN 3-Pyridinecarbonitrile, 5-chloro-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 933766-17-7

CMF C19 H10 Cl N7



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933766-19-9 CAPLUS

CN 3,5-Pyridinedicarbonitrile, 4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)



RN 933766-20-2 CAPLUS


10/565,702

CN 3,5-Pyridinedicarbonitrile, 4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 933766-19-9

CMF C20 H10 N8



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933766-21-3 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3-fluoro-6-methyl- (CA INDEX NAME)



10/565,702


RN 933766-22-4 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3-fluoro-6-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-21-3

CMF C21 H13 F N6



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933766-23-5 CAPLUS

CN 3-Pyridinecarbonitrile, 4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)




10/565,702

RN 933766-24-6 CAPLUS
CN 3-Pyridinecarbonitrile, 4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 933766-23-5

CMF C19 H11 N7




CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 933766-25-7 CAPLUS
CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3,6-difluoro- (CA INDEX NAME)




RN 933766-26-8 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3,6-difluoro-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-25-7

CMF C20 H10 F2 N6



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 933766-27-9 CAPLUS

CN Benzonitrile, 3-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3,6-difluoro-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

yl)-2-fluoro-4-(trifluoromethyl)- (CA INDEX NAME)




RN 933766-28-0 CAPLUS

CN Benzonitrile, 3-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-2-fluoro-4-(trifluoromethyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-27-9

CMF C21 H10 F4 N6



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933766-29-1 CAPLUS

CN Benzonitrile, 3-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-4-methoxy- (CA INDEX NAME)




RN 933766-30-4 CAPLUS

CN Benzonitrile, 3-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-4-methoxy-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-29-1

CMF C21 H14 N6 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933766-31-5 CAPLUS

CN Benzonitrile, 6-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-2,3-dimethoxy- (CA INDEX NAME)




RN 933766-32-6 CAPLUS

CN Benzonitrile, 6-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-2,3-dimethoxy-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-31-5

CMF C22 H16 N6 O2




CM 2

10/565,702

CRN 76-05-1
CMF C2 H F3 O2




RN 933766-33-7 CAPLUS
CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-4,5-dimethoxy- (CA INDEX NAME)



RN 933766-34-8 CAPLUS
CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-4,5-dimethoxy-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-33-7
CMF C23 H15 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933766-35-9 CAPLUS

CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-4-hydroxy-5-methoxy- (CA INDEX NAME)



RN 933766-36-0 CAPLUS


CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-4-hydroxy-5-methoxy-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

10/565,702

CM 1

CRN 933766-35-9

CMF C22 H13 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933766-37-1 CAPLUS

CN Benzonitrile, 4-(1,8-dihydroimidazo[4,5-d]dipyrido[3,4-b:3',2'-f]azepin-2-yl)-2,5-dimethoxy- (CA INDEX NAME)



10/565,702


RN 933766-38-2 CAPLUS

CN Benzonitrile, 4-(1,8-dihydroimidazo[4,5-d]dipyrido[3,4-b:3',2'-f]azepin-2-yl)-2,5-dimethoxy-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-37-1

CMF C22 H16 N6 O2



CM 2


CRN 76-05-1

CMF C2 H3 F3 O2



RN 933766-39-3 CAPLUS


CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(methylsulfonyl)- (CA INDEX NAME)



RN 933766-40-6 CAPLUS
 CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(methylsulfonyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-39-3
 CMF C21 H14 N6 O2 S




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 933766-41-7 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3,5-dimethoxy- (CA INDEX NAME)




RN 933766-42-8 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3,5-dimethoxy-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-41-7

CMF C22 H16 N6 O2




CM 2

10/565,702

CRN 76-05-1
CMF C2 H F3 O2



RN 933766-43-9 CAPLUS
CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3,5-difluoro- (CA INDEX NAME)




RN 933766-44-0 CAPLUS
CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3,5-difluoro-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-43-9
CMF C20 H10 F2 N6

10/565,702



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933766-45-1 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3,4-difluoro- (CA INDEX NAME)




RN 933766-46-2 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3,4-difluoro-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

10/565,702


CRN 933766-45-1
CMF C20 H10 F2 N6



CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 933766-47-3 CAPLUS
CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3-fluoro-6-methoxy- (CA INDEX NAME)




RN 933766-48-4 CAPLUS
CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3-fluoro-6-methoxy-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

10/565,702

CM 1

CRN 933766-47-3

CMF C21 H13 F N6 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933766-49-5 CAPLUS

CN Benzonitrile, 5-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-2-fluoro- (CA INDEX NAME)




RN 933766-50-8 CAPLUS

CN Benzonitrile, 5-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-2-fluoro-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-49-5

CMF C20 H11 F N6



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933766-51-9 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3-fluoro-4-methoxy- (CA INDEX NAME)




RN 933766-52-0 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3-fluoro-4-methoxy-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-51-9

CMF C21 H13 F N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 933766-53-1 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-

10/565,702

yl)-3-fluoro-5-methoxy- (CA INDEX NAME)




RN 933766-54-2 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3-fluoro-5-methoxy-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-53-1

CMF C21 H13 F N6 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2

10/565,702




RN 933766-55-3 CAPLUS
CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(methylthio)- (CA INDEX NAME)



RN 933766-56-4 CAPLUS
CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(methylthio)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-55-3
CMF C22 H13 N7 S



10/565,702

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933766-57-5 CAPLUS

CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(hydroxymethyl)- (CA INDEX NAME)




RN 933766-58-6 CAPLUS

CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(hydroxymethyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-57-5

CMF C22 H13 N7 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933766-59-7 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(hydroxymethyl)- (CA INDEX NAME)




RN 933766-60-0 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(hydroxymethyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

10/565,702

CRN 933766-59-7
CMF C21 H14 N6 O




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 933766-61-1 CAPLUS
CN Benzeneacetonitrile, 3,5-dichloro-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)



RN 933766-62-2 CAPLUS

10/565,702

CN 1,3-Benzenedicarbonitrile, 5-(cyanomethyl)-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)




RN 933766-63-3 CAPLUS

CN 1,3-Benzenedicarbonitrile, 5-(cyanomethyl)-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-62-2

CMF C23 H12 N8



CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/565,702



RN 933766-64-4 CAPLUS

CN Benzeneacetonitrile, 3-cyano-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)




RN 933766-65-5 CAPLUS

CN Benzeneacetonitrile, 3-cyano-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-64-4

CMF C22 H13 N7




CM 2

10/565,702

CRN 76-05-1
CMF C2 H F3 O2



RN 933766-66-6 CAPLUS
CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(methylsulfinyl)- (CA INDEX NAME)




RN 933766-67-7 CAPLUS
CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(methylsulfinyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-66-6
CMF C21 H14 N6 O S

10/565,702



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933766-68-8 CAPLUS

CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(methylsulfonyl)- (CA INDEX NAME)



RN 933766-69-9 CAPLUS


10/565,702

CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(methylsulfonyl)-, 2,2,2-trifluoroacetate (1:2)
(CA INDEX NAME)

CM 1

CRN 933766-68-8

CMF C22 H13 N7 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 933766-70-2 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-hydroxy- (CA INDEX NAME)




RN 933766-71-3 CAPLUS

CN Benzenemethanamine, 3,5-dichloro-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 933766-72-4 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine, 2-[2,6-dichloro-4-(4-morpholinylmethyl)phenyl]-1,8-dihydro- (CA INDEX NAME)



RN 933766-73-5 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-(4-thiomorpholinylmethyl)phenyl]-1,8-dihydro- (CA INDEX
NAME)



RN 933766-74-6 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-(4-thiomorpholinylmethyl)phenyl]-1,8-dihydro-,
2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 933766-73-5

10/565,702

CMF C24 H20 C12 N6 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 933766-75-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-(methoxymethyl)phenyl]-1,8-dihydro- (CA INDEX NAME)




RN 933766-76-8 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-(ethylthio)phenyl]-1,8-dihydro- (CA INDEX NAME)



RN 933766-78-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-[(1-methylethyl)thio]phenyl]-1,8-dihydro- (CA INDEX NAME)




RN 933766-79-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-[(1-methylethyl)thio]phenyl]-1,8-dihydro-,
2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-78-0

CMF C22 H17 Cl2 N5 S




CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 933766-80-4 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-(ethylsulfinyl)phenyl]-1,8-dihydro- (CA INDEX NAME)


RN 933766-81-5 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-(ethylsulfinyl)phenyl]-1,8-dihydro-,
2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-80-4

CMF C21 H15 Cl2 N5 O S



CM 2

CRN 76-05-1


10/565,702

CMF C2 H F3 O2



RN 933766-82-6 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-(ethylsulfonyl)phenyl]-1,8-dihydro- (CA INDEX NAME)



RN 933766-83-7 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-(ethylsulfonyl)phenyl]-1,8-dihydro-,
2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-82-6

CMF C21 H15 Cl2 N5 O2 S

10/565,702



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933766-84-8 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-[(1-methylethyl)sulfinyl]phenyl]-1,8-dihydro- (CA INDEX
NAME)



10/565,702


RN 933766-85-9 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-[(1-methylethyl)sulfinyl]phenyl]-1,8-dihydro-,
2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-84-8

CMF C22 H17 Cl2 N5 O S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933766-86-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-[(1-methylethyl)sulfonyl]phenyl]-1,8-dihydro- (CA INDEX
NAME)




RN 933766-87-1 CAPLUS

CM Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-[(1-methylethyl)sulfonyl]phenyl]-1,8-dihydro-,
2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-86-0

CMF C22 H17 Cl2 N5 O2 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/565,702



RN 933766-88-2 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[3,4-b:3',2'-f]azepin-2-yl)-5-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 933766-89-3 CAPLUS


CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[3,4-b:3',2'-f]azepin-2-yl)-5-[(1-methylethyl)sulfonyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-88-2

CMF C23 H18 N6 O2 S

10/565,702



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933766-90-6 CAPLUS

CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(ethylthio)- (CA INDEX NAME)



RN 933766-91-7 CAPLUS

CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(ethylthio)-, 2,2,2-trifluoroacetate (1:2) (CA


10/565,702

INDEX NAME)

CM 1

CRN 933766-90-6

CMF C23 H15 N7 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933766-93-9 CAPLUS

CN Benzonitrile, 3-chloro-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(ethylthio)- (CA INDEX NAME)




RN 933766-94-0 CAPLUS

CN Benzonitrile, 3-chloro-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(ethylthio)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-93-9

CMF C22 H15 Cl N6 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933766-95-1 CAPLUS

CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-[(1-methylethyl)thio]- (CA INDEX NAME)




RN 933766-96-2 CAPLUS

CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-[(1-methylethyl)thio]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-95-1

CMF C24 H17 N7 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/565,702



RN 933766-97-3 CAPLUS

CN Benzonitrile, 3-chloro-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-[(1-methylethyl)thio]- (CA INDEX NAME)




RN 933766-98-4 CAPLUS

CN Benzonitrile, 3-chloro-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-[(1-methylethyl)thio]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-97-3

CMF C23 H17 Cl N6 S



10/565,702

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933766-99-5 CAPLUS

CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-[(1-methylethyl)sulfinyl]- (CA INDEX NAME)



RN 933767-00-1 CAPLUS


CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-[(1-methylethyl)sulfinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-99-5

CMF C24 H17 N7 O S

10/565,702



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933767-01-2 CAPLUS

CN Benzonitrile, 3-chloro-2-(1,8-dihydroimidazo[4,5-d]dipyrido[3,4-b:3',2'-f]azepin-2-yl)-5-[(1-methylethyl)sulfinyl]- (CA INDEX NAME)




RN 933767-02-3 CAPLUS

CN Benzonitrile, 3-chloro-2-(1,8-dihydroimidazo[4,5-d]dipyrido[3,4-b:3',2'-f]azepin-2-yl)-5-[(1-methylethyl)sulfinyl]-, 2,2,2-trifluoroacetate (1:2)
(CA INDEX NAME)

CM 1

CRN 933767-01-2

CMF C23 H17 Cl N6 O S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 933767-03-4 CAPLUS

CN Acetonitrile, 2-[3,5-dichloro-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)phenoxy]- (CA INDEX NAME)

10/565,702




RN 933767-04-5 CAPLUS

CN Acetonitrile, 2-[3,5-dichloro-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)phenoxy]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933767-03-4

CMF C21 H12 Cl2 N6 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933767-05-6 CAPLUS

CN Propanenitrile, 2-[3,5-dichloro-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)phenoxy]- (CA INDEX NAME)




RN 933767-06-7 CAPLUS

CN Propanenitrile, 2-[3,5-dichloro-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)phenoxy]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933767-05-6

CMF C22 H14 Cl2 N6 O



CM 2

CRN 76-05-1


10/565,702

CMF C2 H F3 O2



RN 933767-08-9 CAPLUS

CN 1,3-Benzenedicarbonitrile, 5-(1-cyanoethoxy)-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)



RN 933767-09-0 CAPLUS


CN 1,3-Benzenedicarbonitrile, 5-(1-cyanoethoxy)-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933767-08-9

CMF C24 H14 N8 O

10/565,702



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933767-10-3 CAPLUS

CN Benzonitrile, 5-(1-cyanoethoxy)-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)




RN 933767-11-4 CAPLUS

CN Benzonitrile, 5-(1-cyanoethoxy)-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933767-10-3

CMF C23 H15 N7 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 933767-12-5 CAPLUS

CN 1,3-Benzenedicarbonitrile, 5-(cyanomethoxy)-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)

10/565,702




RN 933767-13-6 CAPLUS

CN 1,3-Benzenedicarbonitrile, 5-(cyanomethoxy)-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933767-12-5

CMF C23 H12 N8 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933767-14-7 CAPLUS

CN Propanamide, 2-[3,5-dichloro-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)phenoxy]- (CA INDEX NAME)




RN 933767-15-8 CAPLUS

CN Propanamide, 2-[3,5-dichloro-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)phenoxy]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933767-14-7

CMF C22 H16 Cl2 N6 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933767-16-9 CAPLUS

CN Propanamide, 2-[3,5-dicyano-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)phenoxy]- (CA INDEX NAME)



IT	933767-17-0P	933767-19-2P	933767-20-5P
	933767-22-7P	933767-23-8P	933767-24-9P
	933767-25-0P	933767-26-1P	933767-27-2P
	933767-28-3P	933767-29-4P	933767-31-8P
	933767-32-9P	933767-34-1P	933767-35-2P
	933767-36-3P	933767-37-4P	933767-39-6P
	933767-40-9P	933767-41-0P	933767-42-1P
	933767-43-2P	933767-44-3P	933767-45-4P
	933767-46-5P	933767-47-6P	933767-48-7P
	933767-49-8P	933767-50-1P	933767-51-2P
	933767-52-3P	933767-53-4P	933767-54-5P
	933767-55-6P	933767-56-7P	933767-57-8P
	933767-58-9P	933767-60-3P	933767-62-5P
	933767-63-6P	933767-65-8P	933767-66-9P
	933767-68-1P	933767-69-2P	933767-70-5P
	933767-71-6P	933767-72-7P	933767-73-8P
	933767-74-9P	933767-75-0P	933767-76-1P
	933767-77-2P	933767-78-3P	933767-79-4P
	933767-80-7P	933767-81-8P	933767-82-9P
	933767-83-0P	933767-84-1P	933767-85-2P
	933767-87-4P	933767-88-5P	933767-90-9P
	933767-91-0P	933767-92-1P	933767-93-2P
	933767-94-3P	933767-95-4P	933767-96-5P
	933767-97-6P	933767-98-7P	933767-99-8P

933768-00-4P	933768-01-5P	933768-02-6P
933768-03-7P	933768-04-8P	933768-05-9P
933768-18-4P	933768-19-5P	933768-20-8P
933768-45-7P	933768-47-9P	933768-48-0P
933768-49-1P	933768-50-4P	933768-51-5P
933768-53-7P	933768-55-9P	933768-56-0P
933768-57-1P	933768-58-2P	933768-59-3P
933768-60-6P	933768-61-7P	933768-63-9P
933768-64-0P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of tetracyclic inhibitors of Janus kinases)


RN 933767-17-0 CAPLUS

CN Propanamide, 2-[3,5-dicyano-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)phenoxy]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933767-16-9

CMF C24 H16 N8 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933767-19-2 CAPLUS

CN Benamide, 5-(2-amino-1-methyl-2-oxoethoxy)-3-cyano-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)




RN 933767-20-5 CAPLUS

CN Benamide, 5-(2-amino-1-methyl-2-oxoethoxy)-3-cyano-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933767-19-2

CMF C24 H18 N8 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/565,702



RN 933767-22-7 CAPLUS

CN 1,3-Benzenedicarboxamide, 5-(2-amino-1-methyl-2-oxoethoxy)-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)



RN 933767-23-8 CAPLUS


CN 1,3-Benzenedicarboxamide, 5-(2-amino-1-methyl-2-oxoethoxy)-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933767-22-7

CMF C24 H20 N8 O4

10/565,702



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933767-24-9 CAPLUS

CN Acetamide, 2-[3,5-dichloro-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)phenoxy]- (CA INDEX NAME)



RN 933767-25-0 CAPLUS


10/565,702

CN Acetamide, 2-[3,5-dichloro-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)phenoxy]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933767-24-9

CMF C21 H14 Cl2 N6 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 933767-26-1 CAPLUS

CN Acetamide, 2-[3,5-dicyano-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)phenoxy]- (CA INDEX NAME)

10/565,702




RN 933767-27-2 CAPLUS

CN Acetamide, 2-[3,5-dicyano-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)phenoxy]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933767-26-1

CMF C23 H14 N8 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933767-28-3 CAPLUS

CN Acetamide, 2-cyano-2-[3,5-dichloro-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)phenoxy]-N,N-dimethyl- (CA INDEX NAME)



RN 933767-29-4 CAPLUS


CN Acetamide, 2-cyano-2-[3,5-dichloro-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)phenoxy]-N,N-dimethyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933767-28-3

CMF C24 H17 Cl2 N7 O2

10/565,702



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933767-31-8 CAPLUS

CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)



RN 933767-32-9 CAPLUS


CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

10/565,702

CRN 933767-31-8

CMF C21 H11 N7



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933767-34-1 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)




RN 933767-35-2 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

10/565,702


CRN 933767-34-1
CMF C20 H12 N6



CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 933767-36-3 CAPLUS
CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-4-hydroxy- (CA INDEX NAME)




RN 933767-37-4 CAPLUS
CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-4-hydroxy-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

10/565,702

CM 1

CRN 933767-36-3

CMF C20 H12 N6 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933767-39-6 CAPLUS

CN 1,3-Benzodioxole-5-carbonitrile, 4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)




RN 933767-40-9 CAPLUS

CN 1,3-Benzodioxole-5-carbonitrile, 4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933767-39-6

CMF C21 H12 N6 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933767-41-0 CAPLUS

CN Benzonitrile, 3-chloro-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)



RN 933767-42-1 CAPLUS


CN Benzonitrile, 3-chloro-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

10/565,702

CM 1

CRN 933767-41-0

CMF C20 H11 Cl N6



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933767-43-2 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3-fluoro-4-methyl- (CA INDEX NAME)



RN 933767-44-3 CAPLUS


CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-

yl)-3-fluoro-4-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933767-43-2

CMF C21 H13 F N6



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933767-45-4 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3-fluoro- (CA INDEX NAME)




RN 933767-46-5 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3-fluoro-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933767-45-4

CMF C20 H11 F N6



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933767-47-6 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3-methoxy- (CA INDEX NAME)




RN 933767-48-7 CAPLUS

CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-3-methoxy-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933767-47-6

CMF C21 H14 N6 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933767-49-8 CAPLUS


CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-fluoro- (CA INDEX NAME)



RN 933767-50-1 CAPLUS
 CN Benzonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-fluoro-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933767-49-8
 CMF C20 H11 F N6




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 933767-51-2 CAPLUS
 CN Benzonitrile, 3-chloro-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-6-methoxy- (CA INDEX NAME)

10/565,702




RN 933767-52-3 CAPLUS

CN Benzonitrile, 3-chloro-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-6-methoxy-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933767-51-2

CMF C21 H13 Cl N6 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 933767-53-4 CAPLUS

CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-

b:4',3'-f]azepin-2-yl)-4-methoxy- (CA INDEX NAME)




RN 933767-54-5 CAPLUS

CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-4-methoxy-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933767-53-4

CMF C22 H13 N7 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933767-55-6 CAPLUS

CN Carbamic acid, N-[4-(1,8-dihydroimidazo[4,5-d]diprido[2,3-b:4',3'-f]azepin-2-yl)-3-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 933767-56-7 CAPLUS

CN Carbamic acid, N-[4-(1,8-dihydroimidazo[4,5-d]diprido[2,3-b:4',3'-f]azepin-2-yl)-3-pyridinyl]-, 1,1-dimethylethyl ester, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 933767-55-6

CMF C23 H21 N7 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/565,702



RN 933767-57-8 CAPLUS

CN Carbamic acid, N-[4-(3,8-dihydro-3-hydroxyimidazo[4,5-d]dipyrdo[2,3-b:4',3'-f]azepin-2-yl)-3-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 933767-58-9 CAPLUS

CN Carbamic acid, N-[4-(3,8-dihydro-3-hydroxyimidazo[4,5-d]dipyrdo[2,3-b:4',3'-f]azepin-2-yl)-3-pyridinyl]-, 1,1-dimethylethyl ester, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 933767-57-8

CMF C23 H21 N7 O3



CM 2

CRN 76-05-1

10/565,702

CMF C2 H F3 O2




RN 933767-60-3 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3,5-dimethyl-4-pyridinyl)-1,8-dihydro-, 2,2,2-trifluoroacetate (1:2)
(CA INDEX NAME)

CM 1

CRN 933767-59-0

CMF C20 H16 N6



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 933767-62-5 CAPLUS
CN Phenol, 3,5-dichloro-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-
f]azepin-2-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933767-61-4

CMF C19 H11 Cl2 N5 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 933767-63-6 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,6-dichloro-4-methoxyphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933767-65-8 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,6-dichloro-4-ethoxyphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933767-66-9 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-(1-methylethoxy)phenyl]-1,8-dihydro- (CA INDEX NAME)



RN 933767-68-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-(trifluoromethoxy)phenyl]-1,8-dihydro- (CA INDEX NAME)




RN 933767-69-2 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-(trifluoromethoxy)phenyl]-1,8-dihydro-,
2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933767-68-1

CMF C20 H10 Cl2 F3 N5 O




CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 933767-70-5 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(3-methyl-4-pyridinyl)- (CA INDEX NAME)


RN 933767-71-6 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(3-methyl-4-pyridinyl)-, 2,2,2-trifluoroacetate (1:3) (CA
INDEX NAME)

CM 1

CRN 933767-70-5

CMF C19 H14 N6



CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/565,702



RN 933767-72-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(2-methyl-3-pyridinyl)- (CA INDEX NAME)




RN 933767-73-8 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-(2-methyl-3-pyridinyl)-, 2,2,2-trifluoroacetate (1:3) (CA
INDEX NAME)

CM 1

CRN 933767-72-7

CMF C19 H14 N6



CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/565,702



RN 933767-74-9 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,4-dimethyl-3-pyridinyl)-1,8-dihydro- (CA INDEX NAME)




RN 933767-75-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,4-dimethyl-3-pyridinyl)-1,8-dihydro-, 2,2,2-trifluoroacetate (1:3)
(CA INDEX NAME)

CM 1

CRN 933767-74-9

CMF C20 H16 N6



CM 2

CRN 76-05-1


10/565,702

CMF C2 H F3 O2



RN 933767-76-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(5-chloro-2-ethoxyphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933767-77-2 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(5-chloro-2-ethoxyphenyl)-1,8-dihydro-, 2,2,2-trifluoroacetate (1:2)
(CA INDEX NAME)

CM 1

CRN 933767-76-1

CMF C21 H16 Cl N5 O



10/565,702

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933767-78-3 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(5-chloro-2-methoxyphenyl)-1,8-dihydro- (CA INDEX NAME)



RN 933767-79-4 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(5-chloro-2-methoxyphenyl)-1,8-dihydro-, 2,2,2-trifluoroacetate (1:2)
(CA INDEX NAME)

CM 1

CRN 933767-78-3

CMF C20 H14 Cl N5 O

10/565,702



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933767-80-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(5-bromo-2-ethoxyphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933767-81-8 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(5-bromo-2-ethoxyphenyl)-1,8-dihydro-, 2,2,2-trifluoroacetate (1:2) (CA
INDEX NAME)

CM 1

10/565,702


CRN 933767-80-7
CMF C21 H16 Br N5 O



CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 933767-82-9 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,3-difluoro-6-methoxyphenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933767-83-0 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,3-difluoro-6-methoxyphenyl)-1,8-dihydro-, 2,2,2-trifluoroacetate
(1:2) (CA INDEX NAME)

10/565,702

CM 1

CRN 933767-82-9

CMF C20 H13 F2 N5 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933767-84-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1,8-dihydro- (CA INDEX NAME)



10/565,702


RN 933767-85-2 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1,8-dihydro-,
2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933767-84-1

CMF C20 H10 Cl2 F3 N5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933767-87-4 CAPLUS

CN Benzenamine, 3,5-dichloro-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-
f]azepin-2-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 933767-88-5 CAPLUS

CN Benzenamine, 3,5-dichloro-4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-N,N-dimethyl-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 933767-87-4

CMF C21 H16 Cl2 N6




CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 933767-90-9 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,6-dichloro-4-fluorophenyl)-1,8-dihydro- (CA INDEX NAME)


RN 933767-91-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,6-dichloro-4-fluorophenyl)-1,8-dihydro-, 2,2,2-trifluoroacetate (1:2)
(CA INDEX NAME)

CM 1

CRN 933767-90-9

CMF C19 H10 C12 F N5



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 933767-92-1 CAPLUS

CN Benzonitrile, 3-chloro-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-methoxy- (CA INDEX NAME)




RN 933767-93-2 CAPLUS

CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-methoxy- (CA INDEX NAME)




RN 933767-94-3 CAPLUS

CN Benzonitrile, 3-chloro-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-ethoxy- (CA INDEX NAME)




RN 933767-95-4 CAPLUS

CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-ethoxy- (CA INDEX NAME)




RN 933767-96-5 CAPLUS

CN Benzonitrile, 3-chloro-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(1-methylethoxy)- (CA INDEX NAME)




RN 933767-97-6 CAPLUS

CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(1-methylethoxy)- (CA INDEX NAME)



RN 933767-98-7 CAPLUS

CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(trifluoromethoxy)- (CA INDEX NAME)




RN 933767-99-8 CAPLUS

CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(trifluoromethoxy)-, 2,2,2-trifluoroacetate (1:2)
(CA INDEX NAME)

CM 1

CRN 933767-98-7

CMF C22 H10 F3 N7 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 933768-00-4 CAPLUS

CN Benzonitrile, 3-chloro-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(trifluoromethyl)- (CA INDEX NAME)



RN 933768-01-5 CAPLUS

CN Benzonitrile, 3-chloro-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(dimethylamino)- (CA INDEX NAME)




RN 933768-02-6 CAPLUS

CN Benzonitrile, 3-chloro-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-(dimethylamino)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 933768-01-5

CMF C22 H16 Cl N7



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933768-03-7 CAPLUS

CN Benzonitrile, 3-chloro-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-fluoro- (CA INDEX NAME)




RN 933768-04-8 CAPLUS

CN Benzonitrile, 3-chloro-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-5-fluoro-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

10/565,702


CRN 933768-03-7
CMF C20 H10 Cl F N6



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 933768-05-9 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[5-(difluoromethyl)-3-methyl-1H-pyrazol-4-yl]-1,8-dihydro-,
hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 933768-18-4 CAPLUS
 CN 1,3-Benzenedicarbonitrile, 2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 933768-19-5 CAPLUS
 CN Cyclohexaneacetonitrile, 4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-, cis- (CA INDEX NAME)

Relative stereochemistry.


10/565,702



RN 933768-20-8 CAPLUS


CN Cyclohexanecarbonitrile, 4-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 933768-45-7 CAPLUS

CN Benzonitrile, 3-chloro-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 933768-47-9 CAPLUS
 CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
 10-fluoro-3,8-dihydro-2-[3-methyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]-
 (CA INDEX NAME)




RN 933768-48-0 CAPLUS
 CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
 2-[5-(difluoromethyl)-3-methyl-1H-pyrazol-4-yl]-10-fluoro-3,8-dihydro-
 (CA INDEX NAME)




RN 933768-49-1 CAPLUS

CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
2-(3,5-dimethyl-1H-pyrazol-4-yl)-10-fluoro-3,8-dihydro- (CA INDEX NAME)




RN 933768-50-4 CAPLUS

CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
2-(3,5-diethyl-1H-pyrazol-4-yl)-10-fluoro-3,8-dihydro- (CA INDEX NAME)



RN 933768-51-5 CAPLUS

CN 1H-Pyrazole-1-acetonitrile, 4-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][1]benzazepin-2-yl)-5-methyl-3-(trifluoromethyl)- (CA INDEX NAME)




RN 933768-53-7 CAPLUS
CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
2-(2-chloro-6-methylphenyl)-10-fluoro-3,8-dihydro-, 2,2,2-trifluoroacetate
(1:?) (CA INDEX NAME)

CM 1

CRN 933768-52-6

CMF C21 H14 Cl F N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/565,702




RN 933768-55-9 CAPLUS

CN Benzonitrile, 2-(10-fluoro-3,8-dihydroimidazo[4,5-d]pyrido[2,3-b][1]benzazepin-2-yl)-3-methyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 933768-54-8

CMF C22 H14 F N5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933768-56-0 CAPLUS

CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine, 2-(2,6-dimethylphenyl)-10-fluoro-3,8-dihydro- (CA INDEX NAME)




RN 933768-57-1 CAPLUS

CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
2-(2,6-dimethylphenyl)-10-fluoro-3,8-dihydro-, 2,2,2-trifluoroacetate
(1:?) (CA INDEX NAME)

CM 1

CRN 933768-56-0

CMF C22 H17 F N4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933768-58-2 CAPLUS


CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
2-(3,5-dichloro-4-pyridinyl)-10-fluoro-3,8-dihydro- (CA INDEX NAME)



RN 933768-59-3 CAPLUS
 CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
 2-(3,5-dichloro-4-pyridinyl)-10-fluoro-3,8-dihydro-,
 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933768-58-2
 CMF C19 H10 Cl2 F N5




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 933768-60-6 CAPLUS
 CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,

2-(2,4-dimethyl-3-pyridinyl)-10-fluoro-3,8-dihydro- (CA INDEX NAME)




RN 933768-61-7 CAPLUS

CN Imidazo[4,5-d]pyrido[2,3-b][1]benzazepine,
2-(2,4-dimethyl-3-pyridinyl)-10-fluoro-3,8-dihydro-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 933768-60-6

CMF C21 H16 F N5



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 933768-63-9 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,6-dichlorophenyl)-1,8-dihydro- (CA INDEX NAME)




RN 933768-64-0 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[3-methyl-5-(1,1,2,2,2-pentafluoroethyl)-1H-pyrazol-4-yl]-
(CA INDEX NAME)




IT 933768-21-9P 933768-23-1P 933768-29-7P
933768-32-2P 933768-34-4P 933768-39-9P
933768-40-2P 933768-41-3P 933768-42-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; preparation of tetracyclic inhibitors of Janus kinases)
RN 933768-21-9 CAPLUS
CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(3,5-dichloro-4-pyridinyl)-3,8-dihydro-3-hydroxy- (CA INDEX NAME)




RN 933768-23-1 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,6-dichlorophenyl)-3,8-dihydro-3-hydroxy- (CA INDEX NAME)



RN 933768-29-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:3',4'-f]azepine,
2-(3,5-dichloro-4-pyridinyl)-3,8-dihydro-3-hydroxy- (CA INDEX NAME)




RN 933768-32-2 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
1,8-dihydro-2-[5-methyl-1-(tetrahydro-2H-pyran-2-yl)-3-(trifluoromethyl)-
1H-pyrazol-4-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 933768-31-1

CMF C23 H20 F3 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/565,702




RN 933768-34-4 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
3,8-dihydro-3-hydroxy-2-[5-methyl-1-(tetrahydro-2H-pyran-2-yl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]-, 2,2,2-trifluoroacetate (1:?) (CA
INDEX NAME)

CM 1

CRN 933768-33-3

CMF C23 H20 F3 N7 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 933768-39-9 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[3-(difluoromethyl)-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-

yl]-3,8-dihydro-3-hydroxy- (CA INDEX NAME)



RN 933768-40-2 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-[[[tris(1-methylethyl)silyl]oxy]methyl]phenyl]-3,8-
dihydro-3-hydroxy- (CA INDEX NAME)

RN 933768-41-3 CAPLUS


CN Benzenemethanol, 3,5-dichloro-4-[(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-
b:4',3'-f]azepin-2-yl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 933766-14-4

CMF C20 H13 Cl2 N5 O

10/565,702



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 933768-42-4 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2,6-dichloro-4-(chloromethyl)phenyl]-1,8-dihydro- (CA INDEX NAME)



IT 933768-44-6 1182709-65-4 1182709-67-6


1182709-68-7 1182709-69-8 1182709-83-6

1182709-84-7 1182709-99-4

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of tetracyclic inhibitors of Janus kinases)

RN 933768-44-6 CAPLUS


CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-(2,6-dichlorophenyl)-1,8-dihydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 1182709-65-4 CAPLUS

CN Benzenemethanol, 3-chloro-4-(1,8-dihydroimidazo[4,5-d]dipyrido[3,4-b:3',2'-f]azepin-2-yl)- (CA INDEX NAME)




RN 1182709-67-6 CAPLUS

CN Benzeneacetonitrile, 3-chloro-4-(1,8-dihydroimidazo[4,5-d]dipyrido[3,4-b:3',2'-f]azepin-2-yl)- (CA INDEX NAME)




RN 1182709-68-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[3,4-b:3',2'-f]azepine,
2-[2-chloro-4-(methylsulfinyl)phenyl]-1,8-dihydro- (CA INDEX NAME)




RN 1182709-69-8 CAPLUS

CN Phenol, 3-chloro-4-(1,8-dihydroimidazo[4,5-d]dipyrido[3,4-b:3',2'-f]azepin-
2-yl)- (CA INDEX NAME)




RN 1182709-83-6 CAPLUS

CN Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine,
2-[2-chloro-4-[(1-methylethyl)sulfonyl]phenyl]-1,8-dihydro- (CA INDEX
NAME)




RN 1182709-84-7 CAPLUS

CN Imidazo[4,5-d]dipyrido[3,4-b:3',2'-f]azepine,
2-(2-chloro-6-methoxyphenyl)-1,8-dihydro- (CA INDEX NAME)



RN 1182709-99-4 CAPLUS

CN Benzamide, 5-(2-amino-1-methyl-2-oxoethoxy)-3-chloro-2-(1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepin-2-yl)- (CA INDEX NAME)



OS.CITING REF COUNT:	2	THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 23 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:150615 CAPLUS

DOCUMENT NUMBER: 146:201595

TITLE: Use of a GSK-3 inhibitor to maintain potency of cultured multipotent non-embryonic progenitor cells

INVENTOR(S): Mays, Robert W.

PATENT ASSIGNEE(S): Athersys, Inc., USA

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007016485	AZ	20070208	WO 2006-US29736	20060731
WO 2007016485	A3	20070322		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20080194021	A1	20080814	US 2008-996890	20080125
PRIORITY APPLN. INFO.:			US 2005-704169P	P 20050729
			WO 2006-US29736	W 20060731

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 146:201595

AB The present invention is directed to the culture of non-embryonic cells, that can differentiate into cell types of more than one embryonic lineage, in culture under conditions that maintain differentiation capacity during expansion. In particular, the invention relates to culturing non-embryonic cells in the presence of at least one GSK-3 inhibitor, such as 6-bromoindirubin-3'-oxime (BIO). It was shown that the addition of BIO, or other GSK-3 inhibitors (including other indirubins), to non-embryonic cells, including multipotent adult progenitor cells, leads to the maintenance of a pluripotent phenotype for the cells, leading to more robust differentiation responses. Thus, this class of compds. provides an improvement in non-embryonic cell culturing and the ability to maintain pluripotency during expansion.


IT 676596-65-9

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(GSK-3 inhibitor; use of GSK-3 inhibitor to maintain potency of cultured multipotent non-embryonic progenitor cells)

RN 676596-65-9 CAPLUS

CN Pyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one, 9-bromo-7,12-dihydro- (CA INDEX NAME)



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 24 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2006:1176630 CAPLUS
 DOCUMENT NUMBER: 145:489215
 TITLE: Azapaulones as immunomodulators, their preparation, pharmaceutical compositions, and use for preventing and treating pancreatic autoimmune disorders
 INVENTOR(S): Mussmann, Rainer; Kunick, Conrad; Stukenbrock, Hendrik; Geese, Marcus; Kegel, Simone; Burk, Ulrike
 PATENT ASSIGNEE(S): Develogen Aktiengesellschaft, Germany; Technische Universitaet Carolo-Wilhelmina zu Braunschweig
 SOURCE: PCT Int. Appl., 83pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006117221	A1	20061109	WO 2006-EP4186	20060504
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1879591	A1	20080123	EP 2006-724715	20060504
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
US 20080287423	A1	20081120	US 2008-913486	20080603
PRIORITY APPLN. INFO.:			EP 2005-9846	A 20050504
			EP 2005-15986	A 20050722
			EP 2005-23168	A 20051024
			EP 2006-1327	A 20060123
			WO 2006-EP4186	W 20060504

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 145:489215; MARPAT 145:489215

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to azapaulones of general formula I, which are immunomodulators. In compds. 1, R1 and R2 are independently selected from H, (un)substituted C1-6 alkyl, and (un)substituted C2-7 acyl; each R3 and R4 is independently selected from halo, cyano, nitro, OR1, (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl, (un)substituted C2-6 alkynyl, (un)substituted C3-10 cycloalkyl, (un)substituted C3-10 heterocyclyl, (un)substituted C6-10 aryl, and (un)substituted 5- to 10-membered


heteroaryl; and each of m and n is independently 0-3. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound of

formula I optionally together with pharmaceutically acceptable carriers, diluents, and adjuvants and optionally including an immunosuppressive agent, as well as to the use of the compns., particularly in combination with immunomodulating agents, in the prevention, and/or treatment of pancreatic autoimmune disorders, e.g., type I diabetes, latent autoimmune diabetes in adults (LADA), and neurodegenerative disorders. Condensation of pyridoazepinedione II with 4-hydrazinobenzonitrile gave the corresponding hydrazone, which underwent heterocyclization to give pyridoazepinoindole III. The compds. of the invention are immunomodulators, e.g., III expressed IC50 values of 15 nM and 500 nM to glycogen synthase kinase-3 (GSK3) and cyclin-dependent kinase 1 (CDK1)/cyclinB, resp.

IT 914088-60-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of azapallones for treatment and prevention of pancreatic autoimmune disorders)

RN 914088-60-1 CAPLUS


CN Pyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one, 7,12-dihydro-9-methoxy- (CA INDEX NAME)




IT 914088-62-3P 914088-64-5P 914088-65-6P
 914088-67-8P 914088-69-0P 914088-70-3P
 914088-72-5P 914088-73-6P 914088-77-0P
 914088-79-2P 914088-81-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of azapallones for treatment and prevention of pancreatic autoimmune disorders)

RN 914088-62-3 CAPLUS


CN Pyrido[3',2':2,3]azepino[4,5-b]indole-9-carboxylic acid, 5,6,7,12-tetrahydro-6-oxo- (CA INDEX NAME)




RN 914088-64-5 CAPLUS
CN Pyrido[3',2':2,3]azepino[4,5-b]indole-9-carbonitrile,
5,6,7,12-tetrahydro-6-oxo- (CA INDEX NAME)



RN 914088-65-6 CAPLUS
CN Pyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one, 7,12-dihydro-9-hydroxy-
(CA INDEX NAME)




RN 914088-67-8 CAPLUS
CN Pyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one, 9-chloro-7,12-dihydro-
(CA INDEX NAME)




RN 914088-69-0 CAPLUS

CN Pyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one,
8,10-dichloro-7,12-dihydro- (CA INDEX NAME)




RN 914088-70-3 CAPLUS

CN Pyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one, 7,12-dihydro-9-methyl-
(CA INDEX NAME)




RN 914088-72-5 CAPLUS

CN Pyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one, 9-fluoro-7,12-dihydro-
(CA INDEX NAME)




RN 914088-73-6 CAPLUS

CN Pyrido[3',2':2,3]azepino[4,5-b]indole-5,12-diacetic acid,
9-bromo-6,7-dihydro-6-oxo-, 5,12-dimethyl ester (CA INDEX NAME)




RN 914088-77-0 CAPLUS

CN Pyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one, 7,12-dihydro- (CA INDEX NAME)




RN 914088-79-2 CAPLUS

CN Pyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one, 7,12-dihydro-9-(trifluoromethyl)- (CA INDEX NAME)



RN 914088-81-6 CAPLUS

CN Pyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one, 7,12-dihydro-9-iodo- (CA INDEX NAME)




IT 676596-65-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of azapallones for treatment and prevention
of pancreatic autoimmune disorders)

RN 676596-65-9 CAPLUS

CN Pyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one, 9-bromo-7,12-dihydro- (CA
INDEX NAME)



REFERENCE COUNT:

11

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L28 ANSWER 25 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2006:1176629 CAPLUS
 DOCUMENT NUMBER: 145:483725
 TITLE: Use of GSK-3 inhibitors for preventing and treating
 pancreatic autoimmune disorders
 INVENTOR(S): Musmann, Rainer; Austen, Matthias; Kelter,
 Arndt-Rene; Harder, Friedrich; Aicher, Babette; Lomow,
 Alexander
 PATENT ASSIGNEE(S): Develogen Aktiengesellschaft, Germany
 SOURCE: PCT Int. Appl., 84pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006117212	A2	20061109	WO 2006-EP4170	20060504
WO 2006117212	A3	20070215		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1728873	A1	20061206	EP 2005-11599	20050530
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
EP 1885454	A2	20080213	EP 2006-724711	20060504
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
US 20080207594	A1	20080828	US 2007-913612	20071105
PRIORITY APPLN. INFO.:			EP 2005-9846	A 20050504
			EP 2005-11599	A 20050530
			EP 2005-15986	A 20050722
			EP 2005-23168	A 20051024
			WO 2006-EP4170	W 20060504

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 145:483725

AB This invention relates to the use of Pax4 stimulating compds., e.g. Glycogen synthase kinase-3 (GSK-3) inhibitors, particularly in combination with immunomodulating agents, in the prevention, and/or treatment of pancreatic autoimmune disorders, e.g. type I diabetes or LADA. More particularly, this invention relates to the use of compds. selected from paullones, indirubines, substituted ureas, maleimide derivs. and pyrimidine thiones. Further, the present invention relates to a method of identifying and/or characterizing pancreatic beta-cell mitogens by using cells expressing a pancreatic gene or a gene whose function is controlled by a pancreatic gene, particularly the Pax4 gene, and which are

transfected with a reporter gene.
 IT 676596-65-9, 1-Azakenpauillone
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (use of GSK3 inhibitors for preventing and treating pancreatic
 autoimmune disorders)
 RN 676596-65-9 CAPLUS
 CN Pyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one, 9-bromo-7,12-dihydro- (CA
 INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)
 REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 26 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:710823 CAPLUS
 DOCUMENT NUMBER: 145:145984
 TITLE: Preparation of anti-inflammatory erythromycin
 macrolide conjugates
 INVENTOR(S): Mercep, Mladen; Mesic, Milan; Markovic, Stribor;
 Pesic, Dijana; Ozimec Landak, Ivana; Komac, Marijana;
 Makaruha Stegic, Oresta; Selmani, Selvira; Banjanac,
 Mihailo
 PATENT ASSIGNEE(S): Pliva-Istrazivacki Institut D.O.O., Croatia;
 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O.
 SOURCE: PCT Int. Appl., 117 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006075255	A2	20060720	WO 2006-IB1079	20060113
WO 2006075255	A3	20061026		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1844053	A2	20071017	EP 2006-727557	20060113
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
JP 2008532927	T	20080821	JP 2007-550873	20060113
US 20080096830	A1	20080424	US 2007-813882	20070713
PRIORITY APPLN. INFO.:			US 2005-643931P	P 20050113
			WO 2006-IB1079	W 20060113
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): CASREACT 145:145984; MARPAT 145:145984				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates (a) to new compds. represented by formula M-L-D: wherein M represents a macrolide subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, D represents a dibenzo[e,z]azulene subunit with anti-inflammatory, analgesic and/or antipyretic activity and L represents a linking group covalently linking M and D; (b) to their pharmacol. acceptable salts,

prodrugs and solvates, (c) to processes and intermediates for their preparation, and (d) to their use in the treatment of inflammatory diseases and conditions in humans and animals. Thus, macrolide conjugate I was prepared and tested in mice and in vitro as antiinflammatory agent, wherein the inflammatory process comprises pro-inflammatory cytokine production, the method further comprising exposing human peripheral leukocytes to an amount of compound effective to reduce production of at least one of TNF- α , IL-1 α , IL-1 β , IL-6, IL-8, IL-2, IL-5, and IFN- α , compared to control leukocytes.

IT 899810-20-9P 899810-21-0P 899810-22-1P

899810-23-2P 899810-24-3P 899810-57-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of antiinflammatory erythromycin macrolide conjugates)


RN 899810-20-9 CAPLUS

CN 8H-Dibenzo[b,f]thieno[2,3-d]azepine-2-carboxamide,
N-[3-[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-15-oxo-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy]-1-oxa-6-azacyclotetradec-6-yl]propyl]-
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 899810-21-0 CAPLUS

CN 8H-Dibenzo[b,f]thieno[2,3-d]azepine-2-carboxamide,
N-[3-[(2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10,11,13-
pentahydroxy-3,5,8,10,12,14-hexamethyl-15-oxo-1-oxa-6-azacyclopentadec-6-
yl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.








RN 899810-22-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[[2,6-dideoxy-4-C-[[[2-[(8H-dibenzo[b,f]thieno[2,3-d]azepin-2-ylcarbonyl)amino]ethyl]amino]methyl]-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 899810-23-2 CAPLUS
 CN 8H-Dibenzo[b,f]thieno[2,3-d]azepine-2-carboxamide,
 8-benzoyl-N-[3-[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-3-C-
 methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-
 trihydroxy-3,5,8,10,12,14-hexamethyl-15-oxo-11-[[3,4,6-trideoxy-3-
 (dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadec-
 6-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 899810-24-3 CAPLUS


CN 2-Propenamide, 3-(8H-dibenzo[b,f]thieno[2,3-d]azepin-2-yl)-N-[3-
 [(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-
 methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,8,10,12,14-hexamethyl-15-oxo-11-[[3,4,6-trideoxy-3-(dimethylamino)-
 β -D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadec-6-yl]propyl]-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.

PAGE 1-A




PAGE 1-B




RN 899810-57-2 CAPLUS
 CN 2-Propenamide, 3-(8H-dibenzo[b,f]thieno[2,3-d]azepin-2-yl)-N-[3-
 [(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-
 methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,8,10,12,14-hexamethyl-15-oxo-11-[[3,4,6-trideoxy-3-(dimethylamino)-
 β -D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadec-6-yl]propyl]-,
 (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


PAGE 1-A




PAGE 1-B




IT 899810-76-5 899810-77-6 899810-78-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of antiinflammatory erythromycin macrolide conjugates)
 RN 899810-76-5 CAPLUS
 CN 8H-Dibenzo[b,f]thieno[3,2-d]azepine-2-carboxylic acid (CA INDEX NAME)



RN 899810-77-6 CAPLUS
 CN 8H-Dibenzo[b,f]thieno[2,3-d]azepine-2-carboxylic acid, 8-benzoyl- (CA INDEX NAME)



RN 899810-78-7 CAPLUS
 CN 2-Propenoic acid, 3-(8H-dibenzo[b,f]thieno[2,3-d]azepin-2-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
 (3 CITINGS)
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 27 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2006:195980 CAPLUS
 DOCUMENT NUMBER: 144:274313
 TITLE: Preparation of tetraaza-benzo[f]azulenes as
 vasopressin Via antagonists
 INVENTOR(S): Andrzej, Roman Batt; Baxter, Andrew John; Heeney,
 Celine; Stockley, Martin Lee; Bryan Roe, Michael;
 Hudson, Peter; Handy, Rachel
 PATENT ASSIGNEE(S): Ferring B.V., Neth.
 SOURCE: PCT Int. Appl., 463 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006021213	A2	20060302	WO 2005-DK540	20050824
WO 2006021213	A3	20060817		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1632494	A1	20060308	EP 2004-104062	20040824
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
AU 2005276790	A1	20060302	AU 2005-276790	20050824
AU 2005276790	B2	20090326		
CA 2567776	A1	20060302	CA 2005-2567776	20050824
CA 2567776	C	20100713		
CA 2688865	A1	20060302	CA 2005-2688865	20050824
CA 2688912	A1	20060302	CA 2005-2688912	20050824
CA 2689274	A1	20060302	CA 2005-2689274	20050824
EP 1781661	A2	20070509	EP 2005-773384	20050824
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR			
JP 2008510684	T	20080410	JP 2007-525172	20050824
BR 2005014661	A	20080617	BR 2005-14661	20050824
KR 2009083475	A	20090803	KR 2009-712993	20050824
RU 2370497	C2	20091020	RU 2007-101239	20050824
CN 101563347	A	20091021	CN 2005-80019690	20061215
KR 2007032313	A	20070321	KR 2007-700447	20070108
MX 2007001392	A	20080311	MX 2007-1392	20070202
IN 2007DN1047	A	20070803	IN 2007-DN1047	20070207
ZA 2007001257	A	20080130	ZA 2007-1257	20070212
US 20090029965	A1	20090129	US 2008-659798	20080114
AU 2009201167	A1	20090423	AU 2009-201167	20090324
AU 2009201168	A1	20090423	AU 2009-201168	20090324

AU 2009201169	A1	20090423	AU 2009-201169	20090324
PRIORITY APPLN. INFO.:			EP 2004-104062	A 20040824
			US 2004-603557P	P 20040824
			AU 2005-276790	A3 20050824
			CA 2005-2567776	A3 20050824
			WO 2005-DK540	W 20050824
			KR 2007-700447	A3 20070108

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 144:274313; MARPAT 144:274313

GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [G = NR5R6, II-V; A1 = CH2, CH(OH), NH, N(alkyl), O and S; A2 = CH2, CH(OH), C(O), NH; A3, A12 = S, NH, N(alkyl), etc.; A4, A13 = CR9, N; A5, A14 = CR10, N; A6 = CH2, NH, N(alkyl), O; A7, A11 = C, N; A8, A9 = CH, N, NH, S, etc.; A10 = CH:CH, CH, N, NH, etc.; the ring constituted by A7-A11 is aromatic; R1-R3 = H, alkyl, O(alkyl), NO2, F, Cl, Br; R4 = H, alkyl, aryl, heteroaryl, etc.; R5, R6 = alkyl, aryl, (CH2)f-aryl, (CH2)f-heteroaryl; R9, R10 = H, alkyl, alkoxy, etc.; W = O, NH; X = (CH2)m, C(O), SOj; Y = O, S, NH, N(alkyl); a, f, j = 1-2; m = 0-2; with provisos] which are vasopressin V1a receptor antagonists, were prepared and formulated. E.g., a multi-step synthesis of 4-(3,3-dimethylbutyl)piperazine-1-carboxylic acid 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluorobenzylamide, starting from 4-(tert-butoxycarbonylamino-methyl)-3-fluorobenzoic acid and 3,6-dimethyl-3,4,9,10-tetrahydro-2,3,4,9-tetraazabenzofazulene (prepn. of the reactants was provided), was given. Compds. I were assayed to determine their ability to inhibit the cellular consequences of AVP stimulation on intact cells. In the assay, compds. I cause significant inhibition of cellular activation at concns. of 30 μ M or less. Preferred compds. I cause significant inhibition at concns. of 300 nM. Pharmaceutical compns. of the compds. I are useful as treatment of dysmenorrhea.

IT 877860-01-0P
 RL: BYP (Byproduct); PREP (Preparation)
 (preparation of tetraaza-benzo[f]azulenes as vasopressin V1a antagonists)

RN 877860-01-0 CAPLUS

CN Methanone, (4,5-dihydro-2-methyl-6H-oxazolo[4,5-d][1]benzazepin-6-yl)phenyl- (CA INDEX NAME)




IT 877858-04-3P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of tetraaza-benzo[f]azulenes as vasopressin V1a antagonists)

RN 877858-04-3 CAPLUS

CN 4-Piperidinecarboxamide, N-[[4-[[4,5-dihydro-2-methyl-1-(phenylmethyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-methylphenyl]methyl]-1-(3,3-dimethylbutyl)- (CA INDEX NAME)

PAGE 1-A






IT 318237-73-9P 877843-65-7P 877844-13-8P
 877844-14-9P 877844-15-0P 877844-16-1P
 877847-45-5P 877853-91-3P 877857-70-0P
 877857-74-4P 877857-75-5P 877858-03-2P
 877858-05-4P 877858-06-5P 877858-26-9P
 877858-27-0P 877859-73-9P 877859-75-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tetraaza-benzo[f]azulenes as vasopressin V1a antagonists)


RN 318237-73-9 CAPLUS

CN Imidazo[4,5-d][1]benzazepine, 1,4,5,6-tetrahydro-2-methyl- (CA INDEX NAME)



RN 877843-65-7 CAPLUS


CN Imidazo[4,5-d][1]benzazepine, 9-chloro-1,4,5,6-tetrahydro-2-methyl- (CA INDEX NAME)




RN 877844-13-8 CAPLUS

CN 4-Piperidinecarboxamide, N-[[4-[(9-chloro-4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]-2-methylphenyl]methyl]-1-(3,3-dimethylbutyl)- (CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 877844-14-9 CAPLUS
 CN 4-Piperidinecarboxamide, N-[[4-[(4,5-dihydro-2,9-dimethylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]-2-methylphenyl)methyl]-1-(3,3-dimethylbutyl)- (CA INDEX NAME)




RN 877844-15-0 CAPLUS
 CN 4-Piperidinecarboxamide, N-[[4-[(4,5-dihydro-2-methyl-6H-oxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-methylphenyl)methyl]-1-(3,3-dimethylbutyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877844-16-1 CAPLUS
 CN 4-Piperidinecarboxamide, N-[[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]-2-methylphenyl]methyl]-1-(3,3-dimethylbutyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877847-45-5 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,5-dihydro-2,9-dimethylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]cyclohexyl)methyl]-4-(3,3-dimethylbutyl)-
 (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 877853-91-3 CAPLUS
 CN 1-Propanone, 3-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]-2-methylphenyl]-1-[4-(3,3-dimethylbutyl)-1-piperazinyl]- (CA INDEX NAME)




RN 877857-74-4 CAPLUS

CN Methanone, (4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)[4-[3-(3,3-dimethylbutyl)-1-piperazinyl]propoxy]-3-fluorophenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877857-75-5 CAPLUS

CN Methanone, (4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl){4-[3-(4-(3,3-dimethylbutyl)-1-piperazinyl)propoxy]-3-methylphenyl}- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 877858-03-2 CAPLUS
 CN Cyclopropanecarboxamide, N-[[4-[(4,5-dihydro-2-methyl-6H-oxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-methylphenyl)methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 877858-05-4 CAPLUS
 CN Cyclopropanecarboxamide, N-[[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]-2-methylphenyl)methyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 877858-06-5 CAPLUS
 CN Propanamide, N-[[4-[(9-chloro-4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]-2-methylphenyl]methyl]-2-methyl- (CA
 INDEX NAME)




RN 877858-26-9 CAPLUS

CN Imidazo[4,5-d][1]benzazepine, 1,4,5,6-tetrahydro-2-methyl-1-(phenylmethyl)-
(CA INDEX NAME)



RN 877858-27-0 CAPLUS


CN 4H-Oxazo[4,5-d][1]benzazepine, 5,6-dihydro-2-methyl- (CA INDEX NAME)




RN 877859-73-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(3,3-dimethylbutyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877859-75-1 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,5-dihydro-2-methyl-6H-oxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-methylphenyl)methyl]-4-(3,3-dimethylbutyl)- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




IT 1172623-30-1 1172624-86-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of tetraaza-benzo[f]azulenes as vasopressin V1a antagonists)
 RN 1172623-30-1 CAPLUS
 CN Methanone, [4-(aminomethyl)-2-fluorophenyl] (4,5-dihydro-2,9-dimethylimidazo[4,5-d][1]benzazepin-6(1H)-yl)- (CA INDEX NAME)



RN 1172624-86-0 CAPLUS

CN Methanone, [4-(aminomethyl)cyclohexyl] (4,5-dihydro-2,9-dimethylimidazo[4,5-d][1]benzazepin-6(1H)-yl)- (CA INDEX NAME)




IT	877858-24-7P	877858-25-8P	877858-98-5P
	877858-99-6P	877859-00-2P	877859-01-3P
	877859-02-4P	877859-03-5P	877859-41-1P
	877859-42-2P	877859-44-4P	877859-45-5P
	877859-46-6P	877859-49-9P	877859-50-2P
	877859-51-3P		

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of tetraaza-benzo[f]azulenes as vasopressin V1a antagonists)


RN 877858-24-7 CAPLUS

CN Methanone, (4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)phenyl- (CA INDEX NAME)



RN 877858-25-8 CAPLUS


CN Methanone, [4,5-dihydro-2-methyl-1-(phenylmethyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]phenyl- (CA INDEX NAME)




RN 877858-98-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[4-[[4,5-dihydro-2-methyl-1-(phenylmethyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-fluorophenoxy]propyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 877858-99-6 CAPLUS

CN Methanone, [4,5-dihydro-2-methyl-1-(phenylmethyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl][3-fluoro-4-[3-(1-piperazinyl)propoxy]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 877859-00-2 CAPLUS
 CN Methanone, [4,5-dihydro-2-methyl-1-(phenylmethyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl][4-[3-[4-(3,3-dimethylbutyl)-1-piperazinyl]propoxy]-3-fluorophenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877859-01-3 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[3-[4-[[4,5-dihydro-2-methyl-1-(phenylmethyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-methylphenoxy]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 877859-02-4 CAPLUS
 CN Methanone, [4,5-dihydro-2-methyl-1-(phenylmethyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl][3-methyl-4-[3-(1-piperazinyl)propoxy]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 877859-03-5 CAPLUS
 CN Methanone, [4,5-dihydro-2-methyl-1-(phenylmethyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl][4-[3-[4-(3,3-dimethylbutyl)-1-piperazinyl]propoxy]-3-methylphenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 877859-41-1 CAPLUS
 CN Carbamic acid, [[4-[(4,5-dihydro-2-methyl-6H-oxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-methylphenyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 877859-42-2 CAPLUS


CN Methanone, [4-(aminomethyl)-3-methylphenyl][4,5-dihydro-2-methyl-6H-oxazolo[4,5-d][1]benzazepin-6-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 877859-44-4 CAPLUS

CN Benzonitrile, 4-[[4,5-dihydro-2-methyl-1-(phenylmethyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-methyl- (CA INDEX NAME)



RN 877859-45-5 CAPLUS


CN Methanone, [4-(aminomethyl)-3-methylphenyl][4,5-dihydro-2-methyl-1-(phenylmethyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]- (CA INDEX NAME)



RN 877859-46-6 CAPLUS

CN Cyclopropanecarboxamide, N-[[4-[[4,5-dihydro-2-methyl-1-(phenylmethyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-methylphenyl]methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 877859-49-9 CAPLUS
 CN Benzonitrile, 4-[[9-chloro-1-(4-cyano-3-methylbenzoyl)-4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877859-50-2 CAPLUS

CN Benzonitrile, 4-[(9-chloro-4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]-2-methyl- (CA INDEX NAME)



RN 877859-51-3 CAPLUS

CN Methanone, [4-(aminomethyl)-3-methylphenyl] (9-chloro-4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 28 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:167754 CAPLUS

DOCUMENT NUMBER: 144:254156

TITLE: Preparation of heterocyclic condensed compounds useful as antidiuretic agents

INVENTOR(S): Pitt, Gary Robert William

PATENT ASSIGNEE(S): Ferring B.V., Neth.

SOURCE: PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006018443	A1	20060223	WO 2005-EP54081	20050818
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1627876	A1	20060222	EP 2004-104006	20040820
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
AU 2005273875	A1	20060223	AU 2005-273875	20050818
AU 2005273875	B2	20090827		
CA 2567782	A1	20060223	CA 2005-2567782	20050818
EP 1778677	A1	20070502	EP 2005-781746	20050818
EP 1778677	B1	20100203		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
CN 1968947	A	20070523	CN 2005-80019297	20050818
JP 2008509972	T	20080403	JP 2007-526462	20050818
RU 2359969	C2	20090627	RU 2007-101237	20050818
AT 457026	T	20100215	AT 2005-781746	20050818
PT 1778677	E	20100317	PT 2005-781746	20050818
ES 2339786	T3	20100525	ES 2005-781746	20050818
IN 2006DN06342	A	20070831	IN 2006-DN6342	20061027
KR 2007027761	A	20070309	KR 2007-7002387	20070130
KR 877336	B1	20090107		
MX 2007001861	A	20070424	MX 2007-1861	20070215
HK 1100290	A1	20100820	HK 2007-108386	20070801
US 20080234250	A1	20080925	US 2008-660207	20080516
PRIORITY APPLN. INFO.:			EP 2004-104006	A 20040820
			US 2004-602890P	P 20040820
			WO 2005-EP54081	W 20050818


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 144:254156; MARPAT 144:254156

GI



I



II

AB The title compds. I [W = N, CR₄; X = O, S, C(O), etc.; G₁ = bicyclic or tricyclic fused azepine; R₁, R₂ = H, halo, alkyl, etc.; R₃ = H, alkyl; R₄-R₇ = H, halo, alkyl, etc.; a = 1-3] which are vasopressin V₂ receptor agonists, were prepared and formulated. E.g., a multi-step synthesis of II, starting from 1,2-difluoro-3-nitrobenzene and β-alanine Me ester hydrochloride, was given. V₂ receptor agonist activity was determined for all compds. and all the compds. I cause significant cellular activation at 30 μM or less. Pharmaceutical compns. of the compds. I are useful as antidiuretic agents.

IT 877230-00-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic condensed compds. useful as antidiuretic agents)


RN 877230-00-7 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, N-[[4-[(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)carbonyl]-2-methylphenyl]methyl]-8-fluoro-3,4-dihydro-3-oxo- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 29 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2005:1026867 CAPLUS
 DOCUMENT NUMBER: 143:319140
 TITLE: Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (GSK-3)
 INVENTOR(S): Martin, Michael
 PATENT ASSIGNEE(S): The Uab Research Foundation, USA
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005086814	A2	20050922	WO 2005-US7586	20050309
WO 2005086814	A3	20061102		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20080175923	A1	20080724	US 2006-598671	20060907
PRIORITY APPLN. INFO.:				
			US 2004-551646P	P 20040309
			WO 2005-US7586	W 20050309
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
AB	This invention relates generally to a method of treating inflammation and associated diseases and disorders by administering an agent that inhibits glycogen synthase kinase 3 activity.			
IT	676596-65-9, 1-Azakenpaulone RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (methods and comps. related to regulation of cytokine production by inhibitors of glycogen synthase kinase 3 for treatment of inflammation)			
RN	676596-65-9 CAPLUS			
CN	Pyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one, 9-bromo-7,12-dihydro- (CA INDEX NAME)			



10/565,702

OS.CITING REF COUNT:	2	THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 30 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2005:471945 CAPLUS
 DOCUMENT NUMBER: 143:13343
 TITLE: 1-Thia-3-azadibenzo[e,h]azulene pharmaceuticals for the treatment of central nervous system diseases
 INVENTOR(S): Mercep, Mladen; Mesic, Milan; Modric, Marina; Pesic, Dijana; Kidemet, Davor
 PATENT ASSIGNEE(S): Pliva-Istrazivacki Institut D.O.O., Croatia
 SOURCE: PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049020	A1	20050602	WO 2004-HR55	20041119
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
HR 2003000957	A2	20050831	HR 2003-957	20031121
EP 1684751	A1	20060802	EP 2004-798734	20041119
EP 1684751	B1	20070912		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU			
JP 2007512309	T	20070517	JP 2006-540632	20041119
AT 372771	T	20070915	AT 2004-798734	20041119
ES 2291960	T3	20080301	ES 2004-798734	20041119
US 20070078123	A1	20070405	US 2006-595929	20060811
PRIORITY APPLN. INFO.:			HR 2003-957	A 20031121
			WO 2004-HR55	W 20041119

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): MARPAT 143:13343

AB The present invention relates to the use of derivs. from the group of 1-thia-3-azadibenzo[e,h]azulenes and of their salts and solvates for the manufacture of a pharmaceutical formulation for the treatment and prevention of diseases, damages and disorders of the central nervous system (CNS) caused by disorders of the neurochem. equilibrium of biogenic amines or other neurotransmitters.

IT 852461-60-0
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (thia-azadibenzoazulene pharmaceuticals for treatment of central nervous system diseases)

RN 852461-60-0 CAPLUS

CN Ethanone, 1-[2-(4-pyridinyl)-8H-dibenzo[b,f]thiazolo[4,5-d]azepin-8-yl]- (CA INDEX NAME)



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 31 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:220132 CAPLUS

DOCUMENT NUMBER: 142:298092

TITLE: Preparation of azepino[4,5-b]indole derivatives as modulators of nuclear receptors

INVENTOR(S): Busch, Brett; Flatt, Brenton T.; Gu, Xiao-Hui; Martin, Richard; Mohan, Raju; Wang, Tie-Lin; Wu, Jason H.

PATENT ASSIGNEE(S): X-Ceptor Therapeutics Inc., USA; Exelixis, Inc.

SOURCE: U.S. Pat. Appl. Publ., 106 pp., Cont.-in-part of U.S. Ser. No. 447,302.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050054634	A1	20050310	US 2003-895431	20031202
US 7595311	B2	20090929		
US 20040023947	A1	20040205	US 2003-447302	20030527
US 7485634	B2	20090203		
AU 2004297198	A1	20050623	AU 2004-297198	20041201
CA 2555279	A1	20050623	CA 2004-2555279	20041201
WO 2005056554	A2	20050623	WO 2004-US40352	20041201
WO 2005056554	A3	20050818		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1692136	A2	20060823	EP 2004-812795	20041201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1914207	A	20070214	CN 2004-80041235	20041201
BR 2004017260	A	20070306	BR 2004-17260	20041201
JP 2007513168	T	20070524	JP 2006-542742	20041201
NZ 548179	A	20091127	NZ 2004-548179	20041201
ZA 2006004352	A	20081231	ZA 2006-4352	20060529
MX 2006006140	A	20061110	MX 2006-6140	20060531
IN 2006KN01497	A	20070504	IN 2006-KN1497	20060601
KR 2006124662	A	20061205	KR 2006-713217	20060630
NO 2006003080	A	20060823	NO 2006-3080	20060703
US 20090326218	A1	20091231	US 2009-362269	20090129
US 20100173824	A1	20100708	US 2009-535453	20090804
PRIORITY APPLN. INFO.:				
			US 2002-383574P	P 20020524
			US 2003-447302	A2 20030527
			US 2003-895431	A 20031202
			WO 2004-US40352	W 20041201

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S):
GI

CASREACT 142:298092; MARPAT 142:298092




AB The title compds. (I) [R1 = -C(J)OR14, -C(J)SR14, (un)substituted -C(J)NH2; J = O, S, (un)substituted NH; R2 = H, halo, (un)substituted alkyl; R3 = -C(O)R9; R4, R5, R6 and R7 are together selected from (a), (b), etc. below: (a) R4, R5 = H or halo and R6, R7 = halo, each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclalkyl, heterocyclalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl, etc.; or R6 and R7, together with the carbon atom to which they are attached, form each (un)substituted cycloalkyl, heterocyclalkyl, cycloalkenyl, alkylidene, cycloalkylidene, heterocyclalkylidene, aralkylidene or substituted heteroaralkylidene; (b) R4, R5 = halo, each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclalkyl, heterocyclalkyl, aryl, heteroaryl, or heteroaralkyl, etc.; or R4 and R5, together with the carbon atom to which they are attached, form (un)substituted cycloalkyl, heterocyclalkyl, cycloalkenyl, alkylidene, cycloalkylidene, heterocyclalkylidene, aralkylidene or heteroaralkylidene, and R6, R7 = H or halo; R8a, R8b, R8c, R8d = H, halo, pseudohalo, cyano, azido, amidino, guanidino, each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclalkyl, heterocyclalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl, etc.; R14 = each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclalkyl, heterocyclalkyl, etc.] are prepared. These compds. modulate nuclear receptors, in particular farnesoid X receptor and are agonists, partial agonists, inverse agonists, partial antagonists, or antagonists of farnesoid X receptor. They are useful for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the above receptors, including hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, dyslipidemia, lipodystrophy, atherosclerosis, atherosclerotic disease, atherosclerotic disease events, atherosclerotic cardiovascular disease, Syndrome X, diabetes mellitus, type II diabetes, insulin insensitivity, hyperglycemia, cholestasis and obesity. Thus, to a solution of Et 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate (52 mg, 0.2 mmol) in CH2Cl2 was added 4-fluorobenzoyl chloride (36 μ L, 0.2 mmol) and TEA (56 μ L, 0.4 mmol) and the mixture was shaken overnight at 20°, treated with Trisamine resin (50 mg), and shaken for 2 h at 20°. The resin was removed by filtration through a Florisil cartridge. Evaporation of solvent gave a crude product, which was purified by trituration with methanol to give Et 3-(4-fluorobenzoyl)-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate. Et 3-(3,4-difluorobenzoyl)-1-methyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate was administered daily by oral gage for 7 days to young adult male mice. Plasma total cholesterol and triglyceride levels were significantly lowered.

IT 629664-84-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)(intermediate; preparation of azepino[4,5-b]indole derivs. as modulators of
nuclear receptors, in particular farnesoid X receptor)

RN 629664-84-2 CAPLUS


CN Spiro[azepino[4,5-b]indole-1(2H),1'-cyclopentane]-5-carboxylic acid,
3,6-dihydro-, ethyl ester (CA INDEX NAME)

IT 629663-80-5P 629664-83-1P 847865-38-7P

847865-39-8P 847865-40-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)(preparation of azepino[4,5-b]indole derivs. as modulators of nuclear
receptors, in particular farnesoid X receptor)

RN 629663-80-5 CAPLUS

CN Spiro[azepino[4,5-b]indole-1(2H),2'-[1,3]dioxolane]-5-carboxylic acid,
3-(4-fluorobenzoyl)-3,6-dihydro-, ethyl ester (CA INDEX NAME)


RN 629664-83-1 CAPLUS

CN Spiro[azepino[4,5-b]indole-1(2H),1'-cyclopentane]-5-carboxylic acid,
3-(3,4-difluorobenzoyl)-3,6-dihydro-, ethyl ester (CA INDEX NAME)




RN 847865-38-7 CAPLUS

CN Spiro[azepino[4,5-b]indole-1(2H),1'-cyclobutane]-5-carboxylic acid,
3-(3,4-difluorobenzoyl)-3,6-dihydro-, ethyl ester (CA INDEX NAME)



RN 847865-39-8 CAPLUS

CN Spiro[azepino[4,5-b]indole-1(2H),1'-cyclopropane]-5-carboxylic acid,
3-(3,4-difluorobenzoyl)-3,6-dihydro-, ethyl ester (CA INDEX NAME)



RN 847865-40-1 CAPLUS

CN Spiro[azepino[4,5-b]indole-1(2H),1'-cyclopropane]-5-carboxylic acid,
3-(3,4-difluorobenzoyl)-3,6-dihydro-, 1-methylethyl ester (CA INDEX NAME)

L28 ANSWER 32 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:99333 CAPLUS

DOCUMENT NUMBER: 142:198048

TITLE: Azepine derivatives as pharmaceutical agents, specifically as farnesoid X receptor ligands, and their preparation, pharmaceutical compositions, and use in the treatment of lipid disorders, atherosclerosis, and diabetes

INVENTOR(S): Martin, Richard; Wang, Tie-Lin; Flatt, Brenton T.; Gu, Xiao-Hui

PATENT ASSIGNEE(S): X-Ceptor Therapeutics Inc., USA

SOURCE: PCT Int. Appl., 133 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009387	A2	20050203	WO 2004-US23745	20040723
WO 2005009387	A3	20060302		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004259009	A1	20050203	AU 2004-259009	20040723
CA 2532798	A1	20050203	CA 2004-2532798	20040723
EP 1648408	A1	20060426	EP 2004-779004	20040723
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
BR 2004012262	A	20060919	BR 2004-12262	20040723
CN 1852748	A	20061025	CN 2004-80027076	20040723
JP 2006528637	T	20061221	JP 2006-521272	20040723
KR 2006052867	A	20060519	KR 2006-701566	20060123
MX 2006000875	A	20060907	MX 2006-875	20060123
NO 2006000871	A	20060424	NO 2006-871	20060222
US 20070015746	A1	20070118	US 2006-565702	20060913
PRIORITY APPLN. INFO.:			US 2003-489854P	P 20030723
			WO 2004-US23745	W 20040723


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 142:198048; MARPAT 142:198048

GI



- AB Comps., compns., and methods are provided for modulating the activity of farnesoid X receptors, and for the treatment, prevention, or amelioration of one or more symptoms of diseases or disorders related to the activity of the receptors. In particular, compds. I are disclosed [wherein: X = O, S(O)O-2, NH or its alkyl, acylated, oxyacylated, or sulfonylated derivs.; Y = (un)substituted CH or N; Z = (un)substituted CH or N; or YZ bond is fused to a carbo- or heterocyclic ring, but not benzo or naphtho; R1, R2, R4-R7 = H, halo, (un)substituted alk(en/yn)yl, (hetero)aryl, numerous functional groups; R3 = H, (un)substituted alk(en/yn)yl, (hetero)aryl, numerous functional groups; R4R5 and/or R6R7 may form oxo, thioxo, (un)substituted imino or oxime or hydrazone, or an exocyclic double bond; or R4R5, R4R6, R4R7, R5R6, R5R7, and/or R6R7 may form ring(s); including isomer(s), solvates, polymorphs, prodrugs, and pharmaceutically acceptable salts]. Fifteen synthetic examples and several biol. examples are given. For instance, thiophene-3-acetonitrile was converted to invention compound II in four steps: (1) di- α -methylation using NaH and MeI in DMF; (2) reduction of the nitrile to a primary amine using LiAlH₄; (3) cyclocondensation of the amine with Et bromopyruvate to form the azepine ring; and (4) N-acylation using 3,4-difluorobenzoyl chloride. II exhibited agonist activity at 100 nM or less, with > 100% efficacy (vs. CDCA), as measured in a co-transfection assay using full length human farnesoid X receptor.
- II 837429-84-2P, 3,6,7,8-Tetrahydroimidazo[4,5-d]azepine-4-carboxylic acid ethyl ester
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of azepine derivs. as farnesoid X receptor ligands for treatment of lipid disorders, atherosclerosis, and diabetes)
- RN 837429-84-2 CAPLUS
- CN Imidazo[4,5-d]azepine-4-carboxylic acid, 3,6,7,8-tetrahydro-, ethyl ester (CA INDEX NAME)




IT 837429-85-3P, 6-(4-Fluorobenzoyl)-3,6,7,8-tetrahydroimidazo[4,5-d]azepine-4-carboxylic acid ethyl ester 837429-86-4P, 6-(3,4-Difluorobenzoyl)-5,6-dihydro-4H-thieno[2,3-d]azepine-8-carboxylic acid ethyl ester 837429-88-6P, 3-(4-Fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydroazepino[4,5-b]indole-5-carboxylic acid ethyl ester 837429-89-7P, 3-(4-Fluorobenzoyl)-1,1-dimethyl-1,2,3,6,7,8,9,10-octahydroazepino[4,5-b]indole-5-carboxylic acid ethyl ester 837429-90-0P, 6-(3,4-Difluorobenzoyl)-4,4-dimethyl-5,6-dihydro-4H-thieno[2,3-d]azepine-8-carboxylic acid ethyl ester 837429-91-1P, 6-(3,4-Difluorobenzoyl)-4,4-dimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid diethyl ester 837429-92-2P, 6-(3,4-Difluorobenzoyl)-4,4-dimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid 2-ethyl ester 8-isopropyl ester 837429-93-3P, 6-(3,4-Difluorobenzoyl)-1,4,4-trimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid 2-ethyl ester 8-isopropyl ester
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of azepine derivs. as farnesoid X receptor ligands for treatment of lipid disorders, atherosclerosis, and diabetes)


RN 837429-85-3 CAPLUS

CN Imidazo[4,5-d]azepine-4-carboxylic acid, 6-(4-fluorobenzoyl)-3,6,7,8-tetrahydro-, ethyl ester (CA INDEX NAME)




RN 837429-86-4 CAPLUS


CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid, 6-(3,4-difluorobenzoyl)-5,6-dihydro-, ethyl ester (CA INDEX NAME)




RN 837429-88-6 CAPLUS
 CN Azepino[4,5-b]indole-5-carboxylic acid,
 3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-, ethyl ester (CA INDEX
 NAME)



RN 837429-89-7 CAPLUS
 CN Azepino[4,5-b]indole-5-carboxylic acid,
 3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-1,1-dimethyl-, ethyl ester
 (CA INDEX NAME)




RN 837429-90-0 CAPLUS
 CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid,
 6-(3,4-difluorobenzoyl)-5,6-dihydro-4,4-dimethyl-, ethyl ester (CA INDEX
 NAME)




RN 837429-91-1 CAPLUS

CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-diethyl
ester (CA INDEX NAME)




RN 837429-92-2 CAPLUS

CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2-ethyl
8-(1-methylethyl) ester (CA INDEX NAME)




RN 837429-93-3 CAPLUS


CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-1,4,4-trimethyl-, 2-ethyl
8-(1-methylethyl) ester (CA INDEX NAME)




- IT 837429-95-5P, 5,6-Dihydro-4H-thieno[2,3-d]azepine-8-carboxylic acid ethyl ester 837429-96-6P, 4,4-Dimethyl-5,6-dihydro-4H-thieno[2,3-d]azepine-8-carboxylic acid ethyl ester 837430-02-1P, 4,4-Dimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid diethyl ester 837430-03-2P, 4,4-Dimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid 2-ethyl ester 8-isopropyl ester 837430-05-4P, 1,4,4-Trimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid 2-ethyl ester 8-isopropyl ester
- RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
- (intermediate; preparation of azepine derivs. as farnesoid X receptor ligands for treatment of lipid disorders, atherosclerosis, and diabetes)
- RN 837429-95-5 CAPLUS
- CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid, 5,6-dihydro-, ethyl ester (CA INDEX NAME)




- RN 837429-96-6 CAPLUS
- CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid, 5,6-dihydro-4,4-dimethyl-, ethyl ester (CA INDEX NAME)




RN 837430-02-1 CAPLUS
 CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
 1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-diethyl ester (CA INDEX NAME)



RN 837430-03-2 CAPLUS
 CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
 1,4,5,6-tetrahydro-4,4-dimethyl-, 2-ethyl 8-(1-methylethyl) ester (CA
 INDEX NAME)



RN 837430-05-4 CAPLUS
 CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
 1,4,5,6-tetrahydro-1,4,4-trimethyl-, 2-ethyl 8-(1-methylethyl) ester (CA
 INDEX NAME)



OS.CITING REF COUNT:	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT:	1	THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 33 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:902218 CAPLUS

DOCUMENT NUMBER: 141:400891

TITLE: Drug for nerve regeneration containing glycogen synthase kinase-3 inhibitors

INVENTOR(S): Morishita, Tsuyoshi; Sakurada, Kazuhiro; Suzuki, Keiko; Ikeda, Shunichi

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan

SOURCE: PCT Int. Appl., 115 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091663	A1	20041028	WO 2004-JP5503	20040416
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2522712	A1	20041028	CA 2004-2522712	20040416
EP 1645286	A1	20060412	EP 2004-728057	20040416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1774265	A	20060517	CN 2004-80010384	20040416
US 20060217368	A1	20060928	US 2005-552061	20051004
PRIORITY APPLN. INFO.:			JP 2003-114579	A 20030418
			WO 2004-JP5503	W 20040416

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 141:400891


AB It is intended to provide a drug for nerve degeneration, a nerve stem cell neurogenesis promoter, a neuron obtained by culturing a nerve stem cell in the presence of the neurogenesis promoter, and a method of producing the neuron. To achieve the above objects, a drug for nerve degeneration which contains as the active ingredient a substance inhibiting the activity of a glycogen synthase kinase-3, a nerve stem cell neurogenesis promoter containing this substance as the active ingredient, a neuron obtained by culturing a nerve stem cell in the presence of the neurogenesis promoter, and a method of producing the neuron are provided. The above-described drugs are useful as remedies for nerve diseases such as Parkinson's disease, Alzheimer's disease, Down's disease, cerebrovascular disorder, cerebral stroke, spinal injury, Huntington's chorea, multiple sclerosis, amyotrophic lateral sclerosis, epilepsy, anxiety disorder, integration dysfunction syndrome, depression and manic-depressive. The effects of lithium chloride, Kenpaullone, indirubin-3'-monoxime, and short interference RNA (siRNA) on neurogenesis promotion were in vitro tested. Also, a tablet SB-216763 5 mg/100 mg tablet was formulated.

IT 252894-50-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(glycogen synthase kinase-3 inhibitors for nerve regeneration)


RN 252894-50-1 CAPLUS

CN Pyrido[3',2':4,5]pyrrolo[3,2-d][1]benzazepin-6(5H)-one, 7,12-dihydro- (CA
INDEX NAME)




OS.CITING REF COUNT:	4	THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT:	15	THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L28 ANSWER 34 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2004:848383 CAPLUS
 DOCUMENT NUMBER: 142:6329
 TITLE: Synthesis of the sterically fixed biliverdin derivative bearing the Z-anti C/D-ring component
 AUTHOR(S): Hamman, Mostafa A. S.; Murata, Yasue; Kinoshita, Hideki; Inomata, Katsuhiko
 CORPORATE SOURCE: Division of Material Sciences, Graduate School of Natural Science and Technology, Kanazawa University, Kanazawa, 920-1192, Japan
 SOURCE: Chemistry Letters (2004), 33(10), 1258-1259
 CODEN: CMLTAG; ISSN: 0366-7022
 PUBLISHER: Chemical Society of Japan
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 142:6329
 GI



AB A sterically locked biliverdin derivative I was synthesized by developing an efficient method for the preparation of Z-anti C/D-ring component toward investigation of the stereochem. and function of the phytochrome chromophores.
 IT 797050-86-3P 797050-93-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis of the sterically fixed biliverdin derivative bearing the Z-anti C/D-ring component)
 RN 797050-86-3 CAPLUS
 CN Dipyrrolo[1,2-a:2',3'-d]azepine-3-propanoic acid, 8-ethyl-2-formyl-1,4,5,7-tetrahydro-9-methyl-7-oxo-, 2-propen-1-yl ester (CA INDEX NAME)




RN 797050-93-2 CAPLUS
 CN Dipyrrolo[1,2-a:2',3'-d]azepine-3-propanoic acid,
 2-[(1,1-dimethylethoxy)carbonyl]-8-ethyl-1,4,5,7-tetrahydro-9-methyl-7-oxo-
 , 2-propen-1-yl ester (CA INDEX NAME)



OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS
 RECORD (11 CITINGS)
 REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L28 ANSWER 35 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2004:375983 CAPLUS
 DOCUMENT NUMBER: 141:106415
 TITLE: A new synthetic route to YM087, an arginine
 vasopressin antagonist
 AUTHOR(S): Tsunoda, Takashi; Tanaka, Akihiro; Mase, Toshiyasu;
 Sakamoto, Shuichi
 CORPORATE SOURCE: Chemical Technology Labs., Yamanouchi Pharmaceutical
 Co., Ltd., Takahagi, 318-0001, Japan
 SOURCE: Heterocycles (2004), 63(5), 1113-1122
 CODEN: HTCYAM; ISSN: 0385-5414
 PUBLISHER: Japan Institute of Heterocyclic Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:106415
 GI



AB A synthesis of N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-[1,1'-biphenyl]-2-carboxamide monohydrochloride (YM 087) (I) via imidazobenzazepine intermediates is described. This method remarkably improved the overall yield of I, compared to the original synthesis, providing a more safe, reliable, and cost-efficient approach to I. The key intermediate in this synthesis, based on retro-synthetic anal., was 1,4,5,6-tetrahydro-2-methyl-6-[(4-methylphenyl)sulfonyl]imidazo[4,5-d][1]benzazepine.

IT 717917-16-3P
 RL: BYP (Byproduct); PREP (Preparation)
 (byproduct from the preparation of methylimidazobenzazepine via tosylation of aminobenzoate followed by alkylation with chlorobutanenitrile, heterocyclization, hydrolysis, α -bromination, heterocyclization, and detosylation)

RN 717917-16-3 CAPLUS
 CN 4H-Oxazolo[4,5-d][1]benzazepine, 5,6-dihydro-2-methyl-6-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




IT 182202-71-7P 195531-22-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-(phenylbenzoylamino)benzoylmethylimidazobenzazepine via N-acylation of methylimidazobenzazepine with nitrobenzoic acid followed by reduction and amidation with biphenylcarboxylic acid)

RN 182202-71-7 CAPLUS


CN Methanone, (4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl) (4-nitrophenyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 195531-22-7 CAPLUS


CN Methanone, (4-aminophenyl) (4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)- (CA INDEX NAME)



IT 318237-73-9P 717917-14-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of methylimidazobenzazepine via tosylation of aminobenzoate
 followed by alkylation with chlorobutanenitrile, heterocyclization,
 hydrolysis, α -bromination, heterocyclization, and detosylation in
 the preparation of YM087)
 RN 318237-73-9 CAPLUS
 CN Imidazo[4,5-d][1]benzazepine, 1,4,5,6-tetrahydro-2-methyl- (CA INDEX
 NAME)



RN 717917-14-1 CAPLUS
 CN Imidazo[4,5-d][1]benzazepine, 1,4,5,6-tetrahydro-2-methyl-6-[(4-
 methylphenyl)sulfonyl]- (CA INDEX NAME)




OS.CITING REF COUNT:	4	THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT:	16	THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 36 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2004:117842 CAPLUS
 DOCUMENT NUMBER: 140:152009
 TITLE: Arginine vasopressin receptor antagonists containing
 1,4,5,6-tetrahydroimidazo[4,5-d]benzazepine
 derivatives
 INVENTOR(S): Koshio, Hiroyuki; Kakefuda, Akio; Sato, Ippei;
 Wakayama, Ryutaro; Sanagi, Masanao
 PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 29 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004043456	A	20040212	JP 2003-141799	20030520
PRIORITY APPLN. INFO.:			JP 2002-149935	A 20020524
OTHER SOURCE(S):	MARPAT	140:152009		

GI



I

AB The invention provide pharmaceutical compds. I (ring D = phenylene, etc.; X, Y = CH, N; R1, R2, R3 = H, OH, halo, lower alkyl) as arginine vasopressin receptor antagonists, suitable for treatment of cardiac failure and hyponatremia. A compound N-[4-(2-(2-pyridyl)-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]biphenyl-2-carboxamide (II) hydrochloride was prepared. The compound showed antagonistic effect on V1A and V2 receptors without

inhibiting CYP3A4 enzyme in in vitro assay. An injection composition containing II

1 mg/mL was formulated.


IT	1222456-11-2	1222456-14-5	1222456-17-8
	1222456-19-0	1222456-21-4	1222456-24-7
	1222456-26-9	1222456-29-2	1222456-31-6
	1222456-33-8	1222456-35-0	1222456-39-4
	1222456-41-8	1222456-43-0	1222456-46-3
	1222456-48-5	1222456-51-0	1222456-53-2
	1222456-55-4	1222456-57-6	1222456-60-1
	1222456-63-4	1222456-65-6	1222456-67-8
	1222456-69-0	1222456-72-5	1222456-74-7
	1222456-75-8	1222456-78-1	1222456-79-2
	1222456-81-6	1222456-83-8	1222456-85-0
	1222456-87-2	1222456-89-4	1222456-91-8
	1222456-93-0	1222456-96-3	1222456-99-6
	1222457-01-3	1222457-04-6	

RL: PRPH (Prophetic)

(Arginine vasopressin receptor antagonists containing 1,4,5,6-tetrahydroimidazo[4,5-d]benzazepine derivatives)


RN 1222456-11-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-pyrazinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-2'-fluoro-
(CA INDEX NAME)




RN 1222456-14-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-pyrazinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-fluorophenyl]-
(CA INDEX NAME)



RN 1222456-17-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[6-[[4,5-dihydro-2-(2-pyrazinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-pyridinyl]-
(CA INDEX NAME)




RN 1222456-19-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[5-[[4,5-dihydro-2-(2-


RN 1222456-24-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[[4,5-dihydro-2-(2-pyrimidinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-2'-fluoro- (CA INDEX NAME)




RN 1222456-26-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[[4,5-dihydro-2-(2-pyrimidinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-fluorophenyl]- (CA INDEX NAME)



RN 1222456-29-2 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[6-[[4,5-dihydro-2-(2-pyrimidinyl)imidazo[4,5-d][1H]benzazepin-6(1H)-yl]carbonyl]-3-pyridinyl]-
(CA INDEX NAME)



RN 1222456-31-6 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[5-[[4,5-dihydro-2-(2-

pyrimidinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-pyridinyl]-
(CA INDEX NAME)




RN 1222456-33-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[[4,5-dihydro-2-(2-pyrimidinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-hydroxyphenyl]- (CA INDEX NAME)




RN 1222456-35-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(6-methyl-2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-2'-fluoro-
(CA INDEX NAME)




RN 1222456-39-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(6-methyl-2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-fluorophenyl]-
(CA INDEX NAME)



RN 1222456-41-8 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[6-[[4,5-dihydro-2-(6-methyl-2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-pyridinyl]-
(CA INDEX NAME)



RN 1222456-43-0 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[5-[[4,5-dihydro-2-(6-methyl-2-


pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-pyridinyl]-
(CA INDEX NAME)



RN 1222456-46-3 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(6-methyl-2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-hydroxyphenyl]-
(CA INDEX NAME)





RN 1222456-53-2 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-2'-hydroxy-
(CA INDEX NAME)



RN 1222456-55-4 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[[4,5-dihydro-2-(2-

pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-3'-hydroxy-
(CA INDEX NAME)




RN 1222456-57-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[2-(6-chloro-2-pyridinyl)-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)




RN 1222456-60-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(5-methyl-2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)




RN 1222456-63-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[3-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-2'-fluoro- (CA INDEX NAME)




RN 1222456-65-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[3-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)




RN 1222456-67-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-4-pyridinyl]- (CA INDEX NAME)




RN 1222456-69-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[5-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-pyridinyl]- (CA INDEX NAME)




RN 1222456-75-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[3-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-4-fluorophenyl]-
(CA INDEX NAME)




RN 1222456-78-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[3-[[4,5-dihydro-2-(2-pyrimidinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-
(CA INDEX NAME)




RN 1222456-79-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[3-[[4,5-dihydro-2-(2-pyrazinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)




RN 1222456-81-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[3-[[4,5-dihydro-2-(6-methyl-2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)




RN 1222456-83-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-2'-fluoro- (CA INDEX NAME)




RN 1222456-85-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)




RN 1222456-87-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-pyridinyl]-
(CA INDEX NAME)




RN 1222456-89-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[3-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-4-pyridinyl]-
(CA INDEX NAME)




RN 1222456-91-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-pyridinyl]-(CA INDEX NAME)




RN 1222456-93-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[3-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-pyridinyl]-(CA INDEX NAME)




RN 1222456-96-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-fluorophenyl]-(CA INDEX NAME)




RN 1222456-99-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[[4,5-dihydro-2-(2-pyrimidinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)




RN 1222457-01-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[[4,5-dihydro-2-(2-pyrazinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)



RN 1222457-04-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[[4,5-dihydro-2-(6-methyl-2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)



IT 433263-22-0P 433263-34-4P 433263-38-8P

433263-40-2P 433263-48-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(arginine vasopressin receptor inhibitors containing

1,4,5,6-tetrahydroimidazo[4,5-d]benzazepine derivs.)


RN 433263-22-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 433263-34-4 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-2'-fluoro-, hydrochloride (1:1) (CA INDEX NAME)



RN 433263-38-8 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[5-[[4,5-dihydro-2-(2-

pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-pyridinyl]-,
hydrochloride (1:1) (CA INDEX NAME)




RN 433263-40-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[6-[[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-pyridinyl]-,
hydrochloride (1:1) (CA INDEX NAME)



RN 433263-48-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)




IT 433263-20-8P 433263-46-8P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
USES (Uses)(arginine vasopressin receptor inhibitors containing
1,4,5,6-tetrahydroimidazo[4,5-d]benzazepine derivs.)


RN 433263-20-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)



RN 433263-46-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-phenylpyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-hydroxyphenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 433263-24-2P
433263-32-2P

433263-26-4P
433263-42-4P

433263-28-6P
433263-51-5P

433263-53-7P 433263-55-9P 433263-58-2P


652987-18-3P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(arginine vasopressin receptor inhibitors containing
1,4,5,6-tetrahydroimidazo[4,5-d]benzazepine derivs.)

RN 433263-24-2 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-pyrazinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 433263-26-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(6-methyl-2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 433263-28-6 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-pyrimidin-4-yl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 433263-32-2 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-

pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-fluorophenyl]-,
hydrochloride (1:1) (CA INDEX NAME)




RN 433263-42-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-hydroxyphenyl]-
(CA INDEX NAME)




RN 433263-51-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-fluorophenyl]-
(CA INDEX NAME)




RN 433263-53-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-2'-fluoro-
(CA INDEX NAME)



RN 433263-55-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[5-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-pyridinyl]-2-carboxamide (CA INDEX NAME)




RN 433263-58-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[6-[[4,5-dihydro-2-(2-

10/565,702

pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-pyridinyl]-
(CA INDEX NAME)




RN 652987-18-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 433263-20-8

CMF C36 H27 N5 O2




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.




IT 433263-61-7P 433263-65-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of 1,4,5,6-tetrahydroimidazo[4,5-d]benzazepine derivs. as
 arginine vasopressin receptor inhibitors)
 RN 433263-61-7 CAPLUS
 CN Imidazo[4,5-d][1]benzazepine, 1,4,5,6-tetrahydro-6-[(4-
 methylphenyl)sulfonyl]-2-(2-pyridinyl)- (CA INDEX NAME)

10/565,702



RN 433263-65-1 CAPLUS

CN Imidazo[4,5-d][1]benzazepine, 1,4,5,6-tetrahydro-2-(2-pyridinyl)- (CA INDEX NAME)



L28 ANSWER 37 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:1001979 CAPLUS

DOCUMENT NUMBER: 140:303559

TITLE: 1-Azakenpauillone is a selective inhibitor of glycogen synthase kinase-3 β

AUTHOR(S): Kunick, Conrad; Lauenroth, Kathrin; Leost, Maryse; Meijer, Laurent; Lemcke, Thomas

CORPORATE SOURCE: Institut fur Pharmazeutische Chemie, Technische Universitat Braunschweig, Braunschweig, 38106, Germany
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(2), 413-416

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 140:303559

AB Kenpauillone derivs. with a modified parent ring system were synthesized in order to develop kinase inhibitors with enhanced selectivity. Among the novel structures, 1-azakenpauillone was found to act as a selective GSK-3 β vs. CDK1 inhibitor. The charge distribution within the 1-azakenpauillone mol. is discussed as a possible explanation for the enhanced GSK-3 β selectivity of 1-azakenpauillone compared to other pauillone derivs.

IT 676596-60-4P, 4-Azakenpauillone 676596-65-9P, 1-Azakenpauillone
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and biol. activity of aza derivs. of kenpauillone as inhibitors of glycogen synthase kinase-3 β)


RN 676596-60-4 CAPLUS

CN Pyrido[2',3':2,3]azepino[4,5-b]indol-6(5H)-one, 9-bromo-7,12-dihydro- (CA INDEX NAME)



RN 676596-65-9 CAPLUS

CN Pyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one, 9-bromo-7,12-dihydro- (CA INDEX NAME)



OS.CITING REF COUNT: 57

REFERENCE COUNT: 23

THERE ARE 57 CAPLUS RECORDS THAT CITE THIS
RECORD (58 CITINGS)


THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 38 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2003:961357 CAPLUS
 DOCUMENT NUMBER: 140:156741
 TITLE: Evaluation and Comparison of 3D-QSAR CoMSIA Models for CDK1, CDK5, and GSK-3 Inhibition by Paullones
 AUTHOR(S): Kunick, Conrad; Lauenroth, Kathrin; Wieking, Karen; Xie, Xu; Schultz, Christiane; Gussio, Rick; Zaharevitz, Daniel; Leost, Maryse; Meijer, Laurent; Weber, Alexander; Jorgensen, Flemming S.; Lemcke, Thomas
 CORPORATE SOURCE: Institut fuer Pharmazie, Abteilung fuer Pharmazeutische Chemie, Universitaet Hamburg, Hamburg, D-20146, Germany
 SOURCE: Journal of Medicinal Chemistry (2004), 47(1), 22-36
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 140:156741


AB With a view to the rational design of selective GSK-3 β inhibitors, 3D-QSAR CoMSIA models were developed for the inhibition of the three serine/threonine kinases CDK1/cyclin B, CDK5/p25, and GSK-3 β by compds. from the paullone inhibitor family. The models are based on the kinase inhibition data of 52 paullone entities, which were aligned by a docking routine into the ATP-binding cleft of a CDK1/cyclin B homol. model. Variation of grid spacing and column filtering were used during the optimization of the models. The predictive ability of the models was shown by a leave-one-out cross-validation and the prediction of an independent set of test compds., which were synthesized especially for this purpose. Besides paullones with the basic indolo[3,2-d][1]benzazepine core, the test set comprised novel thieno[3',2':2,3]azepino[4,5-b]indoles, pyrido[2',3':2,3]azepino[4,5-b]indoles, and a pyrido[3',2':4,5]pyrrolo[3,2-d][1]benzazepine. The best statistical values for the CoMSIA were obtained for the CDK1-models ($r^2 = 0.929$ and $q^2 = 0.699$), which were clearly superior to the models for CDK5 ($r^2 = 0.874$ and $q^2 = 0.652$) and GSK-3 ($r^2 = 0.871$ and $q^2 = 0.554$).

IT 252894-50-1P, NSC 709128 654076-11-6P, NSC 716453
 654076-12-7P, NSC 718541 654076-13-8P, NSC 719342
 654076-17-2P, NSC 720311
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (evaluation and comparison of 3D-QSAR CoMSIA models for CDK1, CDK5, and GSK-3 inhibition by paullones)


RN 252894-50-1 CAPLUS
 CN Pyrido[3',2':4,5]pyrrolo[3,2-d][1]benzazepin-6(5H)-one, 7,12-dihydro- (CA INDEX NAME)




RN 654076-11-6 CAPLUS
 CN Pyrido[2',3':2,3]azepino[4,5-b]indol-6(5H)-one, 7,12-dihydro-9-methoxy-
 (CA INDEX NAME)



RN 654076-12-7 CAPLUS
 CN Pyrido[2',3':2,3]azepino[4,5-b]indol-6(5H)-one, 9-chloro-7,12-dihydro-
 (CA INDEX NAME)




RN 654076-13-8 CAPLUS
 CN Pyrido[2',3':2,3]azepino[4,5-b]indol-6(5H)-one,
 7,12-dihydro-9-(trifluoromethyl)- (CA INDEX NAME)



10/565,702

RN 654076-17-2 CAPLUS

CN Pyrido[2',3':2,3]azepino[4,5-b]indol-6(5H)-one, 7,12-dihydro-9-methyl-
(CA INDEX NAME)




OS.CITING REF COUNT: 51 THERE ARE 51 CAPLUS RECORDS THAT CITE THIS
RECORD (51 CITINGS)

REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 39 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2003:951028 CAPLUS
 DOCUMENT NUMBER: 140:16715
 TITLE: Preparation of azepinoindole and pyridoindole
 derivatives as modulators of farnesoid X and/or orphan
 nuclear receptors
 INVENTOR(S): Martin, Richard; Wang, Tie-Lin; Flatt, Brenton Todd;
 Gu, Xiao-Hui; Griffith, Ronald
 PATENT ASSIGNEE(S): X-Ceptor Therapeutics, Inc., USA
 SOURCE: PCT Int. Appl., 268 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099821	A1	20031204	WO 2003-US16767	20030527
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2485909	A1	20031204	CA 2003-2485909	20030527
AU 2003243328	A1	20031212	AU 2003-243328	20030527
AU 2003243328	B2	20100520		
EP 1532153	A1	20050525	EP 2003-755523	20030527
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005531585	T	20051020	JP 2004-507478	20030527
PRIORITY APPLN. INFO.:			US 2002-383574P	P 20020524
			WO 2003-US16767	W 20030527
OTHER SOURCE(S):	MARPAT 140:16715			
GI				



AB The present invention is directed to azepinoindole and pyridoindole derivs. (shown as I and II; variables defined below; e.g. Et 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate). These compds. were used in pharmaceutical compns. and methods for modulating the activity of farnesoid X receptor and/or orphan nuclear receptors. A farnesoid X receptor/ECREx7 co-transfection assay and a TR-FRET assay were used to establish the EC50/IC50 values for potency and percent activity or inhibition for efficacy; efficacy defines the activity of a compound relative to a high control (chenodeoxycholic acid, CDCA) or a low control (DMSO/vehicle). Most of the compds. disclosed and tested exhibited activity in at least one of the assays (EC50 or IC50 <10 μ M); most showed activity at <1 μ M, e.g. Pr 3-(4-fluorobenzoyl)-2-methyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate exhibited agonist activity <1 μ M EC50 and >100 % efficacy and 8-(3-cyclopropyl-1-methylureido)-3-(4-fluorobenzoyl)-1,1-dimethyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylic acid Et ester exhibited antagonist activity with IC50 <100 nM and 100 % inhibition. Although the methods of preparation are not claimed, 74 example preps. of I and II and characterization data for many more I and II are included. For I and II: n = 0-4; A is -N(R9)-, -O- or -S(O)t- (t = 0-2); R1 and R2 = H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, aralkyl, heteroaralkyl, -OR14, -SR14, -N(R15)R16, -N(R15)S(O)2R43, -N(R17)N(R15)R16, -N(R17)N(R15)S(O)2R43, -C(O)R18, -C(O)OR14, -C(S)OR14, -C(O)SR14, -C(O)N(R15)R16, -C(O)N(R15)S(O)2R43, -C(O)N(R15)N:R16 and -C(O)N(R17)N(R15)R16; or -C(O)N(R17)N(R15)S(O)2R43; or R1 and R2, together with the atom to which they are attached, form a cycloalkyl, heterocyclyl, aryl, or heteroaryl ring. R3 is H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heteroaralkyl, -C(O)R10, -C(O)OR10, -S(O)2R10, -C(O)N(R11)R12, -C(O)N(R11)S(O)2R43, -C(O)N(R13)N(R11)R12, -C(O)N(R13)N(R11)S(O)2R43, -N(R13)C(O)R10, -N(R13)C(O)N(R11)R12, -N(R13)C(O)N(R11)S(O)2R43, -N(R10)C(O)N(R13)N(R11)R12, -N(R10)C(O)N(R13)N(R11)S(O)2R43, -N(R13)C(O)OR10, or -P(O)OR10, or -P(O)OR19)OR12. R4, R5, R6 and R7 = H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, aralkyl, heteroaralkyl, -OR14, -SR14, -S(O)2R14, -N(R15)R16, -N(R15)S(O)2R43, -C(O)R18, -C(O)OR20, -C(O)N(R21)R22, -C(O)N(R21)S(O)2R43; -C(O)N(R42)N(R21)R22; or -C(O)N(R42)N(R21)S(O)2R43; or R4 and R5, or R4

and R6, or R4 and R7, or R5 and R6, or R5 and R7, or R6 and R7, together with the C atom to which they are attached, form a cycloalkyl, heterocyclyl, or cycloalkenyl ring, or together form a double bond and the others of R4, R5, R6 and R7 are as described above; or R6 and R7 together form an exo, thioxo, imine, oxime or a hydrazone, or R6 and R7, together with the C atom to which they are attached, form an exocyclic double bond, and R4 and R5 are as described above. R8 = alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, halo, pseudohalo, cyano, nitro, -C(O)OR23, -C(O)N(R24)R25, -C(O)N(R24)S(O)2R43, -C(O)R26, -OR27, -SR27, -C(S)OR23, -C(O)SR23, -N(R28)R29, and -N(R28)S(O)2R43, or two adjacent R8 groups, together with the carbons to which they are attached, form an aryl, cycloalkyl, heterocyclyl or heteroaryl; addnl. details including


IT 629663-80-5P 629664-83-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of azepinoindole and pyridoindole derivs. as modulators of farnesoid X and/or orphan nuclear receptors)


RN 629663-80-5 CAPLUS

CN Spiro[azepino[4,5-b]indole-1(2H),2'-[1,3]dioxolane]-5-carboxylic acid, 3-(4-fluorobenzoyl)-3,6-dihydro-, ethyl ester (CA INDEX NAME)



RN 629664-83-1 CAPLUS

CN Spiro[azepino[4,5-b]indole-1(2H),1'-cyclopentane]-5-carboxylic acid, 3-(3,4-difluorobenzoyl)-3,6-dihydro-, ethyl ester (CA INDEX NAME)




IT 629664-84-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of azepinoindole and pyridoindole derivs. as modulators of farnesoid X and/or orphan nuclear receptors)

RN 629664-84-2 CAPLUS

CN Spiro[azepino[4,5-b]indole-1(2H),1'-cyclopentane]-5-carboxylic acid, 3,6-dihydro-, ethyl ester (CA INDEX NAME)




OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 40 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2003:945402 CAPLUS
 DOCUMENT NUMBER: 140:769
 TITLE: Benzoazepine derivatives as Meniere's disease remedies
 INVENTOR(S): Matsukawa, Utane; Fujimori, Akira; Arai, Yukinori;
 Sudo, Katsumi
 PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 20 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003342175	A	20031203	JP 2002-149965	20020524
PRIORITY APPLN. INFO.:			JP 2002-149965	20020524
OTHER SOURCE(S):	MARPAT 140:769			
GI				



I

AB The new 1,4,5,6-tetrahydroimidazo[4,5-d]benzoazepine derivs. (I; ring D = phenylene, pyridindyl; X, Y = CH, N; R1, R2, R3 = H, OH, halogen, low alkyl) and their pharmaceutically acceptable salts are claimed as Meniere's disease and hearing disorder remedies. I were prepared, and formulation examples of injections and capsules were given.

IT	1222456-11-2P	1222456-14-5P	1222456-17-8P
	1222456-19-0P	1222456-21-4P	1222456-24-7P
	1222456-26-9P	1222456-29-2P	1222456-31-6P
	1222456-33-8P	1222456-35-0P	1222456-39-4P
	1222456-41-8P	1222456-43-0P	1222456-46-3P
	1222456-48-5P	1222456-51-0P	1222456-53-2P
	1222456-55-4P	1222456-57-6P	1222456-60-1P
	1222456-63-4P	1222456-65-6P	1222456-67-8P
	1222456-69-0P	1222456-72-5P	1222456-74-7P
	1222456-75-8P	1222456-78-1P	1222456-79-2P
	1222456-81-6P	1222456-83-8P	1222456-85-0P

1222456-87-2P 1222456-89-4P 1222456-91-8P

1222456-93-0P 1222456-96-3P 1222456-99-6P


1222457-01-3P 1222457-04-6P

RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(benzazepine derivs. as Meniere's disease remedies)


RN 1222456-11-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[[4,5-dihydro-2-(2-pyrazinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-2'-fluoro-
(CA INDEX NAME)




RN 1222456-14-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[[4,5-dihydro-2-(2-pyrazinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-fluorophenyl]-
(CA INDEX NAME)



RN 1222456-17-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[6-[[4,5-dihydro-2-(2-pyrazinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-pyridinyl)-(CA INDEX NAME)




RN 1222456-19-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[5-[[4,5-dihydro-2-(2-


RN 1222456-24-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[[4,5-dihydro-2-(2-pyrimidinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-2'-fluoro- (CA INDEX NAME)




RN 1222456-26-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[[4,5-dihydro-2-(2-pyrimidinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-fluorophenyl]- (CA INDEX NAME)



RN 1222456-29-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[6-[[4,5-dihydro-2-(2-pyrimidinyl)imidazo[4,5-d][1,2-b]benzazepin-6(1H)-yl]carbonyl]-3-pyridinyl]-
(CA INDEX NAME)




RN 1222456-31-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[5-[[4,5-dihydro-2-(2-


RN 1222456-35-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(6-methyl-2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-2'-fluoro-
(CA INDEX NAME)




RN 1222456-39-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(6-methyl-2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-fluorophenyl]-
(CA INDEX NAME)



RN 1222456-41-8 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[6-[[4,5-dihydro-2-(6-methyl-2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-pyridinyl]-(CA INDEX NAME)



RN 1222456-43-0 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[5-[[4,5-dihydro-2-(6-methyl-2-


pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-pyridinyl]-
(CA INDEX NAME)



RN 1222456-46-3 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[[4,5-dihydro-2-(6-methyl-2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-hydroxyphenyl]-
(CA INDEX NAME)





RN 1222456-53-2 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-2'-hydroxy-(CA INDEX NAME)



RN 1222456-55-4 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[[4,5-dihydro-2-(2-

pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-3'-hydroxy-
(CA INDEX NAME)




RN 1222456-57-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[2-(6-chloro-2-pyridinyl)-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)




RN 1222456-60-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(5-methyl-2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)




RN 1222456-63-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[3-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-2'-fluoro- (CA INDEX NAME)




RN 1222456-65-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[3-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)




RN 1222456-67-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-4-pyridinyl]- (CA INDEX NAME)




RN 1222456-69-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[5-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-pyridinyl]- (CA INDEX NAME)




RN 1222456-72-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-pyridinyl]-
(CA INDEX NAME)




RN 1222456-74-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[6-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-pyridinyl]-
(CA INDEX NAME)




RN 1222456-75-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[3-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-4-fluorophenyl]-
(CA INDEX NAME)




RN 1222456-78-1 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[3-[[4,5-dihydro-2-(2-pyrimidinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-
(CA INDEX NAME)



RN 1222456-79-2 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[3-[[4,5-dihydro-2-(2-phenylpyrazinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)




RN 1222456-81-6 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[3-[[4,5-dihydro-2-(6-methyl-2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)




RN 1222456-83-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-2'-fluoro-
(CA INDEX NAME)




RN 1222456-85-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA
INDEX NAME)




RN 1222456-87-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-pyridinyl]-
(CA INDEX NAME)




RN 1222456-89-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[3-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-4-pyridinyl]-
(CA INDEX NAME)




RN 1222456-91-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-pyridinyl]-
(CA INDEX NAME)




RN 1222456-93-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[3-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-pyridinyl]-
(CA INDEX NAME)




RN 1222456-96-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-fluorophenyl]-
(CA INDEX NAME)




RN 1222456-99-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[[4,5-dihydro-2-(2-pyrimidinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)




RN 1222457-01-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[[4,5-dihydro-2-(2-pyrazinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)



RN 1222457-04-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[[4,5-dihydro-2-(6-methyl-2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)



IT 433263-22-0P 433263-24-2P 433263-26-4P

433263-28-6P 433263-32-2P 433263-34-4P


433263-40-2P 433263-46-8P 433263-48-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(benzazepine derivs. as Meniere's disease remedies)

RN 433263-22-0 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 433263-24-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-phenylpyrazinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 433263-26-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(6-methyl-2-


pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 433263-28-6 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-pyrimidinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 433263-32-2 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-fluorophenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 433263-34-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-2'-fluoro-, hydrochloride (1:1) (CA INDEX NAME)



RN 433263-40-2 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[6-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 433263-46-8 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-

pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-hydroxyphenyl]-
 , hydrochloride (1:1) (CA INDEX NAME)



RN 433263-48-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)



L28 ANSWER 41 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:861136 CAPLUS

DOCUMENT NUMBER: 140:59574

TITLE: Practical Synthesis of
N-[4-[(2-Methyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]biphenyl-2-carboxamide
Monohydrochloride: an Arginine Vasopressin Antagonist
Tsunoda, Takashi; Yamazaki, Atsuki; Iwamoto, Hidenori;
Sakamoto, Shuichi

AUTHOR(S):
CORPORATE SOURCE: Chemical Technology Labs, Yamanouchi Pharmaceutical
Co., Ltd., Takahagi-shi, Ibaraki, 318-0001, Japan

SOURCE: Organic Process Research & Development (2003), 7(6),
883-887

CODEN: OPRDFK; ISSN: 1083-6160

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:59574

AB A novel, reliable, and cost-effective synthetic route to
N-[4-[(2-methyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-
yl)carbonyl]phenyl]biphenyl-2-carboxamide monohydrochloride (YM087), a
potent arginine vasopressin antagonist, has been developed. Using
moisture-controlled potassium carbonate, imidazole formation from
 α -bromoketone furnished imidazobenzazepine, avoiding potential
oxazole-ring formation. Catalytic reduction of nitro imidazobenzazepine
afforded the corresponding amine in high yields. Treatment of the
imidazole-containing amine directly, with a carbonyl chloride, afforded the
target amide circumventing protection of the imidazole.


IT 168626-93-5P

RL: BYP (Byproduct); PREP (Preparation)
(practical synthesis of [(methylimidazo[4,5-
d][1]benzazepinyl)carbonyl]phenyl]biphenylcarboxamide monohydrochloride
(arginine vasopressin antagonist))

RN 168626-93-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methyl-6H-oxazolo[4,5-
d][1]benzazepin-6-yl)carbonyl]phenyl]- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



- IT 168626-71-9P, 1,4,5,6-Tetrahydro-2-methyl-6-(4-nitrobenzoyl)imidazo[4,5-d][1]benzazepine 182202-75-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (practical synthesis of [(methylimidazo[4,5-d][1]benzazepinyl)carbonyl]phenyl]biphenylcarboxamide monohydrochloride (arginine vasopressin antagonist))
- RN 168626-71-9 CAPLUS
- CN Methanone, (4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl) (4-nitrophenyl)- (CA INDEX NAME)



RN 182202-75-1 CAPLUS
 CN Methanone, (4-aminophenyl) (4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
 REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 42 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:428907 CAPLUS

DOCUMENT NUMBER: 137:6180

TITLE: Preparation of
1,4,5,6-tetrahydroimidazo[4,5-d]benzazepine
derivatives as vasopressin antagonistsINVENTOR(S): Koshio, Hiroyuki; Kakefuda, Akio; Sato, Ippei;
Wakayama, Ryutaro; Sanagi, Masanao

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 37 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002044179	A1	20020606	WO 2001-JP10328	20011127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002024115	A	20020611	AU 2002-24115	20011127
JP 2002226480	A	20020814	JP 2001-361126	20011127
JP 4061891	B2	20080319		
CA 2425892	A1	20030411	CA 2001-2425892	20011127
EP 1338597	A1	20030827	EP 2001-998171	20011127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040034012	A1	20040219	US 2003-432732	20030527
US 7056910	B2	20060606		
US 20060142268	A1	20060629	US 2006-353995	20060215
PRIORITY APPLN. INFO.:			JP 2000-360809	A 20001128
			WO 2001-JP10328	W 20011127
			US 2003-432732	A1 20030527

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 137:6180

GI




AB The title compds. I [ring D = phenylene, etc.; X, Y = CH, N; R1 - R3 = H, halo, etc.] are prepared In an in vitro V1A receptor binding assay, compds. of this invention showed the pKi values of 8.12 to 8.71.

IT 433263-20-8P 433263-48-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of tetrahydroimidazobenzazepine derivs. as vasopressin antagonists)


RN 433263-20-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)



RN 433263-26-4 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[[4,5-dihydro-2-(6-methyl-2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 433263-28-6 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[[4,5-dihydro-2-(2-

pyrimidinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-,
hydrochloride (1:1) (CA INDEX NAME)




RN 433263-32-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-fluorophenyl]-,
hydrochloride (1:1) (CA INDEX NAME)




RN 433263-34-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-2'-fluoro-, hydrochloride (1:1) (CA INDEX NAME)




RN 433263-38-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[5-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 433263-40-2 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[6-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 433263-42-4 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-

pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-hydroxyphenyl]-
(CA INDEX NAME)



RN 433263-46-8 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-hydroxyphenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 433263-51-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-fluorophenyl]-
(CA INDEX NAME)




RN 433263-53-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(2-pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-2'-fluoro-
(CA INDEX NAME)



RN 433263-55-9 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[5-[[[4,5-dihydro-2-(2-fluorophenyl)-2-pyridinyl]imido[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-pyridinyl]-
(CA INDEX NAME)




RN 433263-58-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[6-[[[4,5-dihydro-2-(2-phenyl)-2-pyridinyl]imido[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-2-pyridinyl]-
(CA INDEX NAME)

pyridinyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]-3-pyridinyl)-
(CA INDEX NAME)




IT 433263-61-7P 433263-65-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of tetrahydroimidazobenzazepine derivs. as vasopressin
 antagonists)
 RN 433263-61-7 CAPLUS
 CN Imidazo[4,5-d][1]benzazepine, 1,4,5,6-tetrahydro-6-[(4-
 methylphenyl)sulfonyl]-2-(2-pyridinyl)- (CA INDEX NAME)



RN 433263-65-1 CAPLUS

CN Imidazo[4,5-d][1]benzazepine, 1,4,5,6-tetrahydro-2-(2-pyridinyl)- (CA
INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L28 ANSWER 43 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2002:276524 CAPLUS
 DOCUMENT NUMBER: 136:294818
 TITLE: Preparation of indolobenzazepinones and related compounds as cyclin dependent kinase inhibitors
 INVENTOR(S): Zaharevitz, Daniel W.; Gussio, Rick P.; Jalluri, Ravi K.; Sausville, Edward A.; Kunick, Conrad; Meijer, Laurent
 PATENT ASSIGNEE(S): Centre National De La Recherche Scientifique, USA
 SOURCE: U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of Appl. No. PCT/US99/13579.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020042412	A1	20020411	US 2000-739534	20001214
US 6610684	B2	20030826		
WO 9965910	A1	19991223	WO 1999-US13579	19990616

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1998-89619P P 19980616
 WO 1999-US13579 A2 19990616

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 136:294818
 GI



AB Title compds. (I; A = O, S; dotted line = optional double bond; R1 = alkoxy, amino, acyl, alkyl, alkenyl, alkynyl, cyano, NO₂, CO₂H, etc.; R2 = H, PhCH₂, alkyl, alkyl ester; R3 = H, alkyl, cycloalkyl; Y, Z = atoms to form conjugated rings; with a proviso), were prepared Thus, 1H-[1]benzazepine-2,5(3H,4H)-dione and 4-bromophenylhydrazine were heated with NaOAc in HOAc at 70° for 1 h to give 58%
 9-bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one. This was refluxed 12 h with CuCN in DMF to give 42%
 9-cyano-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one. The latter inhibited cdk5 with IC₅₀ = 0.044 nM.

10/565,702


IT 252894-50-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of indolobenzazepinones and related compds. as cyclin dependent
kinase inhibitors)

RN 252894-50-1 CAPLUS

CN Pyrido[3',2':4,5]pyrrolo[3,2-d][1]benzazepin-6(5H)-one, 7,12-dihydro- (CA
INDEX NAME)



L28 ANSWER 44 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2002:235879 CAPLUS
 DOCUMENT NUMBER: 136:268144
 TITLE: Water-soluble compositions containing conivaptan hydrochloride
 INVENTOR(S): Kakuta, Takashi; Koshio, Hiroyuki; Taniguchi, Nobuaki; Asakura, Takashi
 PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002087962	A	20020327	JP 2000-275755	20000912


PRIORITY APPLN. INFO.: JP 2000-275755 20000912

AB This invention relates to stable water-soluble comps. containing conivaptan·HCl (I) crystals which show a specified lattice spacing and relative intensity in the powder x-ray diffraction spectrum obtained by using Cu-Kα line. A mixture was prepared containing I 100, HPMC 2910 300, and Polysorbate-80 50 g, and dissolved in MeOH/water (9:1). The mixture was blended with lactose 442 g and NaHCO₃ 150 g and then, granulated. The granules 834 g, Avicel PH102 240 g, Ac-Di-Sol 120g, and Mg stearate 6 g were mixed and compressed to give tablets (each containing 10 mg I).

IT 318237-73-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of conivaptan hydrochloride crystals and water-soluble comps. containing them)

RN 318237-73-9 CAPLUS

CN Imidazo[4,5-d][1]benzazepine, 1,4,5,6-tetrahydro-2-methyl- (CA INDEX NAME)



L28 ANSWER 45 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2001:17852 CAPLUS
 DOCUMENT NUMBER: 134:86254
 TITLE: Preparation of crystal of condensed benzazepine derivative
 INVENTOR(S): Inakoshi, Masatoshi; Kakuta, Takashi; Kato, Yoshinori
 PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan; Astellas Pharma Inc.
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001002678	A	20010109	JP 1999-170444	19990617
JP 4461512	B2	20100512		


PRIORITY APPLN. INFO.: JP 1999-170444 19990617

AB α -Type crystal of 4'-[(2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine-6-yl)carbonyl]-2-phenylbenzanilide hydrochloride (I) having specific peaks in X-ray diffraction spectrum is prepared in a large industrial scale starting from crude I crystal via dislocation of δ -type crystal to the α -type crystal. I possesses the antagonist activity against vasopressin receptor (no data). Thus, 0.25 mL oxalyl chloride and a catalytic amount of DMF were added to a solution of 373 mg o-phenylbenzoic acid in 7.5 mL CH₂Cl₂ at -15° with stirring, warmed to room temperature over a period of 2 h, stirred for 2 h, concentrated under reduced pressure, and coevaporated with CH₂Cl₂ to give a residue (o-phenylbenzoyl chloride). The residue was dissolved in 7.5 mL dry MeCN, added dropwise to a suspension of 0.5 g 6-(4-aminobenzoyl)-2-methyl-1,2,4,5-tetrahydro-imidazo[4,5-d][1]benzazepine in dry MeCN and 0.608 mL pyridine under ice-cooling, warmed to room temperature, refluxed for .apprx.1 h, cooled, stirred with 4 N HCl/AcOEt, and filtered to give 1.18 g crude I crystal. Crude I crystal (80 g) was added to a mixture of MeCN 400, MeOH 400, and H₂O 80 mL, heated at 45° to dissoln., followed by filtering the solution to remove floating particles and washing the filter with 80 mL MeOH, and the combined filtrate and the washing was distilled under normal pressure until a total of 480 mL liquid was distilled. To the residue was added 1,200 mL MeCN, refluxed for 3 h, slowly cooled to 20°, and the precipitated crystals were filtered, washed with 200 mL MeCN, and vacuum-dried at 80° to give 70.2% I (62.02 g).


IT 195531-22-7 318237-73-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of α -type crystal of imidazobenzazepine hydrochloride derivative by crystal dissoln. as vasopressin receptor antagonist)

RN 195531-22-7 CAPLUS

CN Methanone, (4-aminophenyl)(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)- (CA INDEX NAME)




RN 318237-73-9 CAPLUS
 CN Imidazo[4,5-d][1]benzazepine, 1,4,5,6-tetrahydro-2-methyl- (CA INDEX NAME)



IT 168626-93-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of α -type crystal of imidazobenzazepine hydrochloride
 derivative by crystal dissoln. as vasopressin receptor antagonist)
 RN 168626-93-5 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methyl-6H-oxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L28 ANSWER 46 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2000:441796 CAPLUS
 DOCUMENT NUMBER: 133:74016
 TITLE: preparation of spirotricyclic compounds as H1 receptor antagonists
 INVENTOR(S): Janssens, Frans Eduard; Leenaerts, Joseph Elisabeth
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 64 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000037470	A1	20000629	WO 1999-EP10176	19991215
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2355939	A1	20000629	CA 1999-2355939	19991215
AU 2000030412	A	20000712	AU 2000-30412	19991215
AU 764820	B2	20030828		
BR 9916371	A	20010918	BR 1999-16371	19991215
EP 1144411	A1	20011017	EP 1999-964625	19991215
EP 1144411	B1	20050427		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 2001001711	T2	20011221	TR 2001-1711	19991215
HU 2001004779	A2	20020429	HU 2001-4779	19991215
HU 2001004779	A3	20031229		
EE 2001000328	A	20020815	EE 2001-328	19991215
EE 4917	B1	20071015		
JP 2002533344	T	20021008	JP 2000-589540	19991215
NZ 512870	A	20031128	NZ 1999-512870	19991215
AT 294178	T	20050515	AT 1999-964625	19991215
PT 1144411	E	20050930	PT 1999-964625	19991215
ES 2242443	T3	20051101	ES 1999-964625	19991215
CN 1258533	C	20060607	CN 1999-814705	19991215
PL 196262	B1	20071231	PL 1999-348295	19991215
SK 286158	B6	20080407	SK 2001-814	19991215
IL 143767	A	20100328	IL 1999-143767	19991215
CZ 301953	B6	20100811	CZ 2001-2069	19991215
TW 250981	B	20060311	TW 1999-88122194	19991217
EG 24605	A	20100110	EG 1999-1626	19991218
IN 2001MN00441	A	20050304	IN 2001-MN441	20010423
IN 212018	A1	20080125		
BG 105546	A	20011231	BG 2001-105546	20010529
BG 65133	B1	20070330		
NO 2001002710	A	20010601	NO 2001-2710	20010601
NO 318891	B1	20050518		
HR 2001000453	A2	20020630	HR 2001-453	20010615

HR 2001000453	B1	20100731		
MX 2001006244	A	20010910	MX 2001-6244	20010618
ZA 2001004977	A	20020618	ZA 2001-4977	20010618
US 7148214	B1	20061212	US 2001-868535	20010726
HK 1043128	A1	20070119	HK 2002-104999	20020703
US 20050026901	A1	20050203	US 2004-898844	20040726
US 7087595	B2	20060808		


PRIORITY APPLN. INFO.:

EP 1998-204347	A	19981219
WO 1999-EP10176	W	19991215
US 2001-868535	A1	20010726

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 133:74016

GI



AB Title compds. [I; R = Z2Z3R5, Z2NHCOR5, Z2R5; R1 = H, halo, alkyl, acyl, etc.; R2 = H, halo, alkyl, aryl, etc.; R3R4 = YCH:CH, CH:CHY, CH:CHCH:CH; R5 = (un)substituted heteroaryl, -tetrahydrofuranyl, etc.; Y = O, S, (alkyl)imino, alkanoylimino; Z = alkylene, CH:CH, CH2CH(OH), CH2O, etc.; Z1 = CH2 or CH2CH2; Z3 = O, S, NH] were prepared. Thus, 1-phenylmethyl-1H-imidazole was condensed with 1-phenylmethyl-4-piperidone and the product cyclized to give, after hydrogenation, I (R1 = R2 = H, R3R4 = CH:CHCH:CH, Z = CH2, Z1 = CH2CH2) (II; R = H) which was N-alkylated by 1-(2-bromoethyl)-4-ethyl-1,4-dihydro-5H-tetrazol-5-one to give II [R = 2-(4-ethyl-5-oxo-1,4-dihydro-1H-tetrazol-1-yl)ethyl]. Data for biol. activity of I were given.

IT 279253-82-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of spirotricyclic compds. as H1 receptor antagonists)

RN 279253-82-6 CAPLUS

CN Spiro[cyclohexane-1,10'-[10H]imidazo[1,2-a]thieno[3,2-d]azepine],
(2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 279253-81-5

CMF C15 H16 N2 S

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


10/565,702

CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.




OS.CITING REF COUNT:	5	THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
REFERENCE COUNT:	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L28 ANSWER 47 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2000:211386 CAPLUS
 DOCUMENT NUMBER: 132:347544
 TITLE: Synthesis of 1,4,5,6-tetrahydropyrazolo[3,4-d]pyrido[3,2-b]azepine
 AUTHOR(S): Albright, J. Donald; Du, Xuemei
 CORPORATE SOURCE: Wyeth-Ayerst Research, Pearl River, NY, 10965-1299, USA
 SOURCE: Journal of Heterocyclic Chemistry (2000), 37(1), 41-46
 CODEN: JHTCAD; ISSN: 0022-152X
 PUBLISHER: HeteroCorporation
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 132:347544
 AB The synthesis of 7,8-dihydro-5(6H)-quinolinone (3) from com. available 3-amino-2-cyclohexen-1-one and 3-(dimethylamino)acrolein in 23% yield avoids the preparation of a propynal intermediate. Conversion of 5-(4-methylphenylsulfonyl)-6,7,8,9-tetrahydro-5H-pyrido[3,2-b]azepine to 6-(4-methylphenylsulfonyl)-1,4,5,6-tetrahydropyrazolo[3,4-d]pyrido[3,2-b]azepine is described. Removal of the N-(4-methylphenylsulfonyl) group with 40% sulfuric acid in acetic acid gave a tricyclic azepine. Application of a similar series of reactions to 5-(4-nitrobenzoyl)-6,7,8,9-tetrahydro-5H-pyrido[3,2-b]-azepine afforded
 IT 203636-53-7P 269404-10-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of)
 RN 203636-53-7 CAPLUS
 CN Methanone, (4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl) (4-nitrophenyl)- (CA INDEX NAME)



RN 269404-10-6 CAPLUS
 CN Pyrazolo[3,4-d]pyrido[3,2-b]azepine,
 1,4,5,6-tetrahydro-6-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)



IT 269404-11-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of tetrahydropyrazolo[3,4-d]pyrido[3,2-b]azepine)
 RN 269404-11-7 CAPLUS
 CN Ethanone, 1-(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)- (CA
 INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
 (8 CITINGS)
 REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 48 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2000:69208 CAPLUS

DOCUMENT NUMBER: 132:231505

TITLE: Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4'-(1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine-6-carbonyl)benzanilide derivatives and 4'-(5,6-dihydro-4H-thiazolo[5,4-d][1]benzazepine-6-carbonyl)benzanilide derivative

AUTHOR(S): Matsuhisa, Akira; Taniguchi, Nobuaki; Koshio, Hiroyuki; Yatsu, Takeyuki; Tanaka, Akihiro

CORPORATE SOURCE: Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tsukuba, 305-8585, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (2000), 48(1), 21-31

CODEN: CPBTAL; ISSN: 0009-2363

PUBLISHER: Pharmaceutical Society of Japan

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Arginine vasopressin (AVP) has a dual action mainly in the periphery, i.e., vasoconstriction and water reabsorption via V1A and V2 receptors; it may play a role in a number of diseases, including congestive heart failure (CHF), hypertension, renal disease, edema, and hyponatremia. We have attempted to develop a new series of orally active AVP antagonists for both V1A and V2 receptors based on the hypothesis that the blockade of both V1A and V2 receptors might be beneficial to CHF patients. In this report, a series of compds. structurally related to 4'-(1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine-6-carbonyl)benzanilide and 4'-(5,6-dihydro-4H-thiazolo[5,4-d][1]benzazepine-6-carbonyl)benzanilide were synthesized and examined for AVP antagonist activity for both V1A and V2 receptors. As a result, it was found that the 4'-(1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine-6-carbonyl)-2-phenylbenzanilide derivs. showed potent binding affinity for both V1A and V2 receptors. Especially, 4'-(2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine-6-carbonyl)-2-phenylbenzanilide monohydrochloride (YM087, conivaptan hydrochloride) exhibited potent binding affinity and AVP antagonist activity, after i.v. administration, for both V1A and V2 receptors. Furthermore, YM087 exhibited the most potent oral activity for the V2 receptor. Details of the synthesis and pharmacol. properties of this series are presented.

IT 168626-93-5P 168626-96-8P 168626-97-9P

168626-98-0P 168626-99-1P 168627-00-7P

168627-01-8P 168627-02-9P 168627-03-0P

168627-04-1P 168627-06-3P 168627-07-4P

168627-12-1P 168627-13-2P 261787-71-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and pharmacol. properties of imidazo- and thiazolo(benzazepinylcarbonyl)benzanilide derivs. as arginine vasopressin antagonists for both V1A and V2 receptors)

RN 168626-93-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methyl-6H-oxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 168626-96-8 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-4'-methyl-, hydrochloride (1:1)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 168626-97-9 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(2-ethyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 168626-98-0 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-propylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 168626-99-1 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(phenylmethyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 168627-00-7 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(2-cyclopropyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● HCl

RN 168627-01-8 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 168627-02-9 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● HCl

RN 168627-03-0 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-ethoxy-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● HCl

RN 168627-04-1 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-(1-methylethoxy)-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● HCl

RN 168627-06-3 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 168627-07-4 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 168627-12-1 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[2-(2-aminoethyl)-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● 2 HCl

RN 168627-13-2 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[2-(3-aminopropyl)-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● 2 HCl


RN 261787-71-7 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[2-(4-aminobutyl)-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-, hydrochloride (3:5) (CA INDEX NAME)



● 5/3 HCl

IT 168626-66-2P 168626-67-3P 168626-68-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and pharmacol. properties of imidazo- and
 thiazolo(benzazepinylcarbonyl)benzanilide derivs. as arginine
 vasopressin antagonists for both V1A and V2 receptors)
 RN 168626-66-2 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[2-[2-(1,3-dihydro-1,3-dioxo-2H-
 isoindol-2-yl)ethyl]-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-
 yl]carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 168626-67-3 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[2-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 168626-68-4 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[2-[4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)butyl]-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



OS.CITING REF COUNT:	24	THERE ARE 24 CAPLUS RECORDS THAT CITE THIS RECORD (25 CITINGS)
REFERENCE COUNT:	21	THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L28 ANSWER 49 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1999:811246 CAPLUS
 DOCUMENT NUMBER: 132:49953
 TITLE: Preparation of indolobenzazepinones and related compounds as cyclin dependent kinase inhibitors.
 INVENTOR(S): Kunick, Conrad; Meijer, Laurent; Zaharevitz, Daniel W.; Gussio, Rick; Jalluri, Ravi K.; Sausville, Edward A.
 PATENT ASSIGNEE(S): United States of America, Department of Health and Human Services, USA
 SOURCE: PCT Int. Appl., 116 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9965910	A1	19991223	WO 1999-US13579	19990616
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2335115	A1	19991223	CA 1999-2335115	19990616
CA 2335115	C	20090127		
AU 9945714	A	20000105	AU 1999-45714	19990616
AU 778735	B2	20041216		
EP 1086105	A1	20010328	EP 1999-928715	19990616
EP 1086105	B1	20060301		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 2002518395	T	20020625	JP 2000-554735	19990616
AT 318818	T	20060315	AT 1999-928715	19990616
US 20020042412	A1	20020411	US 2000-739534	20001214
US 6610684	B2	20030826		
AU 2001015009	A	20020718	AU 2001-15009	20010116
AU 780528	B2	20050324		
PRIORITY APPLN. INFO.:			US 1998-89619P	P 19980616
			WO 1999-US13579	W 19990616
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):	MARPAT	132:49953		
GI				



AB Title compds. (I; A = O, S; dotted line = optional double bond; R1 = alkoxy, amino, acyl, alkyl, alkenyl, alkynyl, cyano, NO₂, CO₂H, etc.; R2 = H, PhCH₂, alkyl, alkyl ester; R3 = H, alkyl, cycloalkyl; Y, Z = atoms to form conjugated rings; with a proviso), were prepared. Thus, 1H-[1]benzazepine-2,5(3H,4H)-dione and 4-bromophenylhydrazine were heated with NaOAc in HOAc at 70° for 1 h to give 58% 9-bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one. This was refluxed 12 h with CuCN in DMF to give 42% 9-cyano-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one. The latter inhibited cdk5 with IC₅₀ = 0.044 nM.

IT 252894-50-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of indolobenzazepinones and related compds. as cyclin dependent kinase inhibitors)
 RN 252894-50-1 CAPLUS
 CN Pyrido[3',2':4,5]pyrrolo[3,2-d][1]benzazepin-6(5H)-one, 7,12-dihydro- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
 REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 50 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1999:495193 CAPLUS
 DOCUMENT NUMBER: 131:120908
 TITLE: Vasopressin antagonists as preventives or remedies for vision disorders
 INVENTOR(S): Ogawa, Takahiro; Watanabe, Noriko; Waki, Mitsunori
 PATENT ASSIGNEE(S): Senju Pharmaceutical Co., Ltd., Japan; Yamanouchi Pharmaceutical Co., Ltd.
 SOURCE: PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9938533	A1	19990805	WO 1999-JP261	19990125
W: CA, JP, KR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2319649	A1	19990805	CA 1999-2319649	19990125
EP 1050308	A1	20001108	EP 1999-901151	19990125
R: DE, ES, FR, GB, IT				
US 6268359	B1	20010731	US 2000-601216	20000728
PRIORITY APPLN. INFO.:				
			JP 1998-15538	A 19980128
			WO 1999-JP261	W 19990125

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 131:120908


AB Disclosed are preventives or remedies for vision disorders based on ocular circulatory disorders, e.g. intraocular hypertension and glaucoma, and vision disorders based on ciliary tension, e.g. nearsightedness, wherein the preventives or remedies contain vasopressin antagonists, i.e. benzazepine derivs. as the active ingredients. A suspension eyedrop containing 4'-[(2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine-6-yl)carbonyl]2-phenylbenzanilide·HCl 1, NaPH2 0.1, polysorbate 80 0.1, NaCl 0.9 g, NaOH q.s., and water q.s. to 100 mL was prepared, and its effects on ocular circulation, intraocular pressure, etc. were tested using rabbits.

IT 168626-97-9 168626-98-0 168627-00-7
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (vasopressin antagonists containing benzazepine derivs. for treatment of vision disorders)

RN 168626-97-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(2-ethyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 168626-98-0 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-propylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 168627-00-7 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(2-cyclopropyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● HCl

OS.CITING REF COUNT:	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
REFERENCE COUNT:	7	THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 51 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1999:130582 CAPLUS

DOCUMENT NUMBER: 130:182471

TITLE: Preparation of
5,6-Heteroaryl-dipyrido[2,3-b:3',2'-f]azepines and
their use in the prevention or treatment of HIV
infection

INVENTOR(S): Proudfoot, John R.; Hargrave, Karl; Kapadia, Suresh

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9907379	A1	19990218	WO 1998-US16706	19980811
W: CA, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2295620	A1	19990218	CA 1998-2295620	19980811
US 5908841	A	19990601	US 1998-132527	19980811
US 5919779	A	19990706	US 1998-132526	19980811
EP 1001782	A1	20000524	EP 1998-939913	19980811
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001513502	T	20010904	JP 2000-506969	19980811
MX 2000001365	A	20001020	MX 2000-1365	20000208
PRIORITY APPLN. INFO.:				
			US 1997-55189P	P 19970811
			US 1997-5189P	P 19970811
			WO 1998-US16706	W 19980811

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 130:182471

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Disclosed are novel heteroaryl-dipyridoazepines represented by formula [I, II, and III; A and D are carbon (unsubstituted or optionally substituted with Me, Et, iso-Pr, vinyl, isopropenyl, ethynyl, halogen, nitro, cyano, amino, methylamino, dimethylamino, hydroxy, methoxy, mercapto or methylthio) or nitrogen; and B is oxygen, sulfur or nitrogen (unsubstituted or optionally substituted with Me, Et, iso-Pr, hydroxy or methoxy); and R1 is a hydrogen atom, C1-4 alkyl, C1-4 fluoroalkyl having 1 to 3 fluorine atoms, C3-6 cycloalkyl, oxetanyl, thietanyl, tetrahydrofuran-yl, tetrahydrothienyl, tetrahydropyran-yl, tetrahydrothiopyran-yl, alkenylmethyl or C3-4 alkynylmethyl, or C2-3 alkyloxyalkyl or alkylthioalkyl, alkanoyl or C2-5 alkyl(thiocarbonyl), or C2-3 cyanoalkyl; R2 is a hydrogen atom, C1-6 alkyl, C3-6 cycloalkyl, or C2-6 alkenyl or alkynyl, trihalomethyl, C1-6 hydroxyalkyl, or C2-6 alkyloxy or alkylthio, or C2-6 alkyloxyalkyl or alkylthioalkyl, pyrrolidinyl, pyrrolinyl, piperidinyl, mono- or di-alkylamino, etc.; R3 is


a hydrogen atom, Me or halogen; R4 is a hydrogen atom, Me, Et or halogen; R5 is a hydrogen atom, hydroxy, amino, hydroxymethyl or aminomethyl or a pharmaceutically acceptable salt. These compds. inhibit the enzymic activity of HIV-1 reverse transcriptase (RT), in particular the RNA-dependent DNA polymerase activity of HIV-1 RT. It is known (data not shown) that they also inhibit the DNA-dependent DNA polymerase activity of HIV-1 RT. Thus, to a solution of 3-(2-fluoropyridin-3-yl)-4-(2-ethylaminopyridin-3-yl)thiophene (0.021 g) in THF (1.5 mL) was added potassium bistrimethylsilylamide (0.5M in toluene) until no yellow color appeared on addition of further reagent. The mixture was stirred for 5 min, ethanol was added, the mixture was diluted with Et acetate, washed with water, dried, filtered, and evaporated to give, after chromatog., 8-ethylthienyl[3',4':6,5]dipyrido[2,3-b:3',2'-f]azepine (IV; R2 = H). IV (R2 = H) and IV (R2 = Cl) at 1 μ M inhibited wild-type HIV-1 RT (RNA-dependent DNA polymerase) by 96 and 97%, resp. Pharmaceutical formulations containing the title compds. were given.

IT 220557-08-4P 220557-09-5P 220557-10-8P
220557-11-9P 220557-12-0P 220557-13-1P
220557-14-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 5,6-Heteroaryl-dipyrido[2,3-b:3',2'-f]azepines for prevention or treatment of HIV infection)


RN 220557-08-4 CAPLUS

CN 8H-Dipyrido[2,3-b:3',2'-f]thieno[3,2-d]azepine, 8-ethyl- (CA INDEX NAME)




RN 220557-09-5 CAPLUS

CN 8H-Dipyrido[2,3-b:3',2'-f]thiazolo[4,5-d]azepine, 8-ethyl- (CA INDEX NAME)




RN 220557-10-8 CAPLUS

CN 8H-Oxazolo[4,5-d]dipyrdo[2,3-b:3',2'-f]azepine, 8-ethyl- (CA INDEX NAME)




RN 220557-11-9 CAPLUS

CN 8H-Dipyrdo[2,3-b:3',2'-f]-1,2,3-thiadiazolo[4,5-d]azepine, 8-ethyl- (CA INDEX NAME)




RN 220557-12-0 CAPLUS

CN 8H-Dipyrdo[2,3-b:3',2'-f]-1,2,3-thiadiazolo[5,4-d]azepine, 5-bromo-8-ethyl- (CA INDEX NAME)




RN 220557-13-1 CAPLUS

CN 8H-Dipyrdo[2,3-b:3',2'-f]-1,2,3-thiadiazolo[4,5-d]azepine, 8-ethyl-5-ethynyl- (CA INDEX NAME)



RN 220557-14-2 CAPLUS

CN 8H-Dipyrido[2,3-b:3',2'-f]-1,2,3-thiadiazolo[4,5-d]azepine,
8-ethyl-5-(2-phenylethyl)- (CA INDEX NAME)

IT 220557-24-4P 220557-25-5P 220557-31-3P


220557-32-4P 220557-42-6P 220557-43-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)(preparation of 5,6-Heteroaryl-dipyrido[2,3-b:3',2'-f]azepines for
prevention or treatment of HIV infection)

RN 220557-24-4 CAPLUS


CN 8H-Dipyrido[2,3-b:3',2'-f]thiazolo[5,4-d]azepine,
8-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)

10/565,702




RN 220557-25-5 CAPLUS

CN 8H-Dipyrido[2,3-b:3',2'-f]thiazolo[5,4-d]azepine (CA INDEX NAME)




RN 220557-31-3 CAPLUS

CN 8H-Oxazolo[5,4-d]dipyrido[2,3-b:3',2'-f]azepine,
8-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 220557-32-4 CAPLUS

CN 8H-Oxazolo[5,4-d]dipyrido[2,3-b:3',2'-f]azepine (CA INDEX NAME)




RN 220557-42-6 CAPLUS

CN 8H-Dipyrido[2,3-b:3',2'-f]-1,2,3-thiadiazolo[5,4-d]azepine,
8-ethyl-5-[2-(trimethylsilyl)ethynyl]- (CA INDEX NAME)



RN 220557-43-7 CAPLUS

CN 8H-Dipyrido[2,3-b:3',2'-f]-1,2,3-thiadiazolo[4,5-d]azepine,
8-ethyl-5-(2-phenylethynyl)- (CA INDEX NAME)




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 52 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1999:104514 CAPLUS
 DOCUMENT NUMBER: 130:153583
 TITLE: Tricyclic benzazepine oxytocin and vasopressin antagonists
 INVENTOR(S): Albright, Jay Donald; Sum, Fuk-Wah
 PATENT ASSIGNEE(S): American Cyanamid Company, USA
 SOURCE: U.S., 110 pp., Cont.-in-part of U.S. Ser. No. 254,823.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 10
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5869483	A	19990209	US 1996-639014	19960424
US 5512563	A	19960430	US 1994-254823	19940613
NZ 299340	A	20000825	NZ 1994-299340	19940728
US 5693635	A	19971202	US 1996-662546	19960613
US 5834461	A	19981110	US 1997-874314	19970613
US 5843952	A	19981201	US 1997-889858	19970708
PRIORITY APPLN. INFO.:			US 1993-100003	B2 19930729
			US 1994-254823	A2 19940613
			NZ 1994-264116	A1 19940728
			US 1996-639014	A2 19960424
			US 1996-663400	B1 19960613

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 130:153583
 GI



AB This invention relates to title compds. I wherein: Y = e.g., (CH₂)_n, O, S wherein n is an integer from 0-2; A-B is (CH₂)_mNR₃ or NR₃(CH₂)_m, wherein m is an integer from 1-2, provided that when Y is (CH₂)_n and n=2, m may also be zero and when n is zero, m may also be three, provided also that when Y is (CH₂)_n and n is 2, m may not also be two; R₁ = e.g., H, halo, OH; R₂ = e.g., H, halo, OH; R₃ is the moiety COAr where Ar is selected from, e.g., substituted Ph, (un)substituted 5-indolyl; the aromatic Z ring represents, e.g., fused (un)substituted Ph, 5- or 6-membered atom, heterocycle, that exhibit antagonist activity at V₁ and/or V₂ receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compds. in treating diseases characterized by excess renal reabsorption of water, and processes for preparing such compds. I are also antagonists of the peptide hormone oxytocin and are useful in the control of premature birth. Thus, e.g., acylation of 6,11-dihydro-5H-dibenz[b,e]azepine (preparation given) with

4-[(2-methylbenzoyl)amino]benzoyl chloride (preparation given) afforded N-[4-[(6,11-dihydro-5H-dibenz[b,e]azepin-5-yl)carbonyl]phenyl]-2-methylbenzamide which exhibited binding to rat hepatic V1 receptors and rat kidney medullary V2 receptors with $IC_{50} = 0.15$ and $0.068 \mu M$, resp., and oxytocin receptor binding with $IC_{50} = 2.9 \mu M$.


IT	1099466-57-5	1099466-58-6	1099466-59-7
	1099466-60-0	1099471-79-0	1099471-80-3
	1099471-81-4	1099471-82-5	1099471-83-6
	1099471-84-7	1099471-85-8	1099471-86-9
	1099471-87-0	1099471-88-1	1099471-89-2
	1099471-90-5	1099471-91-6	1099471-92-7
	1099471-93-8	1101631-21-3	1101631-22-4
	1101631-23-5	1101631-24-6	1101631-25-7
	1101631-26-8	1101631-28-0	1101631-29-1
	1101631-30-4	1101631-31-5	1101631-32-6
	1101631-33-7	1101631-35-9	

RL: PRPH (Prophetic)

(Tricyclic benzazepine oxytocin and vasopressin antagonists)


RN 1099466-57-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1099466-58-6 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-2-methyl- (CA INDEX NAME)



RN 1099466-59-7 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-4-fluoro- (CA INDEX NAME)


PAGE 1-A



F

RN 1099466-60-0 CAPLUS


CN Benzamide, 2,3-dichloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]- (CA INDEX NAME)



RN 1099471-79-0 CAPLUS

CN Benzamide, 4-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


C1

RN 1099471-80-3 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)



RN 1099471-81-4 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 1099471-82-5 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 1099471-83-6 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 1099471-84-7 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(methylthio)- (CA INDEX NAME)

10/565,702




RN 1099471-85-8 CAPLUS

CN Benzamide, 2,3-dichloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1099471-86-9 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)



RN 1099471-87-0 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1099471-88-1 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-89-2 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-90-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-3-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-91-6 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099471-92-7 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-fluoro-5-(trifluoromethyl)- (CA INDEX NAME)




RN 1099471-93-8 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-fluoro-6-(trifluoromethyl)- (CA INDEX NAME)




RN 1101631-21-3 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 1101631-22-4 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)




RN 1101631-23-5 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)



RN 1101631-24-6 CAPLUS


CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1101631-25-7 CAPLUS

CN Benzamide, 2-chloro-N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1101631-26-8 CAPLUS


CN Benzamide, 2,3-dichloro-N-[(3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl)-2,3-dichlorophenyl]- (CA INDEX NAME)




RN 1101631-28-0 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2-methyl- (CA INDEX NAME)




RN 1101631-29-1 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2,3-dimethyl- (CA INDEX NAME)



RN 1101631-30-4 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 1101631-31-5 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1101631-32-6 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-4-fluoro-2-methyl- (CA INDEX NAME)


PAGE 1-A



F


RN 1101631-33-7 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2-(methylthio)- (CA INDEX NAME)



RN 1101631-35-9 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




IT 169879-79-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tricyclic benzazepine oxytocin and vasopressin antagonists)

RN 169879-79-2 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)



IT 169878-98-2P 169878-99-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (tricyclic benzazepine oxytocin and vasopressin antagonists)
 RN 169878-98-2 CAPLUS
 CN Methanone, (4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl) (4-
 nitrophenyl)- (CA INDEX NAME)



RN 169878-99-3 CAPLUS
 CN Methanone, (4-aminophenyl) (4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-
 yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
 (2 CITINGS)
 REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 53 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1998:816103 CAPLUS

DOCUMENT NUMBER: 130:52440

TITLE: Preparation of tricyclic benzazepine vasopressin antagonists

INVENTOR(S): Albright, Jay D.; Venkatesan, Aranapakam M.; Delos Santos, Efren G.

PATENT ASSIGNEE(S): American Cyanamid Company, USA

SOURCE: U.S., 82 pp., Cont.-in-part of U.S. Ser. No. 373,169, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5849735	A	19981215	US 1995-548805	19951222
ZA 9600300	A	19970715	ZA 1996-300	19960115
CA 2210688	A1	19960725	CA 1996-2210688	19960116
WO 9622282	A1	19960725	WO 1996-US1051	19960116
W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AZ, BY, KZ, RU, TJ, TM RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9649042	A	19960807	AU 1996-49042	19960116
BR 9606977	A	19971104	BR 1996-6977	19960116
EP 804420	A1	19971105	EP 1996-905227	19960116
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV				
CN 1190391	A	19980812	CN 1996-192568	19960116
HU 9801219	A2	19981028	HU 1998-1219	19960116
HU 9801219	A3	20000728		
JP 10512865	T	19981208	JP 1996-522448	19960116
IL 116777	A	20001121	IL 1996-116777	19960116
TW 449584	B	20010811	TW 1996-85100462	19960116
PRIORITY APPLN. INFO.:				
			US 1995-373169	B2 19950117
			US 1995-548805	A 19951222
			WO 1996-US1051	W 19960116


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 130:52440

GI




- AB The title compds. [I; Y = NH, N(Ac), N(C1-3 alkyl); AB = CH₂N(R₃), N(R₃)CH₂; R₁ = H, halo, OH, etc.; R₂ = H, OH, halo, etc.; R₃ = C(O)Ar; Ar = (un)substituted thienyl, furanyl, Ph, etc.; Z together with two carbon atoms attached = (un)substituted Ph, 5-membered aromatic (un)saturated heterocyclic ring having one heteroatom selected from O, N or S, etc.], which exhibit antagonist activity at V₁ and/or V₂ receptors, in vivo vasopressin antagonist activity, and oxytocin antagonist activity, and therefore are useful in treating diseases characterized by excess renal reabsorption of water as well as congestive heart failure, liver cirrhosis, nephrotic syndrome, CNS injuries, lung disease and hyponatremia, were prepared. Thus, reaction of 10,11-dihydrodibenz[b,f][1,4]oxazepine with 6-[(5-fluoro-2-methylbenzoyl)amino]pyridine-3-carbonyl in the presence of Et₃N in CH₂Cl₂ afforded the title compound II which showed IC₅₀ of 0.24 μ M and 0.054 μ M against rat hepatic V₁ receptors binding and rat kidney medullary V₂ receptors binding, resp.
- IT 217475-60-0P 217475-61-1P 217475-62-2P
217475-63-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic benzazepine vasopressin antagonists)
- RN 217475-60-0 CAPLUS
- CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydropyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 217475-61-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 217475-62-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[5-[(4,5-dihydropyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 217475-63-3 CAPLUS

CN Benzamide, N-[5-[(4,5-dihydropyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]-2-pyridinyl]-5-fluoro-2-methyl- (CA INDEX NAME)




IT 217475-68-8P 217475-69-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclic benzazepine vasopressin antagonists)

RN 217475-68-8 CAPLUS


10/565,702

CN Pyrazolo[4,3-d][1]benzazepine, 1,4,5,6-tetrahydro-6-[(2-methylphenyl)sulfonyl]- (CA INDEX NAME)



RN 217475-69-9 CAPLUS

CN Pyrazolo[4,3-d][1]benzazepine, 1,4,5,6-tetrahydro- (CA INDEX NAME)



OS.CITING REF COUNT:	10	THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
REFERENCE COUNT:	26	THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L28 ANSWER 54 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1998:366893 CAPLUS
 DOCUMENT NUMBER: 129:54301
 ORIGINAL REFERENCE NO.: 129:11320h,11321a
 TITLE: Preparation of tricyclic benzazepine vasopressin antagonists
 INVENTOR(S): Albright, Jay Donald; Reich, Marvin Fred
 PATENT ASSIGNEE(S): American Cyanamid Co., USA
 SOURCE: U.S., 103 pp., Cont.-in-part of U. S. 5,512,563.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 10
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5760031	A	19980602	US 1996-637911	19960425
US 5512563	A	19960430	US 1994-254823	19940613
NZ 299340	A	20000825	NZ 1994-299340	19940728
PRIORITY APPLN. INFO.:			US 1993-100003	B2 19930729
			US 1994-254823	A2 19940613
			NZ 1994-264116	A1 19940728


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 129:54301

GI



I



II

AB The title compds. [I; R1 = H, Cl, F, etc.; R2 = H, Cl, Br, etc.; R1R2 = methylenedioxy, ethylenedioxy; R5 = H, Me, Et, etc.; R6 = N(Ra)COAr', CON(Ra)Ar', etc. (Ra = H, Me, Et; Ar' = (un)substituted Ph, thienyl, etc.); R7 = H, Me, Et, etc.; Z = (un)substituted fused oxazole, Ph], which exhibit antagonist activity at V1 and/or V2 receptors and in vivo vasopressin antagonist activity as well as antagonist activity at oxytocin receptors, and as such useful in treating diseases characterized by excess renal reabsorption of water (e.g., congestive heart failure, nephrotic syndrome, hyponatremia, coronary vasospasm, cardiac ischemia, renal vasospasm, liver cirrhosis, brain edema, cerebral ischemia, cerebral hemorrhage-stroke), were prepared Thus, reaction of 4-[(2-methylbenzoyl)amino]benzoyl chloride with 10,11-dihydro-5H-dibenz[b,f]azepine in the presence of 4-(dimethylamino)pyridine in pyridine at 80° for 18 h followed by the addition of NaH afforded the compound II which showed IC50 of 2.5 μM

against rat hepatic V1 receptor binding and IC50 of 0.86 μ M against rat kidney medullary V2 receptor binding.

IT	1099466-42-8	1099466-57-5	1099466-58-6
	1099466-59-7	1099466-60-0	1099466-69-9
	1099466-70-2	1099466-71-3	1099467-03-4
	1099467-04-5	1099467-05-6	1099467-06-7
	1099467-07-8	1099467-08-9	1099467-09-0
	1099467-10-3	1099467-11-4	1099467-12-5
	1099467-13-6	1099467-14-7	1099467-15-8
	1099467-16-9	1099467-17-0	1099467-18-1
	1099467-19-2	1099467-20-5	1099467-21-6
	1099467-22-7	1099467-23-8	1099467-24-9
	1099467-25-0		


RL: PRPH (Prophetic)

(Preparation of tricyclic benzazepine vasopressin antagonists)

RN 1099466-42-8 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-(methylthio)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



10/565,702


RN 1099466-57-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1099466-58-6 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-2-methyl- (CA INDEX NAME)




10/565,702

RN 1099466-59-7 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099466-60-0 CAPLUS

CN Benzamide, 2,3-dichloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]- (CA INDEX NAME)




RN 1099466-69-9 CAPLUS
 CN Benzamide, 4-chloro-N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099466-70-2 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099466-71-3 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-03-4 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro-3-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099467-04-5 CAPLUS
 CN Benzamide, 2-chloro-N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-05-6 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099467-06-7 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099467-07-8 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-3-fluoro-5-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099467-08-9 CAPLUS
 CN Benzamide, 2-chloro-N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-5-(methylthio)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-09-0 CAPLUS
 CN 3-Thiophenecarboxamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-10-3 CAPLUS
 CN 3-Furancarboxamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-11-4 CAPLUS

CN Benzeneacetamide, 2-chloro-N-[4-((4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-12-5 CAPLUS
 CN Benzeneacetamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-13-6 CAPLUS
 CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-14-7 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-15-8 CAPLUS

CN Benzamide, 2,3-dichloro-N-[3-chloro-4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099467-16-9 CAPLUS

CN Benzamide, 2,4-dichloro-N-[3-chloro-4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-17-0 CAPLUS
 CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099467-18-1 CAPLUS
 CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099467-19-2 CAPLUS
 CN Benzamide, 2-chloro-N-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-20-5 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]-3-methylphenyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-21-6 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]-3-methylphenyl]-2,3-dimethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099467-22-7 CAPLUS
 CN Benzamide, 2-chloro-N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]-3-methylphenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-23-8 CAPLUS

CN Benzamide, N-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]-3-methylphenyl]-3-fluoro-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099467-24-9 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]-3-methylphenyl]-5-fluoro-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099467-25-0 CAPLUS
 CN Benzamide, 2,4-dichloro-N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]-3-methylphenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




IT 169879-79-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of tricyclic benzazepine vasopressin antagonists)

RN 169879-79-2 CAPLUS


CN Benamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)



IT 169878-98-2P 169878-99-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of tricyclic benzazepine vasopressin antagonists)
 RN 169878-98-2 CAPLUS
 CN Methanone, (4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl) (4-
 nitrophenyl)- (CA INDEX NAME)



RN 169878-99-3 CAPLUS
 CN Methanone, (4-aminophenyl) (4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-
 yl)- (CA INDEX NAME)




OS.CITING REF COUNT:	8	THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
REFERENCE COUNT:	14	THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L28 ANSWER 55 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1998:289524 CAPLUS
 DOCUMENT NUMBER: 128:321569
 ORIGINAL REFERENCE NO.: 128:63744h,63745a
 TITLE: Preparation of tricyclic benzazepine vasopressin antagonists
 INVENTOR(S): Albright, Jay Donald; Reich, Marvin Fred
 PATENT ASSIGNEE(S): American Cyanamid Co., USA
 SOURCE: U.S., 101 pp., Cont.-in-part of U.S. Ser. No. 5,512,563.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 10
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5747487	A	19980505	US 1996-638067	19960425
US 5512563	A	19960430	US 1994-254823	19940613
NZ 299340	A	20000825	NZ 1994-299340	19940728
PRIORITY APPLN. INFO.:			US 1993-100003	B2 19930729
			US 1994-254823	A2 19940613
			NZ 1994-264116	A1 19940728

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 128:321569
 GI



I




II


AB The title compds. [I; Y = a bond; AB = (CH₂)₂N(R₃); R₁ = H, halo, OH, etc.; R₂ = H, halo, OH, etc.; R₁R₂ = methylenedioxy, ethylenedioxy; R₃ = C(O)Ar (wherein Ar = (un)substituted Ph, thienyl, etc.); Z = (un)substituted fused benzo, thiazole, etc.), which exhibit antagonistic activity at V₁ and/or V₂ receptors, in vivo vasopressin antagonist activity, and antagonistic activity at oxytocin receptors, and therefore useful in treating diseases characterized by excess renal reabsorption of water such as congestive heart failure, nephrotic syndrome, hyponatremia, coronary vasospasm, cardiac ischemia, liver cirrhosis, brain edema, cerebral ischemia, or cerebral hemorrhage-stroke, were prepared Thus, reaction of 4-[(2-methylbenzoyl)amino]benzoyl chloride with 10,11-dihydro-5H-dibenz[b,f]azepine in the presence of

4-(dimethylamino)pyridine in pyridine afforded the title compound II which showed IC50 of 2.5 μ M against rat hepatic V1 receptors binding and IC50 of 0.86 μ M against rat kidney medullary V2 receptors binding.

IT	1099466-57-5	1099466-58-6	1099466-59-7
	1099466-60-0	1099471-79-0	1099471-80-3
	1099471-81-4	1099471-82-5	1099471-83-6
	1099471-84-7	1099471-85-8	1099471-86-9
	1099471-88-1	1099471-89-2	1099471-90-5
	1099471-91-6	1099471-92-7	1099471-93-8
	1101631-21-3	1101631-22-4	1101631-23-5
	1101631-24-6	1101631-25-7	1101631-26-8
	1101631-28-0	1101631-29-1	1101631-30-4
	1101631-31-5	1101631-32-6	1101631-33-7
	1101631-35-9	1175339-15-7	1175339-18-0
	RL: PRPH (Prophetic)		
	(Preparation of tricyclic benzazepine vasopressin antagonists)		
RN	1099466-57-5	CAPLUS	
CN	Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-5-fluoro-2-methyl- (CA INDEX NAME)		




RN	1099466-58-6	CAPLUS
CN	Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-2-methyl- (CA INDEX NAME)	



RN 1099466-59-7 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-4-fluoro- (CA INDEX NAME)


PAGE 1-A



F

RN 1099466-60-0 CAPLUS


CN Benzamide, 2,3-dichloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]- (CA INDEX NAME)



RN 1099471-79-0 CAPLUS

CN Benzamide, 4-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

C1


RN 1099471-80-3 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)




RN 1099471-81-4 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 1099471-82-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 1099471-83-6 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 1099471-84-7 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(methylthio)- (CA INDEX NAME)

10/565,702




RN 1099471-85-8 CAPLUS

CN Benzamide, 2,3-dichloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]- (CA INDEX NAME)



RN 1099471-86-9 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)



RN 1099471-88-1 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-89-2 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-90-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-3-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-91-6 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099471-92-7 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-fluoro-5-(trifluoromethyl)- (CA INDEX NAME)




RN 1099471-93-8 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-fluoro-6-(trifluoromethyl)- (CA INDEX NAME)




RN 1101631-21-3 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 1101631-22-4 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)




RN 1101631-23-5 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)



RN 1101631-24-6 CAPLUS


CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1101631-25-7 CAPLUS

CN Benzamide, 2-chloro-N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1101631-26-8 CAPLUS


CN Benzamide, 2,3-dichloro-N-[(3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl)-2,3-dichlorophenyl]- (CA INDEX NAME)




RN 1101631-28-0 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2-methyl- (CA INDEX NAME)




RN 1101631-29-1 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2,3-dimethyl- (CA INDEX NAME)



RN 1101631-30-4 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 1101631-31-5 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1101631-32-6 CAPLUS

CN Benzanide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-4-fluoro-2-methyl- (CA INDEX NAME)


PAGE 1-A



F


RN 1101631-33-7 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2-(methylthio)- (CA INDEX NAME)



RN 1101631-35-9 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 1175339-15-7 CAPLUS


CN Benzamide, 2-chloro-4-fluoro-N-[3-fluoro-4-[(5,6,9,10-tetrahydro-4H-thieno[3,2-d][1]benzazepin-5-yl)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




F


RN 1175339-18-0 CAPLUS
 CN Benzamide, 5-fluoro-2-methyl-N-[3-methyl-4-[(5,6,9,10-tetrahydro-4H-thieno[3,2-d][1]benzazepin-5-yl)carbonyl]phenyl]- (CA INDEX NAME)




IT 169879-79-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of tricyclic benzazepine vasopressin antagonists)
 RN 169879-79-2 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)



IT 169878-98-2P 169878-99-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of tricyclic benzazepine vasopressin antagonists)
 RN 169878-98-2 CAPLUS
 CN Methanone, (4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl) (4-
 nitrophenyl)- (CA INDEX NAME)



RN 169878-99-3 CAPLUS
 CN Methanone, (4-aminophenyl) (4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-
 yl)- (CA INDEX NAME)




OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	13	THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 56 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1998:226808 CAPLUS
 DOCUMENT NUMBER: 128:282791
 ORIGINAL REFERENCE NO.: 128:55979a,55982a
 TITLE: Preparation of tricyclic benzazepine vasopressin antagonists
 INVENTOR(S): Albright, Jay Donald; Reich, Marvin Fred; Sum, Fuk-wah; Du, Xuemei
 PATENT ASSIGNEE(S): American Cyanamid Co., USA
 SOURCE: U.S., 104 pp., Cont.-in-part of U.S. 5,512,563.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 10
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5739128	A	19980414	US 1996-637058	19960424
US 5512563	A	19960430	US 1994-254823	19940613
NZ 299340	A	20000825	NZ 1994-299340	19940728
US 5786353	A	19980728	US 1997-893497	19970711
PRIORITY APPLN. INFO.:			US 1993-100003	B2 19930729
			US 1994-254823	A2 19940613
			NZ 1994-264116	A1 19940728
			US 1996-637058	A3 19960424

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 128:282791
 GI



AB The title compds. [I; Z-containing ring = (un)substituted fused Ph; Y = NH, NCOMe; N(Cl-3 alkyl); R1 = H, halo, OH, etc.; R2 = H, Cl, Br, I, F, OH, etc.; R1R2 = methylenedioxy, ethylenedioxy; R3 = C(O)Ar (wherein Ar = (un)substituted Ph, furanyl, thienyl, pyrrolyl)] which exhibit antagonist activity at V1 and/or V2 receptors, in vivo vasopressin antagonist activity, and antagonist activity at oxytocin receptors, and are therefore useful in treating diseases characterized by excess renal reabsorption of water, were prepared Thus, reaction of 4-[(2-methylbenzoyl)amino]benzoyl chloride with 10,11-dihydro-5H-dibenz[b,f]azepine in the presence of

4-(dimethylamino)pyridine and NaH in pyridine afforded compound II which showed IC₅₀ of 2.5 μ M against rat hepatic V1 receptor binding and IC₅₀ of 0.86 μ M against rat kidney medullary V2 receptor binding.

IT	1099466-42-8	1099466-59-7	1099466-60-0
	1099466-69-9	1099466-70-2	1099466-71-3
	1099467-03-4	1099467-04-5	1099467-05-6
	1099467-06-7	1099467-07-8	1099467-08-9
	1099467-09-0	1099467-10-3	1099467-11-4
	1099467-12-5	1099467-13-6	1099467-14-7
	1099467-15-8	1099467-16-9	1099467-17-0
	1099467-18-1	1099467-19-2	1099467-20-5
	1099467-21-6	1099467-22-7	1099467-23-8
	1099467-24-9	1099467-25-0	1099471-79-0
	1099471-80-3	1099471-81-4	1099471-82-5
	1099471-83-6	1099471-84-7	1099471-85-8
	1099471-86-9	1099471-87-0	1099471-88-1
	1099471-89-2	1099471-90-5	1099471-91-6
	1099471-92-7	1099471-93-8	1099471-94-9
	1099471-95-0	1099471-96-1	1099471-97-2
	1099471-98-3	1099471-99-4	1099472-00-0
	1099472-01-1	1099472-02-2	1099472-03-3
	1099472-04-4	1099472-05-5	1099472-06-6
	1099472-07-7	1099472-08-8	


RL: PRPH (Prophetic)

(Preparation of tricyclic benzazepine vasopressin antagonists)

RN 1099466-42-8 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-(methylthio)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099466-59-7 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099466-60-0 CAPLUS


CN Benzamide, 2,3-dichloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]- (CA INDEX NAME)




RN 1099466-69-9 CAPLUS

CN Benzamide, 4-chloro-N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099466-70-2 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099466-71-3 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-03-4 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro-3-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099467-04-5 CAPLUS
 CN Benzamide, 2-chloro-N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-05-6 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099467-06-7 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099467-07-8 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-3-fluoro-5-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099467-08-9 CAPLUS
 CN Benzamide, 2-chloro-N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-5-(methylthio)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-09-0 CAPLUS
 CN 3-Thiophenecarboxamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-10-3 CAPLUS
 CN 3-Furancarboxamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-11-4 CAPLUS

CN Benzeneacetamide, 2-chloro-N-[4-((4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-12-5 CAPLUS

CN Benzeneacetamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-13-6 CAPLUS
 CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-14-7 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-15-8 CAPLUS

CN Benzamide, 2,3-dichloro-N-[(3-chloro-4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099467-16-9 CAPLUS

CN Benzamide, 2,4-dichloro-N-[3-chloro-4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-17-0 CAPLUS
 CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099467-18-1 CAPLUS
 CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099467-19-2 CAPLUS

CN Benzamide, 2-chloro-N-[3-chloro-4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-20-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]-3-methylphenyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-21-6 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]-3-methylphenyl]-2,3-dimethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099467-22-7 CAPLUS
 CN Benzamide, 2-chloro-N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]-3-methylphenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099467-23-8 CAPLUS

CN Benzamide, N-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]-3-methylphenyl]-3-fluoro-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099467-24-9 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]-3-methylphenyl]-5-fluoro-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099467-25-0 CAPLUS

CN Benzamide, 2,4-dichloro-N-[4-[(4,5-dihydro-1-methylpyrazolo[4,3-d][1]benzazepin-6(1H)-yl)carbonyl]-3-methylphenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-79-0 CAPLUS

CN Benzamide, 4-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


C1

RN 1099471-80-3 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)



RN 1099471-81-4 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 1099471-82-5 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 1099471-83-6 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 1099471-84-7 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(methylthio)- (CA INDEX NAME)


10/565,702



RN 1099471-85-8 CAPLUS
 CN Benzamide, 2,3-dichloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1099471-86-9 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)



RN 1099471-87-0 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1099471-88-1 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-89-2 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-90-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-3-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-91-6 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099471-92-7 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-fluoro-5-(trifluoromethyl)- (CA INDEX NAME)




RN 1099471-93-8 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-fluoro-6-(trifluoromethyl)- (CA INDEX NAME)




RN 1099471-94-9 CAPLUS

CN Benzamide, N-[2-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 1099471-95-0 CAPLUS

CN Benzamide, N-[2-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)




RN 1099471-96-1 CAPLUS

CN Benzamide, N-[2-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1099471-97-2 CAPLUS


CN Benzamide, N-[2-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)



RN 1099471-98-3 CAPLUS

CN Benzamide, 2-chloro-N-[2-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099471-99-4 CAPLUS

CN Benzamide, 2,3-dichloro-N-[(2-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl)-2-chlorophenyl]- (CA INDEX NAME)




RN 1099472-00-0 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-methylphenyl]-2-methyl- (CA INDEX NAME)




RN 1099472-01-1 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-methylphenyl]-2,3-dimethyl- (CA INDEX NAME)



RN 1099472-02-2 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-methylphenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 1099472-03-3 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-methylphenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1099472-04-4 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-methylphenyl]-4-fluoro-2-methyl- (CA INDEX NAME)


PAGE 1-A



F


RN 1099472-05-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-methylphenyl]-2-(methylthio)- (CA INDEX NAME)




RN 1099472-06-6 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-methylphenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 1099472-07-7 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-methoxyphenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1099472-08-8 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-methoxyphenyl]-2-methyl- (CA INDEX NAME)




IT 169879-79-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic benzazepine vasopressin antagonists)

RN 169879-79-2 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)



IT 169878-98-2P 169878-99-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of tricyclic benzazepine vasopressin antagonists)
 RN 169878-98-2 CAPLUS
 CN Methanone, (4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl) (4-
 nitrophenyl)- (CA INDEX NAME)



RN 169878-99-3 CAPLUS
 CN Methanone, (4-aminophenyl) (4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-
 yl)- (CA INDEX NAME)





OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)
 REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 57 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1998:219347 CAPLUS
 DOCUMENT NUMBER: 128:257347
 ORIGINAL REFERENCE NO.: 128:50947a
 TITLE: Tricyclic benzazepine oxytocin and vasopressin antagonists
 INVENTOR(S): Albright, Jay Donald; Du, Xuemei
 PATENT ASSIGNEE(S): American Cyanamid Company, USA
 SOURCE: U.S., 109 pp., Cont.-in-part of U.S. 5,512,563.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 10
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5736538	A	19980407	US 1996-638059	19960425
US 5512563	A	19960430	US 1994-254823	19940613
NZ 299340	A	20000825	NZ 1994-299340	19940728
PRIORITY APPLN. INFO.:			US 1993-100003	B2 19930729
			US 1994-254823	A2 19940613
			NZ 1994-264116	A1 19940728

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 128:257347
 GI



AB This invention relates to title compds. I wherein: Y = e.g., (CH₂)_n, O, S wherein n is an integer from 0-2; A-B is (CH₂)_mNR₃ or NR₃(CH₂)_m, wherein m is an integer from 1-2, provided that when Y is (CH₂)_n and n=2, m may also be zero and when n is zero, m may also be three, provided also that when Y is (CH₂)_n and n is 2, m may not also be two; R₁ = e.g., H, halo, OH; R₂ = e.g., H, halo, OH; R₃ is the moiety COAr where Ar is selected from, e.g., substituted Ph, (un)substituted 5-indolyl; the aromatic Z ring represents, e.g., fused (un)substituted Ph, 5- or 6-membered atom. heterocycle, that exhibit antagonist activity at V1 and/or V2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compds. in treating diseases characterized by excess renal reabsorption of water, and processes for preparing such compds. I are also antagonists of the peptide hormone oxytocin and are useful in the control

of premature birth. Thus, e.g., acylation of 6,11-dihydro-5H-dibenz[b,e]azepine (preparation given) with 4-[(2-methylbenzoyl)amino]benzoyl chloride (preparation given) afforded N-[4-[(6,11-dihydro-5H-dibenz[b,e]azepin-5-yl)carbonyl]phenyl]-2-methylbenzamide (II) which exhibited binding to rat hepatic V1 receptors and rat kidney medullary V2 receptors with $IC_{50} = 0.15$ and $0.068 \mu M$, resp., and oxytocin receptor binding with $IC_{50} = 2.9 \mu M$.


IT	1099466-57-5	1099466-58-6	1099466-59-7
	1099466-60-0	1099471-79-0	1099471-80-3
	1099471-81-4	1099471-82-5	1099471-83-6
	1099471-84-7	1099471-85-8	1099471-86-9
	1099471-87-0	1099471-88-1	1099471-89-2
	1099471-90-5	1099471-91-6	1099471-92-7
	1099471-93-8	1101631-21-3	1101631-22-4
	1101631-23-5	1101631-24-6	1101631-25-7
	1101631-26-8	1101631-28-0	1101631-29-1
	1101631-30-4	1101631-31-5	1101631-32-6
	1101631-35-9	1146445-27-3	

RL: PRPH (Prophetic)

(Tricyclic benzazepine oxytocin and vasopressin antagonists)


RN 1099466-57-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1099466-58-6 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-2-methyl- (CA INDEX NAME)



RN 1099466-59-7 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-4-fluoro- (CA INDEX NAME)


PAGE 1-A



F

RN 1099466-60-0 CAPLUS


CN Benzamide, 2,3-dichloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]- (CA INDEX NAME)



RN 1099471-79-0 CAPLUS

CN Benzamide, 4-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


C1

RN 1099471-80-3 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)



RN 1099471-81-4 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 1099471-82-5 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 1099471-83-6 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 1099471-84-7 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(methylthio)- (CA INDEX NAME)

10/565,702




RN 1099471-85-8 CAPLUS

CN Benzamide, 2,3-dichloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1099471-86-9 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)



RN 1099471-87-0 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1099471-88-1 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-89-2 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-90-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-3-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-91-6 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099471-92-7 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-fluoro-5-(trifluoromethyl)- (CA INDEX NAME)




RN 1099471-93-8 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-fluoro-6-(trifluoromethyl)- (CA INDEX NAME)




RN 1101631-21-3 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 1101631-22-4 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)




RN 1101631-23-5 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)



RN 1101631-24-6 CAPLUS


CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1101631-25-7 CAPLUS

CN Benzamide, 2-chloro-N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1101631-26-8 CAPLUS
 CN Benzamide, 2,3-dichloro-N-[(3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl)-2,3-dichlorophenyl]- (CA INDEX NAME)




RN 1101631-28-0 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2-methyl- (CA INDEX NAME)




RN 1101631-29-1 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2,3-dimethyl- (CA INDEX NAME)



RN 1101631-30-4 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 1101631-31-5 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1101631-32-6 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-4-fluoro-2-methyl- (CA INDEX NAME)


PAGE 1-A



F


RN 1101631-35-9 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 1146445-27-3 CAPLUS

CN Benzenecarbothioamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2-methyl- (CA INDEX NAME)




IT 169879-79-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tricyclic benzazepine oxytocin and vasopressin antagonists)

RN 169879-79-2 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)



IT 169878-98-2P 169878-99-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (tricyclic benzazepine oxytocin and vasopressin antagonists)
 RN 169878-98-2 CAPLUS
 CN Methanone, (4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl) (4-
 nitrophenyl)- (CA INDEX NAME)



RN 169878-99-3 CAPLUS
 CN Methanone, (4-aminophenyl) (4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-
 yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
 (3 CITINGS)
 REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 58 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1998:203750 CAPLUS

DOCUMENT NUMBER: 128:282795

ORIGINAL REFERENCE NO.: 128:55983a,55986a

TITLE: Synthesis of pyrrolidinothieno-(or
[1]benzothieno)[3]azepinones from the corresponding
azepinediones or N-(thienyl or
[1]benzothienyl)acetylprolinal

AUTHOR(S): Othman, Mohamed; Netchitailo, Pierre; Decroix, Bernard
CORPORATE SOURCE: Lab. Chimie, Fac. Scis. Techniques, Univ. Havre, Le
Havre, 76600, Fr.



SOURCE: Heterocycles (1998), 48(2), 335-346
CODEN: HETCYM; ISSN: 0385-5414

PUBLISHER: Japan Institute of Heterocyclic Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

GI




AB Title compds. I [RR1 = CH:CHS, SCH:CH, o-C6H4S, o-SC6H4] were prepared from the diones or by direct cyclization of prolinal II.

IT 205761-43-9P 205761-47-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of pyrrolidinothienoazepinones)


RN 205761-43-9 CAPLUS

CN 5H-Pyrrolo[1,2-a]thieno[2,3-d]azepin-5-one, 4,7,8,9-tetrahydro- (CA INDEX NAME)



RN 205761-47-3 CAPLUS


CN 5H-[1]Benzothieno[2,3-d]pyrrolo[1,2-a]azepin-5-one, 1,2,3,6-tetrahydro- (CA INDEX NAME)



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	10	THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 59 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1998:146590 CAPLUS
DOCUMENT NUMBER: 128:192647
ORIGINAL REFERENCE NO.: 128:38063a
TITLE: Preparation of tricyclic benzazepine derivatives as
vasopressin antagonists
INVENTOR(S): Albricht, Jay D.; Delos Santos, Efren G.; Du, Xuemei;
Reich, Marvin F.
PATENT ASSIGNEE(S): American Cyanamid Co., USA
SOURCE: U.S., 56 pp., Cont.-in-part of U.S. 5,532,235.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5719278	A	19980217	US 1996-657830	19960531
US 5532235	A	19960702	US 1995-373139	19950117
PRIORITY APPLN. INFO.:			US 1995-373139	A2 19950117
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE			IN LSUS DISPLAY FORMAT	
OTHER SOURCE(S):	MARPAT 128:192647			
GI				



AB Title tricyclic compds. I (Y = e.g., bond, CH₂, CH(OH); A-B is a moiety selected from (CH₂)nR3 and NR3(CH₂)n where n = 1 or 2 provided that when Y = bond, n = 2; ring Z represents: (1) an unsatd. 6-membered heterocyclic aromatic ring containing one nitrogen atom, optionally substituted by one or two substituents selected from C1-3 lower alkyl, halogen, amino, C1-3 lower alkoxy or C1-3 lower alkylamino; (2) a 5-membered aromatic (unsatd.) heterocyclic ring having one heteroatom selected from O, or S; ring E represents: (1) an unsatd. 6-membered heterocyclic aromatic ring containing one or two nitrogen atoms, optionally substituted by one or two substituents selected from C1-3 lower alkyl, halogen, amino, C1-3 lower alkoxy or C1-3 lower alkylamino; (2) a 5-membered aromatic (unsatd.) heterocyclic ring having one heteroatom selected from O, N or S; (3) a 5-membered aromatic (unsatd.) heterocyclic ring having two adjacent nitrogen atoms; (4) a 5-membered aromatic (unsatd.) heterocyclic ring having one nitrogen atom together with either one oxygen or one sulfur atom; wherein the 5 or 6-membered heterocyclic rings are optionally substituted by C1-3 lower alkyl, halogen, or C1-3 lower alkoxy; R3 = COAr where Ar = substituted Ph.

furyl, thienyl, pyrrolyl, thiazolyl, pyridyl) were prepared. Thus, e.g., acylation of 6-(4-aminobenzoyl)-1,4,5,6-tetrahydropyrazolo[3,4-d]thieno[3,2-b]azepine (preparation given) with 2-chloro-4-fluorobenzoyl chloride afforded N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-chloro-4-fluorobenzamide (II) which exhibited $IC_{50} = 2.0$ and $0.34 \mu M$, resp., for binding to rat hepatic V1 receptors and rat kidney medullary V2 receptors, and $IC_{50} = 2.5 \mu M$ for binding to oxytocin receptors. N-[4-[(4,5-Dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-3-chlorophenyl]-5-fluoro-2-methylbenzamide exhibited $IC_{50} = 0.0061 \mu M$ for V2 receptor binding.

IT	1101696-19-8	1101696-20-1	1101696-21-2
	1101696-22-3	1101696-24-5	1101696-25-6
	1101696-26-7	1101696-27-8	1101696-28-9
	1101696-29-0	1101696-30-3	1101696-31-4
	1101696-32-5	1101696-33-6	1101696-34-7
	1101696-35-8	1101696-36-9	1101696-37-0
	1101696-38-1	1101696-39-2	1101696-40-5
	1101696-41-6	1101696-42-7	1101696-43-8
	1101696-44-9	1101696-45-0	1101696-46-1
	1101696-47-2	1101696-48-3	1101696-49-4
	1101696-50-7	1101696-51-8	1101696-52-9
	1101696-53-0	1101696-54-1	1101696-55-2
	1101696-56-3	1101696-57-4	1101696-58-5
	1101696-59-6	1101696-60-9	1101696-61-0
	1101696-62-1	1101696-63-2	1101696-64-3
	1101696-65-4	1101696-66-5	1101696-67-6
	1101696-68-7	1101696-69-8	1101696-70-1
	1101696-71-2	1101696-72-3	1101696-73-4
	1101696-79-0	1101696-80-3	1101696-81-4
	1101696-82-5	1101696-83-6	1101696-84-7
	1101696-85-8	1101696-86-9	1101696-87-0
	1101696-88-1	1101696-89-2	1101696-90-5
	1101696-91-6	1101696-92-7	1101696-93-8
	1101696-94-9	1101696-95-0	1101696-96-1
	1101696-97-2	1101696-98-3	1101696-99-4
	1101697-00-0	1101697-01-1	1101697-02-2
	1101697-03-3	1101697-04-4	1101697-05-5
	1101697-06-6	1101697-07-7	1101697-08-8
	1101697-09-9	1101697-10-2	1101697-11-3
	1101697-12-4	1101697-13-5	1101697-14-6
	1101697-15-7	1101697-16-8	1101697-17-9
	1101697-18-0	1101697-19-1	1101697-20-4
	1101697-21-5	1101697-22-6	1101697-23-7
	1101697-24-8	1101697-25-9	1101697-26-0
	1101697-27-1	1101697-28-2	1101697-29-3
	1101697-30-6	1101697-31-7	1101697-32-8
	1101697-33-9	1101697-34-0	1101697-35-1
	1101697-36-2	1101697-37-3	1101697-38-4
	1101697-39-5	1101697-40-8	1101697-41-9
	1101697-42-0	1101697-43-1	1101697-44-2
	1101697-45-3	1101697-46-4	1101697-47-5
	1101697-48-6	1101697-49-7	1101697-50-0
	1101697-51-1	1101697-52-2	1101697-53-3
	1101697-54-4	1101697-55-5	1101697-56-6
	1101697-57-7	1101697-58-8	1101697-59-9
	1101697-60-2	1101697-61-3	1101697-62-4
	1101697-63-5	1101697-64-6	1101697-65-7


1101697-66-8	1101697-67-9	1101697-68-0
1101697-69-1	1101697-70-4	1101697-71-5
1101697-72-6	1101697-73-7	1101697-74-8
1101697-75-9	1101697-76-0	1101697-77-1
1101697-83-9	1101697-84-0	1101697-85-1
1101697-86-2	1101697-87-3	1101697-88-4
1101697-89-5	1101697-90-8	1101697-91-9
1101697-92-0	1101697-93-1	1101697-94-2
1101697-95-3	1101697-96-4	1101697-97-5
1101697-98-6	1101697-99-7	1101698-00-3
1101698-01-4	1101698-02-5	1101698-03-6
1101698-04-7	1101698-05-8	1101698-06-9
1101698-08-1	1101698-09-2	1101698-10-5
1101698-11-6	1101698-12-7	1101698-13-8
1101698-14-9	1101698-40-1	1101698-41-2
1101698-42-3	1101698-43-4	1101698-44-5
1101698-45-6	1175342-15-0	1175342-16-1
1175342-17-2	1200803-49-1	1200803-55-9

RL: PRPH (Prophetic)

(Preparation of tricyclic benzazepine derivatives as vasopressin antagonists)


RN 1101696-19-8 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)




RN 1101696-20-1 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 1101696-21-2 CAPLUS

CN Benamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(phenylmethyl)- (CA INDEX NAME)




RN 1101696-22-3 CAPLUS

CN Benamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)



RN 1101696-24-5 CAPLUS

CN Benzamide, 2-bromo-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101696-25-6 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-

yl)carbonyl]phenyl]-2,4-difluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1101696-26-7 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

F


RN 1101696-27-8 CAPLUS

CN Benzamide, 5-bromo-2-chloro-N-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101696-28-9 CAPLUS

CN Benzamide, N-[3-bromo-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)




RN 1101696-29-0 CAPLUS

CN Benzamide, 2,5-dichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)



RN 1101696-30-3 CAPLUS


CN Benamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)



RN 1101696-31-4 CAPLUS


CN Benamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-

6(1H)-yl)carbonyl]phenyl]-5-fluoro- (CA INDEX NAME)




RN 1101696-32-5 CAPLUS

CN Benamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-(trifluoromethyl)- (CA INDEX NAME)




RN 1101696-33-6 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-6-fluoro- (CA INDEX NAME)



RN 1101696-34-7 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,6-dimethyl- (CA INDEX NAME)



10/565,702

RN 1101696-35-8 CAPLUS


CN Benzamide, 2-chloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro- (CA INDEX NAME)



RN 1101696-36-9 CAPLUS

CN Benzamide, 2-chloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1101696-37-0 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 1101696-38-1 CAPLUS

CN Benzamide, 2,3,5-trichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)



RN 1101696-39-2 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(methylthio)- (CA INDEX NAME)



RN 1101696-40-5 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-4-nitro- (CA INDEX NAME)


PAGE 1-A






RN 1101696-41-6 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 1101696-42-7 CAPLUS

CN Benzamide, 5-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)



RN 1101696-43-8 CAPLUS


CN Benzamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-(methylthio)- (CA INDEX NAME)



RN 1101696-44-9 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro-4-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1101696-45-0 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-nitro- (CA INDEX NAME)




RN 1101696-46-1 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro- (CA INDEX NAME)




RN 1101696-47-2 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 1101696-48-3 CAPLUS

CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-5-fluoro-2-methyl- (CA INDEX NAME)




RN 1101696-49-4 CAPLUS

CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-3,4,5-trimethoxy- (CA INDEX NAME)




RN 1101696-50-7 CAPLUS

CN Benzamide, 2-chloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 1101696-51-8 CAPLUS

CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2,4-difluoro- (CA INDEX NAME)




RN 1101696-52-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 1101696-53-0 CAPLUS

CN Benzamide, 2-bromo-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 1101696-54-1 CAPLUS

CN Benzamide, 5-bromo-2-chloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 1101696-55-2 CAPLUS


CN Benzamide, N-[3-bromo-5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-methyl- (CA INDEX NAME)




RN 1101696-56-3 CAPLUS
 CN Benzamide, N-[3-chloro-5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-5-fluoro-2-methyl- (CA INDEX NAME)




RN 1101696-57-4 CAPLUS
 CN Benzamide, 2,5-dichloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 1101696-58-5 CAPLUS
 CN Benzamide, 2-chloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-5-fluoro- (CA INDEX NAME)




RN 1101696-62-1 CAPLUS
 CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-(2-pyridinyl)- (CA INDEX NAME)



RN 1101696-63-2 CAPLUS
 CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-(2-thienyl)- (CA INDEX NAME)




RN 1101696-64-3 CAPLUS
 CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2,6-dimethyl-2-(thiophen-2-yl)- (CA INDEX NAME)




RN 1101696-65-4 CAPLUS

CN Benzamide, 2-chloro-N-[3-chloro-5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-5-fluoro- (CA INDEX NAME)




RN 1101696-66-5 CAPLUS

CN Benzamide, 2-chloro-N-[3-chloro-5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-4-fluoro- (CA INDEX NAME)




RN 1101696-67-6 CAPLUS


CN Benzamide, 2,3-dichloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 1101696-68-7 CAPLUS
 CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-methoxy- (CA INDEX NAME)



RN 1101696-69-8 CAPLUS
 CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 1101696-70-1 CAPLUS
 CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 1101696-71-2 CAPLUS

CN Benzamide, 2,3,5-trichloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 1101696-72-3 CAPLUS

CN Benzamide, 5-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro- (CA INDEX NAME)




RN 1101696-73-4 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)




RN 1101696-79-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101696-80-3 CAPLUS

CN Benzamide, 2-chloro-N-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101696-81-4 CAPLUS

CN Benzamide, 2-chloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101696-82-5 CAPLUS

CN Benzamide, 2,4-dichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101696-83-6 CAPLUS

CN Benzamide, 2,4-dichloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101696-84-7 CAPLUS

CN Benzamide, 2,5-dichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101696-85-8 CAPLUS


CN Benzamide, 2,5-dichloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101696-86-9 CAPLUS
 CN Benzamide, 5-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro- (CA INDEX NAME)



RN 1101696-87-0 CAPLUS
 CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)




RN 1101696-88-1 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)




RN 1101696-89-2 CAPLUS

CN Benamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)




RN 1101696-90-5 CAPLUS

CN Benamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 1101696-91-6 CAPLUS

CN Benamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 1101696-92-7 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 1101696-93-8 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 1101696-94-9 CAPLUS

CN Benzamide, 2,6-dichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101696-95-0 CAPLUS

CN Benzamide, 2,6-dichloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101696-96-1 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,6-dimethyl- (CA INDEX NAME)




RN 1101696-97-2 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,6-dimethyl- (CA INDEX NAME)




RN 1101696-98-3 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(methylthio)- (CA INDEX NAME)




RN 1101696-99-4 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(methylthio)- (CA INDEX NAME)




RN 1101697-00-0 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 1101697-01-1 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 1101697-02-2 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)




RN 1101697-03-3 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)




RN 1101697-04-4 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro- (CA INDEX NAME)




RN 1101697-05-5 CAPLUS


CN Benzamide, 2-chloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro- (CA INDEX NAME)




RN 1101697-06-6 CAPLUS
 CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-nitro- (CA INDEX NAME)



RN 1101697-07-7 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-nitro- (CA INDEX NAME)




RN 1101697-08-8 CAPLUS
 CN Benzamide, 2-amino-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101697-09-9 CAPLUS

CN Benzamide, 2-amino-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101697-10-2 CAPLUS

CN Benzeneacetamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101697-11-3 CAPLUS

CN Benzeneacetamide, 2,6-dichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101697-12-4 CAPLUS

CN Benzeneacetamide, 2-chloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 1101697-13-5 CAPLUS

CN Benzeneacetamide, 2,4-dichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101697-14-6 CAPLUS

CN Benzeneacetamide, 2,4-dichloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 1101697-15-7 CAPLUS

CN Benzeneacetamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro- (CA INDEX NAME)




RN 1101697-16-8 CAPLUS

CN Benzeneacetamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 1101697-17-9 CAPLUS

CN Benzeneacetamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-methoxy- (CA INDEX NAME)




RN 1101697-18-0 CAPLUS

CN Benzeneacetamide, 5-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 1101697-19-1 CAPLUS

CN Benzeneacetamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,5-dimethoxy- (CA INDEX NAME)




RN 1101697-20-4 CAPLUS

CN Benzeneacetamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2,5-dimethoxy- (CA INDEX NAME)




RN 1101697-21-5 CAPLUS

CN Benzeneacetamide, 5-chloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-methoxy- (CA INDEX NAME)




RN 1101697-22-6 CAPLUS

CN Benzeneacetamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 1101697-23-7 CAPLUS

CN Benzeneacetamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-3-fluoro- (CA INDEX NAME)




RN 1101697-24-8 CAPLUS

CN Benzeneacetamide, 2,3-dichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101697-25-9 CAPLUS

CN Benzeneacetamide, 2,3-dichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101697-26-0 CAPLUS

CN Benzeneacetamide, 2,3-dichloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 1101697-27-1 CAPLUS

CN Benzeneacetamide, 3-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro- (CA INDEX NAME)




RN 1101697-28-2 CAPLUS

CN Benzeneacetamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-fluoro- (CA INDEX NAME)




RN 1101697-29-3 CAPLUS

CN Benzeneacetamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(methylthio)- (CA INDEX NAME)




RN 1101697-30-6 CAPLUS

CN Benzeneacetamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-(methylthio)- (CA INDEX NAME)




RN 1101697-31-7 CAPLUS

CN Benzeneacetamide, 5-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro- (CA INDEX NAME)




RN 1101697-32-8 CAPLUS

CN Benzeneacetamide, 5-chloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-fluoro- (CA INDEX NAME)




RN 1101697-33-9 CAPLUS

CN Benzeneacetamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro- (CA INDEX NAME)




RN 1101697-34-0 CAPLUS

CN Benzamide, 2-chloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-4-nitro- (CA INDEX NAME)




RN 1101697-35-1 CAPLUS

CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2,5-dimethyl- (CA INDEX NAME)




RN 1101697-36-2 CAPLUS

CN Benzamide, 5-amino-2-chloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2,5-dimethyl- (CA INDEX NAME)




RN 1101697-37-3 CAPLUS

CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-fluoro-3-(trifluoromethyl)- (CA INDEX NAME)




RN 1101697-38-4 CAPLUS

CN Benzamide, 5-chloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-methoxy- (CA INDEX NAME)




RN 1101697-39-5 CAPLUS


CN Benzamide, 2-chloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-5-(methylthio)- (CA INDEX NAME)




RN 1101697-40-8 CAPLUS
 CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-fluoro-6-(trifluoromethyl)- (CA INDEX NAME)




RN 1101697-41-9 CAPLUS
 CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-fluoro-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1101697-42-0 CAPLUS
 CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)




RN 1101697-43-1 CAPLUS
 CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-nitro- (CA INDEX NAME)



RN 1101697-44-2 CAPLUS
 CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-fluoro- (CA INDEX NAME)




RN 1101697-45-3 CAPLUS
 CN Benzamide, 4-amino-2-chloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 1101697-46-4 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)



RN 1101697-47-5 CAPLUS


CN Benzamide, 2-chloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)



RN 1101697-48-6 CAPLUS

CN Benamide, 2,4-dichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

—
Cl

RN 1101697-49-7 CAPLUS

CN Benzamide, 2,4-dichloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

—
Cl


RN 1101697-50-0 CAPLUS

CN Benzamide, 2,5-dichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101697-51-1 CAPLUS

CN Benzamide, 2,5-dichloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101697-52-2 CAPLUS

CN Benzamide, 5-chloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro- (CA INDEX NAME)



RN 1101697-53-3 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)



RN 1101697-54-4 CAPLUS


CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-

6 (1H)-yl carbonyl]phenyl]-2-methyl- (CA INDEX NAME)




RN 1101697-55-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6 (1H)-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)




RN 1101697-56-6 CAPLUS

CN Benamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)



RN 1101697-57-7 CAPLUS


CN Benamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)



10/565,702


RN 1101697-58-8 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 1101697-59-9 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 1101697-60-2 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(dimethylamino)- (CA INDEX NAME)




RN 1101697-61-3 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(dimethylamino)- (CA INDEX NAME)




RN 1101697-62-4 CAPLUS

CN Benzamide, 5-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 1101697-63-5 CAPLUS

CN Benzamide, 2,3-dichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101697-64-6 CAPLUS

CN Benamide, 2,3-dichloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101697-65-7 CAPLUS

CN Benamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro-6-(trifluoromethyl)- (CA INDEX NAME)



RN 1101697-66-8 CAPLUS


CN Benamide, 2,3,5-trichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)



RN 1101697-67-9 CAPLUS


CN Benamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,3,5-trichloro- (CA INDEX NAME)

yl)carbonyl]phenyl]-2-(methylamino)- (CA INDEX NAME)




RN 1101697-68-0 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(methylamino)- (CA INDEX NAME)




RN 1101697-69-1 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 1101697-70-4 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 1101697-71-5 CAPLUS

CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-methyl- (CA INDEX NAME)




RN 1101697-72-6 CAPLUS

CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-(methylthio)- (CA INDEX NAME)




RN 1101697-73-7 CAPLUS

CN Benzeneacetamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 1101697-74-8 CAPLUS


CN Benzeneacetamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 1101697-75-9 CAPLUS
 CN Benzeneacetamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 1101697-76-0 CAPLUS
 CN Benzeneacetamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-4-fluoro-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 1101697-77-1 CAPLUS
 CN Benzeneacetamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)




RN 1101697-83-9 CAPLUS
 CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)

6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 1101697-84-0 CAPLUS

CN Benzamide, 2,6-dichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101697-85-1 CAPLUS

CN Benzamide, 2,6-dichloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)



RN 1101697-86-2 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,6-dimethyl- (CA INDEX NAME)



10/565,702


RN 1101697-87-3 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,6-dimethyl- (CA INDEX NAME)




RN 1101697-88-4 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(methylthio)- (CA INDEX NAME)




RN 1101697-89-5 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(methylthio)- (CA INDEX NAME)




RN 1101697-90-8 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 1101697-91-9 CAPLUS


CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 1101697-92-0 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1101697-93-1 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1101697-94-2 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro- (CA INDEX NAME)




RN 1101697-95-3 CAPLUS

CN Benzamide, 2-chloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro- (CA INDEX NAME)




RN 1101697-96-4 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-nitro- (CA INDEX NAME)



RN 1101697-97-5 CAPLUS


CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-nitro- (CA INDEX NAME)



RN 1101697-98-6 CAPLUS


CN Benzamide, 2-amino-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-

6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101697-99-7 CAPLUS

CN Benzamide, 2-amino-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101698-00-3 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(dimethylamino)- (CA INDEX NAME)



RN 1101698-01-4 CAPLUS


CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(dimethylamino)- (CA INDEX NAME)



10/565,702


RN 1101698-02-5 CAPLUS

CN Benzamide, 5-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 1101698-03-6 CAPLUS

CN Benzamide, 2,3-dichloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101698-04-7 CAPLUS

CN Benzamide, 2,3-dichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101698-05-8 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro-6-(trifluoromethyl)- (CA INDEX NAME)




RN 1101698-06-9 CAPLUS

CN Benzamide, 2,3,5-trichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101698-08-1 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(methylamino)- (CA INDEX NAME)



RN 1101698-09-2 CAPLUS


CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(methylamino)- (CA INDEX NAME)



RN 1101698-10-5 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-

yl)carbonyl]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 1101698-11-6 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 1101698-12-7 CAPLUS

CN Benzeneacetamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)




RN 1101698-13-8 CAPLUS

CN Benzeneacetamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]pyridinyl]-2-methyl- (CA INDEX NAME)




RN 1101698-14-9 CAPLUS

CN Benzeneacetamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 1101698-40-1 CAPLUS

CN Benzamide, 5-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro- (CA INDEX NAME)




RN 1101698-41-2 CAPLUS

CN Benzamide, 5-amino-2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101698-42-3 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro-3-(trifluoromethyl)- (CA INDEX NAME)



RN 1101698-43-4 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro-6-(trifluoromethyl)- (CA INDEX NAME)




RN 1101698-44-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-

yl)carbonyl]phenyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1101698-45-6 CAPLUS

CN Benzamide, 4-amino-2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1175342-15-0 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazino[2,3-b]pyrazolo[3,4-d]azepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 1175342-16-1 CAPLUS

CN Benzamide, 2,5-dichloro-N-[4-[(4,5-dihydropyrazino[2,3-b]pyrazolo[3,4-d]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1175342-17-2 CAPLUS

CN Benzamide, 2,3-dichloro-N-[4-[(4,5-dihydropyrazino[2,3-b]pyrazolo[3,4-d]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)



RN 1200803-49-1 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(2-pyridinyl)- (CA INDEX NAME)



RN 1200803-55-9 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-

yl)carbonyl]phenyl]-2-(2-thienyl)- (CA INDEX NAME)




IT 203636-61-7P 203636-62-8P 203636-63-9P
 203636-64-0P 203636-66-2P 203636-67-3P
 203636-68-4P 203636-69-5P 203636-70-8P
 203636-71-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of tricyclic benzazepine derivs. as vasopressin antagonists)


RN 203636-61-7 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)




RN 203636-62-8 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)




RN 203636-63-9 CAPLUS
 CN Benamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 203636-64-0 CAPLUS
 CN Benamide, 5-chloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro- (CA INDEX NAME)




RN 203636-66-2 CAPLUS
 CN Benamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)




RN 203636-67-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydropyrzolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 203636-68-4 CAPLUS


CN Methanone, [1,1'-biphenyl]-4-yl(4,5-dihydropyrido[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)- (CA INDEX NAME)



RN 203636-69-5 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 203636-70-8 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)



RN 203636-71-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)




IT 203636-73-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of tricyclic benzazepine derivs. as vasopressin antagonists)

RN 203636-73-1 CAPLUS

CN Methanone, (4-amino-2-chlorophenyl) (4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)- (CA INDEX NAME)



IT 180339-70-2P 180339-71-3P 180339-94-0P


180339-95-1P 180340-73-2P 203636-53-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of tricyclic benzazepine derivs. as vasopressin antagonists)


RN 180339-70-2 CAPLUS

CN Methanone, (2-chloro-4-nitrophenyl) (4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)- (CA INDEX NAME)




RN 180339-71-3 CAPLUS

CN Methanone, (4-amino-2-chlorophenyl) (4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)- (CA INDEX NAME)




RN 180339-94-0 CAPLUS

CN Methanone, (4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl) (4-nitrophenyl)- (CA INDEX NAME)




RN 180339-95-1 CAPLUS

CN Methanone, (4-aminophenyl) (4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)- (CA INDEX NAME)




RN 180340-73-2 CAPLUS

CN Methanone, (4-aminophenyl) (4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)- (CA INDEX NAME)



RN 203636-53-7 CAPLUS



CN Methanone, (4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl) (4-nitrophenyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT:	26	THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 60 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1998:13962 CAPLUS
 DOCUMENT NUMBER: 128:75393
 ORIGINAL REFERENCE NO.: 128:14747a,14750a
 TITLE: Preparation of tricyclic benzazepines as vasopressin antagonists
 INVENTOR(S): Albright, Jay Donald; Reich, Marvin Fred
 PATENT ASSIGNEE(S): American Cyanamid Company, USA
 SOURCE: PCT Int. Appl., 289 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 10
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9747624	A1	19971218	WO 1997-US9548	19970603
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9732964	A	19980107	AU 1997-32964	19970603
PRIORITY APPLN. INFO.:			US 1996-663400	A 19960613
			WO 1997-US9548	W 19970603
OTHER SOURCE(S):		MARPAT 128:75393		
GI				



AB The title compds. [I; Y = a bond, CH₂; AB = (CH₂)₂NR₃, NR₃(CH₂)₂; R₁ = H, halo, OH, etc.; R₂ = H, halo, OH, etc.; R₁R₂ = methylenedioxy, ethylenedioxy; R₃ = C(O)Ar; Ar = (un)substituted Ph, 5-indolyl, thienyl, etc.; Z = (un)substituted fused pyrazole, benzene, etc.] and their salts which exhibit vasopressin antagonist activity and are useful in treating

diseases characterized by excess renal reabsorption of water, were prepared. Thus, reaction of 4-[(2-methylbenzoyl)amino]benzoyl chloride with 6,11-dihydro-5H-dibenz[b,e]azepine in the presence of Et₃N in THF afforded the title compound II which showed IC₅₀ of 0.15 μ M against rat hepatic V1 receptor binding and IC₅₀ of 0.068 μ M against rat kidney medullary V2 receptor binding. Compound II also showed 73% inhibition of oxytocin receptor binding at 10 μ M.


IT	1099466-57-5	1099466-58-6	1099466-59-7
	1099466-60-0	1099471-79-0	1099471-80-3
	1099471-81-4	1099471-82-5	1099471-83-6
	1099471-84-7	1099471-85-8	1099471-86-9
	1099471-87-0	1099471-88-1	1099471-89-2
	1099471-90-5	1099471-91-6	1099471-92-7
	1099471-93-8	1101631-21-3	1101631-22-4
	1101631-23-5	1101631-24-6	1101631-25-7
	1101631-26-8	1101631-28-0	1101631-29-1
	1101631-30-4	1101631-31-5	1101631-32-6
	1101631-33-7	1101631-35-9	

RL: PRPH (Prophetic)

(Preparation of tricyclic benzazepines as vasopressin antagonists)


RN 1099466-57-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1099466-58-6 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-2-methyl- (CA INDEX NAME)



RN 1099466-59-7 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-4-fluoro- (CA INDEX NAME)


PAGE 1-A



F

RN 1099466-60-0 CAPLUS


CN Benzamide, 2,3-dichloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]- (CA INDEX NAME)



RN 1099471-79-0 CAPLUS

CN Benzamide, 4-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

C1


RN 1099471-80-3 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)




RN 1099471-81-4 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 1099471-82-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 1099471-83-6 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 1099471-84-7 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(methylthio)- (CA INDEX NAME)

10/565,702




RN 1099471-85-8 CAPLUS

CN Benzamide, 2,3-dichloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1099471-86-9 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)



RN 1099471-87-0 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1099471-88-1 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-89-2 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-90-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-3-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-91-6 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099471-92-7 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-fluoro-5-(trifluoromethyl)- (CA INDEX NAME)




RN 1099471-93-8 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-fluoro-6-(trifluoromethyl)- (CA INDEX NAME)




RN 1101631-21-3 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 1101631-22-4 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)




RN 1101631-23-5 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)



RN 1101631-24-6 CAPLUS


CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1101631-25-7 CAPLUS

CN Benzamide, 2-chloro-N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1101631-26-8 CAPLUS
 CN Benzamide, 2,3-dichloro-N-[(3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl)-2,3-dichlorophenyl]- (CA INDEX NAME)




RN 1101631-28-0 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2-methyl- (CA INDEX NAME)




RN 1101631-29-1 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2,3-dimethyl- (CA INDEX NAME)



RN 1101631-30-4 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 1101631-31-5 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1101631-32-6 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-4-fluoro-2-methyl- (CA INDEX NAME)


PAGE 1-A



F


RN 1101631-33-7 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2-(methylthio)- (CA INDEX NAME)



RN 1101631-35-9 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




IT 169879-79-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic benzazepines as vasopressin antagonists)

RN 169879-79-2 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)




IT 200729-57-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of tricyclic benzazepines as vasopressin antagonists)

RN 200729-57-3 CAPLUS

CN Methanone, (4-aminophenyl) (4,5-dihydropyrazolo[4,3-d][1]benzazepin-6(1H)-yl)- (CA INDEX NAME)



IT 169878-98-2P 169878-99-3P 200729-55-1P


200729-56-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of tricyclic benzazepines as vasopressin antagonists)


RN 169878-98-2 CAPLUS

CN Methanone, (4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl) (4-nitrophenyl)- (CA INDEX NAME)




RN 169878-99-3 CAPLUS

CN Methanone, (4-aminophenyl) (4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)- (CA INDEX NAME)




RN 200729-55-1 CAPLUS

CN Methanone, (2-chloro-4-nitrophenyl)(4,5-dihydropyrazolo[4,3-d][1]benzazepin-6(1H)-yl)- (CA INDEX NAME)



RN 200729-56-2 CAPLUS

CN Methanone, (4-amino-2-chlorophenyl)(4,5-dihydropyrazolo[4,3-d][1]benzazepin-6(1H)-yl)- (CA INDEX NAME)





OS.CITING REF COUNT:	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 61 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1997:772293 CAPLUS
 DOCUMENT NUMBER: 128:48246
 ORIGINAL REFERENCE NO.: 128:9479a,9482a
 TITLE: Preparation of tricyclic benzazepines as vasopressin antagonists
 INVENTOR(S): Albright, Jay Donald; Reich, Marvin Fred
 PATENT ASSIGNEE(S): American Cyanamid Co., USA
 SOURCE: U.S., 103 pp., Cont.-in-part of U.S. Ser. No. 639,014.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 10
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5693635	A	1997/1202	US 1996-662546	19960613
US 5512563	A	19960430	US 1994-254823	19940613
NZ 299340	A	20000825	NZ 1994-299340	19940728
US 5869483	A	19990209	US 1996-639014	19960424
WO 9747625	A1	1997/1218	WO 1997-US9549	19970603
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9732965	A	19980107	AU 1997-32965	19970603
PRIORITY APPLN. INFO.:				
			US 1993-100003	B2 19930729
			US 1994-254823	A2 19940613
			US 1996-639014	A2 19960424
			NZ 1994-264116	A1 19940728
			US 1996-662546	A 19960613
			WO 1997-US9549	W 19970603


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 128:48246
 GI




AB The title compds. [I; Y = a bond; AB= (CH2)2NR3, NR3(CH2)2; R1 = H, halo,

OH, etc.; R2 = H, halo, OH, etc.; R1R2 = methylenedioxy, ethylenedioxy; R3 = COAr (wherein Ar = substituted Ph); Z with two carbon atoms attached represents a (un)substituted fused thiophene ring, Ph, etc.] which exhibit antagonist activity at V1 and/or V2 receptors, in vivo vasopressin antagonist activity, and also antagonist activity at oxytocin receptors, and are useful in treating diseases characterized by excess renal reabsorption of water, were prepared. Thus, reaction of 4-[(2-methylbenzoyl)amino]benzoyl chloride with 10,11-dihydro-5H-dibenz[b,f]azepine in the presence of NaH and 4-(dimethylamino)pyridine in pyridine afforded II which showed IC50 of 2.5 µM against rat hepatic V1 receptor binding and IC50 of 0.86 µM against rat kidney medullary V2 receptor binding.

IT	1099466-57-5	1099466-58-6	1099466-59-7
	1099471-79-0	1099471-80-3	1099471-81-4
	1099471-82-5	1099471-83-6	1099471-84-7
	1099471-85-8	1099471-86-9	1099471-87-0
	1099471-88-1	1099471-89-2	1099471-90-5
	1099471-91-6	1099471-92-7	1099471-93-8
	1101631-21-3	1101631-22-4	1101631-23-5
	1101631-24-6	1101631-25-7	1101631-26-8
	1101631-28-0	1101631-29-1	1101631-30-4
	1101631-31-5	1101631-32-6	1101631-33-7
	1101631-35-9	1230705-29-9	
	RL: PRPH (Prophetic)		
	(Preparation of tricyclic benzazepines as vasopressin antagonists)		
RN	1099466-57-5	CAPLUS	
CN	Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-5-fluoro-2-methyl- (CA INDEX NAME)		




RN	1099466-58-6	CAPLUS
CN	Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-2-methyl- (CA INDEX NAME)	



RN 1099466-59-7 CAPLUS

CN Benamide, 2-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-79-0 CAPLUS
 CN Benzamide, 4-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1099471-80-3 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)




RN 1099471-81-4 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 1099471-82-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 1099471-83-6 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 1099471-84-7 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(methylthio)- (CA INDEX NAME)

10/565,702




RN 1099471-85-8 CAPLUS

CN Benzamide, 2,3-dichloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1099471-86-9 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)



RN 1099471-87-0 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1099471-88-1 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-89-2 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-90-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-3-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-91-6 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099471-92-7 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-fluoro-5-(trifluoromethyl)- (CA INDEX NAME)




RN 1099471-93-8 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-fluoro-6-(trifluoromethyl)- (CA INDEX NAME)




RN 1101631-21-3 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 1101631-22-4 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)




RN 1101631-23-5 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)



RN 1101631-24-6 CAPLUS


CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1101631-25-7 CAPLUS

CN Benzamide, 2-chloro-N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1101631-26-8 CAPLUS

CN Benzamide, 2,3-dichloro-N-[(3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl)-2,3-dichlorophenyl]- (CA INDEX NAME)




RN 1101631-28-0 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2-methyl- (CA INDEX NAME)




RN 1101631-29-1 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2,3-dimethyl- (CA INDEX NAME)



RN 1101631-30-4 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 1101631-31-5 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1101631-32-6 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-4-fluoro-2-methyl- (CA INDEX NAME)


PAGE 1-A



F


RN 1101631-33-7 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2-(methylthio)- (CA INDEX NAME)




RN 1101631-35-9 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 1230705-29-9 CAPLUS

CN Benzamide, 2,3-dichloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]- (CA INDEX NAME)



IT 200115-00-0P 200115-04-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT


(Reactant or reagent); USES (Uses)

(preparation of tricyclic benzazepines as vasopressin antagonists)


RN 200115-00-0 CAPLUS

CN 4H-Thieno[3,2-d][1]benzazepine-2-carboxylic acid,
6-[4-[(5-fluoro-2-methylbenzoyl)amino]benzoyl]-5,6-dihydro-, ethyl ester
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 200115-04-4 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




IT	169879-79-2P	200115-02-2P	200115-05-5P
	200115-16-8P	200115-29-3P	200115-32-8P
	200115-33-9P	200115-37-3P	200115-38-4P
	200115-39-5P	200115-40-8P	200115-44-2P
	200115-45-3P	200115-46-4P	200115-47-5P
	200115-48-6P	200115-49-7P	200115-73-7P
	200116-00-3P	200116-23-0P	200116-49-0P
	200116-73-0P	200116-82-1P	200116-83-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic benzazepines as vasopressin antagonists)

RN 169879-79-2 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)




RN 200115-02-2 CAPLUS


CN 4H-Thieno[3,2-d][1]benzazepine-2-carboxylic acid,
6-[4-[(5-fluoro-2-methylbenzoyl)amino]benzoyl]-5,6-dihydro- (CA INDEX
NAME)

PAGE 1-A






RN 200115-05-5 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)




RN 200115-16-8 CAPLUS
 CN Benzamide, N-[4-(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 200115-29-3 CAPLUS

CN Benzamide, N-[4-(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)phenyl]-2-methyl- (CA INDEX NAME)




RN 200115-32-8 CAPLUS

CN Benzamide, N-[4-(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)




RN 200115-33-9 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 200115-37-3 CAPLUS


CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)



RN 200115-38-4 CAPLUS
 CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)




RN 200115-39-5 CAPLUS
 CN Benzamide, 2-chloro-N-[3-chloro-4-[(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)carbonyl]phenyl]-5-fluoro- (CA INDEX NAME)




RN 200115-40-8 CAPLUS

CN Benzamide, N-[2,5-dichloro-4-(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)




RN 200115-44-2 CAPLUS


CN Benzamide, N-[3-chloro-4-(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)phenyl]-5-fluoro-2-(methylthio)- (CA INDEX NAME)




RN 200115-45-3 CAPLUS
 CN Benzamide, 2-chloro-N-[4- (4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)phenyl]-5-fluoro- (CA INDEX NAME)




RN 200115-46-4 CAPLUS
 CN Benzamide, 3-chloro-N-[3-chloro-4-[(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)



RN 200115-47-5 CAPLUS
 CN Benzamide, 2-chloro-N-[3-chloro-4-[(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 200115-48-6 CAPLUS
 CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)carbonyl]phenyl]-5-fluoro-2-methoxy- (CA INDEX NAME)



RN 200115-49-7 CAPLUS


CN Benzamide, 2-chloro-N-[3-chloro-4-[(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




|
F

RN 200115-73-7 CAPLUS
 CN Benzamide, N-[4-(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)-3-methylphenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 200116-00-3 CAPLUS
 CN Benzamide, N-[4-(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)-3-methoxyphenyl]-2-methyl- (CA INDEX NAME)




RN 200116-23-0 CAPLUS

CN Benzamide, N-[4-(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)-3-methoxyphenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 200116-49-0 CAPLUS

CN Benzamide, N-[4-(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 200116-73-0 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)carbonyl]-3-fluorophenyl]-2-methyl- (CA INDEX NAME)




RN 200116-82-1 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 200116-83-2 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-5-fluoro- (CA INDEX NAME)


IT 169878-98-2P
200122-34-5P
200122-37-8P169878-99-3P
200122-35-6P200122-33-4P
200122-36-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of tricyclic benzazepines as vasopressin antagonists)


RN 169878-98-2 CAPLUS

CN Methanone, (4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl) (4-nitrophenyl)- (CA INDEX NAME)




RN 169878-99-3 CAPLUS

CN Methanone, (4-aminophenyl) (4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)- (CA INDEX NAME)




RN 200122-33-4 CAPLUS


CN 4H-Thieno[3,2-d][1]benzazepine-2-carboxylic acid, 5,6-dihydro-6-(4-nitrobenzoyl)-, ethyl ester (CA INDEX NAME)



RN 200122-34-5 CAPLUS
 CN 4H-Thieno[3,2-d][1]benzazepine-2-carboxylic acid,
 6-(4-aminobenzoyl)-5,6-dihydro-, ethyl ester (CA INDEX NAME)




RN 200122-35-6 CAPLUS
 CN 4H-Thieno[3,2-d][1]benzazepine-2-carboxylic acid,
 5,6-dihydro-6-(4-nitrobenzoyl)- (CA INDEX NAME)




RN 200122-36-7 CAPLUS

CN Methanone, (4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl) (4-nitrophenyl)-
(CA INDEX NAME)



RN 200122-37-8 CAPLUS

CN Methanone, (4-aminophenyl) (4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)-
(CA INDEX NAME)



OS.CITING REF COUNT:	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT:	8	THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 62 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1997:735922 CAPLUS
 DOCUMENT NUMBER: 128:22824
 ORIGINAL REFERENCE NO.: 128:4475a,4478a
 TITLE: Pyridobenzoxazepine and pyridobenzothiazepine
 vasopressin antagonists
 INVENTOR(S): Albright, Jay Donald; Du, Xuemei
 PATENT ASSIGNEE(S): American Cyanamid Co., USA
 SOURCE: U.S., 107 pp., Cont.-in-part of U.S. 5,512,563.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 10
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5686445	A	19971111	US 1996-637908	19960425
US 5512563	A	19960430	US 1994-254823	19940613
NZ 299340	A	20000825	NZ 1994-299340	19940728
US 5854236	A	19981229	US 1997-834706	19970401
PRIORITY APPLN. INFO.:			US 1993-100003	B2 19930729
			US 1994-254823	A2 19940613
			NZ 1994-264116	A1 19940728
			US 1996-637908	A3 19960425

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 128:22824


AB Approx. 80 title compds., primarily N-(substituted benzoylaminobenzoyl)dibenzazepines, were prepared by N-acylation of the azepine. E.g., acylation of 10,11-dihydro-5H-dibenz[b,f]azepine with o-MeC6H4CONHC6H4COC1-p gave N-[4-(10,11-dihydro-5H-dibenz[b,f]azepin-5-ylcarbonyl)phenyl]-2-methylbenzamide. The title compds. exhibit antagonist activity at V1 and/or V2 receptors and extensive data is given for vasopressin antagonist activity.

IT 1099466-57-5 1099466-58-6 1099466-59-7
 1099466-60-0 1099471-79-0 1099471-80-3
 1099471-81-4 1099471-82-5 1099471-83-6
 1099471-84-7 1099471-85-8 1099471-86-9
 1099471-87-0 1099471-88-1 1099471-89-2
 1099471-90-5 1099471-91-6 1099471-92-7
 1099471-93-8 1101631-21-3 1101631-22-4
 1101631-23-5 1101631-24-6 1101631-25-7
 1101631-26-8 1101631-28-0 1101631-29-1
 1101631-30-4 1101631-32-6 1101631-35-9
 1146445-27-3 1230763-45-7

RL: PRPH (Prophetic)
 (Pyridobenzoxazepine and pyridobenzothiazepine vasopressin antagonists)


RN 1099466-57-5 CAPLUS

CN Benzamide, N-[4-[4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1099466-58-6 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-2-methyl- (CA INDEX NAME)



RN 1099466-59-7 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

F

RN 1099466-60-0 CAPLUS


CN Benzamide, 2,3-dichloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]- (CA INDEX NAME)



RN 1099471-79-0 CAPLUS


CN Benzamide, 4-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A




|
C1

RN 1099471-80-3 CAPLUS
CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)




RN 1099471-81-4 CAPLUS
CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 1099471-82-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 1099471-83-6 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 1099471-84-7 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(methylthio)- (CA INDEX NAME)




RN 1099471-85-8 CAPLUS
 CN Benzamide, 2,3-dichloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]- (CA INDEX NAME)



RN 1099471-86-9 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 1099471-87-0 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1099471-88-1 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-89-2 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-90-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-3-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-91-6 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099471-92-7 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-fluoro-5-(trifluoromethyl)- (CA INDEX NAME)




RN 1099471-93-8 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-fluoro-6-(trifluoromethyl)- (CA INDEX NAME)




RN 1101631-21-3 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 1101631-22-4 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)




RN 1101631-23-5 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)



RN 1101631-24-6 CAPLUS


CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1101631-25-7 CAPLUS

CN Benzamide, 2-chloro-N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1101631-26-8 CAPLUS

CN Benzamide, 2,3-dichloro-N-[(3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl)-2,3-dichlorophenyl]- (CA INDEX NAME)




RN 1101631-28-0 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2-methyl- (CA INDEX NAME)




RN 1101631-29-1 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2,3-dimethyl- (CA INDEX NAME)




RN 1101631-30-4 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-3-fluoro-2-methyl- (CA INDEX NAME)



RN 1101631-32-6 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-4-fluoro-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1101631-35-9 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 1146445-27-3 CAPLUS

CN Benzenecarbothioamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2-methyl- (CA INDEX NAME)



RN 1230763-45-7 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-3-fluoro-5-methyl- (CA INDEX NAME)




IT 169879-79-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and vasopressin antagonist activity of
(benzoylaminobenzoyl)dibenzazepines)

RN 169879-79-2 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)



IT 169878-98-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and vasopressin antagonist activity of
 (benzoylaminobenzoyl)dibenzazepines)
 RN 169878-98-2 CAPLUS
 CN Methanone, (4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl) (4-
 nitrophenyl)- (CA INDEX NAME)



IT 169878-99-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and vasopressin antagonist activity of
 (benzoylaminobenzoyl)dibenzazepines)
 RN 169878-99-3 CAPLUS
 CN Methanone, (4-aminophenyl) (4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-
 yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
 (2 CITINGS)
 REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 63 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1997:568814 CAPLUS

DOCUMENT NUMBER: 127:248029

ORIGINAL REFERENCE NO.: 127:48461a, 48464a

TITLE: Preparation of oxime group-containing benzazepines as arginine vasopressin V1 receptor antagonists for treatment of diabetic nephropathy

INVENTOR(S): Tanaka, Akihiro; Kono, Norimasa; Matsuhisa, Akira; Shimada, Yoshiaki; Akane, Hiroaki; Yazu, Takeyuki

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 27 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09221475	A	19970826	JP 1996-25094	19960213

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 127:248029

GI For diagram(s), see printed CA Issue.

AB Title compds. I [R1 = (lower alkoxy-substituted) lower alkyl; R2 = H, (lower alkoxy-substituted) lower alkyl; A = Q1, Q2; R3 = H, halo, lower alkyl, (alkyl)amino, lower alkoxy; ring B = (un)substituted N-containing 5-membered heterocyclyl (containing O or S); D1, D2 = bond, lower alkylene, lower alkenylene; R4 = H, lower alkyl, lower alkenyl, cycloalkyl, OH, CO2H, cyano, (un)substituted aryl, etc.; E = Q3, Q4, NR5D5 (the N may be oxidized); m = 0, 1; p = 0-3; D3-D5 = bond, lower alkylene, lower alkenylene; R5 = H, lower alkyl; p, q = 1-3; p + q = 3-5; n = 2-7] or their pharmaceutically acceptable salts are prepared

2-Methoxyiminopropionic acid (147 mg) was chlorinated by oxalyl chloride in CH2Cl2, then treated with 200 mg

6-(4-aminobenzoyl)-2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine under reflux to give 264 mg II.


IT 195531-37-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of benzazepines as arginine vasopressin V1 receptor antagonists for treatment of diabetic nephropathy)

RN 195531-37-4 CAPLUS

CN Propanamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-[(methoxymethoxy)imino]- (CA INDEX NAME)




IT 195530-96-2P 195530-97-3P 195530-98-4P
 195530-99-5P 195531-00-1P 195531-01-2P
 195531-02-3P 195531-03-4P 195531-04-5P
 195531-05-6P 195531-06-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzazepines as arginine vasopressin V1 receptor antagonists for treatment of diabetic nephropathy)


RN 195530-96-2 CAPLUS

CN Propanamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-(methoxyimino)-, hydrochloride (1:1) (CA INDEX NAME)




RN 195530-97-3 CAPLUS

CN Propanamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-(ethoxyimino)- (CA INDEX NAME)




RN 195530-98-4 CAPLUS

CN Butanamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-(methoxyimino)-, hydrochloride (1:1) (CA INDEX NAME)




RN 195530-99-5 CAPLUS

CN Butanamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-(hydroxyimino)-, hydrochloride (1:1) (CA INDEX NAME)




RN 195531-00-1 CAPLUS

CN Butanamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-(ethoxyimino)-, hydrochloride (1:1) (CA INDEX NAME)




RN 195531-01-2 CAPLUS

CN Propanamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-[(1,1-dimethylethoxy)imino]- (CA INDEX NAME)




RN 195531-02-3 CAPLUS

CN Propanamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-[(methoxymethoxy)imino]-, hydrochloride (1:1) (CA INDEX NAME)




RN 195531-03-4 CAPLUS

CN Pentanamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-(hydroxyimino)- (CA INDEX NAME)




RN 195531-04-5 CAPLUS

CN Pentanamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-(methoxyimino)-, hydrochloride (1:1) (CA INDEX NAME)




RN 195531-05-6 CAPLUS

CN Butanamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-(methoxyimino)-3-methyl-, hydrochloride (1:1) (CA INDEX NAME)



RN 195531-06-7 CAPLUS

CN Propanamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-3-methoxy-2-(methoxyimino)-, hydrochloride (1:1) (CA INDEX NAME)




IT 195531-22-7

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of benzazepines as arginine vasopressin V1 receptor antagonists for treatment of diabetic nephropathy)

RN 195531-22-7 CAPLUS


CN Methanone, (4-aminophenyl) (4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)- (CA INDEX NAME)



IT 195531-23-8P 195531-28-3P 195531-31-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of benzazepines as arginine vasopressin V1 receptor antagonists
 for treatment of diabetic nephropathy)
 RN 195531-23-8 CAPLUS
 CN Propanamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-
 yl)carbonyl]phenyl]-2-oxo-, hydrochloride (1:1) (CA INDEX NAME)




RN 195531-28-3 CAPLUS
 CN Pentanamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-
 yl)carbonyl]phenyl]-2-oxo- (CA INDEX NAME)





RN 195531-31-8 CAPLUS

CN Butanamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-3-methyl-2-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L28 ANSWER 64 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1997:140708 CAPLUS
 DOCUMENT NUMBER: 126:131678
 ORIGINAL REFERENCE NO.: 126:25437a,25440a
 TITLE: Flow Thermolysis Rearrangements in the Indole Alkaloid Series: Strictamine and Akuammicine Derivatives. The Absolute Configurations of Ngouniensiine and epi-Ngouniensiine
 AUTHOR(S): Hugel, Georgette; Royer, Daniel; Le Men-Olivier, Louisette; Richard, Bernard; Jacquier, Marie-Jose; Levy, Jean
 CORPORATE SOURCE: Laboratoire de Transformations et Synthese de Substances Naturelles et Laboratoire de Pharmacognosie, Universite de Reims Champagne-Ardenne Faculte de Pharmacie, Reims, F-51096, Fr.
 SOURCE: Journal of Organic Chemistry (1997), 62(3), 578-583 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 126:131678
 GI




AB Flow thermolysis of strictamine generated two of the predictable rearrangement products, resulting from [1,5]-sigmatropic shifts: akuammicine and indolenine I. Besides formation of these two compds., a quite different pathway gave rise to a novel rearrangement leading to a indole, with the framework of the natural alkaloid ngouniensiine. Rearrangement to the ngouniensiine skeleton became the major pathway when the akuammicine derivs. were submitted to thermolysis. These results allowed us to assign the absolute configuration of (-)-ngouniensiine (II) (3R,20R) and that of (-)-epingouniensiine (3R,20S).

IT 186252-97-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (flow thermolysis rearrangements of indole alkaloids strictamine and akuammicine derivs., absolute configurations of ngouniensiine and epi-ngouniensiine)
 RN 186252-97-1 CAPLUS
 CN 5H-Pyrido[1',2':1,2]azepino[4,5-b]indole-6-carboxaldehyde, 9-ethyl-9,10,12,13-tetrahydro-, (9S)- (CA INDEX NAME)

10/565,702

Absolute stereochemistry.



OS.CITING REF COUNT:	5	THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT:	30	THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 65 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1996:725149 CAPLUS

DOCUMENT NUMBER: 126:74775

ORIGINAL REFERENCE NO.: 126:14473a,14476a

TITLE: Synthesis and biological activity of some new heterocyclic annelated compounds from 2,3,4,5-tetrahydro-1-benzazepines

AUTHOR(S): Peesapati, Venkateswarlu; Anuradha, Kancharla
CORPORATE SOURCE: Dep. Chem., Osmania Univ., Hyderabad, 500 007, India

SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1996), 35B(12), 1287-1293

CODEN: IJSBDB; ISSN: 0376-4699

PUBLISHER: Publications & Information Directorate, CSIR

DOCUMENT TYPE: Journal


LANGUAGE: English

AB Synthesis of a number of tricyclic compds. with a fused isoxazole, pyrazole, thiophene and thiadiazole ring systems starting from 4-methoxycarbonyl and 4-hydroxymethylene-2,3,4,5-tetrahydro-1-tosyl-1-benzazepin-5(1H)-one has been described. These compds. are effective bactericides and fungicides.

IT 185348-99-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation and biol. activity of heterocyclic annelated tetrahydrobenzazepines)

RN 185348-99-6 CAPLUS

CN 4H-Isloxazolo[4,5-d][1]benzazepine,
5,6-dihydro-8,9-dimethoxy-6-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)


IT 185349-20-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and biol. activity of heterocyclic annelated tetrahydrobenzazepines)

RN 185349-20-6 CAPLUS

CN 4H-Thieno[3,2-d][1]benzazepine-2-carboxylic acid,
5,6-dihydro-8,9-dimethoxy-6-[(4-methylphenyl)sulfonyl]-, methyl ester (CA


INDEX NAME)



IT 185349-38-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 185349-38-6 CAPLUS

CN Pyrazolo[4,3-d][1]benzazepin-3(2H)-one,
1,4,5,6-tetrahydro-8,9-dimethoxy-6-[(4-methylphenyl)sulfonyl]- (CA INDEX
NAME)

OS.CITING REF COUNT:	6	THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT:	9	THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 66 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1996:641143 CAPLUS
 DOCUMENT NUMBER: 125:275872
 ORIGINAL REFERENCE NO.: 125:51601a,51604a
 TITLE: Method for industrial manufacture of condensed benzazepine derivatives as AVP antagonists
 INVENTOR(S): Tsunoda, Takashi; Yamazaki, Atsuki; Tanaka, Akihiro
 PATENT ASSIGNEE(S): Yamanouchi Pharma Co Ltd, Japan; Astellas Pharma Inc.
 SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08198879	A	19960806	JP 1995-6172	19950119
JP 3733606	B2	20060111		
JP 2004231668	A	20040819	JP 2004-146924	20040517
JP 4085178	B2	20080514		
PRIORITY APPLN. INFO.:			JP 1995-6172	A3 19950119
OTHER SOURCE(S):	MARPAT	125:275872		


GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Benzazepine derivs. [I; R1, R2 = H, halo, lower alkyl, alkoxy, etc.; R3 = H, alkyl, alkenyl, imidazolyl, pyridinyl, etc.; X1, X2 = N, O, S, NR4 (wherein R4 = H, alkyl, etc.); ring C is optionally substituted], useful as AVP antagonists (no data), are manufactured with good yields in two ways: (1) by reacting intermediate II (Ra = protecting group) with III; or (2) by reacting intermediate IV with V. Thus, VI was prepared by reacting 2-phenylbenzoic acid with 6-(4-aminobenzoyl)-2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine (preparation given). VI was also prepared by reacting 4-(2-phenylbenzamido)benzoic acid with 2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine.

IT 182202-69-3P 182202-71-7P 182202-73-9P
 182202-75-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (industrial manufacture of condensed benzazepine derivs. useful as AVP antagonists)


RN 182202-69-3 CAPLUS
 CN Imidazo[4,5-d][1]benzazepine, 1,4,5,6-tetrahydro-2-methyl-6-[(4-methylphenyl)sulfonyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 182202-71-7 CAPLUS

CN Methanone, (4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl) (4-nitrophenyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 182202-73-9 CAPLUS

CN Imidazo[4,5-d][1]benzazepine, 1,4,5,6-tetrahydro-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)


10/565,702



● HCl

RN 182202-75-1 CAPLUS

CN Methanone, (4-aminophenyl) (4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L28 ANSWER 67 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1996:567275 CAPLUS

DOCUMENT NUMBER: 125:221884

ORIGINAL REFERENCE NO.: 125:41473a,41476a

TITLE: Preparation of tricyclic benzazepines and

benzodiazepines as vasopressin antagonists

INVENTOR(S): Albright, Jay Donald; Venkatesan, Aranapakam Mudumbai;

Delos Santos, Efren Guillermo

PATENT ASSIGNEE(S): American Cyanamid Company, USA

SOURCE: PCT Int. Appl., 357 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9622282	A1	19960725	WO 1996-US1051	19960116
W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AZ, BY, KZ, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5849735	A	19981215	US 1995-548805	19951222
AU 9649042	A	19960807	AU 1996-49042	19960116
BR 9606977	A	19971104	BR 1996-6977	19960116
EP 804420	A1	19971105	EP 1996-905227	19960116
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV				
JP 10512865	T	19981208	JP 1996-522448	19960116
PRIORITY APPLN. INFO.:			US 1995-373169	A 19950117
			US 1995-548805	A 19951222
			WO 1996-US1051	W 19960116

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 125:221884


GI




AB The title compds. [I; Y = (CH₂)_n (wherein n = 0-2), O, S, etc.; AB = (N-substituted) (CH₂)_mNH, NH(CH₂)_m (wherein m = 1-2); R₁, R₂ = H, halo, OH, etc.; Z = (substituted) fused Ph, 5-membered fused heteroaryl, etc.]

which exhibit antagonist activity at V1 and/or V2 receptors and therefore useful as diuretics and antihypertensives, and in the treatment and/or prevention of congestive heart failure, liver cirrhosis, brain edema, cerebral ischemia, cerebral hemorrhage-stroke, thrombosis-bleeding, etc., were prepared. Thus, reaction of 10,11-dihydrodibenz[b,f][1,4]oxazepine with 6-[(5-fluoro-2-methylbenzoyl)amino]pyridine-3-carbonyl chloride in the presence of Et3N in CH2Cl2 afforded the desired product II which showed IC50 of 0.24 μ M against rat hepatic V1 receptors and of 0.054 μ M against rat kidney medullary V2 receptors.


IT 181131-09-9P 181131-20-4P 181131-51-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of tricyclic benzazepines and benzodiazepines as vasopressin antagonists)
 RN 181131-09-9 CAPLUS
 CN Benzamide, N-[5-[(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)carbonyl]-2-pyridinyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 181131-20-4 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[5-[(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 181131-51-1 CAPLUS
 CN Methanone, [1,1'-biphenyl]-4-yl (4,5-dihydropyrazolo[4,3-d][1]benzazepin-6(1H)-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS
 RECORD (13 CITINGS)
 REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 68 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1996:452764 CAPLUS

DOCUMENT NUMBER: 125:167976

ORIGINAL REFERENCE NO.: 125:31481a,31484a

TITLE: Tricyclic azepine oxytocin and vasopressin receptor antagonists

INVENTOR(S): Albright, Jay D.; Delos Santos, Efren G.; Du, Xuemei; Reich, Marvin E.; Venkatesan, Aranapakam M.

PATENT ASSIGNEE(S): American Cyanamid Co., USA

SOURCE: U.S., 53 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5532235	A	19960702	US 1995-373139	19950117
ZA 9600299	A	19970715	ZA 1996-299	19960115
CA 2210632	A1	19960725	CA 1996-2210632	19960116
WO 9622295	A1	19960725	WO 1996-US1472	19960116
W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AZ, BY, KZ, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9647755	A	19960807	AU 1996-47755	19960116
EP 804440	A1	19971105	EP 1996-903777	19960116
EP 804440	B1	20071219		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV				
BR 9607186	A	19971111	BR 1996-7186	19960116
CN 1181084	A	19980506	CN 1996-192597	19960116
CN 1061658	C	20010207		
HU 9702219	A2	19980728	HU 1997-2219	19960116
HU 9702219	A3	19990528		
JP 10512867	T	19981208	JP 1996-522462	19960116
JP 4219978	B2	20090204		
NZ 302159	A	20000128	NZ 1996-302159	19960116
IL 116773	A	20001206	IL 1996-116773	19960116
TW 426684	B	20010321	TW 1996-85100459	19960116
AT 381570	T	20080115	AT 1996-903777	19960116
ES 2297835	T3	20080501	ES 1996-903777	19960116
US 5719278	A	19980217	US 1996-657830	19960531
PRIORITY APPLN. INFO.:			US 1995-373139	A 19950117
			WO 1996-US1472	W 19960116

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 125:167976

GI



AB Title tricyclic compds. I are provided wherein: Y = e.g., bond, CH₂, CH(OH); A-B is a moiety selected from (CH₂)_nNR₃ and NR₃(CH₂)_n where n = 1 or 2 provided that when Y = bond, n = 2; ring Z represents: (1) an unsatd. 6-membered heterocyclic aromatic ring containing one nitrogen atom, optionally substituted by one or two substituents selected from C1-3 lower alkyl, halogen, amino, C1-3 lower alkoxy or C1-3 lower alkylamino; (2) a 5-membered aromatic (unsatd.) heterocyclic ring having one heteroatom selected from O, or S; ring E represents: (1) an unsatd. 6-membered heterocyclic aromatic ring containing one or two nitrogen atoms, optionally substituted by one or two substituents selected from C1-3 lower alkyl, halogen, amino, C1-3 lower alkoxy or C1-3 lower alkylamino; (2) a 5-membered aromatic (unsatd.) heterocyclic ring having one heteroatom selected from O, N or S; (3) a 5-membered aromatic (unsatd.) heterocyclic ring having two adjacent nitrogen atoms; (4) a 5-membered aromatic (unsatd.) heterocyclic ring having one nitrogen atom together with either one oxygen or one sulfur atom; wherein the 5 or 6-membered heterocyclic rings are optionally substituted by C1-3 lower alkyl, halogen, or C1-3 lower alkoxy; R₃ = COAr where Ar = substituted Ph, furyl, thienyl, pyrrolyl, thiazolyl, pyridyl. Thus, e.g., acylation of 6-(4-aminobenzoyl)-1,4,5,6-tetrahydropyrazolo[3,4-d]thieno[3,2-b]azepine (preparation given) with 2-chloro-4-fluorobenzoyl chloride afforded N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-chloro-4-fluorobenzamide (II) which exhibited IC₅₀ = 2.0 and 0.34 μM, resp., for binding to rat hepatic V1 receptors and rat kidney medullary V2 receptors, and IC₅₀ = 2.5 μM for binding to oxytocin receptors. N-[4-[(4,5-Dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-3-chlorophenyl]-5-fluoro-2-methylbenzamide exhibited IC₅₀ = 0.0061 μM for V2 receptor binding.

IT	203636-64-0	203636-66-2	1101696-19-8
	1101696-20-1	1101696-21-2	1101696-22-3
	1101696-24-5	1101696-25-6	1101696-26-7
	1101696-27-8	1101696-28-9	1101696-29-0
	1101696-30-3	1101696-31-4	1101696-32-5
	1101696-33-6	1101696-34-7	1101696-35-8
	1101696-36-9	1101696-37-0	1101696-38-1
	1101696-39-2	1101696-40-5	1101696-41-6
	1101696-42-7	1101696-43-8	1101696-44-9
	1101696-45-0	1101696-46-1	1101696-47-2
	1101696-49-4	1101696-50-7	1101696-51-8
	1101696-52-9	1101696-53-0	1101696-54-1
	1101696-55-2	1101696-57-4	1101696-58-5
	1101696-59-6	1101696-60-9	1101696-61-0
	1101696-62-1	1101696-63-2	1101696-64-3


1101696-67-6	1101696-68-7	1101696-69-8
1101696-70-1	1101696-71-2	1101696-72-3
1101696-73-4	1101696-79-0	1101696-80-3
1101696-81-4	1101696-82-5	1101696-83-6
1101696-84-7	1101696-85-8	1101696-86-9
1101696-87-0	1101696-88-1	1101696-89-2
1101696-90-5	1101696-91-6	1101696-92-7
1101696-93-8	1101696-94-9	1101696-95-0
1101696-96-1	1101696-97-2	1101696-98-3
1101696-99-4	1101697-00-0	1101697-01-1
1101697-02-2	1101697-03-3	1101697-04-4
1101697-05-5	1101697-06-6	1101697-07-7
1101697-08-8	1101697-09-9	1101697-34-0
1101697-35-1	1101697-36-2	1101697-37-3
1101697-38-4	1101697-39-5	1101697-40-8
1101697-41-9	1101697-42-0	1101697-43-1
1101697-44-2	1101697-45-3	1101697-46-4
1101697-47-5	1101697-48-6	1101697-49-7
1101697-50-0	1101697-51-1	1101697-52-2
1101697-53-3	1101697-54-4	1101697-55-5
1101697-56-6	1101697-57-7	1101697-58-8
1101697-59-9	1101697-60-2	1101697-61-3
1101697-62-4	1101697-63-5	1101697-64-6
1101697-66-8	1101697-67-9	1101697-68-0
1101697-69-1	1101697-70-4	1101697-71-5
1101697-72-6	1101697-83-9	1101697-84-0
1101697-85-1	1101697-86-2	1101697-87-3
1101697-88-4	1101697-89-5	1101697-90-8
1101697-91-9	1101697-92-0	1101697-93-1
1101697-94-2	1101697-95-3	1101697-96-4
1101697-97-5	1101697-98-6	1101697-99-7
1101698-00-3	1101698-01-4	1101698-02-5
1101698-03-6	1101698-04-7	1101698-06-9
1101698-08-1	1101698-09-2	1101698-10-5
1101698-11-6	1101698-40-1	1101698-41-2
1101698-42-3	1101698-43-4	1101698-44-5
1101698-45-6	1200803-49-1	1200803-55-9
1229795-72-5	1229795-73-6	1229795-75-8
1229795-76-9	1229795-77-0	1229795-78-1
1229795-79-2	1229795-80-5	1229795-81-6
1229795-82-7	1229795-83-8	1229795-84-9
1229795-85-0	1229795-86-1	1229795-87-2
1229795-88-3	1229795-89-4	1229795-91-8
1229795-92-9	1229795-93-0	1229795-94-1
1229795-95-2	1229795-96-3	1229795-97-4
1229795-98-5	1229795-99-6	1229796-00-2
1229796-01-3	1229796-02-4	1229796-04-6
1229796-05-7	1229796-06-8	1229796-08-0
1229796-09-1	1229796-12-6	1229796-13-7
1229796-14-8	1229796-15-9	1229796-16-0
1229796-17-1	1229796-18-2	

RL: PRPH (Prophetic)


(Tricyclic azepine oxytocin and vasopressin receptor antagonists)

RN 203636-64-0 CAPLUS


CN Benzamide, 5-chloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro- (CA INDEX NAME)



RN 203636-66-2 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)




RN 1101696-19-8 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)




RN 1101696-20-1 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 1101696-21-2 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(phenylmethyl)-6-fluorobenzamide (CA INDEX NAME)



RN 1101696-22-3 CAPLUS


CN Benzamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)



RN 1101696-24-5 CAPLUS

CN Benzamide, 2-bromo-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-


6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)



RN 1101696-25-6 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,4-difluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1101696-26-7 CAPLUS
 CN Benzamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1101696-27-8 CAPLUS
 CN Benzamide, 5-bromo-2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101696-28-9 CAPLUS

CN Benzamide, N-[3-bromo-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)




RN 1101696-29-0 CAPLUS

CN Benzamide, 2,5-dichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)



RN 1101696-30-3 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)



RN 1101696-31-4 CAPLUS


CN Benzamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-

6(1H)-yl)carbonyl]phenyl]-5-fluoro- (CA INDEX NAME)




RN 1101696-32-5 CAPLUS

CN Benamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-(trifluoromethyl)- (CA INDEX NAME)




RN 1101696-33-6 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-6-fluoro- (CA INDEX NAME)



RN 1101696-34-7 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,6-dimethyl- (CA INDEX NAME)



10/565,702

RN 1101696-35-8 CAPLUS


CN Benzamide, 2-chloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro- (CA INDEX NAME)



RN 1101696-36-9 CAPLUS

CN Benzamide, 2-chloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1101696-37-0 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 1101696-38-1 CAPLUS

CN Benzamide, 2,3,5-trichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)



RN 1101696-39-2 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(methylthio)- (CA INDEX NAME)



RN 1101696-40-5 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-4-nitro- (CA INDEX NAME)


PAGE 1-A






RN 1101696-41-6 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 1101696-42-7 CAPLUS

CN Benzamide, 5-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)



RN 1101696-43-8 CAPLUS


CN Benzamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-(methylthio)- (CA INDEX NAME)



RN 1101696-44-9 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro-4-(trifluoromethyl)- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1101696-45-0 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-nitro- (CA INDEX NAME)




RN 1101696-46-1 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro- (CA INDEX NAME)




RN 1101696-47-2 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 1101696-49-4 CAPLUS

CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-3,4,5-trimethoxy- (CA INDEX NAME)




RN 1101696-50-7 CAPLUS

CN Benzamide, 2-chloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 1101696-51-8 CAPLUS

CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2,4-difluoro- (CA INDEX NAME)




RN 1101696-52-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 1101696-53-0 CAPLUS

CN Benzamide, 2-bromo-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 1101696-54-1 CAPLUS

CN Benzamide, 5-bromo-2-chloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 1101696-55-2 CAPLUS

CN Benzamide, N-[3-bromo-5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-methyl- (CA INDEX NAME)




RN 1101696-57-4 CAPLUS


CN Benzamide, 2,5-dichloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 1101696-58-5 CAPLUS
 CN Benzamide, 2-chloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-5-fluoro- (CA INDEX NAME)



RN 1101696-59-6 CAPLUS
 CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2,3-dimethyl- (CA INDEX NAME)




RN 1101696-60-9 CAPLUS
 CN Benzamide, 2-chloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-5-(trifluoromethyl)- (CA INDEX NAME)




RN 1101696-61-0 CAPLUS

CN Benzamide, 2,6-dichloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-(2-pyridinyl)- (CA INDEX NAME)




RN 1101696-62-1 CAPLUS

CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-(2-pyridinyl)- (CA INDEX NAME)




RN 1101696-63-2 CAPLUS

CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-(2-thienyl)- (CA INDEX NAME)




RN 1101696-64-3 CAPLUS

CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2,6-dimethyl- (CA INDEX NAME)




RN 1101696-67-6 CAPLUS

CN Benzamide, 2,3-dichloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 1101696-68-7 CAPLUS

CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-methoxy- (CA INDEX NAME)




RN 1101696-69-8 CAPLUS

CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 1101696-70-1 CAPLUS

CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 1101696-71-2 CAPLUS

CN Benzamide, 2,3,5-trichloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 1101696-72-3 CAPLUS

CN Benzamide, 5-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro- (CA INDEX NAME)




RN 1101696-73-4 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)




RN 1101696-79-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101696-80-3 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101696-81-4 CAPLUS

CN Benamide, 2-chloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101696-82-5 CAPLUS

CN Benamide, 2,4-dichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101696-83-6 CAPLUS

CN Benamide, 2,4-dichloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101696-84-7 CAPLUS

CN Benzamide, 2,5-dichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101696-85-8 CAPLUS

CN Benzamide, 2,5-dichloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101696-86-9 CAPLUS

CN Benzamide, 5-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro- (CA INDEX NAME)




RN 1101696-87-0 CAPLUS


CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)




RN 1101696-88-1 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)



RN 1101696-89-2 CAPLUS
 CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)




RN 1101696-90-5 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 1101696-91-6 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 1101696-92-7 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 1101696-93-8 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 1101696-94-9 CAPLUS

CN Benzamide, 2,6-dichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101696-95-0 CAPLUS

CN Benamide, 2,6-dichloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101696-96-1 CAPLUS

CN Benamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,6-dimethyl- (CA INDEX NAME)




RN 1101696-97-2 CAPLUS

CN Benamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,6-dimethyl- (CA INDEX NAME)




RN 1101696-98-3 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(methylthio)- (CA INDEX NAME)




RN 1101696-99-4 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(methylthio)- (CA INDEX NAME)




RN 1101697-00-0 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 1101697-01-1 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 1101697-02-2 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)




RN 1101697-03-3 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)




RN 1101697-04-4 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro- (CA INDEX NAME)




RN 1101697-05-5 CAPLUS

CN Benzamide, 2-chloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro- (CA INDEX NAME)




RN 1101697-06-6 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-nitro- (CA INDEX NAME)




RN 1101697-07-7 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-nitro- (CA INDEX NAME)




RN 1101697-08-8 CAPLUS

CN Benzamide, 2-amino-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101697-09-9 CAPLUS

CN Benzamide, 2-amino-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101697-34-0 CAPLUS

CN Benzamide, 2-chloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-4-nitro- (CA INDEX NAME)




RN 1101697-35-1 CAPLUS


CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2,5-dimethyl- (CA INDEX NAME)




RN 1101697-36-2 CAPLUS
 CN Benzamide, 5-amino-2-chloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 1101697-37-3 CAPLUS
 CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-fluoro-3-(trifluoromethyl)- (CA INDEX NAME)




RN 1101697-38-4 CAPLUS
 CN Benzamide, 5-chloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-methoxy- (CA INDEX NAME)




RN 1101697-39-5 CAPLUS
 CN Benzamide, 2-chloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-5-(methylthio)- (CA INDEX NAME)




RN 1101697-40-8 CAPLUS
 CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-fluoro-6-(trifluoromethyl)- (CA INDEX NAME)




RN 1101697-41-9 CAPLUS
 CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-fluoro-4-(trifluoromethyl)- (CA INDEX NAME)




RN 1101697-42-0 CAPLUS
 CN Benamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)



RN 1101697-43-1 CAPLUS
 CN Benamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-nitro- (CA INDEX NAME)




RN 1101697-44-2 CAPLUS
 CN Benamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-fluoro- (CA INDEX NAME)




RN 1101697-45-3 CAPLUS

CN Benzamide, 4-amino-2-chloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 1101697-46-4 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)



RN 1101697-47-5 CAPLUS


CN Benzamide, 2-chloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)



RN 1101697-48-6 CAPLUS

CN Benzamide, 2,4-dichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1101697-49-7 CAPLUS

CN Benzamide, 2,4-dichloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1101697-50-0 CAPLUS

CN Benzamide, 2,5-dichloro-N-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101697-51-1 CAPLUS

CN Benzamide, 2,5-dichloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101697-52-2 CAPLUS

CN Benzamide, 5-chloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro- (CA INDEX NAME)



RN 1101697-53-3 CAPLUS


CN Benzanide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)



RN 1101697-54-4 CAPLUS


CN Benzanide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-

6 (1H)-yl carbonyl]phenyl]-2-methyl- (CA INDEX NAME)




RN 1101697-55-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6 (1H)-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)




RN 1101697-56-6 CAPLUS

CN Benamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)



RN 1101697-57-7 CAPLUS


CN Benamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)



10/565,702


RN 1101697-58-8 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 1101697-59-9 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 1101697-60-2 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(dimethylamino)- (CA INDEX NAME)




RN 1101697-61-3 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(dimethylamino)- (CA INDEX NAME)




RN 1101697-62-4 CAPLUS

CN Benzamide, 5-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 1101697-63-5 CAPLUS

CN Benzamide, 2,3-dichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101697-64-6 CAPLUS

CN Benamide, 2,3-dichloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101697-66-8 CAPLUS

CN Benamide, 2,3,5-trichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)



RN 1101697-67-9 CAPLUS


CN Benamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(methylamino)- (CA INDEX NAME)



RN 1101697-68-0 CAPLUS


CN Benamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-

6(1H)-yl)carbonyl]phenyl]-2-(methylamino)- (CA INDEX NAME)




RN 1101697-69-1 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 1101697-70-4 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 1101697-71-5 CAPLUS

CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-methyl- (CA INDEX NAME)




RN 1101697-72-6 CAPLUS

CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-(methylthio)- (CA INDEX NAME)




RN 1101697-83-9 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 1101697-84-0 CAPLUS

CN Benzamide, 2,6-dichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101697-85-1 CAPLUS

CN Benzamide, 2,6-dichloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)



RN 1101697-86-2 CAPLUS


CN Benzanide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,6-dimethyl- (CA INDEX NAME)



RN 1101697-87-3 CAPLUS


CN Benzanide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-

6(1H)-yl]carbonyl]phenyl]-2,6-dimethyl- (CA INDEX NAME)




RN 1101697-88-4 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl]carbonyl]phenyl]-2-(methylthio)- (CA INDEX NAME)




RN 1101697-89-5 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(methylthio)- (CA INDEX NAME)



RN 1101697-90-8 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)



10/565,702

RN 1101697-91-9 CAPLUS


CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 1101697-92-0 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1101697-93-1 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1101697-94-2 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro- (CA INDEX NAME)




RN 1101697-95-3 CAPLUS

CN Benzamide, 2-chloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro- (CA INDEX NAME)




RN 1101697-96-4 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-nitro- (CA INDEX NAME)



RN 1101697-97-5 CAPLUS


CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-nitro- (CA INDEX NAME)



RN 1101697-98-6 CAPLUS


CN Benzamide, 2-amino-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-

6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101697-99-7 CAPLUS

CN Benzamide, 2-amino-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101698-00-3 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(dimethylamino)- (CA INDEX NAME)



RN 1101698-01-4 CAPLUS


CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(dimethylamino)- (CA INDEX NAME)



10/565,702


RN 1101698-02-5 CAPLUS

CN Benzamide, 5-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 1101698-03-6 CAPLUS

CN Benzamide, 2,3-dichloro-N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101698-04-7 CAPLUS

CN Benzamide, 2,3-dichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101698-06-9 CAPLUS

CN Benzamide, 2,3,5-trichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101698-08-1 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(methylamino)- (CA INDEX NAME)




RN 1101698-09-2 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(methylamino)- (CA INDEX NAME)



RN 1101698-10-5 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 1101698-11-6 CAPLUS


CN Benzamide, N-[3-chloro-4-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-

6(1H)-yl)carbonyl]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 1101698-40-1 CAPLUS

CN Benzamide, 5-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro- (CA INDEX NAME)




RN 1101698-41-2 CAPLUS

CN Benzamide, 5-amino-2-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)



RN 1101698-42-3 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro-3-(trifluoromethyl)- (CA INDEX NAME)



10/565,702

RN 1101698-43-4 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro-6-(trifluoromethyl)- (CA INDEX NAME)



RN 1101698-44-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1101698-45-6 CAPLUS

CN Benzamide, 4-amino-2-chloro-N-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1200803-49-1 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(2-pyridinyl)- (CA INDEX NAME)




RN 1200803-55-9 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-(2-thienyl)- (CA INDEX NAME)




RN 1229795-72-5 CAPLUS

CN Benzeneacetamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-3-fluoro- (CA INDEX NAME)




RN 1229795-73-6 CAPLUS

CN Benzamide, 2,3-dichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1229795-75-8 CAPLUS


CN Benzamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1229795-76-9 CAPLUS
 CN Benzamide, 2,6-dichloro-N-[5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-4-fluoro- (CA INDEX NAME)




RN 1229795-77-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1229795-78-1 CAPLUS

CN Benzeneacetamide, 2-chloro-N-[3-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-6-fluoro- (CA INDEX NAME)




RN 1229795-79-2 CAPLUS

CN Benzamide, N-[3-chloro-5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-methyl- (CA INDEX NAME)




RN 1229795-80-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1229795-81-6 CAPLUS

CN Benzeneacetamide, 3-chloro-N-[3-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro- (CA INDEX NAME)




RN 1229795-82-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 1229795-83-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1229795-84-9 CAPLUS

CN Benzeneacetamide, N-[3-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-4-fluoro-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 1229795-85-0 CAPLUS

CN Benzeacetamide, 2-chloro-N-[3-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1229795-86-1 CAPLUS

CN Benzeacetamide, N-[3-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 1229795-87-2 CAPLUS

CN Benzeacetamide, N-[3-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)




RN 1229795-88-3 CAPLUS

CN Benzeneacetamide, 2,4-dichloro-N-[3-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1229795-89-4 CAPLUS

CN Benzeneacetamide, 2-chloro-N-[3-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-5-fluoro- (CA INDEX NAME)




RN 1229795-91-8 CAPLUS

CN Benzeneacetamide, 5-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-methoxy- (CA INDEX NAME)




RN 1229795-92-9 CAPLUS

CN Benzeneacetamide, 2,3-dichloro-N-[3-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1229795-93-0 CAPLUS

CN Benzeneacetamide, 5-chloro-N-[3-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 1229795-94-1 CAPLUS

CN Benzeneacetamide, 5-chloro-N-[3-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro- (CA INDEX NAME)




RN 1229795-95-2 CAPLUS

CN Benzeneacetamide, 5-chloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-fluoro- (CA INDEX NAME)




RN 1229795-96-3 CAPLUS

CN Benzeneacetamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-methoxy- (CA INDEX NAME)




RN 1229795-97-4 CAPLUS

CN Benzamide, 2,6-dichloro-N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1229795-98-5 CAPLUS

CN Benzeneacetamide, N-[3-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)



RN 1229795-99-6 CAPLUS


CN Benzeneacetamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2,4-difluoro- (CA INDEX NAME)



RN 1229796-00-2 CAPLUS


CN Benzeneacetamide, N-[3-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-

6(1H)-yl carbonyl]phenyl]-2-(methylthio)- (CA INDEX NAME)




RN 1229796-01-3 CAPLUS

CN Benzeneacetamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2,5-dimethoxy- (CA INDEX NAME)




RN 1229796-02-4 CAPLUS

CN Benzamide, 2-chloro-N-[3-chloro-5-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-6-fluoro- (CA INDEX NAME)




RN 1229796-04-6 CAPLUS

CN Benzeneacetamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-methyl- (CA INDEX NAME)




RN 1229796-05-7 CAPLUS

CN Benzeacetamide, 2,6-dichloro-N-[3-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1229796-06-8 CAPLUS

CN Benzeacetamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 1229796-08-0 CAPLUS

CN Benzeacetamide, N-[5-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-5-fluoro-2-methyl- (CA INDEX NAME)




RN 1229796-09-1 CAPLUS

CN Benzeneacetamide, N-[3-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)




RN 1229796-12-6 CAPLUS

CN Benzeneacetamide, N-[3-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 1229796-13-7 CAPLUS

CN Benzeneacetamide, N-[3-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,5-dimethoxy- (CA INDEX NAME)




RN 1229796-14-8 CAPLUS

CN Benzeneacetamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]-2-pyridinyl]-2-(methylthio)- (CA INDEX NAME)




RN 1229796-15-9 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 1229796-16-0 CAPLUS

CN Benzenacetamide, N-[3-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)



RN 1229796-17-1 CAPLUS


CN Benzenacetamide, N-[3-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)



RN 1229796-18-2 CAPLUS

CN Benzenacetamide, N-[3-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-

6(1H)-yl)carbonyl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)




IT 180340-49-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tricyclic azepine oxytocin and vasopressin receptor antagonists)

RN 180340-49-2 CAPLUS

CN Benamide, N-[4-[(4,5-dihydro-6H-isoxazolo[5,4-d]thieno[3,2-b]azepin-6-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)




IT 180339-77-9 180340-72-1,

6-(4-Nitrobenzoyl)-1,4,5,6-tetrahydropyrazolo[3,4-b]thieno[3,2-b]azepine
RL: RCT (Reactant); RACT (Reactant or reagent)
(tricyclic azepine oxytocin and vasopressin receptor antagonists)


RN 180339-77-9 CAPLUS

CN Methanone, (2-chloro-4-nitrophenyl) (4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)- (CA INDEX NAME)



RN 180340-72-1 CAPLUS

CN Methanone, (4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl) (4-nitrophenyl)- (CA INDEX NAME)



IT 180339-70-2P 180339-71-3P 180339-78-0P

180339-94-0P 180339-95-1P 180339-98-4P


180340-73-2P, 6-(4-Aminobenzoyl)-1,4,5,6-tetrahydropyrazolo[3,4-d]thieno[3,2-b]azepine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(tricyclic azepine oxytocin and vasopressin receptor antagonists)


RN 180339-70-2 CAPLUS

CN Methanone, (2-chloro-4-nitrophenyl) (4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)- (CA INDEX NAME)




RN 180339-71-3 CAPLUS


CN Methanone, (4-amino-2-chlorophenyl) (4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)- (CA INDEX NAME)



RN 180339-78-0 CAPLUS
 CN Methanone, (4-amino-2-chlorophenyl) (4,5-dihydropyrazolo[3,4-d]pyrido[3,2-b]azepin-6(1H)-yl)- (CA INDEX NAME)




RN 180339-94-0 CAPLUS
 CN Methanone, (4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl) (4-nitrophenyl)- (CA INDEX NAME)




RN 180339-95-1 CAPLUS

CN Methanone, (4-aminophenyl) (4,5-dihydropyrazolo[3,4-d]pyrido[2,3-b]azepin-6(1H)-yl)- (CA INDEX NAME)




RN 180339-98-4 CAPLUS

CN Methanone, (4-aminophenyl) (4,5-dihydro-6H-isoxazolo[5,4-d]thieno[3,2-b]azepin-6-yl)- (CA INDEX NAME)



RN 180340-73-2 CAPLUS

CN Methanone, (4-aminophenyl) (4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(1H)-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 7

THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

REFERENCE COUNT: 17

THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 69 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1996:323956 CAPLUS

DOCUMENT NUMBER: 125:86517

ORIGINAL REFERENCE NO.: 125:16313a,16316a

TITLE: Tricyclic benzazepine oxytocin and vasopressin antagonists

INVENTOR(S): Albright, Jay D.; Sum, Fuk Wah; Du, Xuemei

PATENT ASSIGNEE(S): American Cyanamid Company, USA

SOURCE: U.S., 95 pp., Cont.-in-part of U.S. Ser. No. 100,003, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 10

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5512563	A	19960430	US 1994-254823	19940613
EP 640592	A1	19950301	EP 1994-111040	19940715
EP 640592	B1	19981230		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 175198	T	19990115	AT 1994-111040	19940715
ES 2125377	T3	19990301	ES 1994-111040	19940715
SK 281194	B6	20010118	SK 1994-880	19940720
IL 110436	A	20031210	IL 1994-110436	19940725
FI 9403542	A	19950130	FI 1994-3542	19940728
FI 108433	B1	20020131		
NO 9402817	A	19950130	NO 1994-2817	19940728
NO 308601	B1	20001002		
AU 9468776	A	19950209	AU 1994-68776	19940728
AU 676737	B2	19970320		
ZA 9405604	A	19950309	ZA 1994-5604	19940728
JP 07179430	A	19950718	JP 1994-195886	19940728
JP 3630449	B2	20050316		
HU 71548	A2	19951228	HU 1994-2223	19940728
HU 221017	B1	20020729		
RU 2149160	C1	20000520	RU 1994-27580	19940728
NZ 299340	A	20000825	NZ 1994-299340	19940728
CN 1106802	A	19950816	CN 1994-108768	19940729
CN 1064354	C	20010411		
PL 181918	B1	20011031	PL 1994-304496	19940729
TW 402592	B	20000821	TW 1994-83108599	19940916
US 5739128	A	19980414	US 1996-637058	19960424
US 5869483	A	19990209	US 1996-639014	19960424
US 5686445	A	19971111	US 1996-637908	19960425
US 5736538	A	19980407	US 1996-638059	19960425
US 5747487	A	19980505	US 1996-638067	19960425
US 5760031	A	19980602	US 1996-637911	19960425
US 5693635	A	19971202	US 1996-662546	19960613
US 5854236	A	19981229	US 1997-834706	19970401
US 5834461	A	19981110	US 1997-874314	19970613
US 5843952	A	19981201	US 1997-889858	19970708
US 5786353	A	19980728	US 1997-893497	19970711
HK 1011362	A1	20010727	HK 1998-112373	19981127
FI 2001001100	A	20010525	FI 2001-1100	20010525
FI 111077	B1	20030530		

FI 2001001101	A	20010525	FI 2001-1101	20010525
FI 111075	B1	20030530		
FI 2001001102	A	20010525	FI 2001-1102	20010525
FI 111076	B1	20030530		


PRIORITY APPLN. INFO.:

US 1993-100003	B2 19930729
US 1994-254823	A2 19940613
NZ 1994-264116	A1 19940728
US 1996-637058	A3 19960424
US 1996-639014	A2 19960424
US 1996-637908	A3 19960425
US 1996-663400	B1 19960613

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 125:86517

GI



AB This invention relates to title compds. I wherein: Y = e.g., (CH₂)_n, O, S wherein n is an integer from 0-2; A-B is (CH₂)_mNR₃ or NR₃(CH₂)_m, wherein m is an integer from 1-2, provided that when Y is (CH₂)_n and n=2, m may also be zero and when n is zero, m may also be three, provided also that when Y is (CH₂)_n and n is 2, m may not also be two; R₁ = e.g., H, halo, OH; R₂ = e.g., H, halo, OH; R₃ is the moiety COAr where Ar is selected from, e.g., substituted Ph, (un)substituted 5-indolyl; the aromatic Z ring represents, e.g., fused (un)substituted Ph, 5- or 6-membered atom. heterocycle, that exhibit antagonist activity at V₁ and/or V₂ receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compds. in treating diseases characterized by excess renal reabsorption of water, and processes for preparing such compds. I are also antagonists of the peptide hormone oxytocin and are useful in the control of premature birth. Thus, e.g., acylation of 6,11-dihydro-5H-dibenz[b,e]azepine (preparation given) with 4-[(2-methylbenzoyl)amino]benzoyl chloride (preparation given) afforded N-[4-[(6,11-dihydro-5H-dibenz[b,e]azepin-5-yl)carbonyl]phenyl]-2-methylbenzamide (II) which exhibited binding to rat hepatic V₁ receptors and rat kidney medullary V₂ receptors with IC₅₀ = 0.15 and 0.068 μM, resp., and oxytocin receptor binding with IC₅₀ = 2.9 μM.

IT 1099466-57-5	1099466-58-6	1099466-59-7
1099466-60-0	1099471-79-0	1099471-80-3
1099471-81-4	1099471-82-5	1099471-83-6
1099471-84-7	1099471-85-8	1099471-86-9
1099471-87-0	1099471-88-1	1099471-89-2
1099471-90-5	1099471-91-6	1099471-92-7
1099471-93-8	1101631-21-3	1101631-22-4


1101631-23-5	1101631-24-6	1101631-25-7
1101631-26-8	1101631-28-0	1101631-29-1
1101631-30-4	1101631-31-5	1101631-32-6
1101631-35-9	1146445-27-3	

RL: PRPH (Prophetic)

(Tricyclic benzazepine oxytocin and vasopressin antagonists)


RN 1099466-57-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1099466-58-6 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-2-methyl- (CA INDEX NAME)



RN 1099466-59-7 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]-4-fluoro- (CA INDEX NAME)


PAGE 1-A



F

RN 1099466-60-0 CAPLUS


CN Benzamide, 2,3-dichloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methoxyphenyl]- (CA INDEX NAME)



RN 1099471-79-0 CAPLUS

CN Benzamide, 4-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

C1


RN 1099471-80-3 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)




RN 1099471-81-4 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 1099471-82-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 1099471-83-6 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 1099471-84-7 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-(methylthio)- (CA INDEX NAME)

10/565,702




RN 1099471-85-8 CAPLUS

CN Benzamide, 2,3-dichloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1099471-86-9 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)



RN 1099471-87-0 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1099471-88-1 CAPLUS

CN Benzamide, 2-chloro-N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-89-2 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-90-5 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-3-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1099471-91-6 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1099471-92-7 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-fluoro-5-(trifluoromethyl)- (CA INDEX NAME)




RN 1099471-93-8 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-fluoro-6-(trifluoromethyl)- (CA INDEX NAME)




RN 1101631-21-3 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 1101631-22-4 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2,3-dimethyl- (CA INDEX NAME)




RN 1101631-23-5 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)



RN 1101631-24-6 CAPLUS


CN Benzamide, N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1101631-25-7 CAPLUS

CN Benzamide, 2-chloro-N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1101631-26-8 CAPLUS

CN Benzamide, 2,3-dichloro-N-[3-chloro-4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]- (CA INDEX NAME)




RN 1101631-28-0 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2-methyl- (CA INDEX NAME)




RN 1101631-29-1 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2,3-dimethyl- (CA INDEX NAME)



RN 1101631-30-4 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-3-fluoro-2-methyl- (CA INDEX NAME)




RN 1101631-31-5 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-5-fluoro-2-methyl- (CA INDEX NAME)



RN 1101631-32-6 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-4-fluoro-2-methyl- (CA INDEX NAME)


PAGE 1-A



F


RN 1101631-35-9 CAPLUS

CN Benamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 1146445-27-3 CAPLUS

CN Benzenecarbothioamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-3-methylphenyl]-2-methyl- (CA INDEX NAME)




IT 169879-79-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tricyclic benzazepine oxytocin and vasopressin antagonists)

RN 169879-79-2 CAPLUS


CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)



IT 169878-98-2P 169878-99-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (tricyclic benzazepine oxytocin and vasopressin antagonists)
 RN 169878-98-2 CAPLUS
 CN Methanone, (4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl) (4-
 nitrophenyl)- (CA INDEX NAME)




RN 169878-99-3 CAPLUS
 CN Methanone, (4-aminophenyl) (4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-
 yl)- (CA INDEX NAME)




OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS
 RECORD (18 CITINGS)
 REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 70 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1995:898877 CAPLUS
 DOCUMENT NUMBER: 123:313792
 ORIGINAL REFERENCE NO.: 123:56251a,56254a
 TITLE: Preparation of tricyclic benzazepine vasopressin antagonists
 INVENTOR(S): Albright, Jay D.; Reich, Marvin F.; Sum, Fuk-Wah; Du, Xuemei
 PATENT ASSIGNEE(S): American Cyanamid Co., USA
 SOURCE: Can. Pat. Appl., 288 pp.
 CODEN: CPXXEB
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 10
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2128955	A1	19950130	CA 1994-2128955	19940727
CA 2128955	C	20061114		
EP 640592	A1	19950301	EP 1994-111040	19940715
EP 640592	B1	19981230		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 175198	T	19990115	AT 1994-111040	19940715
ES 2125377	T3	19990301	ES 1994-111040	19940715
SK 281194	B6	20010118	SK 1994-880	19940720
IL 110436	A	20031210	IL 1994-110436	19940725
FI 9403542	A	19950130	FI 1994-3542	19940728
FI 108433	B1	20020131		
NO 9402817	A	19950130	NO 1994-2817	19940728
NO 308601	B1	20001002		
AU 9468776	A	19950209	AU 1994-68776	19940728
AU 676737	B2	19970320		
ZA 9405604	A	19950309	ZA 1994-5604	19940728
JP 07179430	A	19950718	JP 1994-195886	19940728
JP 3630449	B2	20050316		
HU 71548	A2	19951228	HU 1994-2223	19940728
HU 221017	B1	20020729		
RU 2149160	C1	20000520	RU 1994-27580	19940728
NZ 299340	A	20000825	NZ 1994-299340	19940728
CN 1106802	A	19950816	CN 1994-108768	19940729
CN 1064354	C	20010411		
PL 181918	B1	20011031	PL 1994-304496	19940729
TW 402592	B	20000821	TW 1994-83108599	19940916
HK 1011362	A1	20010727	HK 1998-112373	19981127
FI 2001001100	A	20010525	FI 2001-1100	20010525
FI 111077	B1	20030530		
FI 2001001101	A	20010525	FI 2001-1101	20010525
FI 111075	B1	20030530		
FI 2001001102	A	20010525	FI 2001-1102	20010525
FI 111076	B1	20030530		
PRIORITY APPLN. INFO.:			US 1993-100003	A 19930729
			NZ 1994-264116	A1 19940728
OTHER SOURCE(S):	MARPAT 123:313792			
GI				




- AB The title compds. [I; AB = (CH₂)_mNR₃, (un)substituted R₃N(CH₂)_m; R₃ = (un)substituted arylcarbonyl, (un)substituted 5-indolylcarbonyl, etc.; m = 1, 2; R₁ = H, halogen, OH, alkylthio, SH, acyl, etc.; R₂ = H, Cl, F, Br, I, alkyl, alkoxy; Z = (un)substituted fused Ph, (un)substituted 5-member heteroarom. ring, etc.], useful as vasopressin antagonists for diseases requiring diuretic application, are prepared Thus, dibenzazepine II was prepared and demonstrated a IC₅₀ for human V₂ receptors of 0.86 μM.
- IT 169879-79-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of tricyclic benzazepine vasopressin antagonists)
- RN 169879-79-2 CAPLUS
- CN Benzamide, N-[4-[(4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)



- IT 169878-98-2P 169878-99-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of tricyclic benzazepine vasopressin antagonists from)
- RN 169878-98-2 CAPLUS


10/565,702

CN Methanone, (4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl) (4-nitrophenyl)- (CA INDEX NAME)



RN 169878-99-3 CAPLUS

CN Methanone, (4-aminophenyl) (4,5-dihydro-6H-isoxazolo[4,5-d][1]benzazepin-6-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)

L28 ANSWER 71 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1995:835467 CAPLUS

DOCUMENT NUMBER: 123:256545

ORIGINAL REFERENCE NO.: 123:45886h,45887a

TITLE: Preparation of fused benzazepine derivs. as arginine vasopressin antagonists

INVENTOR(S): Tanaka, Akihiro; Koshio, Hiroyuki; Taniguchi, Nobuaki; Matsuhisa, Akira; Sakamoto, Ken-ichiro; Yamazaki, Atsuki; Yatsu, Takeyuki

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 150 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9503305	A1	19950202	WO 1994-JP1183	19940719
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KE, KG, KR, KZ, LK, LT, LV, MD, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2167673	A1	19950202	CA 1994-2167673	19940719
CA 2167673	C	20040921		
CA 2453123	A1	19950202	CA 1994-2453123	19940719
CA 2453123	C	20080520		
AU 9471957	A	19950220	AU 1994-71957	19940719
AU 683483	B2	19971113		
EP 709386	A1	19960501	EP 1994-921117	19940719
EP 709386	B1	20030507		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1127508	A	19960724	CN 1994-192831	19940719
CN 1040210	C	19981014		
HU 74582	A2	19970128	HU 1996-102	19940719
JP 2744527	B2	19980428	JP 1995-505056	19940719
RU 2129123	C1	19990420	RU 1996-105390	19940719
PL 177738	B1	20000131	PL 1994-312654	19940719
EP 1097920	A1	20010509	EP 2000-204704	19940719
EP 1097920	B1	20040922		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
AT 239726	T	20030515	AT 1994-921117	19940719
ES 2198418	T3	20040201	ES 1994-921117	19940719
AT 277003	T	20041015	AT 2000-204704	19940719
ES 2228405	T3	20050416	ES 2000-204704	19940719
FI 9600260	A	19960119	FI 1996-260	19960119
FI 113178	B1	20040315		
NO 9600231	A	19960321	NO 1996-231	19960119
US 5723606	A	19980303	US 1996-586686	19960119
AU 9739906	A	19971218	AU 1997-39906	19971002
US 5856564	A	19990105	US 1997-972271	19971118
PRIORITY APPLN. INFO.:			JP 1993-180435	A 19930721
			CA 1994-2167673	A3 19940719
			EP 1994-921117	A3 19940719
			WO 1994-JP1183	W 19940719

US 1996-586686 A3 19960119

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 123:256545

GI For diagram(s), see printed CA Issue.

AB Title compds. I (B = a nitrogenous aromatic 5-membered ring that may be substituted, has at least one nitrogen atom and may further have one oxygen or sulfur atom; R1, R2 = hydrogen, halogen, lower alkyl, amino; A = a single bond or NHCO(CR3R4)n; n = 0, 1, 2, 3; R3, R4 = hydrogen, lower alkyl; R3R4 may be combined together to form a C2-C7 alkylene; C = optionally substituted benzene ring) and their pharmaceutically acceptable salts, useful as arginine vasopressin antagonists, were prepared. Thus, refluxing 2-phenyl-4'-[(5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanilide with CuBr2 in CHCl3 and EtOAc for 3 h followed by refluxing with thiourea in EtOH for 3 h gave 4'-[(2-amino-5,6-dihydro-4H-thiazolo[5,4-d][1]benzazepin-6-yl)carbonyl]-2-phenylbenzanilide hydrobromide (II). II showed pKi values of 8.33 and 7.21 in V1 and V2 receptor binding assay using [H3]-arginine vasopressin for rate liver membrane and rabbit kidney medullary substance membrane, resp. Formulations containing I were given.

IT 168626-93-5P 168626-97-9P 168626-98-0P

168626-99-1P 168627-00-7P 168627-01-8P

168627-04-1P 168627-14-3P 168627-15-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of fused benzazepine derivs. as arginine vasopressin antagonists)

RN 168626-93-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methyl-6H-oxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 168626-97-9 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(2-ethyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● HCl

RN 168626-98-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-propylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● HCl

RN 168626-99-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[4,5-dihydro-2-(phenylmethyl)imidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● HCl

RN 168627-00-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(2-cyclopropyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● HCl

RN 168627-01-8 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● HCl


RN 168627-04-1 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-(1-methylethoxy)-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● HCl

RN 168627-14-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[2-(4-aminobutyl)-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A






● 2 HCl

RN 168627-15-4 CAPLUS

CN Cyclopentanecarboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-1-phenyl-, hydrochloride (1:1)
(CA INDEX NAME)



● HCl

IT 168626-66-2P 168626-67-3P 168626-68-4P

168626-71-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of fused benzazepine derivs. as arginine vasopressin
antagonists)

RN 168626-66-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[2-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 168626-67-3 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[2-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 168626-68-4 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[2-[4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)butyl]-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



RN 168626-71-9 CAPLUS
 CN Methanone, (4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl) (4-nitrophenyl)- (CA INDEX NAME)




IT	168626-95-7P	168626-96-8P	168627-02-9P
	168627-03-0P	168627-05-2P	168627-06-3P
	168627-07-4P	168627-08-5P	168627-09-6P
	168627-10-9P	168627-11-0P	168627-12-1P
	168627-13-2P	168627-16-5P	168627-26-7P
	168627-27-8P	168627-28-9P	168627-29-0P
	168627-30-3P	168627-31-4P	

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fused benzazepine derivs. as arginine vasopressin antagonists)

RN 168626-95-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methyl-6H-oxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]phenyl]-4'-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 168626-96-8 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-4'-methyl-, hydrochloride (1:1)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 168627-02-9 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 168627-03-0 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-ethoxy-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● HCl

RN 168627-05-2 CAPLUS
 CN Benzamide, N-[4-[(2-cyclopropyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-(1-methylethoxy)-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● HCl

RN 168627-06-3 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-fluoro-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 168627-07-4 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 168627-08-5 CAPLUS
 CN Benzeneacetamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 168627-09-6 CAPLUS
 CN Benzeneacetamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl


RN 168627-10-9 CAPLUS

CN Methanone, (4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl) (2'-methoxy[1,1'-biphenyl]-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 168627-11-0 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-(2-ethyl-1H-imidazol-1-yl)-, hydrochloride (1:2)
 (CA INDEX NAME)


PAGE 1-A





● 2 HCl

RN 168627-12-1 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[2-(2-aminoethyl)-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



PAGE 2-A




● 2 HCl

RN 168627-13-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[2-(3-aminopropyl)-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl]carbonyl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● 2 HCl

RN 168627-16-5 CAPLUS

CN Cyclohexanecarboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-1-phenyl-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● HCl

RN 168627-26-7 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 168627-27-8 CAPLUS


CN Benzamide, N-[4-[(2-cyclopropyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-

6(1H)-yl)carbonyl]phenyl]-2-(1-methylethoxy)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 168627-28-9 CAPLUS
 CN Benzamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-(1-methylethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 168627-29-0 CAPLUS
 CN Benzeneacetamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-methoxy- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 168627-30-3 CAPLUS

CN Benzeneacetamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 168627-31-4 CAPLUS

CN Benzamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-2-(2-ethyl-1H-imidazol-1-yl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT:	14	THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (24 CITINGS)
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L28 ANSWER 72 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1995:419668 CAPLUS
 DOCUMENT NUMBER: 122:265125
 ORIGINAL REFERENCE NO.: 122:48400h,48401a
 TITLE: Synthesis of biliverdins with stable extended conformations. Part II
 AUTHOR(S): Bari, Sara E.; Iturraspe, Jose; Frydman, Benjamin
 CORPORATE SOURCE: Fac. Farm. Bioquim., Univ. Buenos Aires, Buenos Aires, 1113, Argent.
 SOURCE: Tetrahedron (1995), 51(8), 2255-66
 CODEN: TETRAB; ISSN: 0040-4020
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 122:265125
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB The synthesis of two hexacyclic, I and II, and one heptacyclic biliverdin, III, with extended conformations was achieved using base catalyzed intramol. substitution reactions of 2-chloroethyl biliverdins. The 2-chloroethyl residues were located at selected β -pyrrole positions as to enable them to react with proximal basic nitrogens at the adjacent pyrrole rings. Seven membered rings were thus formed which distorted either two or the three exocyclic double bonds at the biliverdin meso-bridges away from their usual Z-syn configuration. The hexacyclic biliverdin I is isomorphous with the chromophores of C-phycoerythrin, biliverdin II is an isomer of isophorocabilin, and the heptacyclic biliverdin III has the fullest extended conformation that the biliverdin backbone can achieve.
- IT 118631-58-6P 130877-88-2P 162661-71-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of hexacyclic and heptacyclic biliverdins)
- RN 118631-58-6 CAPLUS
- CN Dipyrrolo[1,2-a:2',3'-d]azepine-9-propanoic acid,
 2-[[4,5-dihydro-9-(3-methoxy-3-oxopropyl)-3,8-dimethyl-7-oxodipyrrolo[1,2-a:2',3'-d]azepin-2(7H)-ylidene]methyl]-1,4,5,7-tetrahydro-3,8-dimethyl-7-oxo-, methyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 130877-88-2 CAPLUS

CN Pyrrolo[1,2-a]pyrrolo[1''',2''':1'',7''']azepino[4''',5''':4'',5'']pyrrolo[1'',2'':1',7']azepino[4',5':4,5]pyrrolo[2,3-d]azepine-2,12-dipropanoic acid, 3,5,6,7,8,13,15,16-octahydro-1,11,17-trimethyl-3,13-dioxo-, 2,12-dimethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B


— OMe

RN 162661-71-4 CAPLUS

CN 10H-Dipyrrolo[1',2'-a':2,3-d]pyrrolo[1,5-a:2,3-d']bisazepine-9-propanoic acid, 2-[[1,5-dihydro-4-(3-methoxy-3-oxopropyl)-3-methyl-5-oxo-2H-pyrrol-2-ylidene]methyl]-4,5,12,13-tetrahydro-3,8,14-trimethyl-10-oxo-, methyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)

L28 ANSWER 73 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1995:419667 CAPLUS

DOCUMENT NUMBER: 122:290543

ORIGINAL REFERENCE NO.: 122:52971a,52974a

TITLE: Synthesis of biliverdins with stable extended conformations. Part I

AUTHOR(S): Iturraspe, Jose; Bari, Sara E.; Frydman, Benjamin
CORPORATE SOURCE: Fac. Farm. Bioquímica, Univ. Buenos Aires, Buenos Aires, 1113, Argent.

SOURCE: Tetrahedron (1995), 51(8), 2243-54

CODEN: TETRAB; ISSN: 0040-4020

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 122:290543

AB Biliverdins with extended conformations stabilized by intramol. Et bridges were obtained by base treatment of helical biliverdins with 2-chloroethyl side chains. Thus, neobiliverdin ICB was obtained by reaction of 13,18-di(2-chloroethyl)-biliverdin with DBH. During the reaction, the 2-chloroethyl-C(13) residue underwent an intramol. substitution reaction with N-24 while the 2-chloroethyl-C(18) residue underwent an elimination reaction to form a vinyl residue. This reaction scheme was unambiguously demonstrated by performing the synthesis of [15N-24]-dihydro-neobiliverdin IX β and of [15N-23]-dihydrophorcabilin. The method was then applied to the synthesis of neobiliverdin IX δ , a natural product isolated from the ovaries of the sea snake *Turbo cornutus*. It was concluded that when the 2-chloroethyl side chains are at C(3) (or the equivalent C(17)) and C(2) (or the equivalent C(18)) positions of the biliverdin, elimination reactions lead to vinyl residues in basic media; at any other of the β -pyrrole sites, treatment with base leads to the formation of seven-membered rings by intramol. substitution reactions.


IT 118631-57-5P 163014-57-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of pentacyclic biliverdins)

RN 118631-57-5 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[2-[(8-ethenyl-1,4,5,7-tetrahydro-3,9-dimethyl-7-oxodipyrrolo[1,2-a:2',3'-d]azepin-2-yl)methylene]-4-(3-methoxy-3-oxopropyl)-3-methyl-2H-pyrrol-5-yl)methylene]-2,5-dihydro-4-methyl-5-oxo-, methyl ester, (Z,Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 163014-57-1 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[[2-[(8-ethyl-1,4,5,7-tetrahydro-3,9-dimethyl-7-oxodipyrrolo[1,2-a:2',3'-d]azepin-2-yl-6-15N)methylene]-4-(3-methoxy-3-oxopropyl)-3-methyl-2H-pyrrol-5-yl]methylene]-2,5-dihydro-4-methyl-5-oxo-, methyl ester, (Z,Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

L28 ANSWER 74 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1994:605360 CAPLUS

DOCUMENT NUMBER: 121:205360

ORIGINAL REFERENCE NO.: 121:37397a,37400a

TITLE: Preparation of antiallergic triazolo(pyrrolo, thieno or furano)azepine derivatives

INVENTOR(S): Janssens, Frans Eduard; Lacrampe, Jean Fernand Armand;

PILATTE, Isabelle Noelle Consta

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9413681	A1	19940623	WO 1993-EP3322	19931125
W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2150804	A1	19940623	CA 1993-2150804	19931125
CA 2150804	C	20061010		
AU 9456280	A	19940704	AU 1994-56280	19931125
AU 676703	B2	19970320		
EP 675889	A1	19951011	EP 1994-901888	19931125
EP 675889	B1	20000705		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
HU 71808	A2	19960228	HU 1995-1619	19931125
HU 223465	B1	20040728		
JP 08503954	T	19960430	JP 1994-513722	19931125
JP 3503065	B2	20040302		
RU 2127737	C1	19990320	RU 1995-115515	19931125
PL 176528	B1	19990630	PL 1993-309255	19931125
AT 194350	T	20000715	AT 1994-901888	19931125
ES 2149861	T3	20001116	ES 1994-901888	19931125
PT 675889	E	20001229	PT 1994-901888	19931125
US 5595988	A	19970121	US 1995-433387	19950508
FI 9502724	A	19950602	FI 1995-2724	19950602
NO 9502200	A	19950803	NO 1995-2200	19950602
NO 311619	B1	20011217		
GR 3034495	T3	20001229	GR 2000-402184	20000928


PRIORITY APPLN. INFO.:

EP 1992-203777	A	19921204
EP 1994-901888	A	19931125
WO 1993-EP3322	W	19931125

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 121:205360

GI




AB Title compds. I (E-G = XCR₁CH, CH:CR₂X wherein X = O, S or R₃N wherein R₃ = H, C₁-6 alkyl, C₁-4 alkylcarbonyl, R₁, R₂ = H, C₁-4 alkyl, halo, (substituted)ethenyl, etc.; BD = CR₄:N, N:CR₅ wherein R₄ H, C₁-4 alkyl, (substituted)ethenyl, HO-C₁-4 alkyl, HCO, HO₂C, R₅ = H, Ph, pyridinyl, etc.; L = H, (substituted)C₁-6 alkyl, (aryl)C₃-6 alkenyl, Alk-Y-Het, Alk-NHCO-Het, Alk-Het wherein Alk = C₁-4 alkanediyl,, Y = O, S, NH, Het = (substituted)heterocyclyl) or a salt or stereomer thereof, are prepared (1-Methyl-4-piperidinyl)[1-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1H-1,2,4-triazol-5-yl]methanone (preparation given) was added to MeSO₃H at 0° followed by NaOH to give after workup II. Pharmaceutical formulations comprising I are given.

IT 1236831-63-2
 RL: PRPH (Prophetic)
 (Preparation of antiallergic triazolo(pyrrolo, thieno or furano)azepine derivatives)

RN 1236831-63-2 CAPLUS


CN INDEX NAME NOT YET ASSIGNED




IT 158144-23-1P 158144-25-3P 158144-26-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of, in preparation of antiallergy agents)

RN 158144-23-1 CAPLUS


CN 10H-Thieno[3,2-d]-1,2,4-triazolo[4,3-a]azepine (CA INDEX NAME)




RN 158144-25-3 CAPLUS
 CN 10H-Thieno[3,2-d][1,2,4]triazolo[1,5-a]azepin-10-one (CA INDEX NAME)



RN 158144-26-4 CAPLUS
 CN 10H-Thieno[3,2-d][1,2,4]triazolo[1,5-a]azepin-10-ol,
 10-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




IT 158143-86-3P 158143-89-6P 158144-02-6P
 158144-10-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as antiallergy agent)
 RN 158143-86-3 CAPLUS
 CN 10H-Thieno[3,2-d]-1,2,4-triazolo[4,3-a]azepine,
 10-(1-methyl-4-piperidinylidene)- (CA INDEX NAME)



RN 158143-89-6 CAPLUS

CN Pyrrolo[3,2-d][1,2,4]triazolo[1,5-a]azepine,
7,10-dihydro-10-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]-7-methyl-
(CA INDEX NAME)



RN 158144-02-6 CAPLUS

CN 10H-Furo[3,2-d][1,2,4]triazolo[1,5-a]azepine,
8-methyl-10-(1-methyl-4-piperidinyl)- (CA INDEX NAME)

L28 ANSWER 75 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1994:244848 CAPLUS

DOCUMENT NUMBER: 120:244848

ORIGINAL REFERENCE NO.: 120:43401a,43404a

TITLE: Thiopheno[3,2-[1]benzazepine,
benzo[3,4]cyclohepta[2,1-b]thiophenes,
thiazolo[5,4-d][1]benzazepine and
benzo[3,4]cyclohepta[2,1-d]thiazoles

AUTHOR(S):

CORPORATE SOURCE: Dep. Chem., Osmania Univ., Hyderabad, 500 007, India

SOURCE: Organic Preparations and Procedures International

(1993), 25(5), 602-6


CODEN: OPPIAK; ISSN: 0030-4948

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 120:244848

GI



AB Cyclocondensation of 2-benzazepinecarboxaldehydes I (R = tosyl, H; R1 = H, MeO; R2 = H, Cl, OMe) gave the thiopheno[3,2-d][1]benzazepines II (same R, R1; R3 = H, Et, etc.) in good yield. The thiazolo[5,4-d]benzazepines III (same R1, R2) were also prepared


IT 153894-28-1P 153894-29-2P 153894-30-5P

153894-33-8P 153894-34-9P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 153894-28-1 CAPLUS


CN 4H-Thieno[3,2-d][1]benzazepine-2-carboxylic acid,
5,6-dihydro-6-[(4-methylphenyl)sulfonyl]-, ethyl ester (CA INDEX NAME)



RN 153894-29-2 CAPLUS
 CN 4H-Thieno[3,2-d][1]benzazepine-2-carboxylic acid,
 8-chloro-5,6-dihydro-6-[(4-methylphenyl)sulfonyl]-, ethyl ester (CA INDEX
 NAME)




RN 153894-30-5 CAPLUS
 CN 4H-Thieno[3,2-d][1]benzazepine-2-carboxylic acid,
 5,6-dihydro-8,9-dimethoxy-6-[(4-methylphenyl)sulfonyl]-, ethyl ester (CA
 INDEX NAME)




RN 153894-33-8 CAPLUS

CN 4H-Thieno[3,2-d][1]benzazepine-2-carboxylic acid, 5,6-dihydro- (CA INDEX NAME)



RN 153894-34-9 CAPLUS

CN 4H-Thieno[3,2-d][1]benzazepine-2-carboxylic acid, 8-chloro-5,6-dihydro- (CA INDEX NAME)



OS.CITING REF COUNT: 6

THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)

L28 ANSWER 76 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1994:133367 CAPLUS

DOCUMENT NUMBER: 120:133367

ORIGINAL REFERENCE NO.: 120:23471a, 23474a

TITLE: Synthesis and conformational flexibility of
4,9-dihydroindolo[3,2-d][1,2,4]triazolo[4,3-
a][1]benzazepines

AUTHOR(S) : Kunick, Conrad

CORPORATE SOURCE: Inst. Pharm., Univ. Hamburg, Hamburg, 20146, Germany


SOURCE: Liebigs Annalen der Chemie (1993), (10), 1141-3

CODEN: LACHDL; ISSN: 0170-2041

DOCUMENT TYPE: Journal

LANGUAGE: German

GI



AB The title compds. (I; R = H, Me, Et, Ph, o-tolyl) were prepared by cyclization of a thiolactam with acyl hydrazides. The influence of R on the barrier to ring inversion in I was studied by dynamic 1H-NMR spectroscopy.


IT 153079-84-6P 153079-85-7P 153079-86-8P

153079-87-9P 153079-88-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and ring inversion barrier of)


RN 153079-84-6 CAPLUS

CN Indolo[3,2-d][1,2,4]triazolo[4,3-a][1]benzazepine, 9,14-dihydro- (CA
INDEX NAME)




RN 153079-85-7 CAPLUS


RN Indolo[3,2-d][1,2,4]triazolo[4,3-a][1]benzazepine, 9,14-dihydro-6-methyl-
 CN (CA INDEX NAME)



RN 153079-86-8 CAPLUS
 CN Indolo[3,2-d][1,2,4]triazolo[4,3-a][1]benzazepine, 6-ethyl-9,14-dihydro-
 (CA INDEX NAME)




RN 153079-87-9 CAPLUS
 CN Indolo[3,2-d][1,2,4]triazolo[4,3-a][1]benzazepine, 9,14-dihydro-6-phenyl-
 (CA INDEX NAME)



RN 153079-88-0 CAPLUS
 CN Indolo[3,2-d][1,2,4]triazolo[4,3-a][1]benzazepine,
 9,14-dihydro-6-(2-methylphenyl)- (CA INDEX NAME)

10/565,702



OS.CITING REF COUNT: 2

THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

L28 ANSWER 77 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1993:213072 CAPLUS

DOCUMENT NUMBER: 118:213072

ORIGINAL REFERENCE NO.: 118:36731a,36734a

TITLE: Preparation of imidazo[1,2-a](pyrrolo, thieno or furano)[3,2-d]azepines as allergy inhibitors
 INVENTOR(S): Janssens, Frans Eduard; Diele, Gaston Stanislas Marcella; Leenaerts, Joseph Elisabeth; Cooymans, Ludwig Paul

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: Eur. Pat. Appl., 60 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 518434	A1	19921216	EP 1992-201665	19920609
R: PT				
IL 101851	A	19960514	IL 1992-101851	19920513
CN 1068116	A	19930120	CN 1992-104830	19920516
CN 1033587	C	19961218		
CA 2102889	A1	19921214	CA 1992-2102889	19920609
CA 2102889	C	20021126		
WO 922553	A1	19921223	WO 1992-EP1331	19920609
W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LG, MG, MW, NO, PL, RO, RU, SD, US				
RM: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
AU 9219011	A	19930112	AU 1992-19011	19920609
AU 652841	B2	19940908		
EP 588859	A1	19940330	EP 1992-911643	19920609
EP 588859	B1	20030813		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
JP 06507890	T	19940908	JP 1992-510734	19920609
JP 3182421	B2	20010703		
HU 70428	A2	19951030	HU 1993-3554	19920609
HU 221013	B1	20020729		
PL 170376	B1	19961231	PL 1992-301819	19920609
AT 247118	T	20030815	AT 1992-911643	19920609
ES 2204892	T3	20040501	ES 1992-911643	19920609
ZA 9204327	A	19931213	ZA 1992-4327	19920612
US 5461050	A	19951024	US 1993-150121	19931129
NO 9304493	A	19940104	NO 1993-4493	19931209
NO 300689	B1	19970707		
FI 104077	B1	19991115	FI 1993-5557	19931210
PRIORITY APPLN. INFO.:			US 1991-714487	A 19910613
			WO 1992-EP1331	A 19920609

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 118:213072

GI For diagram(s), see printed CA Issue.

AB Title compds. [I; R1 = H, alkyl, halo, ethenyl substituted with CO2H or alkoxycarbonyl, hydroxylalkyl, CHO, HO2C, hydroxycarbonylalkyl; R2 = H, alkyl, ethenyl or alkyl substituted with CO2H or alkoxy carbonyl, hydroxyalkyl, CHO, CO2H; R3 = H, alkyl, hydroxyalkyl, Ph, halo; L = H,


(substituted) alkyl, alkenyl, ZYQ1, ZNHCOQ2, ZQ3; Y = O, S, NH; Z = C1-4 alkylene; Q1, Q2 = (substituted) furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrrolyl, pyrazolyl, thiadiazolyl, oxodiazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazo[4,5-c]pyridin-2-yl; Q3 = Q1, (substituted) 4,5-dihydro-5-oxo-1H-tetrazolyl, 2-oxo-3-oxazolidinyl, 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl, etc.; X = O, S, NR5; R5 = H, alkyl, alkoxy, carbonyl; dotted lines = optional double bonds] were prepared as broad spectrum antiallergics with excellent oral availability, lack of sedating properties, fast onset of action, and favorable duration of action (no data). Thus, [2-(1-methyl-1H-pyrrol-2-yl)ethyl]methanesulfonate was refluxed 3 days with imidazole and K2CO3 in THF to give 61.7% 1-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1H-imidazole. The latter and then Et6 1-methyl-4-piperidinecarboxylate were added to a -70° mixture of (MeCH)2NH and BuLi in THF. The mixture was stirred 1 h at -70° and 2 h at room temperature to give 60% (1-methyl-4-piperidinyl)[1-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1H-imidazol-2-yl]methanone. This was stirred with MeSO3H at 80° to give 10.8% title compound II. Pharmaceutical I formulations are given.

IT 146800-71-7P 146800-72-8P 147184-18-7P
147184-19-8P 147184-20-1P 147184-22-3P
147184-24-5P 147184-27-8P 147210-29-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as allergy inhibitor)


RN 146800-71-7 CAPLUS

CN 10H-Imidazo[1,2-a]thieno[3,2-d]azepine, 10-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 146800-72-8 CAPLUS

CN 10H-Imidazo[1,2-a]thieno[3,2-d]azepine, 10-(4-piperidinylidene)- (CA INDEX NAME)




RN 147184-18-7 CAPLUS

CN 10H-Imidazo[1,2-a]thieno[3,2-d]azepine, 10-(1-methyl-4-piperidinylidene)-
(CA INDEX NAME)



RN 147184-19-8 CAPLUS


CN Imidazo[1,2-a]pyrrolo[3,2-d]azepine,
7,10-dihydro-7-methyl-10-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 147184-20-1 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-(10H-imidazo[1,2-a]thieno[3,2-d]azepin-10-ylidene)-, ethyl ester (CA INDEX NAME)

10/565,702



RN 147184-22-3 CAPLUS

CN 10H-Imidazo[1,2-a]thieno[3,2-d]azepine, 10-(4-piperidinylidene)-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 147184-24-5 CAPLUS


CN 10H-Imidazo[1,2-a]thieno[3,2-d]azepine,
10-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinylidene]-, ethanedioate (2:5)
(CA INDEX NAME)

CM 1

CRN 147184-23-4

CMF C24 H25 N3 O S

10/565,702



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 147184-27-8 CAPLUS

CN 10H-Imidazo[1,2-a]thieno[3,2-d]azepine, 10-(1-methyl-4-piperidinyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

10/565,702

RN 147210-29-5 CAPLUS
CN 5H-Thiazolo[3,2-a]pyrimidin-5-one,
6-[2-[4-(10H-imidazo[1,2-a]thieno[3,2-d]azepin-10-ylidene)-1-
piperidinyl]ethyl]-7-methyl-, ethanedioate (1:2) (CA INDEX NAME)

CM 1

CRN 147210-28-4
CMF C24 H23 N5 O S2




CM 2

CRN 144-62-7
CMF C2 H2 O4




IT 146800-88-6P, 4H-Thieno[2,3-d]azepin-5-amine
146800-89-7P 146800-90-0P,
10H-Imidazo[1,2-a]thieno[3,2-d]azepine 146800-91-1P
146800-92-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediates for imidazolazoloazepine inhibitor)
RN 146800-88-6 CAPLUS
CN 4H-Thieno[2,3-d]azepin-5-amine (CA INDEX NAME)


10/565,702




RN 146800-89-7 CAPLUS
CN 4H-Thieno[2,3-d]azepin-5-amine, N-(2,2-dimethoxyethyl)- (CA INDEX NAME)



RN 146800-90-0 CAPLUS
CN 10H-Imidazo[1,2-a]thieno[3,2-d]azepine (CA INDEX NAME)




RN 146800-91-1 CAPLUS
CN 10H-Imidazo[1,2-a]thieno[3,2-d]azepin-10-one (CA INDEX NAME)



RN 146800-92-2 CAPLUS
CN 10H-Imidazo[1,2-a]thieno[3,2-d]azepin-10-ol, 10-(1-methyl-4-piperidinyl)-
(CA INDEX NAME)

10/565,702



OS.CITING REF COUNT: 7

THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
(7 CITINGS)

L28 ANSWER 78 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1993:34948 CAPLUS

DOCUMENT NUMBER: 118:34948

ORIGINAL REFERENCE NO.: 118:6287a,6290a

TITLE: The interplay between basicity, conformation, and enzymic reduction in biliverdins

AUTHOR(S): Bari, Sara; Frydman, Rosalia B.; Grosman, Claudio; Frydman, Benjamin

CORPORATE SOURCE: Fac. Farm. Bioquim., Univ. Buenos Aires, Buenos Aires, Argent.

SOURCE: Biochemical and Biophysical Research Communications (1992), 188(1), 48-56

CODEN: BBRC9; ISSN: 0006-291X

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Biliverdins with extended conformations are reduced by biliverdin reductase (BvR) at higher rates than biliverdins with helical conformations. To find out the mol. basis for this important feature of BvR mechanism, helical and extended biliverdins were titrated for their acid-base equilibrium in a protic solvent (methanol). The basicity of biliverdins increased with the stretching of the conformation. Biliverdin IX γ (all-syn) has a $pK_a = 3.6$; 5,10,15-syn,syn,anti-biliverdin has a $pK_a = 3.7$; 5,10,15-syn,anti,syn-biliverdin has a $pK_a = 6.1$; 5,10,15-syn,anti,anti-biliverdin has a $pK_a = 6.4$; and 5,10,15-all-anti-biliverdin has a $pK_a = 7.9$. The increase in basicity with progressive stretching of conformations closely parallels the increase in the reduction rates by BvR. A biliverdin constrained by a 4-carbon chain to a helical conformation and which is a very weak base ($pK_a = 0.4$) is not reduced by BvR. Nucleophilic addns. of 2-mercaptoethanol at the C10 in biliverdins closely parallel their basicities, as can be expected if the formation of a pos. mesomeric species at C10 is linked to the basicity (i.e., the ease of protonation) of the N23 on the pyrroline ring.

IT 130877-88-2 145089-48-1


RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, with biliverdin reductase, substrate conformation and basicity in relation to)

RN 130877-88-2 CAPLUS

CN Pyrrolo[1,2-a]pyrrolo[1''',2''':1''',7''']azepino[4''',5''':4'',5'']pyrrolo[1'',2'':1'',7']azepino[4'',5'':4,5]pyrrolo[2,3-d]azepine-2,12-dipropionic acid, 3,5,6,7,8,13,15,16-octahydro-1,11,17-trimethyl-3,13-dioxo-, 2,12-dimethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— OMe

RN 145089-48-1 CAPLUS

CN 10H-Dipyrrolo[1',2'-a':2,3-d]pyrrolo[1,5-a:2,3-d']bisazepine-9-propanoic acid, 2-[[1,5-dihydro-4-(3-methoxy-3-oxopropyl)-3-methyl-5-oxo-2H-pyrrol-2-ylidene]methyl]-4,5,12,13-tetrahydro-3,8,14-trimethyl-10-oxo-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— OMe

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)

L28 ANSWER 79 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1992:526659 CAPLUS

DOCUMENT NUMBER: 117:126659

ORIGINAL REFERENCE NO.: 117:21869a,21872a

TITLE: Reconstitution of apomyoglobin with extended biliverdins

AUTHOR(S): Fernandez, Marcelo; Frydman, Rosalia B.; Bari, Sara; Frydman, Benjamin

CORPORATE SOURCE: Fac. Farm. Bioquim., Univ. Buenos Aires, Buenos Aires, Argent.

SOURCE: Biochemical and Biophysical Research Communications (1992), 183(3), 1209-15
CODEN: BBRC9; ISSN: 0006-291X

DOCUMENT TYPE: Journal

LANGUAGE: English

AB An anal. of the reconstitution of biliverdins with extended conformations and horse heart apomyoglobin was carried out. Biliverdins with the 5Z-syn, 10Z-syn, 15Z-anti and 5Z-anti, 10Z-syn, 15Z-anti conformations, as well as biliverdins with the Z,Z,Z all-syn conformation recombined with apomyoglobin. In every case the P enantiomers were bound in excess to the M enantiomers, with the exception of the 5-syn, 10-syn, 15-anti biliverdins where the M enantiomer bound preferentially to the protein. Biliverdins with an anti conformation at the C-10 meso bridge did not recombine with the protein. It was concluded that the presence of a syn conformation at the C-10 methine conferred to the biliverdin the necessary helicity to fit into the apomyoglobin heme pocket. This regioselectivity of the heme pocket is of importance in view of the well-known analogy between the ligand domains of myoglobin and the C-phycocyanins.


IT 130877-84-8 143222-57-5 143222-59-7

RL: PRP (Properties)

(apomyoglobin reconstitution with, structure in relation to)

RN 130877-84-8 CAPLUS

CN Pyrrolo[1,2-a]pyrrolo[1''',2''':1'',7''']azepino[4''',5''':4'',5'']pyrrolo[1'',2'':1',7']azepino[4',5':4,5]pyrrolo[2,3-d]azepine-2,12-dipropanoic acid, 3,5,6,7,8,13,15,16-octahydro-1,11,17-trimethyl-3,13-dioxo- (CA INDEX NAME)




RN 143222-57-5 CAPLUS

CN Dipyrrolo[1,2-a:2',3'-d]azepine-9-propanoic acid, 2-[[4-(2-carboxyethyl)-4,5-dihydro-3,8-dimethyl-7-oxodipyrrolo[1,2-a:2',3'-d]azepin-2(7H)-ylidene]methyl]-1,4,5,7-tetrahydro-3,8-dimethyl-7-oxo-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


CO₂H

RN 143222-59-7 CAPLUS

CN 5H-Dipyrrolo[1',2'-a':2,3-d]pyrrolo[1,5-a:2,3-d']bisazepine-9-propanoic acid, 2-[[4-(2-carboxyethyl)-1,5-dihydro-3-methyl-5-oxo-2H-pyrrol-2-ylidene]methyl]-4,10,12,13-tetrahydro-3,8,14-trimethyl-10-oxo-, (Z)- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

CO₂H

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L28 ANSWER 80 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1991:61950 CAPLUS

DOCUMENT NUMBER: 114:61950

ORIGINAL REFERENCE NO.: 114:10623a,10626a

TITLE: Preparation and formulation of tetra- and decahydroquinoline-4-carboxylic acids and analogs for use in tissue irrigating solutions
 INVENTOR(S): Leclerc, Gerard; Ruhland, Beatrice; Andermann, Guy; De Buriel, Georges; Dietz, Michel
 PATENT ASSIGNEE(S): Laboratoires Alcon S. A., Fr.

SOURCE: U.S., 16 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4952573	A	19900828	US 1988-172047	19880323
			US 1988-172047	19880323

PRIORITY APPLN. INFO.:

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 114:61950

AB The title compds. having γ -aminobutyric acid (GABA) like activity, were prepared for use in tissue irrigating solns. to promote corneal deswelling during otic surgery. Thus, N-methylquinoline-4-carboxamide was stirred with Ni-Al alloy in aqueous MeOH containing KOH and the product refluxed


14 h with aqueous HCl to give 1,2,3,4-tetrahydroquinoline-4-carboxylic acid-HCl, which gave 34.6 μ m reduction of bovine corneal swelling after 3 h perfusion at 0.01 mM compared to 17.2 μ m reduction by GABA under the same conditions.

IT 131753-37-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of, in preparation of otic tissue irrigant)

RN 131753-37-2 CAPLUS

CN 6H-Isoxazolo[4,5-d][1]benzazepine-6-carboxylic acid,
 2,3,4,5-tetrahydro-3-oxo-, ethyl ester (CA INDEX NAME)




IT 131753-38-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as otic tissue irrigant)

RN 131753-38-3 CAPLUS

10/565,702

CN 3H-Isloxazolo[4,5-d][1]benzazepin-3-one, 2,4,5,6-tetrahydro-, hydrobromide
(1:1) (CA INDEX NAME)



● HBr

OS.CITING REF COUNT:	6	THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 81 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1991:2582 CAPLUS

DOCUMENT NUMBER: 114:2582

ORIGINAL REFERENCE NO.: 114:531a,534a

TITLE: The enzymic and chemical reduction of extended biliverdins

AUTHOR(S): Frydman, Rosalia B.; Bari, Sara; Tomaro, Maria L.; Frydman, Benjamin

CORPORATE SOURCE: Fac. Farm. Bioquim., Univ. Buenos Aires, Buenos Aires, Argent.

SOURCE: Biochemical and Biophysical Research Communications (1990), 171(1), 465-73
CODEN: BBRCA9; ISSN: 0006-291X

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The substrate specificity of rat liver biliverdin reductase was probed using helical and extended biliverdins. The former were the ZZZ-all-syn biliverdins IX α and IX γ , and the latter were the 5Z-syn, 10Z-syn, 15Z-anti; 5Z-anti, 10Z-syn, 15Z-anti; 5Z-syn, 10E-anti, 15Z-syn; 5Z-syn, 10E-anti, 15Z-anti and 5Z-anti, 10E-anti, 15E-anti biliverdins. Reduction rates of the biliverdins increased with the progressive stretching of their conformations. The most extended biliverdin was reduced at a higher rate than biliverdin IX α . The chemical reduction rates to bilirubins followed a similar pattern. Nucleophilic addition of 2-mercaptoethanol to the C10 methine was also favored in the extended biliverdins.


IT 130877-88-2

RL: RCT (Reactant); RACT (Reactant or reagent)
(hydrolysis of)

RN 130877-88-2 CAPLUS

CN Pyrrolo[1,2-a]pyrrolo[1''',2''':1'',7''']azepino[4''',5''':4'',5'']pyrrolo[1'',2'':1',7']azepino[4',5':4,5]pyrrolo[2,3-d]azepine-2,12-dipropionic acid, 3,5,6,7,8,13,15,16-octahydro-1,11,17-trimethyl-3,13-dioxo-, 2,12-dimethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— OMe

IT 130877-84-8P

130888-62-9P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and reduction by chemical reagent or mammalian biliverdin reductase,

structure relation to)

RN 130877-84-8 CAPLUS

CN Pyrrolo[1,2-a]pyrrolo[1''',2''':1''',7''']azepino[4''',5''':4'',5'']pyrrolo[1'',2'':1'',7'']azepino[4',5':4,5]pyrrolo[2,3-d]azepine-2,12-dipropanoic acid, 3,5,6,7,8,13,15,16-octahydro-1,11,17-trimethyl-3,13-dioxo- (CA INDEX NAME)




RN 130888-62-9 CAPLUS

CN Dipyrrolo[1,2-a:2',3'-d]azepine-8-propanoic acid, 2-[[8-(2-carboxyethyl)-4,5-dihydro-3,9-dimethyl-7-oxodipyrrolo[1,2-a:2',3'-d]azepin-2(7H)-ylidene]methyl]-1,4,5,7-tetrahydro-3,9-dimethyl-7-oxo-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

CO2H


IT 130877-89-3P 130877-90-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, extended or helical conformation effects on mercapto group nucleophilic addition in)


RN 130877-89-3 CAPLUS

CN Pyrrolo[1,2-a]pyrrolo[1''',2''':1''',7''']azepino[4''',5''':4'',5'']pyrrolo[1'',2'':1'',7'']azepino[4',5':4,5]pyrrolo[2,3-d]azepine-2,12-dipropanoic acid, 3,5,6,7,8,13,15,16-octahydro-18-[(2-hydroxyethyl)thio]-1,11,17-trimethyl-3,13-dioxo- (CA INDEX NAME)



RN 130877-90-6 CAPLUS

CN Dipyrrolo[1,2-a:2',3'-d]azepine-8-propanoic acid,
2-[[8-(2-carboxyethyl)-1,4,5,7-tetrahydro-3,9-dimethyl-7-oxodipyrrolo[1,2-
a:2',3'-d]azepin-2-yl][(2-hydroxyethyl)thio]methylene]-2,4,5,7-tetrahydro-
3,9-dimethyl-7-oxo-, (Z)- (9CI) (CA INDEX NAME)



IT 130888-64-1


RL: RCT (Reactant); RACT (Reactant or reagent)
(saponification of)

RN 130888-64-1 CAPLUS

CN Dipyrrolo[1,2-a:2',3'-d]azepine-8-propanoic acid,
2-[[4,5-dihydro-8-(3-methoxy-3-oxopropyl)-3,9-dimethyl-7-oxodipyrrolo[1,2-
a:2',3'-d]azepin-2(7H)-ylidene]methyl]-1,4,5,7-tetrahydro-3,9-dimethyl-7-
oxo-, methyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A





OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)

L28 ANSWER 82 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1989:75127 CAPLUS

DOCUMENT NUMBER: 110:75127

ORIGINAL REFERENCE NO.: 110:12401a,12404a

TITLE: Total synthesis of "extended" biliverdins. The relation between their conformation and their spectroscopic properties

AUTHOR(S): Iturraspe, Jose B.; Bari, Sara; Frydman, Benjamin

CORPORATE SOURCE: Fac. Farm. Bioquim., Univ. Buenos Aires, Buenos Aires, 1113, Argent.



SOURCE: Journal of the American Chemical Society (1989), 111(4), 1525-7

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Extended biliverdins of the neopterobilin type, e.g., I, were obtained by treatment of Z,Z,Z-2-chloroethylbiliverdins, e.g., II, with DBU at 25°. When the 2-chloroethyl residue was at C(7), rotation at the C(5)-C(6) bond allowed a 5Z-syn to 5Z-anti conformational change followed by an intramol. alkylation at N(21). A seven-membered ring was thus formed, which kept the new biliverdin in a 5Z-anti, 10Z-syn 15Z-syn conformation. When two 2-chloroethyl residues at C(7) and C(13) were present in the bilitriene, the DBU treatment afforded a 5Z-anti, 10Z-syn, 15Z-anti biliverdin with two seven-membered rings which resulted from the intramol. alkylation at N(21) and N(24). When the 2-chloroethyl chain was

at C(8), a seven-membered ring was formed by alkylation at N(23) and the resulting biliverdin had a 5Z-syn, 10E-anti, 15Z-syn conformation. The ¹H-NMR spectra of the extended biliverdins are concentration dependent, indicating that these biliverdins (unlike those with a helicoidal conformation) associate in solution. Their spectra were also temperature dependent and


at -80 °C a mixture of conformers could be detected. The ϵ vis/ ϵ UV ratio of the extended biliverdins increased about a 40-fold over the ratio of the helical-shaped biliverdins, a fact that can be useful for the interpretation of the spectra of biliproteins.

IT 118631-57-5P 118631-58-6P 118631-60-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation, conformation, and spectral characterization of)

RN 118631-57-5 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[[2-[(8-ethenyl-1,4,5,7-tetrahydro-3,9-dimethyl-7-oxodipyrrolo[1,2-a:2',3'-d]azepin-2-yl)methylene]-4-(3-methoxy-3-oxopropyl)-3-methyl-2H-pyrrol-5-yl]methylene]-2,5-dihydro-4-methyl-5-oxo-, methyl ester, (Z,Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 118631-58-6 CAPLUS

CN Dipyrrolo[1,2-a:2',3'-d]azepine-9-propanoic acid, 2-[[[4,5-dihydro-9-(3-methoxy-3-oxopropyl)-3,8-dimethyl-7-oxodipyrrolo[1,2-a:2',3'-d]azepin-2(7H)-ylidene]methyl]-1,4,5,7-tetrahydro-3,8-dimethyl-7-oxo-, methyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




PAGE 1-A



RN 118631-60-0 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[[2-[(8-ethenyl-1,4,5,7-tetrahydro-3,9-dimethyl-7-oxodipyrrolo[1,2-a:2',3'-d]azepin-2-yl-6-15N)methylene]-4-(3-methoxy-3-oxopropyl)-3-methyl-2H-pyrrol-5-yl)methylene]-2,5-dihydro-4-methyl-5-oxo-, methyl ester, (Z,Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

L28 ANSWER 83 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1987:32948 CAPLUS

DOCUMENT NUMBER: 106:32948

ORIGINAL REFERENCE NO.: 106:5523a,5526a

TITLE: Synthesis of pyrazolo[4,5-d]- and
pyrazolo[4,5-c][1]benzazepine derivatives. IV
AUTHOR(S): Melani, Fabrizio; Cecchi, Lucia; Palazzino, Giovanna;
Filacchioni, Guido

CORPORATE SOURCE: Dip. Sci. Farm., Univ. Firenze, Florence, 50121, Italy

SOURCE: Journal of Heterocyclic Chemistry (1986), 23(1), 173-6


CODEN: JHTCAD; ISSN: 0022-152X

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 106:32948


GI




I



II



III



IV

AB Title compds. I and II (R = H, 3-Cl, 4-Cl, 3-Me), analogs of the antitumor agent anthramycin, were prepared starting from pyrazoles III and IV, resp.

IT 106148-11-2P 106148-12-3P 106148-13-4P


106148-14-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of, as antitumor agent)

RN 106148-11-2 CAPLUS


CN Pyrazolo[4,3-d][1]benzazepin-5(1H)-one, 4,6-dihydro-3-methyl-1-phenyl-
(CA INDEX NAME)




RN 106148-12-3 CAPLUS
 CN Pyrazolo[4,3-d][1]benzazepin-5(1H)-one,
 1-(3-chlorophenyl)-4,6-dihydro-3-methyl- (CA INDEX NAME)



RN 106148-13-4 CAPLUS
 CN Pyrazolo[4,3-d][1]benzazepin-5(1H)-one,
 4,6-dihydro-3-methyl-1-(3-methylphenyl)- (CA INDEX NAME)




RN 106148-14-5 CAPLUS
 CN Pyrazolo[4,3-d][1]benzazepin-5(1H)-one,
 1-(4-chlorophenyl)-4,6-dihydro-3-methyl- (CA INDEX NAME)




OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L28 ANSWER 84 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1984:403202 CAPLUS
 DOCUMENT NUMBER: 101:3202
 ORIGINAL REFERENCE NO.: 101:559a,562a
 TITLE: Determination of the radioprotective activity of
 imipramine analogs
 AUTHOR(S): Gansser, C.; Marcot, B.; Viel, C.; Fatome, M.; Laval,
 J. D.
 CORPORATE SOURCE: Lab. Pharm. Chim., Fac. Pharm., Chateau-Malabry, F
 92290, Fr.
 SOURCE: Annales Pharmaceutiques Francaises (1983), 41(5),
 465-71
 CODEN: APFRAD; ISSN: 0003-4509
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 GI




I

AB The radioprotective activity of analogs of imipramine (I) were examined The
 radioprotectant activity was studied in male albino mice exposed to
 γ-irradiation (0.3 Gy/min) and injected with 50-375 mg/kg i.p., and the
 results compared with AET. The I analogs containing pyridoazepine or
 azepinone had radioprotectant activity based on LD50/30, but were all
 inferior to AET.
 IT 90358-80-8 90358-81-9
 RL: BIOL (Biological study)
 (radioprotection by)
 RN 90358-80-8 CAPLUS
 CN 8H-Dibenz[b,f]isoxazolo[5,4-d]azepine-8-ethanamine,
 N,N-dimethyl-3-phenyl-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 90358-81-9 CAPLUS
 CN 8H-Dibenz[b,f]isoxazolo[5,4-d]azepine-8-propanamine,
 N,N,β-trimethyl-3-phenyl-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

L28 ANSWER 85 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1983:143412 CAPLUS

DOCUMENT NUMBER: 98:143412

ORIGINAL REFERENCE NO.: 98:21853a,21856a

TITLE: Dibenzazepine tetracyclic derivatives and

pharmaceutical compositions containing them

INVENTOR(S): Viel, Claude; Marcot, Bernoud; Redeuilh, Gerard;

Djiane, Alain; Cherqui, Jean

PATENT ASSIGNEE(S): Centre National de la Recherche Scientifique, Fr.

SOURCE: Eur. Pat. Appl., 54 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 63525	A1	19821027	EP 1982-400680	19820415
R: BE, CH, DE, FR, GB, IT, NL, SE				
FR 2504140	A1	19821022	FR 1981-7707	19810416
FR 2504140	B1	19831202		
JP 58088384	A	19830526	JP 1982-63793	19820416
PRIORITY APPLN. INFO.:			FR 1981-7707	A 19810416
OTHER SOURCE(S):		CASREACT 98:143412; MARPAT 98:143412		

GI



I



II

AB Azolodibenzazepines I (X = O, NR7; X1 = alkene; R = alkyl, Ph, substituted Ph; R1, R2 = H; R1R2 = bond, R3, R4 = H, alkyl, aralkyl; NR3R4 = heterocyclic; R5, R6 = H, alkyl, alkoxy, CF3, alkylendioxy, OH, SH, OCCl3, OCF3, SCF3, amino, aminosulfonyl, cyano, NO2, CO2H, alkoxycarbonyl, carbamoyl, acyl, sulfinyl, sulfonyl; R7 = Ph, substituted Ph) were prepared. Thus, dibenzazepine was treated with ClCH2CH2NMe2 and cyclized with PhCCl:NOH to give II. At 5 mg/kg i.p. II was antireserpine activity in mice. II gave 70% protection against phenylbenzoquinone writhing in mice at 20 mg/kg i.p. It had an anticholinergic ED50 of 5 + 10-4 mg/mL in the isolated guinea pig ileum.

IT 85008-87-3P 85008-88-4P 85008-90-8P

85008-92-0P 85008-93-1P 85008-94-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);


BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and antidepressant activity of)

RN 85008-87-3 CAPLUS


CN Dibenzo[b,f]pyrazolo[3,4-d]azepine, 1,8-dihydro-1,3-diphenyl- (CA INDEX

NAME)



RN 85008-88-4 CAPLUS


CN 8H-Dibenz[b,f]isoxazolo[4,5-d]azepine-8-propanamine,
N,N-dimethyl-3-phenyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 85008-90-8 CAPLUS


CN Dibenzo[b,f]pyrazolo[4,3-d]azepine-8(1H)-ethanamine,
N,N-dimethyl-1,3-diphenyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 85008-92-0 CAPLUS


CN 8H-Dibenz[b,f]isoxazolo[5,4-d]azepine-8-ethanamine,
N,N-dimethyl-3-phenyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 85008-93-1 CAPLUS

CN 8H-Dibenz[b,f]isoxazolo[5,4-d]azepine-8-propanamine,
N,N,β-trimethyl-3-phenyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 85008-94-2 CAPLUS
 CN Dibenzo[b,f]pyrazolo[4,3-d]azepine-8(1H)-propanamine,
 N,N-dimethyl-1,3-diphenyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 85008-91-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 85008-91-9 CAPLUS
 CN Dibenzo[b,f]pyrazolo[4,3-d]azepine-8(1H)-propanamine,
 N,N,β-trimethyl-1,3-diphenyl-, hydrochloride (1:1) (CA INDEX NAME)

10/565,702



● HCl

OS.CITING REF COUNT: 7

THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
(7 CITINGS)

L28 ANSWER 86 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1980:495115 CAPLUS

DOCUMENT NUMBER: 93:95115

ORIGINAL REFERENCE NO.: 93:15245a,15248a

TITLE: Synthesis of pyrroles, pyridines, and azepines from 2H-azirines

AUTHOR(S): Saruwatari, Masumi; Hatano, Sumiko; Isomura, Kazuaki; Taniguchi, Hiroshi

CORPORATE SOURCE: Fac. Eng., Kyushu Univ., Fukuoka, Japan


SOURCE: Fukuoka Kagaku Toronkai Koen Yoshishu, 12th (1979), 211-15. Kitasato Daigaku Yakugakubu: Tokyo, Japan.

CODEN: 42VCA9

DOCUMENT TYPE: Conference

LANGUAGE: Japanese

GI




AB The controlling factor for the formation of pyrroles, pyridines, and azepines (e.g. I-III) from 2H-azirines (e.g. IV, R = H, Me, Ph) were discussed with mechanistic detail.

IT 63325-41-7P

RL: SPN (Synthetic preparation); PREP (Preparation of)

RN 63325-41-7 CAPLUS

CN 5H-Benzofuro[2,3-d][1]benzazepine-6-carboxylic acid, ethyl ester (CA INDEX NAME)



L28 ANSWER 87 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1979:22951 CAPLUS

DOCUMENT NUMBER: 90:22951

ORIGINAL REFERENCE NO.: 90:3791a,3794a


TITLE: Azabenzocycloheptenones. Part 19. Formation of some heterocyclic annulated compounds from 1,2,3,4-tetrahydro-1-benzazepine derivatives
 AUTHOR(S): Proctor, George R.; Smith, Brian M. L.
 CORPORATE SOURCE: Dep. Pure Appl. Chem., Univ. Strathclyde, Glasgow, UK
 SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1978), (8), 862-70
 CODEN: JCPRB4; ISSN: 0300-922X

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 90:22951

GI




AB 4-(Ethoxycarbonyl)- and 4-(hydroxymethylene)benzazepin-5-one derivs. I were converted into pyrimidobenzazepines II, pyrazolobenzazepine III, and isoxazolobenzazepine IV by reaction with guanidine, NH_2NH_2 , and NH_2OH , resp. E.g., I [R = 4-MeC₆H₄SO₂ (Ts)] (R₁ = CO₂Et, R₂ = H and R₁R₂ = CHOH) with guanidine gave II (R₁ = OH, R₂ = NH₂ and R₁ = H, R₂ = NHMe), I (R = Ts, R₁R₂ = CHOH) with NH_2NH_2 gave 95% III, and I (R = CHO, R₁R₂ = CHOH) with NH_2OH gave 62% IV. [1,2,3]Thiadiazolo[5,4-d]-, quinolino[3,2-d]-, indolo[3,2-c]- and isoxazolo[4,3-d][1]benzazepine derivs. were also prepared

IT 68595-18-6P 68595-20-0P 68595-35-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 68595-18-6 CAPLUS
 CN 4H-isoxazolo[4,5-d][1]benzazepine,
 5,6-dihydro-6-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 68595-20-0 CAPLUS

CN 6H-isoaxazolo[4,5-d][1]benzazepine-6-carboxaldehyde, 4,5-dihydro- (CA INDEX NAME)



RN 68595-35-7 CAPLUS

CN Imidazo[4,5-d][1]benzazepine, 7,9-dibromo-1,4,5,6-tetrahydro- (CA INDEX NAME)



OS.CITING REF COUNT: 5

THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L28 ANSWER 88 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1978:152465 CAPLUS

DOCUMENT NUMBER: 88:152465

ORIGINAL REFERENCE NO.: 88:24025a,24028a

TITLE: Studies on heterocyclic compounds. XLIII. Reaction of 1-phenyl-4-hydrazino-4,5-dihydro-6H-furo[2,3-d][1]benzazepine-5-carboxylic acid hydrazide with aromatic aldehydes

AUTHOR(S): Ito, Kazuo; Yakushijin, Kenichi; Yoshina, Shigetaka

CORPORATE SOURCE: Fac. Pharm., Meijo Univ., Nagoya, Japan



SOURCE: Heterocycles (1978), 9(2), 169-73

CODEN: HTCYAM; ISSN: 0385-5414

DOCUMENT TYPE: Journal

LANGUAGE: English

GI




AB The title compound (I; R = H) reacted with R1CHO (R1 = 2-furyl, Ph, p-ClC6H4) in EtOH to give I (R2 = CHR1) and the monoarylidene derivative II.

IT 66206-57-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and condensation with aldehydes)

RN 66206-57-3 CAPLUS

CN 6H-Furo[2,3-d][1]benzazepine-5-carboxylic acid, 1-phenyl-, hydrazide (CA INDEX NAME)




IT 63874-16-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reaction with hydrazine)


RN 63874-16-8 CAPLUS

CN 6H-Furo[2,3-d][1]benzazepine-5-carboxylic acid, 1-phenyl-, ethyl ester


(CA INDEX NAME)



IT 66206-53-9P 66206-54-0P 66206-55-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 66206-53-9 CAPLUS
 CN 6H-Furo[2,3-d][1]benzazepine-5-carboxylic acid, 1-phenyl-,
 2-(2-furanylmethylene)hydrazide (CA INDEX NAME)




RN 66206-54-0 CAPLUS
 CN 6H-Furo[2,3-d][1]benzazepine-5-carboxylic acid, 1-phenyl-,
 2-(phenylmethylene)hydrazide (CA INDEX NAME)



RN 66206-55-1 CAPLUS

CN 6H-Furo[2,3-d][1]benzazepine-5-carboxylic acid, 1-phenyl-,
2-[(4-chlorophenyl)methylene]hydrazide (CA INDEX NAME)



L28 ANSWER 89 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1977:502204 CAPLUS

DOCUMENT NUMBER: 87:102204

ORIGINAL REFERENCE NO.: 87:16223a,16226a

TITLE: Studies on heterocyclic compounds. Part XXXI.

Synthesis of ethyl 1-phenyl- and

2-methyl-6H-furo[2,3-d][1]benzazepine-5-carboxylates

Yakushijin, Kenichi; Yoshina, Shigetaka; Tanaka, Akira

Fac. Pharm., Meijo Univ., Nagoya, Japan

Heterocycles (1977), 6(6), 721-5


CODEN: HCYAM; ISSN: 0385-5414

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 87:102204

GI




AB Thermolysis of I (R = Ph, R₁ = H; R = H, R₁ = Me) in ligroin gave II, which on thermolysis in boiling xylene gave III. Reduction of III with Zn in AcOH gave IV (R₂ = CO₂Et), which when treated with NaBH₄ in EtOH gave IV (R₂ = CH₂OH), which was also obtained by direct reduction of III with NaBH₄ in EtOH.

IT 63874-16-8P 63874-17-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and reduction of)


RN 63874-16-8 CAPLUS

CN 6H-Furo[2,3-d][1]benzazepine-5-carboxylic acid, 1-phenyl-, ethyl ester (CA INDEX NAME)



RN 63874-17-9 CAPLUS

CN 6H-Furo[2,3-d][1]benzazepine-5-carboxylic acid, 2-methyl-, ethyl ester
(CA INDEX NAME)



L28 ANSWER 90 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1977:453010 CAPLUS

DOCUMENT NUMBER: 87:53010

ORIGINAL REFERENCE NO.: 87:8395a,8398a

TITLE: Compelled azepine ring formation in thermal ring expansion of 2H-azirine

AUTHOR(S): Isomura, Kazuaki; Taguchi, Hiroshi; Tanaka, Tatsuyoshi; Taniguchi, Hiroshi

CORPORATE SOURCE: Fac. Eng., Kyushu Univ., Fukuoka, Japan


SOURCE: Chemistry Letters (1977), (4), 401-4

CODEN: CMLTAG; ISSN: 0366-7022


DOCUMENT TYPE: Journal

LANGUAGE: English


GI




I




II



III



IV



V


AB Thermolyses of benzofuran-2-ylvinyl azides I (R = H, Me, Ph) gave benzofuropyrrrole II, benzofuropyridine III, and benzofurobenzazepine IV, resp. Photolysis of these azides gave the corresponding 2H-azirines V, which on heating gave the same heterocyclic comdps., II-IV, as arose from the thermolysis of I.

IT 63325-41-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 63325-41-7 CAPLUS

CN 5H-Benzofuro[2,3-d][1]benzazepine-6-carboxylic acid, ethyl ester (CA
INDEX NAME)



OS.CITING REF COUNT: 3

THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L28 ANSWER 91 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1977:439331 CAPLUS

DOCUMENT NUMBER: 87:39331

ORIGINAL REFERENCE NO.: 87:6202h,6203a


TITLE: New route to the hexahydroazepino[4,5-b]indole series.
Rearrangement of hexahydroindolo[2,3-a]quinolizine by
the action of cyanogen bromide
Costa, G.; Riche, C.; Husson, H. P.
Inst. Chim. Subst. Nat., CNRS, Gif-sur-Yvette, Fr.
Tetrahedron (1977), 33(3), 315-20
CODEN: TETRAB; ISSN: 0040-4020

DOCUMENT TYPE: Journal


LANGUAGE: French

OTHER SOURCE(S): CASREACT 87:39331


GI




I



II



III



IV


AB The enamine I ($R = H$) with $BrCN$ and Na_2CO_3 in aqueous THF gave 47% hexahydroazepinoindole II and 5% octahydroindoloquinolizine III. II and III are formed via I ($R = Br$) which undergoes further reaction with $BrCN$ to give III and reaction with HO^- followed by rearrangement and further reaction with $BrCN$ to give II. II with base in refluxing xylene gave cyclization product IV, the structure of which was determined by x-ray crystallog. anal.

IT 63281-60-7P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and crystal structure of)


RN 63281-60-7 CAPLUS

CN 5H-Pyrano[3',2':2,3]azepino[4,5-b]indole-5-carbonitrile,
2,3,4,6,7,12-hexahydro- (CA INDEX NAME)




10/565,702

IT 63281-59-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 63281-59-4 CAPLUS
CN 5H-Pyrano[3',2':2,3]azepino[4,5-b]indole-5-carboximidic acid,
2,3,4,6,7,12-hexahydro-, methyl ester (CA INDEX NAME)




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

L28 ANSWER 92 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1975:593122 CAPLUS
 DOCUMENT NUMBER: 83:193122
 ORIGINAL REFERENCE NO.: 83:30369a,30372a
 TITLE: Nucleophilic displacement of aromatic fluorine. III.
 Indoloquinolines and benzofuranoquinolines
 AUTHOR(S): Walser, Armin; Silverman, Gladys; Flynn, Thomas;
 Fryer, R. Ian
 CORPORATE SOURCE: Hoffman-LaRoche Inc., Nutley, NJ, USA
 SOURCE: Journal of Heterocyclic Chemistry (1975), 12(2), 351-8
 CODEN: JHTCAD; ISSN: 0022-152X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 83:193122
 GI For diagram(s), see printed CA Issue.
 AB Several indoloquinoline, benzofuranoquinoline, and indolobenzazepine
 derivs., e.g. I-IV were prepared by intramol nucleophilic displacement of
 fluorine. Thus V (R = OEt) was aminated to give V (R = NH₂), which was
 treated with NaH to give I.
 IT 57046-64-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 57046-64-7 CAPLUS
 CN Indolo[2,3-d][1]benzazepine, 11-chloro-5,8-dihydro-5,8-dimethyl- (CA
 INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
 (8 CITINGS)

L28 ANSWER 93 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1975:43773 CAPLUS
 DOCUMENT NUMBER: 82:43773
 ORIGINAL REFERENCE NO.: 82:6977a,6980a
 TITLE: Heat resistant polymers and solubilization
 AUTHOR(S): Higgins, Jerry
 CORPORATE SOURCE: Dep. Chem., Illinois State Univ., Normal, IL, USA
 SOURCE: Papers presented at [the] Meeting - American Chemical
 Society, Division of Organic Coatings and Plastics
 Chemistry (1973), 33(1), 241-9
 CODEN: ACOCAO; ISSN: 0096-512X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The heat-resistant heterocyclic polymers (such as
 poly(2,4-pyrazinediyl-1,4-phenylene) [25482-93-3],
 benzene-1,2,4,5-tetraamine-benzo[1,2-b:5,4-b'] dipyrrole-2,3,5,6-tetrone
 copolymer [35560-14-6], etc.) were prepared, and their solubilization in
 acids containing H2O2 studied.
 IT 35165-04-9
 RL: PRP (Properties)
 (properties of)
 RN 35165-04-9 CAPLUS
 CN Poly(7H-indolo[2,3-b]pyrazino[2,3-g]quinoxaline-2,3:9,10-tetrayl-9-imino)
 (9CI) (CA INDEX NAME)



L28 ANSWER 94 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1972:488890 CAPLUS

DOCUMENT NUMBER: 77:88890

ORIGINAL REFERENCE NO.: 77:14689a,14692a

TITLE: Polybenzodipyrroloquinoxalines

AUTHOR(S): Janovic, Z.; Higgins, Jerry

CORPORATE SOURCE: Dep. Chem., Illinois State Univ., Normal, IL, USA

SOURCE: Journal of Polymer Science, Part A-1: Polymer

Chemistry (1972), 10(6), 1609-15

CODEN: JPSPC3; ISSN: 0449-296X

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Condensation of benzo[1,2-b:5,4-b']dipyrrolo-2,3,4,5-tetraone (I) with 1,2,4,5-tetraaminobenzene in polyphosphoric acid at 200-50.deg. gave the ladder polymer benzo[1,2-b:5,4-b']dipyrrolo-2,3,4,5-tetraone-1,2,4,5-tetraaminobenzene polymer (II) [35560-14-6]. Semiladder polymers were similarly prepared from I and 3,3'-diaminobenzidine or bis(3,4-diaminophenyl) ether. The polymers had intrinsic viscosity (H₂SO₄) 0.86-0.90, and thermal stability 460.deg. and .leq.700.deg. in air and N, resp. Three model compds. were also prepared from 2,3-indandione and tetraamines.

IT 35165-04-9

RL: PRP (Properties)
(heat resistance of)

RN 35165-04-9 CAPLUS

CN Poly(7H-indolo[2,3-b]pyrazino[2,3-g]quinoxaline-2,3:9,10-tetrayl-9-imino)
(9CI) (CA INDEX NAME)



L28 ANSWER 95 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1972:435327 CAPLUS
 DOCUMENT NUMBER: 77:35327
 ORIGINAL REFERENCE NO.: 77:5885a,5888a
 TITLE: Ladder poly(benzodipyrroloquinoxaline)
 AUTHOR(S): Higgins, Jerry; Janovic, Z.
 CORPORATE SOURCE: Dep. Chem., Illinois State Univ., Normal, IL, USA
 SOURCE: Journal of Polymer Science, Polymer Letters Edition (1972), 10(4), 301-3
 CODEN: JPYBAN; ISSN: 0360-6384

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Heat-resistant poly[7H-indolo[2,3-b]pyrazino[2,3-g]quinoxaline-2,3:9,10-tetrayl-9-imino] (I) [35165-04-9] was prepared by the reaction of benzo[1,2-b:5,4-b']dipyrrolo-2,3,5,6-tetrone and 1,2,4,5-C₆H₂(NH₂)₄ in polyphosphoric acid. 6,8-Dihydrobenzo[1'',2'':4,5:5'',4'':4',5']dipyrrolo[2,3-b:2',3'-b']diuinoxaline (II) [35180-58-6] and 5H-indolo[2,3-b]-9H-indolo[2',3':5,6]pyrazino[2,3-g]quinoxaline (III) [35180-59-7] were prepared as model compds.

IT 35165-04-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 35165-04-9 CAPLUS

CN Poly(7H-indolo[2,3-b]pyrazino[2,3-g]quinoxaline-2,3:9,10-tetrayl-9-imino)
 (9CI) (CA INDEX NAME)



L28 ANSWER 96 OF 96 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1962:436315 CAPLUS

DOCUMENT NUMBER: 57:36315

ORIGINAL REFERENCE NO.: 57:7246d-i, 7247a-i, 7248a-i, 7249a-i, 7250a-c

TITLE: 1,3-Dipolar addition. I. Diphenylnitrilimine and its 1,3-dipolar additions to alkenes and alkynes

AUTHOR(S): Huisgen, Rolf; Seidel, Michael; Wallbillich, Guenter; Knapf, Hans

CORPORATE SOURCE: Univ. Munich, Germany

SOURCE: Tetrahedron (1962), 17, 3-29

CODEN: TETRAB; ISSN: 0040-4020

DOCUMENT TYPE: Journal

LANGUAGE: German

AB The previously undescribed diphenylnitrilimine PhCNNPh (I) is available by elimination of N from 2,5-diphenyltetrazole (II) at 160° or by dehydrochlorination of PhCCl:NNHPh (III) at 20-80° with NET3. I adds in situ to alkenes and alkynes forming 1,3-diphenyl-Δ2 pyrazolines and 1,3-diphenylpyrazoles, resp. PhNNHNEz (40 g.) and 48 g. PC13 refluxed 10 hrs. (H2O-free atmospheric) in 50 ml. anhydrous Et2O and the

clear solution treated with 80 g. PhOH in 60 ml. Et2O and with 80 ml. MeOH, the main part of the Et2O evaporated with rise of internal temperature to 60-70°, and the cooled mixture filtered yielded 58% III, m. 129.530.5°. III (460 mg.) and 0.50 g. norbornene in 4 ml. anhydrous C6H6 treated at 20° with 1.0 ml. NET3 and the mixture kept several hrs., filtered from Et3NHC1, m. 253-5°, and the filtrate and washings evaporated yielded 85% bicyclo[2.2.1]hept-2-ene adduct, 1,3-diphenyl-4,7-methano-3a,4,5,6,7,7a-hexahydroindazole (IV), m. 171-2° (alc.), λ 244, 370 mμ (log ε 4.14, 4.32), strongly blue-green fluorescent in daylight, brown-yellow color in concentrated H2SO4 turning dark green in addition of concentrated HNO3. III (500 mg.) and

0.50 g. norbornene in 5 ml. C6H6 shaken 8 hrs. with 200 mg. KOH in 1.5 ml. H2O at 20° yielded 76% IV, also produced in 94% yield by treating III and norbornene in boiling C6H6 with Et3N. IV in CHCl3 treated with 1.0 mole-equivalent Br (exothermic reaction) and the cooled mixture washed with KOH and H2O, evaporated, and the residue sublimed at 120-40°/ 0.003 mm. gave 1-(p-bromophenyl)-3-phenyl-4,7-methano-3a,4,5,6,7,7a-hexahydroindazole, m. 133-4° (alc.), ν 800, 825 cm.-1 II (2.0 g.) in 10 ml. dicyclopentadiene (V) heated 3 hrs. at 160-5° with liberation of 9.0 millimoles N and the unchanged V distilled at 10 mm. yielded 68% 1,3-diphenyl-4,8-methano-3a,4,4a,7,8,8a - hexahydroindeno [5,6-c] pyrazole (VI), m. 173-4°. III (460 mg.) and 1.2 g. V in 6 ml. C6H6 refluxed 1 hr. with addition of 1.0 ml. Et3N and the filtered solution evaporated

yielded 87% VI, λ 242, 370 mμ (log 4.15, 4.33, CHCl3). VI (3.0 g.) refluxed 42 hrs. with 3.0 g. chloranil in 20 ml. xylene and the dark brown solution extracted repeatedly with 4% KOH, the H2O-washed solution freed from solvent

and distilled at 120-65°/0.003 mm., the glassy product crystallized from 60 ml. hot alc., and the crystalline material (0.90 g.) sublimed in vacuo gave non-fluorescent 1,3-diphenyl-4,8 - methano - 4,4a,7a,8 - tetrahydroindeno[5,6 - c]pyrazole (VII), m. 124.0-4.5°. VI (653 mg.) heated 3 hrs. at 200-55° with 90 mg. S with evolution of H2S and the product sublimed at 120-70°/0.01 mm. yielded 48% 1,3-diphenylpyrazole, m. 84-5° (petr. ether). III (460 mg.) and 2.25 g. bicycloheptadiene in 7 ml. C6H6 heated 3 hrs. at 65° with

1.0 ml. Et3N and kept 16 hrs. at 20°, the mixture filtered from 1.97 millimoles Et3NHCl and the filtrate evaporated, the residue boiled in 50 ml. alc. and filtered from 27 mg. insol. product, the solution cooled, and the crystalline material (79%) recrystd. from ligroine (b. 80-120°) yielded 1,3-diphenyl-4,7-methano-3a,4,7,7a-tetrahydroindazole (VIII), m. 133-5° (decomposition), λ 243, 369 m μ (log ϵ 4.13, 4.30). The insol. product recovered from HCONMe3 gave bright greenish yellow amorphous 1,3,5,7-tetraphenyl-4,8-methano-3a,4,-4a,7a,8,8a-hexahydropyrazolo[4,5-f]indazole, m. above 320° (decomposition), λ 244, 359, m μ (log ϵ 4.39, 4.52). VIII (2.29 g.) heated slowly from 130 to 185° several min. with vigorous evolution of gas through a trap at -78°, condensing 77% cyclopentadiene (identified as maleic anhydride adduct, m. 165.0-5.5°), and the residue distilled at 135-50°/0.003 mm. yielded 98% 1,3-diphenylpyrazole. III (2.00 millimoles) and 4.0 millimoles endo-cis-bicyclo[2.2.1]hept-5-ene-2,3dicarboxylic acid anhydride refluxed 1 hr. in 4 ml. C6H6 with dropwise addition of 1.0 ml. Et3N in 2 ml. C6H6 and the mixture refluxed 1 hr., filtered from Et3NHCl, and the residue on evaporation recrystd. from EtOAc gave 55% pale green 1,3-diphenyl-4,7-methano-3a,4,5,6,7,7a-hexahydroindazole-5,6dicarboxylic acid anhydride, m. 279-81° (decomposition). The dipolarophilic activity of normal unconjugated double bonds is relatively small as shown by a comparative study of the addition of I to non-conjugated alkenes, diphenylketene, and ketene acetal. III (3.98 millimoles), 21.5 millimoles C5HnCH:CH2, and 1.5 ml. Et3N heated 30 hrs. at 80-90° in a sealed tube and the filtered solution evaporated, the residue distilled at 160-80°/0.001 mm. and the yellow oil crystallized from MeOH yielded 85% 1,3-diphenyl-5-pentyl-A2-pyrazoline, m. 56-8° (MeOH), dehydrated (0.75 millimole) by refluxing 2 hrs. with 1.5 millimoles chloranil in 25 ml. xylene, the pale yellow oily 1,3-diphenyl-5-pentylpyrazole oxidized 80 min. in boiling 50% C6H5N with 2 g. KMnO4, washed with Et2O and filtered from MnO2, treated with Na2SO3 and acidified to yield 0.13 g. 1,3-diphenyl-5-pyrazolecarboxylic acid (IX), m. 225-60° (H2O). III (3.98 millimoles) similarly treated with 16.5 millimoles H2C:CH(CH2)8CO2Et and the product distilled at 200-30°/0.003 mm. gave 80% material, recrystd. from MeOH to yield yellow needles of Et 9-(1,3-diphenyl-A2-pyrazolin-5-yl)nonanecarboxylate, m. 40-2°. III with 3 mole-equivs. unsatd. ester in boiling C6H6 and the product distilled yielded also 28% tetraphenyldihydrodetrizine, m. 200-3°, produced by head-to-tail dimerization of I and showing the lacking activity of the dipolarophile. III (1.99 millimoles), 11.3 millimoles cyclopentene and Et3N refluxed 150 min. in 5 ml. C6H6 and the mixture kept 16 hrs., the residue on evaporation of the filtrate sublimed in a high vacuum, and the sublimate recrystd. from alc. yielded 78% 1,3-diphenyl-cis-1,3a,4,5,6,6a-hexahydrocyclopentapyrazole (X), m. 137.5-9.0°, λ 241,365 m μ (log ϵ 4.12, 4.31, CHCl3), with blue-green fluorescence. III (2.00 millimoles), 0.7 g. Ph2C:CO refluxed with Et3N in C6H6 and the filtered solution evaporated, the residue distilled at 150-220°/0.001 mm. and the red oil (1.06 g.) recrystd from alc. gave 0.19 g. 1,3,4,4-tetraphenyl-A2-pyrazol-5-one, m. 160-2°, ν 1712 cm.-1 III (2.00 millimoles) and 7.6 millimoles H2C:C(OEt)2 refluxed with Et3N in C6H6 without separation of Et3NHCl, the filtered solution evaporated, the residue distilled at 160-70°/0.004 mm., the red oil (0.50 g.) chromatographed in C6H6 over Al2O3 (Merck, activity I), and the eluate crystallized from 90% alc. gave 0.42 g. 1,3-diphenyl-5-ethoxypyrazole, m.

the

67-9°, λ 275 μ m (log ϵ 4.36). The pyrazole (0.53 g.) refluxed 9 days in 5 ml. alc. and 7 ml. concentrated HCl, the cooled mixture neutralized with NaOH and extracted with CH₂Cl₂, the product distilled in a high vacuum, and the distillate recrystd. from alc. and ligroine (b. 80-110°) yielded 75% 1,3-diphenyl-A2-pyrazol-5-one, m. 136.0-7.5°, 1708 cm.⁻¹ The orientation in the addition of I to Ph₂C:CO and to H₂C:C(OEt)₂ is that to be expected in regarding PhC+: N-N-Ph as a representation of I. III (2.31 g.) and 2.5 l. butadiene in 40 ml. C₆H₆ shaken 4 hrs. with 3 ml. Et₃N under pressure and kept several days, the blue fluorescent mixture filtered, and the residue on evaporation recrystd. from alc. gave 2.34 g. crystalline 1,3-diphenyl-5-vinyl-A2-pyrazoline (XI), m. 76.0-7.5°, b_{0.001} 130-40°. XI (4.0 millimoles) refluxed 10 hrs. with 4.7 millimoles chloranil in 10 ml. xylene and filtered from 2.9 millimoles tetrachlorohydroquinone, the filtrate extracted with alkali, and the washed solution evaporated gave 0.87 g. noncryst. viscous oil, distilled at 158-80°/0.001 mm. The oil (0.61 g.) in 45 ml. Me₂CO stirred 2 hrs. with gradual addition of 1.25 g. KMnO₄ and kept 30 min. before reduction with SO₂ and extraction with CH₂Cl₂, the residue on evaporation crystallized from CCl₄ and MeOH, and the product (0.41 g.), m. 227.08.5° (decomposition), recrystd. gave IX. PhCH:CHCOCH₂CO₂Et and PhNHNH₂ gave the known Et 1,3-diphenyl-5-methyl-4-pyrazolinecarboxylate (XII), dehydrogenated with chloranil in xylene to Et 1,3-diphenyl-5-methyl-4-pyrazolecarboxylate and saponified by alkali and decarboxylated to 1,3-diphenyl-5-methylpyrazole, m. 46-7° (Et₂O-petr. ether), refluxed (2.0 g.) 2 hrs. with 6 g. KMnO₄ in 100 ml. 1:1 stabilized Me₂CO-H₂O, the filtered solution acidified with 2N HCl, and the product recrystd. from MeOH gave 31% starting material and 24% IX, m. 228-9° (decomposition), neutralization equivalent 261. III (1.99 millimoles) and 3.0 millimoles cyclopentadiene kept 20 hrs. with NET₃ in C₆H₆ and the product purified by crystallization from alc. and sublimation in a high vacuum gave 0.30 g. 1,3-diphenyl-cis-1,3a,4,6a-tetrahydrocyclopentapyrazole, m. 183-4°, λ 242, 367 μ m (log ϵ 4.11, 4.31, CHCl₃), oxidized with KMnO₄ in Me₂CO at 20° to give 1,3-diphenyl-4-pyrazolecarboxylic acid and BzOH, brominated with 1.0 molar equivalent Br in C₆H₆ to 1-(4-bromophenyl)-3-phenyl-cis-1,3a,4,6a-tetrahydrocyclopentapyrazole, m. 148-50° (alc.), v 820 cm.⁻¹ and hydrogenated (300 mg.) in 80 ml. EtOAc at 20° in 50 min. with Raney Ni to give 0.29 g.X. III treated with 5 molar equivs. cyclohexa-1,3-diene in C₆H₆ in the presence of Et₃N yielded 73% 1,3-diphenyl-3a,4,5,7a-tetrahydro-indazole, b_{0.005} 150-60°, m. 119.5-21.0° (alc.), dehydrogenated with chloranil in boiling xylene 18 hrs., the product distilled in a high vacuum and crystallized from MeOH yielded 79% 1,3-diphenylindazole, m. 100.5-2.0°. III (1.99 millimoles) and 0.91 g. freshly distilled styrene kept 2 hrs. at 60° with Et₃N and some hydroquinone in C₆H₆ and the product recrystd. from MeOH yielded 88% 1,3,5-triphenyl-A2pyrazoline, m. 137-8°, λ 240, 361 μ m (log ϵ 4.20, 4.28). II (2.0 g.) heated 3 hrs. at 155-65° in 5 ml. 1,2-dihydronaphthalene with loss of 0.98 molar equivalent N, the excess dihydronaphthalene evapd, i₀ vacuo, and the residue crystallized from MeOH yielded 2.44 g. material, m. 133-48°. Treatment of 3.5 molar equivs. dihydronaphthalene with III in C₆H₆ in the presence of NET₃ yielded 75% product, recrystd. 4 times from alc. to give

1,3-diphenyl-3a,4,5,9b-tetrahydronaphtho[1,2-c]pyrazole, m. 151-2°, dehydrogenated with chloranil in C6H3Cl3 52 hrs. at 170°, the product distilled in a high vacuum and triturated with petr. ether yielded 70% 1,3-diphenylnaphtho[1,2-c]pyrazole (XIII), m. 100.5-2.0° (petr. ether, alc.). PhNNH2 (1.2 ml.) and 2.48 g. 2,1BzClO₆H6OH heated (N atmospheric) 16 hrs. at 150° in 5 ml. EtOCH₂CH₂OH containing 20 mg. p-MeC₆H₄SO₃H, the mixture stirred into H₂O and the red-brown product recrystd. from alc. yielded 72% phenyl 1-hydroxy-2-naphthyl ketone phenylhydrazone (XIV), b_{0.001} 220-30°, m. 130.0-1.5°. XI (1.02 g.) kept 2 hrs. at 95° in 70 ml. polyphosphoric acid and the solution poured into 200 ml. ice H₂O, the yellow precipitate distilled at 210-30°/0.001 mm., and the distillate chromatographed from C₆H₆ on Al₂O₃ (Woelm, acid, activity I) gave 0.56 g. XIII. Treatment of 117 with 3.5 mole-equivs. indene in C₆H₆ in the presence of NET₃ and the product sublimed at 140-70°/0.004 mm. gave 482 mg. 1,3-diphenyl-3a,8b-dihydro-4H-indeno[1,2-c]pyrazole, m. 171-2°, λ 239, 364 m μ (log ϵ 4.15, 4.28). Similarly 2.8 mole-equivs. transstilbene in C₆H₆ yielded 86% 1,3,4,5-tetraphenyl-4,5-trans-dihydropyrazole, m. 166.5-8.0° (alc.), refluxed 50 hrs. in xylene with chloranil, the dehydrogenation product distilled in vacuo and recrystd. from C₆H₁₂ gave 1,3,4,5-tetraphenylpyrazole (XV), m. 217-19°. III (4.0 millimoles) heated 3 days at 50° with 3.6 g. cisstilbene in a sealed tube and the adduct (53%) crystallized from CH₂Cl₂/alc. gave greenish yellow needles of 1,3,4,5-tetraphenyl 4,5-cis-dihydropyrazole, m. 194.5-5.5°, taken up (110 mg.) in 5 ml. boiling Me₂CO and treated gradually with 60 mg. KMnO₄ in 20 ml. Me₂CO, reduced with SO₂, and the Me₂CO evaporated to give 108 mg. XV. III (2.0 millimoles) in C₆H₆ treated with 6.0 millimoles acenaphthylene in the presence of Et₃N 1 hr. at 80° and 7 hrs. at 20°, filtered from Et₃N-HCl, and the product (90%) recrystd. from PhMe gave 7,9diphenyl - 6b,9a - dihydroacenaphtho[1,2 - c] pyrazole, m. 255.5-7.5° (decomposition). Dibenzob,f]azepine (1.20 g.) refluxed 2.5 hrs. in 10 ml. C₆H₆ with 1.43 g. III and 4.3 ml. NET₃ and the precipitate washed free from NET₃HCl with H₂O yielded 55% material, recrystd. repeatedly from xylene to give 1,3-diphenyldibenzo [b,f] pyrazolo [3,4-d] azepine, m. 264.0-5.5°, λ 302, 361 m μ (log ϵ 4.07, 4.14), ν 3335 cm.⁻¹ 111 treated by the usual procedure with 3 mole-equivs. H₂C:CHCO₂Et 45 min. at 20° gave 85% Et 1,3-diphenylA₂-pyrazoline-5-carboxylate, m. 99-101° (MeOH), dehydrogenated with chloranil in boiling xylene to yield 94% Et 1,3-diphenyl-5-pyrazolecarboxylate, m. 84.5-6.0°, hydrolyzed with KOH in MeOH to IX. Similar reaction with 7 mole-equivs. H₂C:CHCN 30 min. at 20° yielded 85% 1,3-diphenyl-5-cyano-A₂-pyrazoline, m. 138-40°, aromatized by refluxing 2 hrs. in xylene with chloranil to give 76% 1,3-diphenyl-5-cyanopyrazole, m. 133-5°, ν 2240 cm.⁻¹, hydrolyzed by 2 hrs. reflux in 1:1 H₂SO₄-AcOH-H₂O to yield IX. II (2.0 g.) heated 8 hrs. at 155-65° in 7 ml. PhCH:CHCO₂Et with liberation of 97% N, the excess ester evaporated, and the residue crystallized from alc. yielded 2.86 g. isomeric mixture, m. 113-16°. The mixture (2.0 g.) refluxed 20 hrs. in 10 ml. xylene with 5.7 millimoles chloranil and the product, m. 127-33°, recrystd. twice from alc. yielded 50% Et 1,3,5-triphenyl-4-pyrazolecarboxylate, m. 142-5°. Treatment of HI with 2 mole-equivs. PhCH:CHCO₂Et in boiling C₆H₆ with NET₃ yielded 83% isomeric mixture, m. 116-23°. The direction of the addition seemed to be influenced more strongly by steric than by electronic factors. II (1.0 g.) heated 2 hrs. at 160-70° in 5 ml. MeCOCH₂CO₂Et with evolution of 104% N and the residue distilled at 170-80°/ 0.01 mm. yielded 67%

rapidly solidifying oil, recrystd. from C₆H₁₂-Et₂O to give XII, also obtained in 19% yield by thermolysis of II in EtOCH:CHCO₂Et, and in 62% yield by decomposition of II in AcOCH:CHCO₂Et. Hydrolysis of XII with 12% KOH in MeOH gave 1,3-diphenyl-5-methyl-4-pyrazolecarboxylic acid, m. 193-4° (alc.). II (9.0 millimoles) and 6 g. maleic anhydride heated 5 hrs. in 20 ml. MeOPh at 155° and the product recrystd. from C₆H₆ gave 1.21 g. 1,3-diphenyl-A₂-pyrazoline-cis-4,5-dicarboxylic anhydride (XVI), m. 191)-2° (decomposition) (determination made in preheated bath at 180°). Decomposition of II at 160-70° caused decomposition of XVI in 3 hrs. with formation of 35% 1,3-diphenylpyrazole. II (9.0 millimoles) heated in 5 g. trans-MeO₂CCH:CHCO₂Me with evolution of 0.94 molequiv. N yielded 88% di-Me 1,3-diphenyl-A₂-pyrazolinetrans-4,5-dicarboxylate (XVII), m. 148-50° (alc.), also prepared in 99% yield by treatment with III in C₆H₆ with NET₃. XVI taken up in hot aqueous Na₂CO₃ and the dicarboxylic acid esterified with CH₂N₂ gave XVII. XVII (1.5 g.) refluxed 20 hrs. in xylene with 6.1 millimoles chloranil and the product crystallized from alc. gave 1.17 g. di-Me 1,3-diphenylpyrazole-4,5-dicarboxylate (XVIII), m. 151.2°. II (9.0 millimoles) in 5 g. cis-MeO₂CCH:CHCO₂Me heated, the excess ester distilled, and the residue fractionated from alc. yielded 51% XVII and 4% di-Me 1,3-diphenyl-A₂-pyrazolinecis-4,5-dicarboxylate, m. 141-3°, also produced in 72% yield by keeping XVI 3 days in dilute Me₂CO and esterifying the product with CH₂N₂. II (9.0 millimoles) refluxed 6 hrs. in 20 ml. MeOPh containing 5.0) g. di-Me maleic anhydride with evolution of 255 ml. N, the solvent and excess dipolarophile distilled, and the residue extracted with Et₂O gave 1.58 g. residue, recrystd. repeatedly from C₆H₁₂ to give 1,3-diphenyl-4,5-dimethyl-A₂-pyrazoline-cis-4,5-dicarboxylic anhydride, m. 138-4°. III (3.98 millimoles), 2.9 g. trans-MeO₂CMe:MeCO₂Me, and 1.5 ml. NET₃ heated 2 days at 50° in a sealed tube and the product crystallized from MeOH yielded 74% di-Me 1,3-diphenyl-4,5-dimethyl-A₂-pyrazoline-trans-4,5-dicarboxylate, m. 107.5-8.5°. Similarly III and 5 mole-equivs. cis-MeO₂CMe:MeCO₂Me gave 33% di-Me 1,3-diphenyl-4,5-dimethyl-A₂-pyrazoline-cis-4,5-dicarboxylate, m. 144-5°, also obtained from the cis-anhydride in 67% yield. II (9.0 millimoles) and 3 g. α-naphthoquinone heated 2 hrs. at 160-70°, the residue digested with Et₂O and crystallized from CHCl₃ yielded 85% 1,3-diphenyl-4,9-dioxo-4,9-dihydronaphtho[2,3-c]pyrazole, m. 257-9°. II (2.25 millimoles) refluxed 3 hrs. in 5 ml. MeOPh with 0.6 g. 2-methyl-α-naphthoquinone gave 0.27 g. 1,3-diphenyl-9a-methyl-4,9-dioxo-3,4,9,9a-tetrahydronaphtho[2,3-c]pyrazole, m. 245-7° (CHCl₃), v 1780 cm.⁻¹ The reciprocal action of I with the CC triple bond led directly to aromatic pyrazole systems. III (1.30 millimoles) in 3 ml. PhC:CH heated on a steam bath with dropwise addition of 1.0 ml. NET₃, kept 1.5 hrs., the cooled mixture filtered from 95% Et₃NHCl, the filtrate distilled at 130-50°/0.003 mm., the red oil chromatographed on basic Al₂O₃, eluted with C₆H₆, and the middle fraction recrystd. from MeOH yielded 72% 1,3,5-triphenylpyrazole (XVIII), m. 138.5-9.5°. II (9.0 millimoles) heated 6 hrs. at 155-65° with PhC:CPh with liberation of 235 ml. N gave 34% XIV, obtained only in 2.6% yield by treatment with III in C₆H₆ in the presence of Et₃N. II (9.0 millimoles) heated in 5 ml. HC:CCH(OPr)₂ and the product distilled at 190-205°/0.001 mm. gave 2.82 g. oily 1,3-diphenylpyrazole-5-aldehyde dipropyl acetal, hydrolyzed 48 hrs. at 20° in 20 ml. dioxane and 10 ml. 50% HCl to yield 79% 1,3-diphenyl-5-pyrazolecarboxaldehyde, m. 138-40°; 2,4-dinitrophenylhydrazones m. 260° (decompn.). The aldehyde refluxed 2 hrs. in MeOCH₂CH₂OH with moist Ag₂O and the neutral and acidic

products gave 35% IX. III with 2.5 mole-equivs. HC:CCO2Me gave 71% Me 1,3-diphenyl-5-pyrazolecarboxylate, m. 111.512.5° (MeOH), hydrolyzed quant. with KOH in MeOH to IX.

- II (5.4 millimoles) decomposed in 4 g. PhC:CCO2Et yielded 84% di-Et 1,3,5-triphenyl-4-pyrazolecarboxylate, m. 144-5° (alc.), saponified with KOH in MeOH to 90% 1,3,5-triphenyl-4-pyrazolecarboxylic acid, m. 239-41° (decomposition) decarboxylated at 245° to XVIII. II (9.0 millimoles) and 5 ml. Me2O2CC:CCO2Me heated and the product distilled at 210-30°/0.001 mm. yielded 56% di-Me 1,3-diphenylpyrazole-4,5-dicarboxylate, m. 153-4°, saponified to the dicarboxylic acid, m. 198-200° (decomposition), neutralization equivalent 170, decarboxylated by heating 30 min. at 200° to give 1,3-diphenylpyrazole-4-carboxylic acid, m. 201-3°, neutralization equivalent 270°. Proof of cis addition and determination of the orientation

rules


represent contributions to the mechanism of 1,3-dipolar addition

IT 85008-87-3P

RL: SPN (Synthetic preparation); PRP (Properties); PREP (Preparation)
(1,3-Dipolar addition. I. Diphenylnitrilimine and its 1,3-dipolar additions to alkenes and alkynes)

RN 85008-87-3 CAPLUS


CN Dibenzo[b,f]pyrazolo[3,4-d]azepine, 1,8-dihydro-1,3-diphenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 106 THERE ARE 106 CAPLUS RECORDS THAT CITE THIS RECORD (107 CITINGS)

10/565,702

L10 ANSWER 123 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
RN 1139-56-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN Furo[2,3-d]pyrrolo[3,2,1-jk][1]benzazepine (8CI, 9CI) (CA INDEX NAME)
MF C14 H9 N O
CI RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/565,702


L10 ANSWER 122 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
RN 7486-12-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN Pyrrolo[3',4':3,4]cyclobut[1,2-d]imidazole (8CI, 9CI) (CA INDEX NAME)
MF C7 H3 N3
CI RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/565,702


L10 ANSWER 121 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
RN 80294-50-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN Oxazolo[5,4-d][1,4]thiazino[2,3,4-jk][1]benzazepine (9CI) (CA INDEX NAME)
MF C13 H8 N2 O S
CI RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/565,702


L10 ANSWER 120 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
RN 80294-51-5 REGISTRY
ED Entered STN: 16 Nov 1984
CN [1,4]Thiazino[2,3,4-jk]thiazolo[5,4-d][1]benzazepine (9CI) (CA INDEX
NAME)
MF C13 H8 N2 S2
CI RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/565,702


L10 ANSWER 119 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
RN 87041-36-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN 3,8-Methano-8H-dibenz[b,f]isoxazolo[4,5-d]azepine (9CI) (CA INDEX NAME)
MF C16 H10 N2 O
CI RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/565,702


L10 ANSWER 116 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
RN 93281-43-7 REGISTRY
ED Entered STN: 18 Dec 1984
CN 1H-[1]Benzo[thieno[5,6-b]azirine (9CI) (CA INDEX NAME)
MF C8 H5 N S
CI RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/565,702

L10 ANSWER 117 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
RN 88084-57-5 REGISTRY
ED Entered STN: 16 Nov 1984
CN Azirino[2,3,1-h]thiazolo[5,4-e]indole (9CI) (CA INDEX NAME)
MF C9 H4 N2 S
CI RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/565,702


L10 ANSWER 118 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
RN 87208-25-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN 4,9-Methano-4H-pyrrolo[1,2-a]thieno[3,2-d]azepine (9CI) (CA INDEX NAME)
MF C12 H9 N S
CI RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/565,702


L10 ANSWER 113 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
RN 147184-23-4 REGISTRY
ED Entered STN: 23 Apr 1993
CN 10H-Imidazo[1,2-a]thieno[3,2-d]azepine,
10-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinylidene]- (CA INDEX NAME)
MF C24 H25 N3 O S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/565,702


L10 ANSWER 114 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
RN 146340-64-9 REGISTRY
ED Entered STN: 09 Mar 1993
CN 4,7:14,17-Diimino-2,22-metheno-9,12-nitriloazepino[4,3-
blazacyclononadecine (9CI) (CA INDEX NAME)
MF C23 H15 N5
CI RPS
SR CA Index Guide or Ring Systems Handbook



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/565,702


L10 ANSWER 115 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
RN 93281-55-1 REGISTRY
ED Entered STN: 18 Dec 1984
CN 2,6-Methano-1H-[1]benzothieno[5,6-b]azirine (9CI) (CA INDEX NAME)
MF C9 H5 N S
CI RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/565,702

L10 ANSWER 110 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
RN 188965-71-1 REGISTRY
ED Entered STN: 13 May 1997
CN 4H-Pyrrolo[1,2-a]thieno[3,2-d]azepine (9CI) (CA INDEX NAME)
MF C11 H9 N S
CI RPS
SR CA Index Guide or Ring Systems Handbook




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/565,702

L10 ANSWER 111 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
RN 179528-39-3 REGISTRY
ED Entered STN: 14 Aug 1996
CN Benzamide, N-[1,1'-biphenyl]-2-yl-4-[(4,5-dihydro-2-methylimidazo[4,5-
d][1]benzazepin-6(1H)-yl)carbonyl]- (CA INDEX NAME)
MF C32 H26 N4 O2
SR CA
LC STN Files: USPATFULL

PAGE 1-A




PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10/565,702

L10 ANSWER 112 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
RN 147210-28-4 REGISTRY
ED Entered STN: 27 Apr 1993
CN 5H-Thiazolo[3,2-a]pyrimidin-5-one,
6-[2-[4-(10H-imidazo[1,2-a]thieno[3,2-d]azepin-10-ylidene)-1-
piperidinyl]ethyl]-7-methyl- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 10H-Imidazo[1,2-a]thieno[3,2-d]azepine, 5H-thiazolo[3,2-a]pyrimidin-5-one
deriv.
MF C24 H23 N5 O S2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L10 ANSWER 105 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
 RN 344881-07-8 REGISTRY
 ED Entered STN: 08 Jul 2001
 CN Dibenzo[b,f]pyrazolo[4,3-d]azepine-8(1H)-ethanamine,
 N,N-dimethyl-1,3-diphenyl- (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Dibenzo[b,f]pyrazolo[3,4-d]azepine-8(1H)-ethanamine,
 N,N-dimethyl-1,3-diphenyl- (9CI)
 MF C31 H28 N4
 CI COM
 SR Reaction Database



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/565,702


L10 ANSWER 106 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
RN 344766-72-9 REGISTRY
ED Entered STN: 06 Jul 2001
CN Dibenzo[b,f]pyrazolo[4,3-d]azepine-8(1H)-propanamine,
N,N, β -trimethyl-1,3-diphenyl- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Dibenzo[b,f]pyrazolo[3,4-d]azepine-8(1H)-propanamine,
N,N, β -trimethyl-1,3-diphenyl- (9CI)
MF C33 H32 N4
CI COM
SR Reaction Database



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/565,702

L10 ANSWER 107 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
RN 341496-75-1 REGISTRY
ED Entered STN: 15 Jun 2001
CN 5H-Pyrano[3',2':2,3]azepino[4,5-b]indole-5-carboxamide,
2,3,4,6,7,12-hexahydro- (CA INDEX NAME)
MF C16 H17 N3 O2
SR Reaction Database




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/565,702

L10 ANSWER 108 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
RN 279253-81-5 REGISTRY
ED Entered STN: 21 Jul 2000
CN Spiro[cyclohexane-1,10'-[10H]imidazo[1,2-a]thieno[3,2-d]azepine] (9CI)
(CA INDEX NAME)
MF C15 H16 N2 S
CI COM, RPS
SR CA

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


L10 ANSWER 100 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
 RN 707539-73-9 REGISTRY
 ED Entered STN: 09 Jul 2004
 CN Methanone, (4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)(2'-methoxy[1,1'-biphenyl]-4-yl)- (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Imidazo[4,5-d][1]benzazepine, 1,4,5,6-tetrahydro-6-[(2'-methoxy[1,1'-biphenyl]-4-yl)carbonyl]-2-methyl- (9CI)
 MF C26 H23 N3 O2
 CI COM
 SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/565,702


L10 ANSWER 101 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
RN 703401-73-4 REGISTRY
ED Entered STN: 02 Jul 2004
CN Butanamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-
yl)carbonyl]phenyl]-2-(methoxyimino)- (CA INDEX NAME)
MF C24 H25 N5 O3
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/565,702


L10 ANSWER 102 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
RN 701193-15-9 REGISTRY
ED Entered STN: 29 Jun 2004
CN 8H-Dibenz[b,f]isoxazolo[5,4-d]azepine-8-propanamine,
N,N, β -trimethyl-3-phenyl- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 8H-Dibenz[b,f]isoxazolo[4,5-d]azepine-8-propanamine,
N,N, β -trimethyl-3-phenyl- (9CI)
MF C27 H27 N3 O
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 103 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
 RN 699532-52-0 REGISTRY
 ED Entered STN: 25 Jun 2004
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(2-cyclopropyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)
 MF C34 H28 N4 O2
 CI COM
 SR CA

PAGE 1-A




PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/565,702

L10 ANSWER 104 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
RN 344882-40-2 REGISTRY
ED Entered STN: 08 Jul 2001
CN Dibenzo[b,f]pyrazolo[4,3-d]azepine-8(1H)-propanamine,
N,N-dimethyl-1,3-diphenyl- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Dibenzo[b,f]pyrazolo[3,4-d]azepine-8(1H)-propanamine,
N,N-dimethyl-1,3-diphenyl- (9CI)
MF C32 H30 N4
CI COM
SR Reaction Database




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/565,702

L10 ANSWER 98 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
RN 724698-06-0 REGISTRY
ED Entered STN: 09 Aug 2004
CN Benzamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-
yl)carbonyl]phenyl]-2-ethoxy- (CA INDEX NAME)
MF C28 H26 N4 O3
CI COM
SR CA

PAGE 1-A




PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/565,702

L10 ANSWER 99 OF 123 REGISTRY COPYRIGHT 2010 ACS on STN
RN 719305-66-5 REGISTRY
ED Entered STN: 30 Jul 2004
CN 4H-Imidazo[1,2-a]oxazolo[4,5-d]azepine (9CI) (CA INDEX NAME)
MF C9 H7 N3 O
CI RPS
SR CA Index Guide or Ring Systems Handbook



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/565,702

=> => d his

(FILE 'HOME' ENTERED AT 13:48:12 ON 16 SEP 2010)

FILE 'REGISTRY' ENTERED AT 13:51:19 ON 16 SEP 2010

L1 STRUCTURE UPLOADED
L2 50 S L1
L3 3126 S L1 SSS FUL
L4 STRUCTURE UPLOADED
L5 1192 S L4 SUB=L3 FUL
L6 1934 S L3 NOT L5
L7 3421 S 2436.13/RID
L8 1182 S L5 AND L7
L9 1811 S L6 AND CAPLUS/LC
L10 123 S L6 NOT L9
L11 1159 S L8 AND CAPLUS/LC
L12 23 S L8 NOT L11

FILE 'CAPLUS' ENTERED AT 13:57:38 ON 16 SEP 2010

L13 440 S L6
L14 26 S L8
L15 ANALYZE L13 1- RN HIT : 1811 TERMS

FILE 'REGISTRY' ENTERED AT 13:58:27 ON 16 SEP 2010

L16 1 S 237430-03-4/RN
L17 100 S 1422737/RN
L18 1 S 210101-16-9/RN
L19 1 S 168626-94-6/RN
L20 7 S L17 AND L6

FILE 'CAPLUS' ENTERED AT 14:02:15 ON 16 SEP 2010

FILE 'REGISTRY' ENTERED AT 14:05:15 ON 16 SEP 2010

L21 492 S 5300.5/RID
L22 11 S 4469.23/RID
L23 1495 S L6 NOT (L21 OR L22)

FILE 'CAPLUS' ENTERED AT 14:08:27 ON 16 SEP 2010

L24 247 S L23
L25 ANALYZE L24 1- RN HIT : 1412 TERMS

FILE 'REGISTRY' ENTERED AT 14:09:41 ON 16 SEP 2010

L26 1493 S L23 NOT (L18 OR L19)

FILE 'CAPLUS' ENTERED AT 14:09:48 ON 16 SEP 2010

L27 120 S L26
L28 96 S L27 NOT (2010/SO OR 2009/SO OR 2008/SO OR 2007/SO OR 2006/SO

FILE 'REGISTRY' ENTERED AT 14:16:04 ON 16 SEP 2010

FILE 'CAPLUS' ENTERED AT 14:18:25 ON 16 SEP 2010

L29 82 S L18
L30 67 S L19
L31 11 S L29 AND L30
L32 8 S L31 NOT (2010/SO OR 2009/SO OR 2008/SO OR 2007/SO OR 2006/SO

=> d ibib abs hitstr total

L32 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:1448448 CAPLUS

DOCUMENT NUMBER: 149:570726

TITLE: Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival

INVENTOR(S): Liu, Yongge; Kambayashi, Junichi

PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 47pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008144269	A2	20081127	WO 2008-US63374	20080512
WO 2008144269	A3	20100121		
<p>W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW</p> <p>RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA</p>				
AU 2008254273	A1	20081127	AU 2008-254273	20080512
CA 2685186	A1	20081127	CA 2008-2685186	20080512
EP 2146721	A2	20100127	EP 2008-755284	20080512
<p>R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS</p>				
KR 2010019439	A	20100218	KR 2009-723586	20080512
AR 66544	A1	20090826	AR 2008-102015	20080513
MX 2009012164	A	20091209	MX 2009-12164	20091110
CN 101808517	A	20100818	CN 2008-80015930	20091113
IN 2009DN07590	A	20100702	IN 2009-DN7590	20091123
PRIORITY APPLN. INFO.:			US 2007-938089P	P 20070515
			WO 2008-US63374	W 20080512

OTHER SOURCE(S): MARPAT 149:570726

AB The invention discloses methods for reducing cardiotoxicity and/or improving survival from treatment with anthracycline agents comprising administering a therapeutically effective amount of a composition comprising a vasopressin antagonist compound or a pharmaceutically acceptable salt thereof as an active ingredient, administered simultaneously or prior to the anthracycline administration.

IT 168626-94-6, Conivaptan hydrochloride 210101-16-9, Conivaptan 210101-16-9D, Conivaptan, salts

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival)

10/565,702

RN 168626-94-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● HCl

RN 210101-16-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 210101-16-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L32 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:1099903 CAPLUS

DOCUMENT NUMBER: 149:347494

TITLE: Method for reducing infarction using vasopressin antagonist compounds, and compositions and combinations thereof

INVENTOR(S): Liu, Yongge; Kambayashi, Junichi; Fujiki, Hiroyuki; Mori, Toyoki

PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan

SOURCE: U.S. Pat. Appl. Publ., 16pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080221084	A1	20080911	US 2007-927153	20071029
PRIORITY APPLN. INFO.:			US 2006-863530P	P 20061030

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 149:347494

AB The invention discloses a method for reducing infarction comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising as an active ingredient a vasopressin antagonist compound, as well as a composition useful therefor. The invention also discloses a method for reducing infarction comprising administering to a patient in need thereof a therapeutically effective amount of a combination of a vasopressin antagonist compound and a β -blocker, as well as combinations useful therefor. The methods, compns. and combinations of the invention can be used for reducing infarction in the heart (myocardial infarction) and the brain (stroke). The methods, compns. and combinations of the invention can also be used for the treatment and/or prevention of hypertension, edema, ascites, heart failure, renal function disorder, vasopressin inappropriate secretion syndrome (SIADH), hepatocirrhosis, hyponatremia, hypokalemia, polycystic kidney disease, diabetes, or circulation disorder.

IT 168626-94-6, Conivaptan hydrochloride 210101-16-9,

Conivaptan 210101-16-9D, Conivaptan, salts

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL


(Biological study); USES (Uses)

(vasopressin antagonist compds., compns., and combinations for reducing infarction)

RN 168626-94-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 210101-16-9 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 210101-16-9 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-([4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L32 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:395085 CAPLUS

DOCUMENT NUMBER: 142:423900

TITLE: Combinations of cyclooxygenase (COX) inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhea

INVENTOR(S): Barker, Laura Daisy; Russell, Rachel Jane; Van der Graaf, Pieter Hadewijn; Wayman, Christopher Peter

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005039565	A1	20050506	WO 2004-IB3386	20041014
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AR 46919	A1	20060104	AR 2004-103890	20041026
PRIORITY APPLN. INFO.:			GB 2003-25021	A 20031027
AB	The invention describes the use of a combination of (A) a vasopressin receptor family antagonist, or a pharmaceutically acceptable derivative thereof; and (B) a COX inhibitor, or a pharmaceutically acceptable derivative thereof, for the treatment or prophylaxis of dysmenorrhea. Preparation of celecoxib is also described.			
IT	168626-94-6, YM 087 210101-16-9, Conivaptan			
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
	(cyclooxygenase inhibitor-vasopressin receptor antagonist combination for treatment of dysmenorrhea)			
RN	168626-94-6 CAPLUS			
CN	[1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)			

PAGE 1-A




PAGE 2-A



● HCl

RN 210101-16-9 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT:

12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:861136 CAPLUS

DOCUMENT NUMBER: 140:59574

TITLE: Practical Synthesis of
 N-[4-[(2-Methyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]biphenyl-2-carboxamide
 Monohydrochloride: an Arginine Vasopressin Antagonist
 AUTHOR(S): Tsunoda, Takashi; Yamazaki, Atsuki; Iwamoto, Hidenori; Sakamoto, Shuichi

CORPORATE SOURCE: Chemical Technology Labs, Yamanouchi Pharmaceutical Co., Ltd., Takahagi-shi, Ibaraki, 318-0001, Japan

SOURCE: Organic Process Research & Development (2003), 7(6), 883-887

CODEN: OPRDFK; ISSN: 1083-6160

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:59574

AB A novel, reliable, and cost-effective synthetic route to N-[4-[(2-methyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]biphenyl-2-carboxamide monohydrochloride (YM087), a potent arginine vasopressin antagonist, has been developed. Using moisture-controlled potassium carbonate, imidazole formation from α -bromoketone furnished imidazobenzazepine, avoiding potential oxazole-ring formation. Catalytic reduction of nitro imidazobenzazepine afforded the corresponding amine in high yields. Treatment of the imidazole-containing amine directly, with a carbonyl chloride, afforded the target amide circumventing protection of the imidazole.


IT 168626-94-6P, N-[4-[(4,5-Dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-[1,1'-biphenyl]-2-carboxamide monohydrochloride

RL: SPN (Synthetic preparation); PREP (Preparation)
 (YM087; practical synthesis of [(methylimidazo[4,5-d][1]benzazepinyl)carbonyl]phenyl]biphenylcarboxamide monohydrochloride (arginine vasopressin antagonist))

RN 168626-94-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

IT 210101-16-9P, N-[4-[(4,5-Dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-[1,1'-Biphenyl]-2-carboxamide
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (practical synthesis of [(methylimidazo[4,5-d][1]benzazepinyl)carbonyl]phenyl)biphenylcarboxamide monohydrochloride
 (arginine vasopressin antagonist))
 RN 210101-16-9 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT:	6	THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT:	12	THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2001:780647 CAPLUS

DOCUMENT NUMBER: 135:335146

TITLE: Time-release coated solid compositions for oral administration

INVENTOR(S): Sawada, Toyohiro; Sako, Kazuhiro; Yoshioka, Tatsunobu; Watanabe, Shunsuke

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 49 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001078686	A1	20011025	WO 2001-JP3229	20010416
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020028240	A1	20020307	US 2001-834410	20010412
EP 1275381	A1	20030115	EP 2001-921849	20010416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20060292221	A1	20061228	US 2006-463570	20060809
US 20080199522	A1	20080821	US 2007-841731	20070820
PRIORITY APPLN. INFO.:			US 2000-198086P	P 20000417
			US 2001-834410	A1 20010412
			WO 2001-JP3229	W 20010416
			US 2006-463570	A1 20060809

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Disclosed are time-release coated solid compns. which are hydrogel-forming coated solid prepn. composed of a tablet core containing a drug, a hydrogel-forming polymer and a hydrophilic base characterized by (1) the tablet core containing a drug and a highly erodible filler, (2) the erosion ratio of the tablet core ranging from about 40 to about 90, and (3) the outer layer being substantially free from the same drug as the above-described drug. The drug is released after a definite time lag, which enables efficient drug delivery to a specific site in the digestive tract. Therefore, these prepn. are useful in the oral administration of drugs considered as exerting the efficacy when delivered to a disease site in the lower part of the digestive tract at a high concentration, drugs considered as being efficacious when absorbed in the lower part of the digestive tract, drugs being efficacious in time-scheduled drug therapy, etc. A time-release tablet was prepared from 4'-[(2-Methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-phenylbenzanilide hydrochloride (I) 1, HPMC2910 3, polysorbate 80 5, malic acid, polyethylene oxide (Polyox WSR303) 62.5, macrogol 6000 187.5 mg. The obtained tablet containing I was administered to a dog with a midazolam soluble. The administration of the time-release tablet showed no

effect on the blood concentration of midazolam soluble as compared with the administration of I-containing solution


IT 168626-94-6

RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (time-release coated solid compns. containing drugs, hydrogels and erodible fillers for oral administration)

RN 168626-94-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● HCl

IT 210101-16-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (time-release coated solid compns. containing drugs, hydrogels and erodible

fillers for oral administration)
 RN 210101-16-9 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
 REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2001:780643 CAPLUS
 DOCUMENT NUMBER: 135:335144
 TITLE: Drug delivery system for avoiding pharmacokinetic interaction between drugs and method thereof
 INVENTOR(S): Sawada, Toyohiro; Sako, Kazuhiro; Yoshioka, Tatsunobu; Watanabe, Shunsuke
 PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 44 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001078681	A1	20011025	WO 2001-JP3228	20010416
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020022054	A1	20020221	US 2001-834414	20010412
US 6761895	B2	20040713		
EP 1275373	A1	20030115	EP 2001-923966	20010416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20050163840	A1	20050728	US 2004-866524	20040610
PRIORITY APPLN. INFO.:			US 2000-197574P	P 20000417
			US 2001-834414	A1 20010412
			WO 2001-JP3228	W 20010416

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


AB Disclosed a system for avoiding an unfavorable pharmacokinetic interaction between a drug and another concomitant drug which comprises controlling the release time and/or release site of the drug and/or the concomitant drug in the body. A controlled-release tablet of conivaptan hydrochloride was prepared and applied to a dog with midazolam oral liquid to examine the blood concentration of midazolam. The obtained conivaptan tablet showed no effect on metabolism of midazolam through drug metabolizing enzyme CYP3A4.

IT 168626-94-6, Conivaptan hydrochloride
 RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (drug delivery system for avoiding pharmacokinetic interaction between drugs and method thereof)

RN 168626-94-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

IT 210101-16-9, Conivaptan
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (drug delivery system for avoiding pharmacokinetic interaction between
 drugs and method thereof)
 RN 210101-16-9 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-
 d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT:	7	THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
REFERENCE COUNT:	12	THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2001:17852 CAPLUS
 DOCUMENT NUMBER: 134:86254
 TITLE: Preparation of crystal of condensed benzazepine derivative
 INVENTOR(S): Inakoshi, Masatoshi; Kakuta, Takashi; Kato, Yoshinori
 PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan; Astellas Pharma Inc.
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001002678	A	20010109	JP 1999-170444	19990617
JP 4461512	B2	20100512		


PRIORITY APPLN. INFO.: JP 1999-170444 19990617

AB α -Type crystal of 4'-[(2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine-6-yl)carbonyl]-2-phenylbenzanilide hydrochloride (I) having specific peaks in X-ray diffraction spectrum is prepared in a large industrial scale starting from crude I crystal via dislocation of δ -type crystal to the α -type crystal. I possesses the antagonist activity against vasopressin receptor (no data). Thus, 0.25 mL oxalyl chloride and a catalytic amount of DMF were added to a solution of 373 mg o-phenylbenzoic acid in 7.5 mL CH₂Cl₂ at -15° with stirring, warmed to room temperature over a period of 2 h, stirred for 2 h, concentrated under reduced pressure, and coevaporated with CH₂Cl₂ to give a residue (o-phenylbenzoyl chloride). The residue was dissolved in 7.5 mL dry MeCN, added dropwise to a suspension of 0.5 g 6-(4-aminobenzoyl)-2-methyl-1,2,4,5-tetrahydro-imidazo[4,5-d][1]benzazepine in dry MeCN and 0.608 mL pyridine under ice-cooling, warmed to room temperature, refluxed for .apprx.1 h, cooled, stirred with 4 N HCl/AcOEt, and filtered to give 1.18 g crude I crystal. Crude I crystal (80 g) was added to a mixture of MeCN 400, MeOH 400, and H₂O 80 mL, heated at 45° to dissoln., followed by filtering the solution to remove floating particles and washing the filter with 80 mL MeOH, and the combined filtrate and the washing was distilled under normal pressure until a total of 480 mL liquid was distilled. To the residue was added 1,200 mL MeCN, refluxed for 3 h, slowly cooled to 20°, and the precipitated crystals were filtered, washed with 200 mL MeCN, and vacuum-dried at 80° to give 70.2% I (62.02 g).

IT 168626-94-6P
 RL: IMF (Industrial manufacture); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (preparation of α -type crystal of imidazobenzazepine hydrochloride derivative by crystal dissoln. as vasopressin receptor antagonist)

RN 168626-94-6 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● HCl

IT 210101-16-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
 USES (Uses)
 (preparation of α -type crystal of imidazobenzazepine hydrochloride
 derivative by crystal dissoln. as vasopressin receptor antagonist)

RN 210101-16-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L32 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1999:495193 CAPLUS
 DOCUMENT NUMBER: 131:120908
 TITLE: Vasopressin antagonists as preventives or remedies for vision disorders
 INVENTOR(S): Ogawa, Takahiro; Watanabe, Noriko; Waki, Mitsunori
 PATENT ASSIGNEE(S): Senju Pharmaceutical Co., Ltd., Japan; Yamanouchi Pharmaceutical Co., Ltd.
 SOURCE: PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9938533	A1	19990805	WO 1999-JP261	19990125
W: CA, JP, KR, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2319649	A1	19990805	CA 1999-2319649	19990125
EP 1050308	A1	20001108	EP 1999-901151	19990125
R: DE, ES, FR, GB, IT				
US 6268359	B1	20010731	US 2000-601216	20000728
PRIORITY APPLN. INFO.:				
			JP 1998-15538	A 19980128
			WO 1999-JP261	W 19990125

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): MARPAT 131:120908

AB Disclosed are preventives or remedies for vision disorders based on ocular circulatory disorders, e.g. intraocular hypertension and glaucoma, and vision disorders based on ciliary tension, e.g. nearsightedness, wherein the preventives or remedies contain vasopressin antagonists, i.e. benzazepine derivs. as the active ingredients. A suspension eyedrop containing 4'-[(2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine-6-yl)carbonyl]2-phenylbenzanilide·HCl 1, NaPH2 0.1, polysorbate 80 0.1, NaCl 0.9 g, NaOH q.s., and water q.s. to 100 mL was prepared, and its effects on ocular circulation, intraocular pressure, etc. were tested using rabbits.

IT 168626-94-6 210101-16-9
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (vasopressin antagonists containing benzazepine derivs. for treatment of vision disorders)

RN 168626-94-6 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 210101-16-9 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT:	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
REFERENCE COUNT:	7	THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT